Page last updated: 2024-11-04

clotrimazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Clotrimazole is an antifungal medication that is used to treat a variety of fungal infections, including athlete's foot, jock itch, and yeast infections. It is available over-the-counter (OTC) and by prescription. Clotrimazole works by disrupting the cell membrane of fungi, which kills them. It is a member of the imidazole class of antifungal drugs, which are known for their broad spectrum of activity against a variety of fungi.'

Cross-References

ID SourceID
PubMed CID2812
CHEMBL ID104
CHEBI ID3764
SCHEMBL ID3850
MeSH IDM0004642

Synonyms (484)

Synonym
BIDD:GT0450
BIDD:PXR0036
HMS3393E11
AB00051951-14
1-[(2-chlorophenyl)-di(phenyl)methyl]imidazole
gtpl2330
mycosporin
1h-imidazole, 1-[(2-chlorophenyl)diphenylmethyl]-
DIVK1C_000665
KBIO1_000665
NCIMECH_000609
1-((2-chlorophenyl)diphenylmethyl)-1h-imidazole
MLS000028502 ,
1-[(2-chlorophenyl)(diphenyl)methyl]-1h-imidazole
CHEBI:3764 ,
smr000058306
gyne-lotrimin 3 combination pack
gyne-lotrimin combination pack
imidazole, 1-(o-chloro-alpha,alpha-diphenylbenzyl)-
trivagizole 3
drg-0072
klotrimazole
pedisafe
1-((o-chloro-phenyl)diphenylmethyl)imidazole
hsdb 3266
einecs 245-764-8
lotrimax
brn 0622318
chlotrimazole
fb 5097
1h-imidazole, 1-((2-chlorophenyl)diphenylmethyl)-
mycelex-g
gyne-lotrimin 3
lotrimin af
clotrimazol
bisphenyl-(2-chlorphenyl)-1-imidazolyl-methan [german]
fem care
clotrimazolum [inn-latin]
rimazole
mycelex-7
b 5097
bis-fenil-(2-clorofenil)-1-imidazolil-metano [italian]
ccris 6245
clotrimazol [inn-spanish]
gynix
mycelex-7 combination pack
desamix f
monobaycuten
mycelex otc
mono-baycuten
nsc 257473
mycelex g
1-(alpha-(2-chlorophenyl)benzhydryl)imidazole
canestine
mycelex troches
mycelex 7
trimysten
lotrimin af jock-itch cream
1-(o-chloro-alpha,alpha-diphenylbenzyl)imidazole
bis-phenyl-(2-chlorophenyl)(1-imidazoyl)methane
lotrimin af cream
EU-0100315
SPECTRUM_001343
LOPAC0_000315
PRESTWICK_120 ,
NCGC00015251-01
cas-23593-75-1
lopac-c-6019
NCGC00015251-02
tibatin
1h-imidazole, 1-[(2-chlorophenyl)-diphenylmethyl]
mycelex: mycosporinrimazole
1-[(2-chlorophenyl)-diphenyl-methyl]imidazole
bay 5097
bay b 5097
lotrimin
NSC257473 ,
BPBIO1_000126
PRESTWICK3_000267
PRESTWICK2_000267
IDI1_000665
SPECTRUM5_000781
BSPBIO_002057
BSPBIO_000114
1-[(2-chlorophenyl)diphenylmethyl]-1h-imidazole
AB00051951
MLS001423972
clotrimazole ,
C06922
23593-75-1
MLS000758243
cpd000058306 ,
1-[(2-chloro-phenyl)-diphenyl-methyl]-1h-imidazole
DB00257
empecid
methane, bis-phenyl-(2-chlorophenyl)-1-imidazolyl-
imidazole,.alpha.-diphenylbenzyl)-
diphenyl-(2-chlorophenyl)-1-imidazolylmethane
bis-phenyl-(2-chlorophenyl)-1-imidazoyl)methane
1-(o-chlorotrityl)imidazole
bay b 9057
1-(o-chloro-.alpha.,.alpha.-diphenylbenzyl)imidazole
bayb 5097
(2-chlorophenyl)diphenyl-1-imidazolylmethane
mycelex
mykosporin
bay b5097
gyne-lotrimin
canesten
(chlorotrityl)imidazole
nsc-257473
diphenyl(2-chlorophenyl)(1-imidazolyl)methane
gyne lotrimin
bay-b 5097
1-(o-chlorophenyldiphenylmethyl)imidazole
D00282
lotrimin (tn)
mycelex (tn)
clotrimazole (jp17/usp/inn)
NCGC00093761-03
NCGC00093761-02
KBIO2_001823
KBIOGR_000850
KBIO2_004391
KBIO2_006959
KBIOSS_001823
KBIO3_001277
SPECTRUM2_000128
PRESTWICK0_000267
PRESTWICK1_000267
SPBIO_000176
NINDS_000665
SPBIO_002333
SPECTRUM3_000359
SPECTRUM4_000295
SPECTRUM1500200
QTL1_000024
NCGC00093761-01
NCGC00093761-05
NCGC00093761-06
NCGC00093761-04
chlortrimazole
clotrimeizol
cid_2812
chembl104 ,
bdbm31774
NCGC00015251-03
C 6019 ,
HMS2051E11
HMS2091G10
3ACDFDF8-38E3-4368-85D0-BDF8AE1E6591
NCGC00015251-09
gnf-pf-3499 ,
bay-5097
svt-15652
trivagizole
HMS502B07
HMS1568F16
HMS1920O21
1-[(2-chlorophenyl)-diphenylmethyl]imidazole
AKOS005607024
SR-01000075771-10
sr-01000075771
STK700023
HMS3260P12
HMS2095F16
NCGC00254538-01
tox21_300415
A816789
nsc756700
pharmakon1600-01500200
nsc-756700
dtxsid7029871 ,
dtxcid009871
tox21_110111
lotrimin cream
canesten combi-pak 3-day therapy
myclo cream
mycelex twin pack
canesten 1-day therapy
femcare
canesten combi-pak 1-day therapy
canesten 6-day therapy
lotrimin lotion
myclo-gyne
mycelex cream
clotrimaderm
canesten 1-day cream combi-pak
lotrimin af lotion
neo-zol cream
canesten cream
mycelax
canesten 3-day therapy
bis-fenil-(2-clorofenil)-1-imidazolil-metano
bisphenyl-(2-chlorphenyl)-1-imidazolyl-methan
clotrimazolum
HMS2235E20
CCG-35563
NCGC00015251-08
NCGC00015251-05
NCGC00015251-04
NCGC00015251-11
NCGC00015251-07
NCGC00015251-10
NCGC00015251-06
clomatin
clotrimazole [usan:usp:inn:ban:jan]
unii-g07gz97h65
canifug
jidesheng
canestene
5-23-04-00291 (beilstein handbook reference)
pan-fungex
esparol
mycofug
g07gz97h65 ,
gino-lotremine
cutistad
stiemazol
nalbix
FT-0603193
NCGC00015251-14
LP00315
clotrimazole [mart.]
clotrimazole [mi]
clotrimazole [green book]
clotrimazole [jan]
clotrimazole [usp impurity]
clotrimazole [orange book]
clotrimazole [who-dd]
clotrimazole [ep monograph]
clotrimazole [usan]
clotrimazole [ep impurity]
clotrimazole component of lotrisone
1-(2-chlorotrityl)imidazole
clotrimazole [inn]
clotrimazole [vandf]
clotrimazole [usp-rs]
lotrisone component clotrimazole
clotrimazole [usp monograph]
S1606
HMS3369I03
HY-10882
CS-1926
NC00035
SCHEMBL3850
tox21_110111_1
NCGC00015251-13
tox21_500315
NCGC00261000-01
clortrimazole
W-107394
1-(2-chloro-?,?-diphenylbenzyl)imidazole
imidazole, 1-(o-chloro-.alpha.,.alpha.-diphenylbenzyl)-
component of otomax (salt/mix)
1-(.alpha.-(2-chlorophenyl)benzhydryl)imidazole
component of lotrimax (salt/mix)
C2867
1-[(2-chlorophenyl)diphenylmethyl]imidazole
clotrimazole crystalline
AB00051951_16
AB00051951_15
mfcd00057220
clotrimazole, european pharmacopoeia (ep) reference standard
clotrimazole, united states pharmacopeia (usp) reference standard
clotrimazole, vetranal(tm), analytical standard
HMS3655I09
clotrimaderm cream
otomax
gyne-lotrimin3 combination pack
gyne-lotrimin3
clotrimazole, pharmaceutical secondary standard; certified reference material
clotrimazole for peak identification, european pharmacopoeia (ep) reference standard
SR-01000075771-1
SR-01000075771-8
SR-01000075771-6
SBI-0050303.P004
MRF-0000070
HMS3712F16
clotrimazole, british pharmacopoeia (bp) reference standard
SW196431-5
Q413546
clotrimazole (canesten)
clotrimazole,(s)
117829-71-7
clotrimazole 100 microg/ml in acetonitrile
AS-13816
BCP02150
BRD-K15916496-001-14-7
SB17418
SDCCGSBI-0050303.P005
NCGC00015251-27
1-(o-chlorotrityl)imidazole;1-(o-chloro-alpha,alpha-diphenylbenzyl)imidazole
NCGC00015251-12
clotrimazole for peak identification
EN300-7409200
SY051361
first aid research antifungal cream 1oz
equate jock itch
first aid research antifungal .5oz
good neighbor pharmacyclotrimazole
lmnoop tinea treatment
cvs clotrimazolemaximum strength
meijerclotrimazole 3
ringworm treatment
1med clotrimazole 1% antifungal cream
a01ab18
terrasil jockitch treatment maximum strength
our familyathletes foot
hua tuo xian gao
clotrimazolejock itch
fungicure manicure pedicure anti fungal
g01af02
forticept antifungal cooling
clotrimazol dual
major clotrimazole
publixathletic foot
dermatinantifungal
fungicureintensive
clotrimazole (ep impurity)
dynarex antifungal
signature carejock itch
rugby clotrimazole antifungal cream
jock itch cream with clotrimazole
terrasil rapid-clear anti-fungal
zapotol clotrimazole
clotrimazole 1%athletes foot
oheal manuka honey eczema cream
votriza-al
fastrin anti-fungal skin care
fungazoil advanced
rite aidantifungal ringworm
fungistat max
quality choice clotrimazole
clotrimazole (mart.)
simply vital antifungal cream
ishancare ringworm treatment
jock itchantifungal
lmnoop jock itch cream
fortinia
pedesilmaximum strength
clotrimazole topical solution usp, 1%
occulusskin hydrating topical foam clo-1 antifungal foam
occulusskin hydrating topical foam clo-1
drs. clotrimazole
perfectheal antifungal
athlete foot cream with clotrimazole
winco foods antifungal
athletes foot antifungalantifungal
aardora anti-fungalmaximum strength
aspiera anti-fungal
topcareantifungal
terrasil tinea treatment
clotrimazole transdermal liquid
femmesil
ringworm
clotrima top
clotrimazole 1% topical antifungal cream
good sense athletes foot
krogerjock itch
walgreensjock itch
d01ac01
terrasil athletes foot antifungal treatment max
jock-eze
good neighbor pharmacyclotrimazole 3
anti-fungal cream
up and up athletes foot
clotrimazole topical
sunmark clotrimazole
clotrimazole (usp-rs)
meijer clotrimazole antifungal
rugby antifungal clotrimazole
clotrimazole 1%
akin anti-fungal
hebantifungal
terrasil jock itch treatment maximum strength
clotrimazole cream 1%
fortinia of
pro-ex
clot
terrasilmed antifungal
careall clotrimazole
hua tuo xian gao antifungal
lucky supersoftathletes foot
terrasil anti-fungal treatmentmax
footlogix intensive carediabetic formula
fungicure manicure pedicure liquid gel
shopko athletes foot
clotrimazole (usp impurity)
lakesia
clotrimazole (usan:usp:inn:ban:jan)
goodsense athletes foot
astonea clotrimazole 1%athletes foot
sunmarkclotrimazole 3
tm-clotrimazole
cvs pharmacyclotrimazole 3
terrasil tinea treatment maximum strength
soundbody clotrimazole antifungal
canestenv
quality choice athletes foot
clotrimazolo
fungicure liquid gel
shoprite antifungal
aptrimazole1.0% antifungal cream
pedesil
footlogix
clotrimazole (ep monograph)
terrasil jock-itch treatment
astonea clotrimazole 1%
athlete s foot
walgreens clotrimazole antifungal
best choiceclotrimazole
micotrin ac
ringworm cream
silkaringworm
manuka honey eczema cream
family wellness clotrimazole
cvsantifungal ringworm
healthy accents antifungal
krogerathletes foot
clotrimazol (inn-spanish)
cura hongoantifungal
mycozyl ac
oheal ringworm cream
clotrimazolum (inn-latin)
terrasil ringworm treatment
1-((2-chlorophenyl)(diphenyl)methyl)-1h-imidazole
athlete s footafac
forticept antifungal foot gel
botanimedix tinearx antifungal drying emulsion
western familyathletes foot
pro-exanti fungal
clotrimazole antifungal
cvs clotrimazole
terrasil tinea treatmentmax
clotrimazole 1.0%
good sense athletes footantifungal
topcare athletes foot
cura hongo
blossom pharmaceuticals antifungal
terrasil antifungal cream maximum strength
jock itchclotrimazole antifungal
meijer athletes foot cream af
terrasil jock-itch treatmentmax
veltrim 1% dermatologic cream
clotrimazoleathletes foot
ishancare athletes foot cream
walgreens clotrimazole
terrasil anti-fungal treatment
exchange select atheletes foot
atopalm clotrimazole antifungal
up and up jock itch relief
lmnoop athletes foot cream
smooth gator fungus eliminator
forticept antifungal foot cream
careoneclotrimazole
rexall athletes foot
meijerathletes foot
alevazol
budpak antifungal clotrimazole
terrasil foot and nail anti-fungalmaximum strength
ishancare jock itch treatment
terrasil ringworm treatmentmax
upandup
rexall jock itch
terrasil foot and nail anti-fungal
thera plus antifungal clotrimazole
mycelex troche
clotrimazole (usp monograph)
dr sheffield athletes foot
coltrimazole
clotrimazole 1% antifungal cream
foot care clotrimazole
walgreensclotrimazole 3
cvshealth antifungal
topcareclotrimazole 3
lmnoop serious antifungal cream
au kah chuen antifungal
leader athletes foot clotrimazole
clotrimazoil antifungal
cvs pharmacyitch relief antifungal
upandupclotrimazole
ishancare anti-fungal treatment
leader clotrimazole anti-fungal

Research Excerpts

Overview

Clotrimazole (CLO) is an imidazole fungicide used in human and veterinary medicine for treating fungal infection. It is a non-prescription and broad-spectrum antifungal drug sold under brand names such as Canesten® and Lotrimin®.

ExcerptReferenceRelevance
"Clotrimazole (CMZ) is a classical antifungal drug for studying crystallization. "( Discovery of a new polymorph of clotrimazole through melt crystallization: Understanding nucleation and growth kinetics.
Cai, T; Chen, Z; Liu, M; Peng, X; Xu, M; Yang, Q; Zeng, Z; Zhang, J, 2023
)
2.64
"Clotrimazole (CLO) is an imidazole fungicide used in human and veterinary medicine for treating fungal infection. "( Morphological, haematological and biochemical changes in African catfish Clarias gariepinus (Burchell 1822) juveniles exposed to clotrimazole.
Aguzie, IO; Andong, FA; Melefa, TD; Mgbenka, BO; Nwakor, U; Nwani, CD, 2020
)
2.21
"Clotrimazole (CLO) is a nonbiodegradable persistent azole compound, with broad-spectrum antifungal activity for which virtually no toxicological data are available, especially towards aquatic plants."( Ecotoxicological effects of the azole antifungal agent clotrimazole on the macrophyte species Lemna minor and Lemna gibba.
Alkimin, GD; Nunes, B; Santos, J; Soares, AMVM, 2020
)
1.53
"Clotrimazole is a non-prescription and broad-spectrum antifungal drug sold under brand names such as Canesten® and Lotrimin®. "( Human-relevant concentrations of the antifungal drug clotrimazole disrupt maternal and fetal steroid hormone profiles in rats.
Boberg, J; Christiansen, S; Draskau, MK; Pedersen, M; Rosenmai, AK; Scholze, M; Svingen, T, 2021
)
2.31
"Clotrimazole is an antifungal medication commonly used in the treatment of fungal infections. "( Yeast caspase-dependent apoptosis in Saccharomyces cerevisiae BY4742 induced by antifungal and potential antitumor agent clotrimazole.
Kavakçıoğlu, B; Tarhan, L, 2018
)
2.13
"Clotrimazole is a common choice for the treatment of vulvovaginal infections, but its low solubility and some side effects pose a challenge to its application. "( Clotrimazole-loaded Eudragit® RS100 nanocapsules: preparation, characterization and in vitro evaluation of antifungal activity against Candida species.
Adams, AI; Alves, SH; Cruz, L; Denardi, LB; Ferreira, LM; Lorenzoni, A; Mattiazzi, J; Santos, SS; Schaffazick, SR, 2013
)
3.28
"Clotrimazole (CTZ) is a persistent imidazole antifungal agent which is frequently detected in the aquatic environment and predicted to bio-concentrate in fish. "( Bioavailability of the imidazole antifungal agent clotrimazole and its effects on key biotransformation genes in the common carp (Cyprinus carpio).
Ball, JS; Corcoran, J; Cumming, RI; Lange, A; Owen, SF; Tyler, CR; Winter, MJ, 2014
)
2.1
"Clotrimazole is a broad-spectrum antimycotic drug mainly used for the treatment of Candida albicans and other fungal infections. "( Clotrimazole as a pharmaceutical: past, present and future.
Crowley, PD; Gallagher, HC, 2014
)
3.29
"Clotrimazole is an antifungal imidazole derivative showing anti- neoplastic effect in some tumors, but its anticancer potential is still unclear in oral squamous cell carcinoma (OSCC). "( The in vitro and in vivo antitumor effects of clotrimazole on oral squamous cell carcinoma.
Chen, X; Cheng, B; Hong, Y; Jia, L; Kuang, Z; Leung, WK; Wang, J; Wu, T; Xia, J, 2014
)
2.1
"Clotrimazole (CLT) is an antifungal azole derivative with promising anticancer effects due to inhibiting the activity of glycolytic enzymes."( Combination of imatinib and clotrimazole enhances cell growth inhibition in T47D breast cancer cells.
Fahim, SA; Motawi, TM; Sadik, NA; Shouman, SA, 2015
)
1.43
"Clotrimazole (CT) is a poorly soluble antifungal drug that is most commonly employed as a topical treatment in the management of vaginal candidiasis. "( Clotrimazole-cyclodextrin based approach for the management and treatment of Candidiasis - A formulation and chemistry-based evaluation.
Doerksen, RJ; Elokely, KM; Khan, NS; Liu, H; Mohammed, NN; Pandey, P; Repka, MA, 2016
)
3.32
"Clotrimazole (CTZ) is a broad spectrum antimycotic agent known to be very effective locally for the treatment of fungal skin infections. "( Effect of chitosan coating on microemulsion for effective dermal clotrimazole delivery.
Kesavan, K; Kumari, B, 2017
)
2.14
"Clotrimazole is a pharmaceutical used for treatment of fungal infections. "( Clotrimazole exposure modulates aromatase activity in gonads and brain during gonadal differentiation in Xenopus tropicalis frogs.
Berg, C; Eriksson, H; Fick, J; Gyllenhammar, I; Lindberg, RH; Söderqvist, A, 2009
)
3.24
"Clotrimazole (CLT) is an antifungal and antimalarial agent also effective as a Gardos channel inhibitor. "( Clotrimazole enhances lysis of human erythrocytes induced by t-BHP.
Ataullakhanov, FI; Lisovskaya, IL; Shcherbachenko, IM; Volkova, RI, 2009
)
3.24
"Clotrimazole (CTZ) is a potent antimycotic drug that also has a free radical scavenger activity."( Anti-apoptotic pro-survival effect of clotrimazole in a normothermic ischemia reperfusion injury animal model.
de Sousa, G; Gugenheim, J; Iannelli, A; Rahmani, R; Saint-Paul, MC; Zucchini, N, 2011
)
1.36
"Clotrimazole is a broad-spectrum antimycotic drug used for the treatment of dermatological and gynecological infections; it is incompletely broken down during sewage treatment and could potentially reach agricultural land through the application of municipal biosolids or wastewater. "( Fate of the antifungal drug clotrimazole in agricultural soil.
Al-Rajab, AJ; Chapman, R; Lapen, DR; Sabourin, L; Topp, E, 2011
)
2.11
"Clotrimazole (CLO) is a local imidazolic antifungal agent. "( Poly(amidoamine) dendrimers increase antifungal activity of clotrimazole.
Sacha, PT; Sosnowska, K; Tryniszewska, E; Wieczorek, P; Winnicka, K, 2011
)
2.05
"Clotrimazole is an azole derivative with promising anti-cancer effects. "( Clotrimazole preferentially inhibits human breast cancer cell proliferation, viability and glycolysis.
de Souza, ML; Furtado, CM; Marcondes, MC; Sola-Penna, M; Zancan, P, 2012
)
3.26
"Clotrimazole is a pharmaceutical fungicide known to inhibit several cytochrome P450 enzyme activities, including several steroidogenic enzymes. "( A critical role of follicle-stimulating hormone (Fsh) in mediating the effect of clotrimazole on testicular steroidogenesis in adult zebrafish.
Baudiffier, D; Brion, F; Chadili, E; Creusot, N; Hinfray, N; Porcher, JM; Schulz, RW; Vosges, M, 2012
)
2.05
"Clotrimazole is an azole fungicide used as a human pharmaceutical that is known to inhibit cytochrome P450 (CYP) enzymatic activities, including several steroidogenic CYP. "( Effect of in vivo chronic exposure to clotrimazole on zebrafish testis function.
Baudiffier, D; Brion, F; Chadili, E; Creusot, N; Hinfray, N; Porcher, JM; Ravaud, C; Schulz, RW, 2013
)
2.1
"Clotrimazole is a safe and effective treatment."( The importance of diagnostic work-up in the management of candidal vulvovaginitis. A prospective study.
Ben-Haroush, A; Kaplan, B; Yogev, Y, 2004
)
1.04
"Clotrimazole is an anti-fungal azole derivative recently recognized as a calmodulin antagonist with promising anti-cancer effect."( Clotrimazole decreases human breast cancer cells viability through alterations in cytoskeleton-associated glycolytic enzymes.
Da Poian, AT; de Freitas, MS; Holandino, C; Marinho-Carvalho, MM; Meira, DD; Sola-Penna, M; Teixeira, CA; Veiga, VF, 2005
)
2.49
"Clotrimazole, which is an imidazole derivative antifungal agent, was widely used for the treatment of mycotic infections of the genitourinary tract. "( Preparation, in vitro and in vivo evaluation of liposomal/niosomal gel delivery systems for clotrimazole.
Chen, X; Gu, Z; Guo, Y; Ning, M; Pan, H, 2005
)
1.99
"Clotrimazole (CLT) is an antimycotic imidazole derivative that is known to inhibit cytochrome P-450, ergosterol biosynthesis and proliferation of cells in culture, and to interfere with cellular Ca(2+) homeostasis. "( Clotrimazole inhibits the Ca2+-ATPase (SERCA) by interfering with Ca2+ binding and favoring the E2 conformation.
Bartolommei, G; Guidelli, R; Hua, S; Inesi, G; Moncelli, MR; Tadini-Buoninsegni, F, 2006
)
3.22
"Clotrimazole is an antifungal azole derivative recently recognized as a calmodulin antagonist with promising anticancer effects. "( Clotrimazole inhibits and modulates heterologous association of the key glycolytic enzyme 6-phosphofructo-1-kinase.
Marcondes, MC; Marinho-Carvalho, MM; Rosas, AO; Sola-Penna, M; Zancan, P, 2007
)
3.23
"Clotrimazole is a wide spectrum local imidazolic antifungal agent used in several dermatological creams, having e.g. "( Rheological and in vitro release behaviour of clotrimazole-containing aqueous SLN dispersions and commercial creams.
Müller, RH; Souto, EB, 2007
)
2.04
"Clotrimazole (CLT) is a widely used drug for the topical treatment of yeast infections of skin, vagina, and mouth. "( Transient receptor potential channels in sensory neurons are targets of the antimycotic agent clotrimazole.
D'Hoedt, D; Donovan-Rodríguez, T; Karashima, Y; Meseguer, V; Nilius, B; Talavera, K; Viana, F; Voets, T, 2008
)
2.01
"Clotrimazole was found to be a tight binding inhibitor of CYP3A with a Ki of 250 pM."( Effect of inhibitor depletion on inhibitory potency: tight binding inhibition of CYP3A by clotrimazole.
Gibbs, MA; Howald, WN; Kunze, KL; Thummel, KE, 1999
)
1.25
"1. Clotrimazole (CLT) is an antimycotic agent with a potential role in the treatment of cancer. "( Clotrimazole inhibits the recombinant human cardiac L-type Ca2+ channel alpha 1C subunit.
Ball, SG; Fearon, IM; Peers, C, 2000
)
2.37
"Clotrimazole (CLT) is a drug known to interfere with cellular calcium homeostasis, which in turn is reported to intervene in cell proliferation and in the reactivity of small blood vessels. "( Clotrimazole inhibits smooth muscle cell proliferation and has a vasodilator effect on resistance arteries.
Costache, G; Florea, S; Popov, D; Raicu, M; Simionescu, M,
)
3.02
"Clotrimazole is an antimycotic imidazole derivative that interferes with cellular Ca(2+) homeostasis. "( The antifungal antibiotic clotrimazole alters calcium homeostasis of leukemic lymphoblasts and induces apoptosis.
Behm, FG; Campana, D; Coustan-Smith, E; Ito, C; Pui, CH; Raimondi, SC; Suzuki, T; Tecchio, C, 2002
)
2.06
"Clotrimazole is a new antifungal agent which is effective topically in dermatophytosis, cutaneous candidiasis, and tinea vesicolor. "( Topical clotrimazole in tinea pedis.
Graham, JL; Smith, EB; Ulrich, JA, 1977
)
2.13
"Clotrimazole is an antifungal agent that has been shown to have excellent in vitro activity against most strains of Acanthamoeba. "( Acanthamoeba keratitis. Potential role for topical clotrimazole in combination chemotherapy.
Adi, M; Driebe, WT; Epstein, RJ; Komadina, T; Stern, GA; Visvesvara, GS, 1988
)
1.97
"Oral clotrimazole is an effective agent for prophylaxis of oropharyngeal candidiasis in susceptible cancer patients."( Prophylaxis of oropharyngeal candidiasis with clotrimazole.
Alvarado, T; Bodey, GP; Fainstein, V; Yeo, E, 1985
)
0.98

Effects

Clotrimazole (CTM) has a doubtful future with respect to use in treatment of the systemic mycoses. The drug has the potential to be retained in the frontal sinus for several days and is distributed effectively in normal canine cadavers.

ExcerptReferenceRelevance
"Clotrimazole (CTM) has a doubtful future with respect to use in treatment of the systemic mycoses. "( Inhibition of potentially pathogenic yeastlike fungi by clotrimazole in combination with 5-fluorocytosine or amphotericin B.
Beggs, WH; Sarosi, GA; Steele, NM, 1976
)
1.94
"Clotrimazole has long been used to treat vulvovaginal candidiasis (VVC), yet the antibiotic resistance, adverse effects and recurrences still bring about a great challenge for the clinicians. "( Improved treatment of vulvovaginal candidiasis with Clotrimazole plus probiotic Lacidophilin Vaginal Capsules: A prospective, real-world study.
An, R; Li, H; Zeng, X; Zhang, Y, 2023
)
2.6
"Clotrimazole (CTZ) has been proposed as an antitumoral agent because of its properties that inhibit glycolytic enzymes and detach them from the cytoskeleton. "( Phosphatidylinositol-3-kinase as a putative target for anticancer action of clotrimazole.
Carvalho, RS; Furtado, CM; Marcondes, MC; Sola-Penna, M; Zancan, P, 2015
)
2.09
"Clotrimazole has been found to show relatively high resistance to ionising irradiation (greater than fluconazole) and probably will be suitable for radiation sterilisation but with doses lower than 25 kGy."( Influence of ionising irradiation on clotrimazole in the solid state.
Dettlaff, K; Marciniec, B; Naskrent, M, 2009
)
1.35
"Clotrimazole (CTZ) has been proposed as a potential anti-neoplastic agent, which inhibits glucose metabolism. "( Clotrimazole potentiates the inhibitory effects of ATP on the key glycolytic enzyme 6-phosphofructo-1-kinase.
Marcondes, MC; Sola-Penna, M; Zancan, P, 2010
)
3.25
"Clotrimazole has anticarcinogenic activity in several cell types. "( The effect of clotrimazole on energy substrate uptake and carcinogenesis in intestinal epithelial cells.
Araújo, JR; Gonçalves, P; Gregório, I; Martel, F, 2012
)
2.18
"Clotrimazole cream has the potential to be retained in the frontal sinus for several days and is distributed effectively in normal canine cadavers. "( Distribution and persistence of topical clotrimazole after sinus infusion in normal canine cadavers.
Demetriou, JL; Hayes, GM, 2012
)
2.09
"Clotrimazole (1%) has been formulated in a suppository using the thermo sensitive polymer P188 (70%) together with propylene glycol (30%)."( Inclusion complex effect on the bioavailability of clotrimazole from poloxamer-based solid suppository.
Balakrishnan, P; Cho, HJ; Choi, HG; Kim, DD; Song, CK; Yang, SG; Yong, CS, 2012
)
1.35
"Clotrimazole (1%) has been formulated in a vaginal gel using the thermosensitive polymer Pluronic F127 (20%) together with mucoadhesive polymers such as Carbopol 934 and hydroxypropylmethylcellulose (0.2% for both)."( Mucoadhesive, thermosensitive, prolonged-release vaginal gel for clotrimazole:beta-cyclodextrin complex.
Bilensoy, E; Hincal, AA; Rouf, MA; Sen, M; Vural, I, 2006
)
1.29
"Clotrimazole (CLT) has recently been shown to be a potent and specific inhibitor of the Ca(2+)-activated K+ channel and to thereby prevent K+ loss and cellular dehydration of sickled erythrocytes. "( HPLC measurement, blood distribution, and pharmacokinetics of oral clotrimazole, potentially useful antisickling agent.
Armsby, CC; Brugnara, C; Law, T; Mikati, M; Platt, O; Rifai, N; Sakamoto, M, 1995
)
1.97
"Clotrimazole troches have been a common treatment for thrush in patients with HIV infection for several years."( A comparison between fluconazole tablets and clotrimazole troches for the treatment of thrush in HIV infection.
Farinacci, GC; Fothergill, AW; Redding, SW; Rinaldi, MG; Smith, JA,
)
1.11
"Clotrimazole (CLT) has been shown to inhibit proliferation in normal and cancer cell lines."( Clotrimazole inhibits lung fibroblast proliferation in vitro: implications for use in the prevention and treatment of obliterative bronchiolitis after lung transplantation.
Cooper, JD; Mohanakumar, T; Naziruddin, B; Patterson, GA; Smith, MA; Zhang, W, 2000
)
2.47
"Clotrimazole has been shown to have potent anti-malarial activity in vitro, one possible mechanism being inhibition of oxidized glutathione (GSSG) export from the infected human red blood cells or from the parasite itself. "( Effects of clotrimazole on transport mediated by multidrug resistance associated protein 1 (MRP1) in human erythrocytes and tumour cells.
Barrand, MA; Hladky, SB; Klokouzas, A, 2001
)
2.14
"Clotrimazole (CTM) has a doubtful future with respect to use in treatment of the systemic mycoses. "( Inhibition of potentially pathogenic yeastlike fungi by clotrimazole in combination with 5-fluorocytosine or amphotericin B.
Beggs, WH; Sarosi, GA; Steele, NM, 1976
)
1.94
"Clotrimazole troches have been previously reported to be effective in the treatment of documented oral Candida infection."( Clotrimazole treatment for prevention of oral candidiasis in patients with acute leukemia undergoing chemotherapy. Results of a double-blind study.
Bottone, EJ; Brenden, R; Cuttner, J; Funaro, L; Troy, KM, 1986
)
2.44

Actions

Clotrimazole can increase insulin secretion at sub-maximal glucose concentrations. Action appears to be independent of membrane ion channel events.

ExcerptReferenceRelevance
"Clotrimazole may increase membrane permeation of Cd(2+)."( Clotrimazole, an antifungal drug possessing diverse actions, increases membrane permeation of cadmium in rat thymocytes.
Matsui, H; Morimoto, M; Oyama, K; Oyama, TB; Oyama, TM; Oyama, Y; Sakanashi, Y, 2007
)
2.5
"Clotrimazole can increase insulin secretion at sub-maximal glucose concentrations by an action which appears to be independent of membrane ion channel events."( Clotrimazole and efaroxan stimulate insulin secretion by different mechanisms in rat pancreatic islets.
Chan, SL; Morgan, NG; Pallett, AL, 1997
)
2.46

Treatment

Clotrimazole treatment resulted in worsening of anemia and hemolysis, with decreased red cell survival. Treatment also resulted in significant induction of epidermal 7-ethoxycoumarin-O-deethylase activity. Clotrimzole pretreatment of polymorphonuclear leucocytes led to a marked suppression of their ability to phagocytose and kill C.

ExcerptReferenceRelevance
"Clotrimazole cream treatment is more effective than tolnaftate for uncomplicated otomycosis. "( Efficacy of topical clotrimazole vs. topical tolnaftate in the treatment of otomycosis. A randomized controlled clinical trial.
Amaro-Flores, E; Castro-Urquizo, Á; Celis-Aguilar, E; Díaz-Pavón, G; Hernández-Castillo, N; Jimenez-Garcia, L; Muñoz Estrada, V,
)
1.9
"Clotrimazole treatment resulted in worsening of anemia and hemolysis, with decreased red cell survival and increased numbers of circulating hyperchromic spherocytes and microspherocytes."( Evidence for a protective role of the Gardos channel against hemolysis in murine spherocytosis.
Brugnara, C; De Franceschi, L; Fleming, MD; Gascard, P; Honczarenko, M; Mohandas, N; Peters, LL; Rivera, A, 2005
)
1.05
"Clotrimazole treatment caused a significant inhibition of intracranial tumor growth."( Inhibition of tumor growth and prolonged survival of rats with intracranial gliomas following administration of clotrimazole.
Caputy, AJ; Khalid, MH; Tokunaga, Y; Walters, E, 2005
)
1.26
"Clotrimazole treatment also resulted in significant induction of epidermal 7-ethoxycoumarin-O-deethylase activity."( Effect of topical application of clotrimazole to rats on epidermal and hepatic monooxygenase activities and cytochrome P-450.
Bickers, DR; Khan, WA; Kuhn, C; Merk, HF; Mukhtar, H, 1989
)
1.28
"Clotrimazole pretreatment of polymorphonuclear leucocytes led to a marked suppression of their ability to phagocytose and kill C."( Effects of azole antifungals in vitro on host/parasite interactions relevant to Candida infections.
Odds, FC; Webster, CE, 1988
)
1
"Clotrimazole treatment, in contrast to phenobarbital treatment, also caused a large induction of l-naphthol glucuronosyltransferase in females."( Induction of hepatic oxidative and conjugative drug metabolism in the hamster by N-substituted imidazoles.
Franklin, MR; Ritter, JK, 1987
)
0.99
"Treatment with clotrimazole 1% solution groups resulted in 88.23% resolution vs."( Efficacy of Clotrimazole 1% Solution Compared to Econazole Nitrate 1% + Triamcinolone Acetonide 0.1% Cream in Patient with Otomycosis.
Ahmed, MB; Ahmed, S; Alam, MM; Islam, MR; Khan, L; Mostafa, MG; Rahman, MA, 2021
)
1.34
"Treatment with clotrimazole resulted in 75% resolution vs 45% resolution with treatment with tolnaftate at one week of treatment (p=0.007)."( Efficacy of topical clotrimazole vs. topical tolnaftate in the treatment of otomycosis. A randomized controlled clinical trial.
Amaro-Flores, E; Castro-Urquizo, Á; Celis-Aguilar, E; Díaz-Pavón, G; Hernández-Castillo, N; Jimenez-Garcia, L; Muñoz Estrada, V,
)
0.79
"Treatment with clotrimazole significantly decreased malondialdehyde, glutathione-peroxidase, superoxide dismutase, and catalase levels in comparison with other groups (P = 0.008). "( Effects of clotrimazole on experimental spinal cord ischemia/reperfusion injury in rats.
Arslan, E; Baykal, S; Cansever, T; Cobanoglu, U; Usul, H, 2008
)
1.09
"Treatment with clotrimazole decreased MDA levels in rats with SCI with a statistically significant difference."( Effects of clotrimazole on experimental spinal cord injury.
Alver, A; Arslan, E; Baykal, S; Cakir, E; Peksoylu, B; Sayin, OC; Topbas, M; Usul, H, 2006
)
1.08
"Treatment with clotrimazole, 15% zinc oxide paste, and dimethicone resulted in eradication of the fungus and in complete healing of the lesions in eight weeks."( The isolation of Phoma eupyrena from a human lesion.
Bakerspigel, A; Lowe, D; Rostas, A, 1981
)
0.6
"When treated with clotrimazole at 37 degrees C, the cultures of germ tube cells lost colony-forming ability much more rapidly than those of yeast cells."( Germ tube-forming cells of Candida albicans are more susceptible to clotrimazole-induced killing than yeast cells.
Kamiyama, A; Nakayama, H; Niimi, M; Tokunaga, J; Tokunaga, M, 1985
)
0.83

Toxicity

Oxymetazoline nasal spray, mupirocin ointment, and clotrimazole cream are safe and effective as off-label medications for tympanostomy tube care in children.

ExcerptReferenceRelevance
"Human diploid fibroblasts cultured in Dulbecco's Modified Eagle's medium (DME) were exposed to different concentrations of 15 antibiotics to determine the limiting toxic concentration."( Toxicity of antibiotics on cultured human skin fibroblasts.
Byarugaba, W; Koske-Westphal, T; Passarge, E; Rüdiger, HW; Wöhler, W, 1975
)
0.25
" LD50 values after oral or intraperitoneal administration were greater than or equal to 1000 mg/kg in both mice and rats, which reveal a very low acute toxicity of flutrimazole."( Toxicity studies with flutrimazole.
Alumá, J; Casadesús, A; Forn, J; García Rafanell, J; Vericat, ML; Zapatero, J, 1992
)
0.28
" Toxic effects depended on substance, concentration and exposure."( Toxicity of antibiotics and antifungals on cultured human corneal cells: effect of mixing, exposure and concentration.
Berry, M; Easty, DL; Gurung, A, 1995
)
0.29
"A double null mouse line (2XENKO) lacking the xenobiotic receptors CAR (constitutive androstane receptor) (NR1I3) and PXR (pregnane X receptor) (NR1I2) was generated to study their functions in response to potentially toxic xenobiotic and endobiotic stimuli."( The constitutive androstane receptor and pregnane X receptor function coordinately to prevent bile acid-induced hepatotoxicity.
Evans, RM; Huang, W; Moore, DD; Qatanani, M; Zhang, J, 2004
)
0.32
" Thus, the poloxamer-based solid suppository system with clotrimazole/P 188/propylene glycol was an effective rectal dosage form for the treatment of tumors with alleviated adverse effects."( Enhanced anti-tumor activity and alleviated hepatotoxicity of clotrimazole-loaded suppository using poloxamer-propylene glycol gel.
Choi, HG; Kim, JA; Lee, MH; Oh, YK; Paek, SH; Woo, JS; Xuan, JJ; Yong, CS, 2006
)
0.82
" Several studies suggest TNT becomes more toxic as it degrades while others suggest TNT becomes less toxic."( The role of metabolism in the toxicity of 2,4,6-trinitrotoluene and its degradation products to the aquatic amphipod Hyalella azteca.
Sims, JG; Steevens, JA, 2008
)
0.35
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" Activation of PXR has the potential to initiate adverse effects, causing drug-drug interactions, and perturbing normal physiological functions."( QSAR model for human pregnane X receptor (PXR) binding: screening of environmental chemicals and correlations with genotoxicity, endocrine disruption and teratogenicity.
Dybdahl, M; Jónsdóttir, SÓ; Niemelä, JR; Nikolov, NG; Wedebye, EB, 2012
)
0.38
" The adverse events of clotrimazole were mainly local."( The efficacy and safety of clotrimazole vaginal tablet vs. oral fluconazole in treating severe vulvovaginal candidiasis.
Fan, S; Guo, X; Li, T; Liang, Y; Liu, X; Zhou, X; Zhu, Y, 2016
)
1.04
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016
)
0.43
" The incidence of adverse events was similar in both groups, and none had related AEs and withdrawals due to an AE."( Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis.
Aguado Mulgado, GE; Cepero Vega, PP; de la Paz Cota, BR; Fiscal Chauteco, E; Lamadrid Bautista, E; Matus Navarrete, JJ; Narváez Huerta, JJ,
)
0.37
"Eberconazole 1% otic solution is an efficacious and safe option to treat otomycosis-affected patients in the general practice."( Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis.
Aguado Mulgado, GE; Cepero Vega, PP; de la Paz Cota, BR; Fiscal Chauteco, E; Lamadrid Bautista, E; Matus Navarrete, JJ; Narváez Huerta, JJ,
)
0.37
" In view of the above, it is concluded that the drug studied caused adverse effects in terms of oxidative stress, at an ecological relevant levels, showing that the presence of clotrimazol in the wild is not innocuous."( Biomarker-based assessment of the toxicity of the antifungal clotrimazol to the microcrustacean Daphnia magna.
Nunes, B; Soares, AMVM; Vieira, M, 2019
)
0.51
"Oxymetazoline nasal spray, mupirocin ointment, and clotrimazole cream are safe and effective as off-label medications for tympanostomy tube care in children."( Oxymetazoline, Mupirocin, Clotrimazole-Safe, Effective, Off-Label Agents for Tympanostomy Tube Care.
Isaacson, G, 2020
)
1.11
"This study investigated the mechanism of action of clotrimazole (CTZ) and its adverse effects in a model of endometriosis."( Clotrimazole is effective, safe and tolerable for the treatment of endometriosis and functions by downregulating inducible nitric oxide synthase and modulating oxidative stress biomarkers.
Alessandra-Perini, J; Coelho, WS; de Campos Gomes Diniz, L; Machado, DE; Perini, JA; Saggioro, EM; Sales Junior, SF; Zancan, P, 2023
)
2.6

Pharmacokinetics

Microsomal sulfonase activity can be abolished by in-vitro interaction with clotrimazole. The pharmacokinetic profile of tacrolimus was examined before and after the discontinuation of clotrimzole.

ExcerptReferenceRelevance
" Flutrimazole presented a biological half-life (t1/2) of 14."( Pharmacokinetic study of [14C]flutrimazole after oral and intravenous administration in dogs. Comparison with clotrimazole.
Basi, N; Conte, L; Forn, J; Mis, R; Ramis, J; Vilageliu, J, 1992
)
0.5
" In order to investigate the fate of clotrimazole reaching systemic circulation, pharmacokinetic studies following oral and intravenous administration were carried out."( Pharmacokinetic fundamentals of vaginal treatment with clotrimazole.
Krause, U; Patzschke, K; Ritter, W; Stettendorf, S, 1982
)
0.78
" Microsomal sulfonase activity can be abolished by in-vitro interaction with clotrimazole and pharmacokinetic studies confirm this interaction."( Effect of clotrimazole on microsomal metabolism and pharmacokinetics of albendazole.
Alvarez, AI; García, JL; Merino, G; Molina, AJ; Prieto, JG; Pulido, MM, 2003
)
0.95
" Plasma concentrations for midazolam and its metabolite 1-hydroxymidazolam were measured and fitted to a noncompartmental model to estimate the pharmacokinetic parameters."( Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam.
Baum, CL; Camp, JR; Chan, LN; Jeong, HY; Molokie, RE; Shord, SS; Vasquez, EM; Xie, H, 2010
)
0.71
" The pharmacokinetic profile of tacrolimus was examined before and after the discontinuation of clotrimazole and in patients with different CYP3A5 genotypes."( Effects of clotrimazole on tacrolimus pharmacokinetics in patients with heart transplants with different CYP3A5 genotypes.
Hosomi, K; Kawase, A; Matsuda, S; Oita, A; Takada, M; Terada, Y; Terakawa, N; Uno, T; Wada, K; Yokoyama, S, 2019
)
1.12

Compound-Compound Interactions

Clotrimazole or heat-treated amphotericin B in fixed ratio combination with artemisinin for antimalarial properties. N strain associated with entomopathogenic nematode Rhabditis (Oscheius) was investigated using the macrodilution method.

ExcerptReferenceRelevance
"The clinically important polyene antibiotic amphotericin B, in combination with two antifungal imidazole compounds, clotrimazole and miconazole, was studied in vitro."( In vitro studies of amphotericin B in combination with the imidazole antifungal compounds clotrimazole and miconazole.
Beezer, AE; Cosgrove, RF; Miles, RJ, 1978
)
0.69
" Weak inhibitory concentrations of CTM were tested in combination with levels of 5-FC or AMB that alone produced transient antifungal effects followed by rapid recovery of proliferative capacity."( Inhibition of potentially pathogenic yeastlike fungi by clotrimazole in combination with 5-fluorocytosine or amphotericin B.
Beggs, WH; Sarosi, GA; Steele, NM, 1976
)
0.5
"The effects of lactoferrin (LF), an antimicrobial protein secreted in body fluids, and its peptides in combination with azole antifungal agents were investigated by the micro-broth-dilution method in a study of Candida albicans."( Cooperative anti-Candida effects of lactoferrin or its peptides in combination with azole antifungal agents.
Abe, S; Kawase, K; Okutomi, T; Tansho, S; Wakabayashi, H; Yamaguchi, H, 1996
)
0.29
" Patients receiving other agents known to interact with cytochrome P450 were excluded from the study."( Clotrimazole increases tacrolimus blood levels: a drug interaction in kidney transplant patients.
Benedetti, E; Pollak, R; Vasquez, E, 2001
)
1.75
" We repurposed clotrimazole or heat-treated amphotericin B in fixed ratio combination with artemisinin for antimalarial properties."( In vitro activity of artemisinin in combination with clotrimazole or heat-treated amphotericin B against Plasmodium falciparum.
Bhasin, VK; Bhattacharya, A; Mishra, LC, 2008
)
0.95
" These mice intravaginally received essential oils such as geranium and tea tree singly or in combination with vaginal washing."( Protective activity of geranium oil and its component, geraniol, in combination with vaginal washing against vaginal candidiasis in mice.
Abe, S; Hisajima, T; Inouye, S; Ishibashi, H; Maruyama, N; Takizawa, T; Yamaguchi, H, 2008
)
0.35
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38
"The results of this study showed that alkaloid compounds in combination with antifungal references (Nystatin and Clotrimazole) exhibited antimicrobial effects against candida strains tested."( Free radical scavenging capacity, anticandicidal effect of bioactive compounds from Sida cordifolia L., in combination with nystatin and clotrimazole and their effect on specific immune response in rats.
Konaté, K; Lepengué, AN; M'Batchi, B; Ouédraogo, M; Sawadogo, LL; Souza, A, 2012
)
0.79
" N strain associated with entomopathogenic nematode Rhabditis (Oscheius) in combination with amphotericin B and clotrimazole was investigated using the macrodilution method."( In vitro synergistic activity of diketopiperazines alone and in combination with amphotericin B or clotrimazole against Candida albicans.
Kumar, SN; Mohandas, C; Nambisan, B; Sundaresan, A, 2013
)
0.82
"BACKGROUND This study aimed to explore the therapeutic effect of external application of ligustrazine combined with holistic nursing on pressure sores, as well as the underlying mechanism."( Therapeutic Effect of External Application of Ligustrazine Combined with Holistic Nursing on Pressure Sores.
Gong, F; Han, L; Niu, J, 2016
)
0.43
" These results also validate that CLZ has significant anticancer activity both alone and in combination and support the strategy of drug repurposing coupled to drug combination for prostate cancer therapy."( Synergistic Interaction of CPP2 Coupled with Thiazole Derivates Combined with Clotrimazole and Antineoplastic Drugs in Prostate and Colon Cancer Cell Lines.
Duarte, D; Vale, N, 2021
)
0.85

Bioavailability

The oral bioavailability and hepatic toxicity of clotrimazole were compared with its beta-cyclodextrin inclusion form which was prepared by the spray-drying method. Overall, results revealed the capability of ufosomes in improving the skin bioavailability of clot rimazole.

ExcerptReferenceRelevance
" These results, together with the very slight systemic absorption rate of flutrimazole from the 1% topical drug form, clearly show that no restrictions should be taken in the use of the cream for reasons of systemic toxicity or dermal tolerance."( Toxicity studies with flutrimazole.
Alumá, J; Casadesús, A; Forn, J; García Rafanell, J; Vericat, ML; Zapatero, J, 1992
)
0.28
"P-glycoprotein (P-gp) is an efflux transporter involved in limiting the oral bioavailability and tissue penetration of a variety of structurally divergent molecules."( Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein.
Dantzig, AH; Ekins, S; Kim, RB; Lan, LB; Leake, BF; Schuetz, EG; Schuetz, JD; Shepard, RL; Wikel, JH; Winter, MA; Wrighton, SA; Yasuda, K, 2002
)
0.31
"The present study was designed to improve the oral bioavailability of two clinically important antifungal drugs-clotrimazole and econazole."( Nano-encapsulation of azole antifungals: potential applications to improve oral drug delivery.
Ahmad, Z; Khuller, GK; Pandey, R; Sharma, S, 2005
)
0.54
"The purpose of this pharmacokinetic study was to determine whether the relative oral bioavailability of tacrolimus is increased with concomitant administration of clotrimazole."( Concomitant clotrimazole therapy more than doubles the relative oral bioavailability of tacrolimus.
Benedetti, E; Shin, GP; Sifontis, N; Vasquez, EM, 2005
)
0.9
" The aim was to increase its dermal bioavailability and to control drug release, thereby potentially reducing its side effects."( Investigation of the factors influencing the incorporation of clotrimazole in SLN and NLC prepared by hot high-pressure homogenization.
Müller, RH; Souto, EB, 2006
)
0.57
" To improve the oral bioavailability of clotrimazole, the inclusion compound of clotrimazole with beta-cyclodextrin was prepared by spray-drying method and characterized by phase solubility, differential scanning calorimetry and dissolution."( Enhanced bioavailability of poorly water-soluble clotrimazole by inclusion with beta-cyclodextrin.
Choi, HG; Kim, JA; Piao, MG; Prabagar, B; Rhee, JD; Woo, JS; Yong, CS; Yoo, BK, 2007
)
0.86
" The oral bioavailability and hepatic toxicity of clotrimazole were compared with its beta-cyclodextrin inclusion form which was prepared by the spray-drying method."( The effect of beta-cyclodextrin complexation on the bioavailability and hepatotoxicity of clotrimazole.
Choi, HG; Kim, JA; Li, DX; Lyoo, WS; Park, BC; Prabagar, B; Rhee, JD; Woo, JS; Yi, SJ; Yong, CS; Yoo, BK, 2007
)
0.81
" The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity."( Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y, 2011
)
0.37
" Results suggested that the prepared SNEDDS formulations produced acceptable properties in terms of immediate drug release and could increase the bioavailability of CT."( Preparation and in vitro evaluation of self-nanoemulsifying drug delivery systems (SNEDDS) containing clotrimazole.
Ammar, AA; Elosaily, GH; Kassem, AA; Marzouk, MA, 2010
)
0.58
"To study the effect of β-cyclodextrin (βCD) inclusion complex on the bioavailability of clotrimazole from poloxamer-based suppository, formulations composed of P 188, propylene glycol and different molar ratio of clotrimazole-βCD inclusion complex were prepared."( Inclusion complex effect on the bioavailability of clotrimazole from poloxamer-based solid suppository.
Balakrishnan, P; Cho, HJ; Choi, HG; Kim, DD; Song, CK; Yang, SG; Yong, CS, 2012
)
0.85
"An early prediction of solubility in physiological media (PBS, SGF and SIF) is useful to predict qualitatively bioavailability and absorption of lead candidates."( Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
Bharate, SS; Vishwakarma, RA, 2015
)
0.42
"Self-micro emulsifying drug delivery system (SMEDDS) is one of the methods to improve solubility and bioavailability of poorly soluble drug(s)."( Prediction of the solubility in lipidic solvent mixture: Investigation of the modeling approach and thermodynamic analysis of solubility.
Patel, S; Patel, SV, 2015
)
0.42
"Results revealed the capacity of ME and MBG in improving skin bioavailability of CTZ while reducing the risk of systemic side effects."( Antidermatophytic Activity and Skin Retention of Clotrimazole Microemulsion and Microemulsion-Based Gel in Comparison to Conventional Cream.
Amnuaikit, T; Boonme, P; Kaewbanjong, J; Souto, EB, 2018
)
0.74
" Overall, results revealed the capability of ufosomes in improving the skin bioavailability of clotrimazole."( Clotrimazole Loaded Ufosomes for Topical Delivery: Formulation Development and In-Vitro Studies.
Bolla, PK; Deaguero, I; Meraz, CA; Renukuntla, J; Rodriguez, VA; Singh, M; Yellepeddi, VK, 2019
)
2.18
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Clotrimazole-resistant clones showed 5- to 10-fold higher resistance than did W5. zeamatin enhanced the efficacy of either of the other two drugs when they were given in combination.

ExcerptRelevanceReference
" Data on biotransformation, kinetics and dosage are reported."( [Pulmonary mycoses; laboratory diagnosis, antimycotic therapy].
Bartmann, K, 1977
)
0.26
" Blood levels 3-times as great as those after the same dosage in tablet form were produced when clotrimazole was given in oil solution and even with 250 mg, effective blood levels were achieved and maintained."( Basic experiments with clotrimazole administered orally.
iida, H; Miura, Y; Seo, M, 1977
)
0.79
" We concluded that in this type of experiment the higher dosed combination showed no advantage contrary to a previous report, but in agreement with another."( Bactericidal or bacteristatic effects of two sulphonamide plus trimethoprim preparations in human urine.
Broughall, JM; Bywater, MJ; Holt, HA; Reeves, DS, 1979
)
0.26
" There have been no published comparisons with nystatin vaginal cream or foaming vaginal tablets - nystatin dosage forms preferred by some clinicians."( Clotrimazole: a review of its antifungal activity and therapeutic efficacy.
Brogden, RN; Pinder, RM; Sawyer, PR; Speight, TM, 1975
)
1.7
" The proposed HPLC methods are applied to the analysis of commercial dosage forms (creams) with solid-phase extraction (SPE) procedure, using a diol sorbent, being found to be a convenient technique for the sample preparation giving quantitative drug recovery."( HPLC analysis of imidazole antimycotic drugs in pharmaceutical formulations.
Andrisano, V; Cavrini, V; Di Pietra, AM; Gatti, R,
)
0.13
" Maximum plasma levels of radioactivity were achieved 24 hours after dosing and ranged from 19 to 44 ng/mL and fell to background levels after 96 to 120 hours."( Three-day treatment with butoconazole nitrate for vulvovaginal candidiasis.
Adamson, DG; Brown, D; Cibley, L; Droegemueller, W; Fleury, F; Henzl, MR; LePage, ME, 1984
)
0.27
" Clotrimazole-resistant clones, WCT-1 and WCT-2, which were spontaneously isolated from the adenovirus 12-transformed cell line W5, showed 5- to 10-fold higher resistance than did W5; the dose-response curves of clotrimazole-resistant clones were similar to those of the untransformed 3Y1 cells."( Imidazole-resistant phenotype and virus transformation in cultured rat cells.
Akiyama, S; Ikezaki, K; Kimura, G; Kuwano, M; Miyazaki, C, 1984
)
1.18
"The introduction of clotrimazole into the therapy of vaginal Candida and Torulopsis infections has significantly shortened the previously customary duration of treatment and reduced the frequency of dosage of the active ingredient."( On the action kinetics of clotrimazole.
Plempel, M, 1982
)
0.89
" The topical agents are available in assorted dosage forms with varying degrees of efficacy and patient acceptability."( Treatment of oropharyngeal candidiasis in HIV-positive patients.
Greenspan, D, 1994
)
0.29
" Topical therapy seems appropriate whenever systemic high dosage schedule cannot be adopted in order to overcome resistance."( In vitro activity of metronidazole alone and in combination with clotrimazole against clinical isolates of Trichomonas vaginalis.
Boldrini, E; Campora, U; Debbia, EA; Massaro, S; Schito, GC, 1996
)
0.53
" An amount of the sample dosage form containing 10 mg of flutrimazole was applied to a Franz type cell."( Influence of formulation on the in vitro transdermal penetration of flutrimazole.
Calpena, A; Conte, L; Domenech, J; Escribano, E; Forn, J; Lauroba, J; Ramis, J; Segado, X, 1997
)
0.3
" Fluconazole in a weekly dosing schedule should be considered in the first-line treatment of tinea gladiatorum."( Comparison of topical and oral treatments for tinea gladiatorum.
Berger, MS; Kohl, TD; Martin, DC, 1999
)
0.3
"The complete separation of a composite mixture that consisted of Betamethasone Dipropionate (BMD), Clotrimazole and their derivatives in a pharmaceutical dosage form was achieved within 15 min using sodium dodecyl sulfate (SDS) micellar electrokinetic chromatography (MEKC)."( Comparison between micellar electrokinetic chromatography and HPLC for the determination of Betamethasone Dipropionate, Clotrimazole and their related substances.
Lin, M; Wu, N, 1999
)
0.73
" The avoidance of multiple-per-day dosing would appear to favor fluconazole."( A comparison between fluconazole tablets and clotrimazole troches for the treatment of thrush in HIV infection.
Farinacci, GC; Fothergill, AW; Redding, SW; Rinaldi, MG; Smith, JA,
)
0.39
" A newly recognized phenomenon known as the post-antifungal effect implies that antifungals, even at sub-therapeutic concentrations, may suppress the virulent attributes of yeasts, especially intra-orally where topical drug levels fluctuate dramatically during dosing intervals."( Antimycotic agents in oral candidosis: an overview: 2. Treatment of oral candidosis.
Ellepola, AN; Samaranayake, LP, 2000
)
0.31
" In this study, a new dosage form was developed by including bioadhesive polymers (polycarbophyl, hydroxypropylmethylcellulose, and hyaluronic sodium salt) into pessaries made of semisynthetic solid triglycerides."( Development of a mucoadhesive dosage form for vaginal administration.
Ceschel, GC; Lombardi Borgia, S; Maffei, P; Ronchi, C; Rossi, S, 2001
)
0.31
" These results indicate that CT-containing vaginal MTG might be further developed for safe, convenient, and effective treatment of vaginal candidasis with reduced dosing interval."( Prolonged antifungal effects of clotrimazole-containing mucoadhesive thermosensitive gels on vaginitis.
Chang, JY; Jang, DD; Kim, CK; Kim, EJ; Kong, HS; Nam, KT; Oh, YK, 2002
)
0.6
"Whereas alone, zeamatin was ineffective, nikkomycin Z was effective only when dosed multiple times per day, and clotrimazole efficacy was variable when administered in experimental vehicles (unlike the complex and undefined commercial preparation), zeamatin enhanced the efficacy of either of the other two drugs when they were given in combination."( Zeamatin, clotrimazole and nikkomycin Z in therapy of a Candida vaginitis model.
Calderon, L; Clemons, KV; Martinez, M; Selitrennikoff, CP; Stevens, DA; Wilson, SJ, 2002
)
0.93
" Liver mRNA was isolated from rats dosed with six different chemicals, dexamethasone, troleandomycin, miconazole, clotrimazole, and methylclofanapate, which are all known to induce different cytochrome P450 genes, and isoniazid, which does not cause histopathological changes."( An evaluation of a low-density DNA microarray using cytochrome P450 inducers.
Bertholet, V; Bonnert, TP; de Longueville, F; Dos Santos-Mendes, S; Evrard, S; Jack, A; Meneses-Lorente, G; Pike, A; Remacle, J; Scott-Stevens, P; Sohal, B, 2003
)
0.53
"To objectively evaluate the performance of new vaginal dosage forms, it is important to determine their time of residence and their distribution."( Retention and distribution of two 99mTc-DTPA labelled vaginal dosage forms.
Chatterton, BE; Hunt, B; Kovacs, JC; Penglis, S; Presnell, B, 2004
)
0.32
"Radioactive tracer methods are useful in assessing and comparing vaginal dosage forms."( Retention and distribution of two 99mTc-DTPA labelled vaginal dosage forms.
Chatterton, BE; Hunt, B; Kovacs, JC; Penglis, S; Presnell, B, 2004
)
0.32
" Therefore, the dosage form might be further developed for safe, convenient, and effective treatment of vaginal candidasis with reduced dosing interval."( Preparation and evaluation of proliposomes containing clotrimazole.
Gu, ZW; Guo, YZ; Ning, MY; Pan, HZ; Yu, HM, 2005
)
0.58
" Thus, the poloxamer-based solid suppository system with clotrimazole/P 188/propylene glycol was an effective rectal dosage form for the treatment of tumors with alleviated adverse effects."( Enhanced anti-tumor activity and alleviated hepatotoxicity of clotrimazole-loaded suppository using poloxamer-propylene glycol gel.
Choi, HG; Kim, JA; Lee, MH; Oh, YK; Paek, SH; Woo, JS; Xuan, JJ; Yong, CS, 2006
)
0.82
" Each molecule was screened in at least seven concentrations, such that dose-response curves were obtained for all molecules in the library."( A high-throughput screen for aggregation-based inhibition in a large compound library.
Austin, CP; Babaoglu, K; Feng, BY; Inglese, J; Jadhav, A; Shoichet, BK; Simeonov, A, 2007
)
0.34
" Their combination induced very potent cytotoxic action on rat thymocytes with "bell-shape" dose-response relation."( Synergic cytotoxic action induced by simultaneous application of zinc and clotrimazole in rat thymocytes.
Ishida, S; Matsui, H; Morimoto, M; Nishimura, Y; Okano, Y; Oyama, Y; Sakanashi, Y, 2007
)
0.57
"Buccal bioadhesive films, releasing topical drugs in the oral cavity at a slow and predetermined rate, provide distinct advantages over traditional dosage forms."( Preparation and evaluation of buccal bioadhesive films containing clotrimazole.
Jain, S; Muthu, MS; Singh, S; Tilak, R; Tiwari, S, 2008
)
0.58
"Timely identification of the pathogen, with repeated culture and smear if necessary, as well as adequate dosage to prevent recurrence is highly recommended in order to preclude the need for therapeutic penetrating keratoplasty."( Medical treatment for combined Fusarium and Acanthamoeba keratitis.
Hsiao, CH; Huang, SC; Lin, HC; Lin, MY; Ma, DH; Tan, HY; Yeh, LK, 2009
)
0.35
" Therapeutic concentrations of TRAM-34 in mice caused no discernible toxicity after repeated dosing and did not compromise the immune response to influenza virus."( The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans.
Azam, P; Chandy, KG; Das, S; Fujiwara, Y; Gutterman, DD; Harder, DR; Hatoum, OA; Mattson, DL; Melvin, JE; Miura, H; Pratt, PF; Raman, G; Saito, T; Toyama, K; Wulff, H, 2008
)
0.35
"In this study, a bioadhesive dosage form of clotrimazole was designed using a combination of bioadhesive polymers Carbopol 934P, sodium carboxymethyl cellulose and sodium alginate in different ratios."( Once daily bioadhesive vaginal clotrimazole tablets: design and evaluation.
Jain, S; Kaur, G; Sharma, G; Tiwary, AK, 2006
)
0.88
"Emulgel dosage form based on Pemulen polymeric emulsifier and JB is a promising vehicle for topical delivery of CZ and further in vivo animal studies are recommended."( Optimized formulation for topical administration of clotrimazole using Pemulen polymeric emulsifier.
Hady, SA; Hammad, M; Mortada, N; Shahin, M, 2011
)
0.62
" Hits were confirmed for activity against biofilms with dose-response measurements."( Novel high-throughput screen against Candida albicans identifies antifungal potentiators and agents effective against biofilms.
Diamond, SL; LaFleur, MD; Lewis, K; Lucumi, E; Napper, AD, 2011
)
0.37
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" A major problem associated with the successful formulation of effective dosage forms containing CLO is its poor aqueous solubility, which presents a hindrance for the local availability of CLO and limits the effective antifungal therapy."( Poly(amidoamine) dendrimers increase antifungal activity of clotrimazole.
Sacha, PT; Sosnowska, K; Tryniszewska, E; Wieczorek, P; Winnicka, K, 2011
)
0.61
" The obtained results indicate that chitosan is a suitable polymer for developing a sustained-release dosage form of clotrimazole for local delivery."( Preparation and in vitro evaluation of chitosan microgranules with clotrimazole.
Szymańska, E; Winnicka, K,
)
0.58
" To achieve these levels, AA RTRs require a significantly higher dosage of TAC compared to C patients (5."( African American renal transplant recipients (RTR) require higher tacrolimus doses to achieve target levels compared to white RTR: does clotrimazole help?
Dayton, M; Feng, L; Kohli, R; Laftavi, MR; Nader, N; Pankewycz, O; Patel, S; Said, M, 2013
)
0.59
" Due to the fast self-cleaning action of the vagina, commercially available vaginal dosage forms with clotrimazole cannot assure prolonged contact time with mucosa, therefore the main objective of this study was to develop a dosage form for vaginal administration of clotrimazole using chitosan-a biodegradable and biocompatible derivative of chitin."( Vaginal chitosan tablets with clotrimazole-design and evaluation of mucoadhesive properties using porcine vaginal mucosa, mucin and gelatine.
Amelian, A; Cwalina, U; Szymańska, E; Winnicka, K, 2014
)
0.91
"The aim of present study was to formulate and evaluate antifungal transdermal spray to improve the permeation of clotrimazole across the skin and to decrease the dosing frequency in fungal infection."( Formulation and evaluation of clotrimazole transdermal spray.
Gandhi, T; Gohel, M; Paradkar, M; Soni, T; Thakkar, V, 2015
)
0.92
"Five different chemometric methods were developed for the simultaneous determination of betamethasone dipropionate (BMD), clotrimazole (CT) and benzyl alcohol (BA) in their combined dosage form (Lotriderm® cream)."( Full spectrum and selected spectrum based multivariate calibration methods for simultaneous determination of betamethasone dipropionate, clotrimazole and benzyl alcohol: Development, validation and application on commercial dosage form.
Abdelaleem, Ael-B; Darwish, HW; Elzanfaly, ES; Saad, AS, 2016
)
0.84
"Two sensitive, accurate, and precise spectrophotometric methods have been developed and validated for the simultaneous estimation of ofloxacin (OFX), clotrimazole (CLZ), and lignocaine hydrochloride (LGN) in their combined dosage form (ear drops) without prior separation."( Simultaneous Estimation of Ofloxacin, Clotrimazole, and Lignocaine Hydrochloride in Their Combined Ear-Drop Formulation by Two Spectrophotometric Methods.
Bodiwala, K; Kalyankar, G; Marolia, B; Patel, Y; Prajapati, P; Shah, S, 2017
)
0.93
" Furthermore, no association was found between categories of dosage of vaginal antimycotics and spontaneous abortions."( Vaginal antimycotics and the risk for spontaneous abortions.
Daniel, S; Koren, G; Levy, A; Lunenfeld, E; Rotem, R, 2018
)
0.48
"Poor water solubility of clotrimazole (CLO) hinders development of the effective pharmaceutical dosage forms."( NANOEMULSION WITH CLOTRIMAZOLE - DESIGN AND OPTIMALIZATION OF MEAN DROPLET SIZE USING MICROFLUIDIZATION TECHNIQUE.
Sosnowska, K; Szymanska, E; Winnicka, K, 2017
)
1.09
" However, the magnitude of the impact of clotrimazole on tacrolimus dosing requirements to maintain goal levels is not well described."( Effects of clotrimazole troches on tacrolimus dosing in heart transplant recipients.
Boilson, B; Crow, SA; Dierkhising, R; Laub, MR; Personett, HA; Razonable, R, 2018
)
1.14
" We unexpectedly discover a new class of aggregating ligands that exhibit negligible interactions with proteins but act as competitive sinks for the free inhibitor, resulting in bell-shaped dose-response curves."( Mechanisms of Specific versus Nonspecific Interactions of Aggregation-Prone Inhibitors and Attenuators.
Ahmed, R; Boulton, S; Cheng, X; Melacini, G; Selvaratnam, R; Van, K, 2019
)
0.51
" It is, however, challenging to propose a flexible and robust formulation platform which can be used for fabrication of tailored solid dosage forms composed of APIs with different properties (e."( Binder jetting 3D printing of challenging medicines: From low dose tablets to hydrophobic molecules.
Dominik, A; Górniak, A; Gołkowska, AM; Karolewicz, B; Kozakiewicz-Latała, M; Malec, K; Nartowski, KP; Rusińska, M; Szymczyk-Ziółkowska, P; Ziółkowski, G; Złocińska, A, 2022
)
0.72
" Novel intravaginal dosage forms focusing on improving patient acceptability and featuring improved biopharmaceutical properties could be interesting alternatives to available antifungal products."( Chitosan-based sponges containing clotrimazole for the topical management of vulvovaginal candidiasis.
das Neves, J; de Camargo, ER; Martins, F; Morgado, DL; Sarmento, B, 2023
)
1.19
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antiinfective agentA substance used in the prophylaxis or therapy of infectious diseases.
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
imidazolesA five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton.
monochlorobenzenesAny member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
conazole antifungal drugAny conazole antifungal agent that has been used for the treatment of fungal infections in animals or humans.
imidazole antifungal drugAny imidazole antifungal agent that has been used for the treatment of fungal infections in humans or animals.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
(4S)-carvone biosynthesis116
sesamin biosynthesis013
sesamin biosynthesis015
taxol biosynthesis1224

Protein Targets (237)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency16.81590.004023.8416100.0000AID485290
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency28.18380.631035.7641100.0000AID504339
Chain A, Ferritin light chainEquus caballus (horse)Potency8.91255.623417.292931.6228AID2323
LuciferasePhotinus pyralis (common eastern firefly)Potency63.26090.007215.758889.3584AID1224835
endonuclease IVEscherichia coliPotency11.22020.707912.432431.6228AID1708
glp-1 receptor, partialHomo sapiens (human)Potency10.00000.01846.806014.1254AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency0.63100.100020.879379.4328AID588453
15-lipoxygenase, partialHomo sapiens (human)Potency23.06010.012610.691788.5700AID887
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency28.27193.189029.884159.4836AID1224846; AID1224894
RAR-related orphan receptor gammaMus musculus (house mouse)Potency6.71520.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency41.69030.173734.304761.8120AID1346859; AID1346924
ATAD5 protein, partialHomo sapiens (human)Potency25.91850.004110.890331.5287AID493106
Fumarate hydrataseHomo sapiens (human)Potency37.22120.00308.794948.0869AID1347053
USP1 protein, partialHomo sapiens (human)Potency23.06010.031637.5844354.8130AID504865
NFKB1 protein, partialHomo sapiens (human)Potency19.95260.02827.055915.8489AID895; AID928
GLS proteinHomo sapiens (human)Potency35.48130.35487.935539.8107AID624146
PPM1D proteinHomo sapiens (human)Potency41.54370.00529.466132.9993AID1347411
SMAD family member 3Homo sapiens (human)Potency41.69030.173734.304761.8120AID1346859; AID1346924
TDP1 proteinHomo sapiens (human)Potency13.56730.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency7.70540.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency20.30680.180013.557439.8107AID1460
ThrombopoietinHomo sapiens (human)Potency12.58930.02517.304831.6228AID917; AID918
AR proteinHomo sapiens (human)Potency20.99510.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743036; AID743042; AID743053; AID743054; AID743063
Smad3Homo sapiens (human)Potency35.48130.00527.809829.0929AID588855
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency5.01190.00137.762544.6684AID914; AID915
thyroid stimulating hormone receptorHomo sapiens (human)Potency39.81070.001318.074339.8107AID926
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency28.63450.000657.913322,387.1992AID1259377; AID1259378; AID1259394
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency13.69040.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency25.63140.000417.946075.1148AID1346784; AID1346795; AID1347036
regulator of G-protein signaling 4Homo sapiens (human)Potency37.68580.531815.435837.6858AID504845
isocitrate dehydrogenase 1, partialHomo sapiens (human)Potency44.66846.309627.099079.4328AID602179
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency0.25840.01237.983543.2770AID1346984; AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency20.27690.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency19.95260.28189.721235.4813AID2326
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency33.91740.000214.376460.0339AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency40.53930.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency20.45120.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency9.98900.001530.607315,848.9004AID1224819; AID1224820; AID1224821; AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency32.58320.375827.485161.6524AID743217; AID743220; AID743239
pregnane X nuclear receptorHomo sapiens (human)Potency5.54460.005428.02631,258.9301AID1346982; AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency30.54740.000229.305416,493.5996AID1259244; AID1259248; AID1259383; AID743069; AID743075; AID743077; AID743078; AID743079; AID743080; AID743091
GVesicular stomatitis virusPotency0.97720.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency9.77170.00108.379861.1304AID1645840
polyproteinZika virusPotency37.22120.00308.794948.0869AID1347053
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency22.38720.707936.904389.1251AID504333
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency39.23610.001024.504861.6448AID743215; AID743227
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency25.75830.001019.414170.9645AID743094; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency36.76350.023723.228263.5986AID743222; AID743223
arylsulfatase AHomo sapiens (human)Potency3.79331.069113.955137.9330AID720538
alpha-galactosidaseHomo sapiens (human)Potency7.94334.466818.391635.4813AID2107
pyruvate kinaseLeishmania mexicana mexicanaPotency25.11890.398113.744731.6228AID945; AID959
IDH1Homo sapiens (human)Potency29.09290.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency23.44510.035520.977089.1251AID504332
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency58.47890.016525.307841.3999AID602332
aryl hydrocarbon receptorHomo sapiens (human)Potency6.26590.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency5.69050.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency43.36920.001628.015177.1139AID1224843; AID1224895; AID1259385; AID1259395
activating transcription factor 6Homo sapiens (human)Potency32.25660.143427.612159.8106AID1159516; AID1159519
thyrotropin-releasing hormone receptorHomo sapiens (human)Potency33.82600.154917.870243.6557AID1346877
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency38.378919.739145.978464.9432AID1159509; AID1159518
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency18.22760.057821.109761.2679AID1159526; AID1159528
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency3.98110.10009.191631.6228AID1346983
Histone H2A.xCricetulus griseus (Chinese hamster)Potency47.51570.039147.5451146.8240AID1224845; AID1224896
Caspase-7Cricetulus griseus (Chinese hamster)Potency48.55770.006723.496068.5896AID1346980
Bloom syndrome protein isoform 1Homo sapiens (human)Potency22.38720.540617.639296.1227AID2364; AID2528
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency24.90530.00207.533739.8107AID891
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency42.561523.934123.934123.9341AID1967
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency20.93480.316212.443531.6228AID902; AID924
cytochrome P450 2C19 precursorHomo sapiens (human)Potency8.97160.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency0.65810.00636.904339.8107AID883
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency34.89370.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency0.00840.006026.168889.1251AID488953
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency32.64270.00419.984825.9290AID504444
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency10.61010.01789.637444.6684AID588834
caspase-3Cricetulus griseus (Chinese hamster)Potency48.55770.006723.496068.5896AID1346980
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency4.31550.000323.4451159.6830AID743065; AID743066; AID743067
heat shock protein beta-1Homo sapiens (human)Potency33.60120.042027.378961.6448AID743210; AID743228
huntingtin isoform 2Homo sapiens (human)Potency11.22020.000618.41981,122.0200AID1688
mitogen-activated protein kinase 1Homo sapiens (human)Potency29.73490.039816.784239.8107AID1454; AID995
flap endonuclease 1Homo sapiens (human)Potency70.79460.133725.412989.1251AID588795
ubiquitin carboxyl-terminal hydrolase 2 isoform aHomo sapiens (human)Potency18.93380.65619.452025.1189AID927
ras-related protein Rab-9AHomo sapiens (human)Potency58.04790.00022.621531.4954AID485297
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency25.76790.000627.21521,122.0200AID743202; AID743219
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency12.58930.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency12.58930.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency12.58930.15855.287912.5893AID540303
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency22.46540.00798.23321,122.0200AID2546; AID2551
lethal(3)malignant brain tumor-like protein 1 isoform IHomo sapiens (human)Potency17.78280.075215.225339.8107AID485360
gemininHomo sapiens (human)Potency23.86540.004611.374133.4983AID463097; AID624296
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency7.75430.005612.367736.1254AID624032
survival motor neuron protein isoform dHomo sapiens (human)Potency35.48130.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency0.06920.031610.279239.8107AID884; AID885
M-phase phosphoprotein 8Homo sapiens (human)Potency26.67950.177824.735279.4328AID488949
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency10.60240.00106.000935.4813AID943; AID944
lamin isoform A-delta10Homo sapiens (human)Potency13.08290.891312.067628.1838AID1459; AID1487
neuropeptide S receptor isoform AHomo sapiens (human)Potency6.47760.015812.3113615.5000AID1461
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency0.06921.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency5.53070.316212.765731.6228AID881
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency24.33650.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency31.78050.00339.158239.8107AID1347407; AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency0.97720.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency28.51670.002319.595674.0614AID651631; AID720552
Integrin beta-3Homo sapiens (human)Potency15.97750.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency15.97750.316211.415731.6228AID924
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency0.06921.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency0.06921.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency0.06921.000012.224831.6228AID885
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency24.33650.001551.739315,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency0.06921.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency0.06921.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency0.06921.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency0.06921.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency0.06921.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency0.06921.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency0.06921.000012.224831.6228AID885
Alpha-synucleinHomo sapiens (human)Potency0.65130.56239.398525.1189AID652106
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency3.44240.00638.235039.8107AID881; AID883
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency10.00000.009610.525035.4813AID1479145
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency0.06921.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency0.06921.000012.224831.6228AID885
Guanine nucleotide-binding protein GHomo sapiens (human)Potency28.18381.995325.532750.1187AID624288
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency0.06921.000012.224831.6228AID885
Disintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)Potency18.93381.584913.004325.1189AID927
TAR DNA-binding protein 43Homo sapiens (human)Potency22.38721.778316.208135.4813AID652104
Rap guanine nucleotide exchange factor 4Homo sapiens (human)Potency14.12543.981146.7448112.2020AID720708
GABA theta subunitRattus norvegicus (Norway rat)Potency0.06921.000012.224831.6228AID885
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency0.97720.01238.964839.8107AID1645842
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency18.16430.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency20.48250.011912.222168.7989AID588378; AID651632
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency0.06921.000012.224831.6228AID885
cytochrome P450 2C9, partialHomo sapiens (human)Potency0.97720.01238.964839.8107AID1645842
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency37.93300.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 1 Homo sapiens (human)IC50 (µMol)11.97000.21005.553710.0000AID1442001
Intermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)IC50 (µMol)0.16670.00600.07970.3600AID315276; AID397426; AID397428
Voltage-dependent L-type calcium channel subunit alpha-1CCavia porcellus (domestic guinea pig)IC50 (µMol)0.59000.02201.64228.9000AID1207633
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)IC50 (µMol)14.47200.00011.00768.7800AID625218
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)Ki7.58100.00000.887110.0000AID625218
Transient receptor potential cation channel subfamily M member 2Homo sapiens (human)IC50 (µMol)3.00000.21001.89115.0000AID1065914; AID1775860
Bile salt export pumpHomo sapiens (human)IC50 (µMol)10.00000.11007.190310.0000AID1443987; AID1449628
Epidermal growth factor receptorHomo sapiens (human)IC50 (µMol)69.42100.00000.536910.0000AID625184
Chymotrypsinogen ABos taurus (cattle)IC50 (µMol)85.00000.98004.05607.2000AID52776
Beta-lactamaseEscherichia coli K-12IC50 (µMol)68.33330.01502.46578.0000AID286782; AID286783; AID43431
Carbonic anhydrase 2Homo sapiens (human)IC50 (µMol)30.10300.00021.10608.3000AID625236
Glucocorticoid receptorHomo sapiens (human)IC50 (µMol)3.25800.00000.495310.0000AID625263
Glucocorticoid receptorHomo sapiens (human)Ki1.48100.00010.38637.0010AID625263
Sarcoplasmic/endoplasmic reticulum calcium ATPase 1Oryctolagus cuniculus (rabbit)Ki35.00000.01902.90955.8000AID1605036
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)IC50 (µMol)66.40500.00010.545310.0000AID625186
Steroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)Ki0.08150.03800.39691.6250AID53377
Histidine-rich protein PFHRP-IIPlasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)2,500,000.00000.07651.12552.9000AID277607
Tyrosine-protein kinase FynHomo sapiens (human)IC50 (µMol)31.85100.00021.67898.6800AID625185
Heme oxygenase 1 Rattus norvegicus (Norway rat)IC50 (µMol)67.50001.10004.320010.0000AID1799166
ATP-dependent translocase ABCB1Mus musculus (house mouse)IC50 (µMol)3.50000.06404.012610.0000AID150754; AID681128
ATP-dependent translocase ABCB1Mus musculus (house mouse)Ki25.10003.50005.60676.9300AID681138
Glycine receptor subunit alpha-1Rattus norvegicus (Norway rat)IC50 (µMol)3.25800.00150.76005.0740AID625263
Glycine receptor subunit alpha-1Rattus norvegicus (Norway rat)Ki1.48100.00070.76537.0010AID625263
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)IC50 (µMol)7.93600.00041.877310.0000AID625207
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)Ki7.87000.00322.28879.3160AID625207
Muscarinic acetylcholine receptor M2Homo sapiens (human)IC50 (µMol)14.53100.00001.23267.7930AID625152
Muscarinic acetylcholine receptor M2Homo sapiens (human)Ki5.16700.00000.690210.0000AID625152
Muscarinic acetylcholine receptor M4Homo sapiens (human)IC50 (µMol)11.75600.00001.15467.5858AID625154
Muscarinic acetylcholine receptor M4Homo sapiens (human)Ki1.64000.00000.79519.1201AID625154
ATP-dependent translocase ABCB1Homo sapiens (human)IC50 (µMol)4.90000.00022.318510.0000AID150752; AID150755; AID681122
ATP-dependent translocase ABCB1Homo sapiens (human)Ki36.96000.02002.35948.5900AID681142; AID681143
Beta-1 adrenergic receptorHomo sapiens (human)IC50 (µMol)11.27900.00021.46819.0000AID625204
Beta-1 adrenergic receptorHomo sapiens (human)Ki6.51300.00011.33919.9840AID625204
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)0.04060.00011.753610.0000AID1557089; AID1634154; AID428564; AID54923; AID625251
Alpha-2A adrenergic receptorHomo sapiens (human)IC50 (µMol)11.88600.00001.44217.3470AID625201
Alpha-2A adrenergic receptorHomo sapiens (human)Ki4.45700.00010.807410.0000AID625201
Adenosine receptor A3Homo sapiens (human)IC50 (µMol)4.75200.00001.89408.5470AID625196
Adenosine receptor A3Homo sapiens (human)Ki2.68600.00000.930610.0000AID625196
Muscarinic acetylcholine receptor M1Homo sapiens (human)IC50 (µMol)6.86900.00001.403910.0000AID625151
Muscarinic acetylcholine receptor M1Homo sapiens (human)Ki1.65400.00000.59729.1201AID625151
AromataseHomo sapiens (human)IC50 (µMol)0.00180.00001.290410.0000AID479369
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)0.01600.00002.800510.0000AID625248
Beta-3 adrenergic receptorHomo sapiens (human)IC50 (µMol)7.20800.00233.24158.0600AID625206
Beta-3 adrenergic receptorHomo sapiens (human)Ki5.40600.00302.30986.0450AID625206
D(2) dopamine receptorHomo sapiens (human)IC50 (µMol)12.18600.00000.74728.0000AID625253
D(2) dopamine receptorHomo sapiens (human)Ki4.06200.00000.651810.0000AID625253
Androgen receptorRattus norvegicus (Norway rat)IC50 (µMol)11.58600.00101.979414.1600AID625228
Androgen receptorRattus norvegicus (Norway rat)Ki7.72400.00031.21858.9270AID625228
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)4.75200.00021.874210.0000AID625196
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)Ki2.68600.00010.949010.0000AID625196
Alpha-2B adrenergic receptorHomo sapiens (human)IC50 (µMol)8.15900.00001.23808.1590AID625202
Alpha-2B adrenergic receptorHomo sapiens (human)Ki3.72500.00020.725710.0000AID625202
Potassium-transporting ATPase subunit betaSus scrofa (pig)IC50 (µMol)5.20000.03001.32255.2000AID1605087
Potassium-transporting ATPase alpha chain 1Sus scrofa (pig)IC50 (µMol)5.20000.03001.06405.2000AID1605087
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)17.68800.00031.38338.4000AID625190
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Ki10.10800.00010.739610.0000AID625190
Muscarinic acetylcholine receptor M3Homo sapiens (human)IC50 (µMol)9.92800.00011.01049.9280AID625153
Muscarinic acetylcholine receptor M3Homo sapiens (human)Ki2.10400.00000.54057.7600AID625153
Glycine receptor subunit betaRattus norvegicus (Norway rat)IC50 (µMol)3.25800.00150.76005.0740AID625263
Glycine receptor subunit betaRattus norvegicus (Norway rat)Ki1.48100.00070.78467.0010AID625263
ATP-dependent translocase ABCB1Mus musculus (house mouse)IC50 (µMol)4.80000.20004.713010.0000AID150753; AID681119
ATP-dependent translocase ABCB1Mus musculus (house mouse)Ki18.30002.10004.31507.4800AID681137
Substance-K receptorHomo sapiens (human)IC50 (µMol)10.15000.00013.12109.5530AID625227
Substance-K receptorHomo sapiens (human)Ki3.38300.00011.92429.7930AID625227
D(1A) dopamine receptorHomo sapiens (human)IC50 (µMol)9.01700.00031.84739.2250AID625252
D(1A) dopamine receptorHomo sapiens (human)Ki4.50800.00010.836310.0000AID625252
D(4) dopamine receptorHomo sapiens (human)IC50 (µMol)19.91900.00011.14239.3280AID625255
D(4) dopamine receptorHomo sapiens (human)Ki6.98500.00000.436210.0000AID625255
Potassium voltage-gated channel subfamily A member 3Homo sapiens (human)IC50 (µMol)6.00000.00203.19698.0000AID397423
Voltage-dependent L-type calcium channel subunit alpha-1CRattus norvegicus (Norway rat)IC50 (µMol)0.59000.00132.24956.9000AID1207633
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)19.41000.00000.933210.0000AID625193
Glycine receptor subunit alpha-2Rattus norvegicus (Norway rat)IC50 (µMol)3.25800.00150.80445.0740AID625263
Glycine receptor subunit alpha-2Rattus norvegicus (Norway rat)Ki1.48100.00070.78467.0010AID625263
Heme oxygenase 2Rattus norvegicus (Norway rat)IC50 (µMol)67.50001.10004.483310.0000AID1799166
Sodium-dependent noradrenaline transporter Homo sapiens (human)IC50 (µMol)7.93600.00081.541620.0000AID625207
Sodium-dependent noradrenaline transporter Homo sapiens (human)Ki7.87000.00031.465610.0000AID625207
Glycine receptor subunit alpha-3Rattus norvegicus (Norway rat)IC50 (µMol)3.25800.00150.76005.0740AID625263
Glycine receptor subunit alpha-3Rattus norvegicus (Norway rat)Ki1.48100.00070.78467.0010AID625263
Thromboxane-A synthase Homo sapiens (human)IC50 (µMol)0.01400.00091.230410.0000AID625229
Histamine H2 receptorHomo sapiens (human)IC50 (µMol)5.16500.02202.298710.0000AID625270
Histamine H2 receptorHomo sapiens (human)Ki5.07900.00062.197310.0000AID625270
C-X-C chemokine receptor type 1Homo sapiens (human)IC50 (µMol)6.77310.00102.022710.0000AID729310; AID729311; AID729312
Alpha-1D adrenergic receptorHomo sapiens (human)IC50 (µMol)15.01200.00020.75688.8970AID625200
Alpha-1D adrenergic receptorHomo sapiens (human)Ki7.37900.00000.360910.0000AID625200
Substance-P receptorHomo sapiens (human)IC50 (µMol)16.03700.00000.09526.8130AID625226
Substance-P receptorHomo sapiens (human)Ki8.74700.00000.79368.7470AID625226
Platelet-activating factor receptorHomo sapiens (human)IC50 (µMol)35.03800.00030.63183.7000AID625168
Platelet-activating factor receptorHomo sapiens (human)Ki22.63500.00020.53762.2700AID625168
5-hydroxytryptamine receptor 2AHomo sapiens (human)IC50 (µMol)11.14200.00010.88018.8500AID625192
5-hydroxytryptamine receptor 2AHomo sapiens (human)Ki3.18300.00000.385510.0000AID625192
5-hydroxytryptamine receptor 2CHomo sapiens (human)IC50 (µMol)14.47200.00011.03029.0000AID625218
5-hydroxytryptamine receptor 2CHomo sapiens (human)Ki7.58100.00010.954910.0000AID625218
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)IC50 (µMol)17.68800.00051.48357.8000AID625190
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)Ki10.10800.00031.29679.2440AID625190
Indoleamine 2,3-dioxygenase 1Mus musculus (house mouse)IC50 (µMol)51.60000.00601.625110.0000AID717846
Adenosine receptor A2aHomo sapiens (human)IC50 (µMol)12.71100.00071.559410.0000AID625195
Adenosine receptor A2aHomo sapiens (human)Ki7.13600.00001.06099.7920AID625195
Vasopressin V2 receptorHomo sapiens (human)IC50 (µMol)9.04020.00001.12137.0000AID729308; AID729309
Adenosine receptor A1Homo sapiens (human)IC50 (µMol)13.42000.00020.68187.7010AID625194
Adenosine receptor A1Homo sapiens (human)Ki7.83000.00020.931610.0000AID625194
Sodium-dependent serotonin transporterHomo sapiens (human)IC50 (µMol)5.76000.00010.86458.7096AID625222
Sodium-dependent serotonin transporterHomo sapiens (human)Ki3.06000.00000.70488.1930AID625222
Cytochrome P450 2C19Homo sapiens (human)IC50 (µMol)0.01600.00002.398310.0000AID625247
Prostaglandin G/H synthase 2Homo sapiens (human)IC50 (µMol)41.79600.00010.995010.0000AID625244
Histamine H1 receptorHomo sapiens (human)IC50 (µMol)29.40600.00000.44365.1768AID625269
Histamine H1 receptorHomo sapiens (human)Ki3.41600.00000.511010.0000AID625269
Mu-type opioid receptorHomo sapiens (human)IC50 (µMol)1.80200.00010.813310.0000AID625163
Mu-type opioid receptorHomo sapiens (human)Ki0.73100.00000.419710.0000AID625163
D(3) dopamine receptorHomo sapiens (human)IC50 (µMol)2.64700.00011.01788.7960AID625254
D(3) dopamine receptorHomo sapiens (human)Ki0.89900.00000.602010.0000AID625254
Delta-type opioid receptorHomo sapiens (human)IC50 (µMol)4.97800.00020.75218.0140AID625161
Delta-type opioid receptorHomo sapiens (human)Ki1.75500.00000.59789.9300AID625161
Kappa-type opioid receptorHomo sapiens (human)IC50 (µMol)6.30300.00001.201110.0000AID625162
Kappa-type opioid receptorHomo sapiens (human)Ki2.52100.00000.362410.0000AID625162
5-hydroxytryptamine receptor 2BHomo sapiens (human)IC50 (µMol)11.60400.00011.18738.9125AID625217
5-hydroxytryptamine receptor 2BHomo sapiens (human)Ki7.38500.00030.769310.0000AID625217
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)4.75200.00001.819410.0000AID625196
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)Ki2.68600.00000.965010.0000AID625196
5-hydroxytryptamine receptor 6Homo sapiens (human)IC50 (µMol)12.54300.00170.83815.4200AID625221
5-hydroxytryptamine receptor 6Homo sapiens (human)Ki5.82400.00020.522910.0000AID625221
C-C chemokine receptor type 4Homo sapiens (human)IC50 (µMol)1.60000.20004.542410.0000AID729298
Transitional endoplasmic reticulum ATPaseHomo sapiens (human)IC50 (µMol)6.70000.07002.19396.6100AID1558383; AID1558384
Sodium-dependent dopamine transporter Homo sapiens (human)IC50 (µMol)5.58100.00071.841946.0000AID625256
Sodium-dependent dopamine transporter Homo sapiens (human)Ki4.43400.00021.11158.0280AID625256
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)3.01990.00091.901410.0000AID576612
Voltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)IC50 (µMol)0.59000.00032.25459.6000AID1207633
Nuclear receptor subfamily 1 group I member 3 Homo sapiens (human)IC50 (µMol)0.29000.08001.38974.0780AID1276954; AID1276956; AID1276957
Nuclear receptor subfamily 1 group I member 3 Homo sapiens (human)Ki0.10000.10000.10000.1000AID1276953
Lanosterol 14-alpha demethylaseHomo sapiens (human)IC50 (µMol)0.13000.05001.43904.0000AID322753
Indoleamine 2,3-dioxygenase 2Mus musculus (house mouse)IC50 (µMol)5.90001.50005.08758.2000AID717845
Bile acid receptorHomo sapiens (human)IC50 (µMol)3.24000.01834.560310.0000AID755454
Cysteinyl leukotriene receptor 1Homo sapiens (human)IC50 (µMol)33.17200.00030.948710.0000AID625145
Cysteinyl leukotriene receptor 1Homo sapiens (human)Ki16.58600.00021.56248.8720AID625145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
heat shock protein 90Candida albicansEC50 (µMol)50.57030.12006.485533.8530AID2387; AID2400; AID2423
calcineurin A1, putativeCandida dubliniensis CD36EC50 (µMol)180.00004.66306.38108.0990AID2388
beta-2 adrenergic receptorHomo sapiens (human)EC50 (µMol)4.69000.00161.87598.4400AID588763
streptokinase A precursorStreptococcus pyogenes M1 GASEC50 (µMol)78.10400.06008.9128130.5170AID1902; AID1914
Estrogen receptorRattus norvegicus (Norway rat)EC50 (µMol)150.00000.006022.3670130.5170AID1914
Cytochrome P450 2C9 Homo sapiens (human)Kd0.07300.07300.07300.0730AID1300321
Cytochrome P450 144Mycobacterium tuberculosis CDC1551Kd3.15670.36002.59905.3000AID1799791
Steroid C26-monooxygenaseMycobacterium tuberculosis CDC1551Kd5.77400.10002.59676.1000AID1799791; AID1799801
Cytochrome P450 130Mycobacterium tuberculosis CDC1551Kd9.70000.10002.59206.1000AID1799801
Cytochrome P450 130Mycobacterium tuberculosis H37RvKd10.90000.10002.59206.1000AID1799801; AID572700
Steroid C26-monooxygenaseMycobacterium tuberculosis CDC1551Kd3.15670.36002.59905.3000AID1799791
Mycocyclosin synthaseMycobacterium tuberculosis H37RvKd0.07300.07301.55476.0000AID1300321
Lanosterol 14-alpha demethylaseMycobacterium tuberculosis H37RvKd0.20000.20000.42001.3000AID572699
Sterol 14-alpha demethylaseAspergillus fumigatus Af293Kd4.79001.01003.03004.7900AID575747
Estrogen receptor betaRattus norvegicus (Norway rat)EC50 (µMol)150.00000.006022.3670130.5170AID1914
14-alpha sterol demethylase Aspergillus fumigatusKd0.10300.03100.84824.0300AID575755
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
heat shock protein HSP 90-alpha isoform 2Homo sapiens (human)AC500.19500.19503.667918.6960AID540270
Epoxide hydrolase 1Rattus norvegicus (Norway rat)E1006.20006.20006.20006.2000AID208343
HSP40, subfamily A [Plasmodium falciparum 3D7]Plasmodium falciparum 3D7AbsAC1000_uM0.38700.12904.116911.3160AID540271
heat shock protein 90, putativePlasmodium falciparum 3D7AC500.19500.19504.992098.5000AID540268
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (1232)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processSolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin transportSolute carrier family 22 member 1 Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSolute carrier family 22 member 1 Homo sapiens (human)
organic cation transportSolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transportSolute carrier family 22 member 1 Homo sapiens (human)
putrescine transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transportSolute carrier family 22 member 1 Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine transportSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transportSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 1 Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 1 Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
monoatomic cation transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
acyl carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
immune system processIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
potassium ion transportIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
calcium ion transportIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
cell volume homeostasisIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
defense responseIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
stabilization of membrane potentialIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
phospholipid translocationIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
saliva secretionIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
positive regulation of protein secretionIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
positive regulation of T cell receptor signaling pathwayIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
establishment of localization in cellIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
positive regulation of potassium ion transmembrane transportIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
potassium ion transmembrane transportIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
temperature homeostasisTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
dendritic cell chemotaxisTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
calcium ion transportTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
response to heatTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
response to purine-containing compoundTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
calcium-mediated signalingTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
regulation of actin cytoskeleton organizationTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
response to hydroperoxideTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
sodium ion transmembrane transportTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
release of sequestered calcium ion into cytosolTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
protein homotetramerizationTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
regulation of filopodium assemblyTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
cellular response to hydrogen peroxideTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
calcium ion transmembrane transportTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
cellular response to calcium ionTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
cellular response to purine-containing compoundTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
manganese ion transmembrane transportTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
cellular response to temperature stimulusTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
zinc ion transmembrane transportTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
dendritic cell differentiationTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
calcium ion transmembrane import into cytosolTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
calcium ion import across plasma membraneTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
MAPK cascadeEpidermal growth factor receptorHomo sapiens (human)
ossificationEpidermal growth factor receptorHomo sapiens (human)
embryonic placenta developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein phosphorylationEpidermal growth factor receptorHomo sapiens (human)
hair follicle developmentEpidermal growth factor receptorHomo sapiens (human)
translationEpidermal growth factor receptorHomo sapiens (human)
signal transductionEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
activation of phospholipase C activityEpidermal growth factor receptorHomo sapiens (human)
salivary gland morphogenesisEpidermal growth factor receptorHomo sapiens (human)
midgut developmentEpidermal growth factor receptorHomo sapiens (human)
learning or memoryEpidermal growth factor receptorHomo sapiens (human)
circadian rhythmEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
diterpenoid metabolic processEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
cerebral cortex cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell growthEpidermal growth factor receptorHomo sapiens (human)
lung developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of superoxide anion generationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
response to cobalaminEpidermal growth factor receptorHomo sapiens (human)
response to hydroxyisoflavoneEpidermal growth factor receptorHomo sapiens (human)
cellular response to reactive oxygen speciesEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
ERBB2-EGFR signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of protein catabolic processEpidermal growth factor receptorHomo sapiens (human)
vasodilationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphorylationEpidermal growth factor receptorHomo sapiens (human)
ovulation cycleEpidermal growth factor receptorHomo sapiens (human)
hydrogen peroxide metabolic processEpidermal growth factor receptorHomo sapiens (human)
negative regulation of apoptotic processEpidermal growth factor receptorHomo sapiens (human)
positive regulation of MAP kinase activityEpidermal growth factor receptorHomo sapiens (human)
tongue developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA repairEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA replicationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of bone resorptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of vasoconstrictionEpidermal growth factor receptorHomo sapiens (human)
negative regulation of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEpidermal growth factor receptorHomo sapiens (human)
regulation of JNK cascadeEpidermal growth factor receptorHomo sapiens (human)
symbiont entry into host cellEpidermal growth factor receptorHomo sapiens (human)
protein autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
astrocyte activationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEpidermal growth factor receptorHomo sapiens (human)
digestive tract morphogenesisEpidermal growth factor receptorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationEpidermal growth factor receptorHomo sapiens (human)
neuron projection morphogenesisEpidermal growth factor receptorHomo sapiens (human)
epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
protein insertion into membraneEpidermal growth factor receptorHomo sapiens (human)
response to calcium ionEpidermal growth factor receptorHomo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicEpidermal growth factor receptorHomo sapiens (human)
positive regulation of glial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
morphogenesis of an epithelial foldEpidermal growth factor receptorHomo sapiens (human)
eyelid development in camera-type eyeEpidermal growth factor receptorHomo sapiens (human)
response to UV-AEpidermal growth factor receptorHomo sapiens (human)
positive regulation of mucus secretionEpidermal growth factor receptorHomo sapiens (human)
regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
cellular response to amino acid stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to mechanical stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to cadmium ionEpidermal growth factor receptorHomo sapiens (human)
cellular response to epidermal growth factor stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to estradiol stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to xenobiotic stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to dexamethasone stimulusEpidermal growth factor receptorHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
liver regenerationEpidermal growth factor receptorHomo sapiens (human)
cell-cell adhesionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein kinase C activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of prolactin secretionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of miRNA transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein localization to plasma membraneEpidermal growth factor receptorHomo sapiens (human)
negative regulation of cardiocyte differentiationEpidermal growth factor receptorHomo sapiens (human)
neurogenesisEpidermal growth factor receptorHomo sapiens (human)
multicellular organism developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of kinase activityEpidermal growth factor receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
digestionChymotrypsinogen ABos taurus (cattle)
antibiotic catabolic processBeta-lactamaseEscherichia coli K-12
response to antibioticBeta-lactamaseEscherichia coli K-12
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
regulation of gluconeogenesisGlucocorticoid receptorHomo sapiens (human)
chromatin organizationGlucocorticoid receptorHomo sapiens (human)
regulation of DNA-templated transcriptionGlucocorticoid receptorHomo sapiens (human)
apoptotic processGlucocorticoid receptorHomo sapiens (human)
chromosome segregationGlucocorticoid receptorHomo sapiens (human)
signal transductionGlucocorticoid receptorHomo sapiens (human)
glucocorticoid metabolic processGlucocorticoid receptorHomo sapiens (human)
gene expressionGlucocorticoid receptorHomo sapiens (human)
microglia differentiationGlucocorticoid receptorHomo sapiens (human)
adrenal gland developmentGlucocorticoid receptorHomo sapiens (human)
regulation of glucocorticoid biosynthetic processGlucocorticoid receptorHomo sapiens (human)
synaptic transmission, glutamatergicGlucocorticoid receptorHomo sapiens (human)
maternal behaviorGlucocorticoid receptorHomo sapiens (human)
intracellular glucocorticoid receptor signaling pathwayGlucocorticoid receptorHomo sapiens (human)
glucocorticoid mediated signaling pathwayGlucocorticoid receptorHomo sapiens (human)
positive regulation of neuron apoptotic processGlucocorticoid receptorHomo sapiens (human)
negative regulation of DNA-templated transcriptionGlucocorticoid receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
astrocyte differentiationGlucocorticoid receptorHomo sapiens (human)
cell divisionGlucocorticoid receptorHomo sapiens (human)
mammary gland duct morphogenesisGlucocorticoid receptorHomo sapiens (human)
motor behaviorGlucocorticoid receptorHomo sapiens (human)
cellular response to steroid hormone stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to glucocorticoid stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to dexamethasone stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to transforming growth factor beta stimulusGlucocorticoid receptorHomo sapiens (human)
neuroinflammatory responseGlucocorticoid receptorHomo sapiens (human)
positive regulation of miRNA transcriptionGlucocorticoid receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayGlucocorticoid receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
cell surface receptor signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of protein phosphorylationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein phosphorylationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
signal transductionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
enzyme-linked receptor protein signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
heart developmentReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neuromuscular junction developmentReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
motor neuron axon guidanceReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
Schwann cell developmentReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
peptidyl-tyrosine phosphorylationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of cell growthReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
regulation of microtubule-based processReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
immature T cell proliferation in thymusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
negative regulation of immature T cell proliferation in thymusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of Rho protein signal transductionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
intracellular signal transductionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ERBB2-ERBB3 signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ERBB2-EGFR signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ERBB2-ERBB4 signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
wound healingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
myelinationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of MAP kinase activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of translationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
regulation of angiogenesisReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of cell adhesionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
oligodendrocyte differentiationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of epithelial cell proliferationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
regulation of ERK1 and ERK2 cascadeReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cellular response to growth factor stimulusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cellular response to epidermal growth factor stimulusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
semaphorin-plexin signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of protein targeting to membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neurotransmitter receptor localization to postsynaptic specialization membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neurogenesisReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of MAPK cascadeReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
negative regulation of apoptotic processReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of kinase activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
multicellular organism developmentReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of cell population proliferationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neuron differentiationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
steroid biosynthetic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
androgen biosynthetic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
glucocorticoid biosynthetic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
sex differentiationSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
steroid metabolic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
hormone biosynthetic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
progesterone metabolic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
response to singlet oxygenTyrosine-protein kinase FynHomo sapiens (human)
neuron migrationTyrosine-protein kinase FynHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusTyrosine-protein kinase FynHomo sapiens (human)
heart processTyrosine-protein kinase FynHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase FynHomo sapiens (human)
calcium ion transportTyrosine-protein kinase FynHomo sapiens (human)
G protein-coupled glutamate receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
axon guidanceTyrosine-protein kinase FynHomo sapiens (human)
learningTyrosine-protein kinase FynHomo sapiens (human)
feeding behaviorTyrosine-protein kinase FynHomo sapiens (human)
regulation of cell shapeTyrosine-protein kinase FynHomo sapiens (human)
gene expressionTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of gene expressionTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of hydrogen peroxide biosynthetic processTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of neuron projection developmentTyrosine-protein kinase FynHomo sapiens (human)
protein ubiquitinationTyrosine-protein kinase FynHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase FynHomo sapiens (human)
protein catabolic processTyrosine-protein kinase FynHomo sapiens (human)
forebrain developmentTyrosine-protein kinase FynHomo sapiens (human)
T cell costimulationTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of protein ubiquitinationTyrosine-protein kinase FynHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase FynHomo sapiens (human)
cellular response to platelet-derived growth factor stimulusTyrosine-protein kinase FynHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of protein catabolic processTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinTyrosine-protein kinase FynHomo sapiens (human)
response to ethanolTyrosine-protein kinase FynHomo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
ephrin receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
dendrite morphogenesisTyrosine-protein kinase FynHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationTyrosine-protein kinase FynHomo sapiens (human)
activated T cell proliferationTyrosine-protein kinase FynHomo sapiens (human)
modulation of chemical synaptic transmissionTyrosine-protein kinase FynHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
leukocyte migrationTyrosine-protein kinase FynHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painTyrosine-protein kinase FynHomo sapiens (human)
cellular response to hydrogen peroxideTyrosine-protein kinase FynHomo sapiens (human)
cellular response to transforming growth factor beta stimulusTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of protein targeting to membraneTyrosine-protein kinase FynHomo sapiens (human)
dendritic spine maintenanceTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of protein localization to nucleusTyrosine-protein kinase FynHomo sapiens (human)
regulation of glutamate receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of dendritic spine maintenanceTyrosine-protein kinase FynHomo sapiens (human)
response to amyloid-betaTyrosine-protein kinase FynHomo sapiens (human)
cellular response to amyloid-betaTyrosine-protein kinase FynHomo sapiens (human)
cellular response to L-glutamateTyrosine-protein kinase FynHomo sapiens (human)
cellular response to glycineTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of protein localization to membraneTyrosine-protein kinase FynHomo sapiens (human)
regulation of calcium ion import across plasma membraneTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activityTyrosine-protein kinase FynHomo sapiens (human)
innate immune responseTyrosine-protein kinase FynHomo sapiens (human)
cell differentiationTyrosine-protein kinase FynHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of heart contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
response to virusMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M2Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M4Homo sapiens (human)
cell surface receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M4Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M4Homo sapiens (human)
G2/M transition of mitotic cell cycleATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic metabolic processATP-dependent translocase ABCB1Homo sapiens (human)
response to xenobiotic stimulusATP-dependent translocase ABCB1Homo sapiens (human)
phospholipid translocationATP-dependent translocase ABCB1Homo sapiens (human)
terpenoid transportATP-dependent translocase ABCB1Homo sapiens (human)
regulation of response to osmotic stressATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
transepithelial transportATP-dependent translocase ABCB1Homo sapiens (human)
stem cell proliferationATP-dependent translocase ABCB1Homo sapiens (human)
ceramide translocationATP-dependent translocase ABCB1Homo sapiens (human)
export across plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
positive regulation of anion channel activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
regulation of chloride transportATP-dependent translocase ABCB1Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
response to coldBeta-1 adrenergic receptorHomo sapiens (human)
heat generationBeta-1 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-1 adrenergic receptorHomo sapiens (human)
fear responseBeta-1 adrenergic receptorHomo sapiens (human)
regulation of circadian sleep/wake cycle, sleepBeta-1 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-1 adrenergic receptorHomo sapiens (human)
regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-1 adrenergic receptorHomo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
positive regulation of cytokine productionAlpha-2A adrenergic receptorHomo sapiens (human)
DNA replicationAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
Ras protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
Rho protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2A adrenergic receptorHomo sapiens (human)
actin cytoskeleton organizationAlpha-2A adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell migrationAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
cellular response to hormone stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2A adrenergic receptorHomo sapiens (human)
vasodilationAlpha-2A adrenergic receptorHomo sapiens (human)
glucose homeostasisAlpha-2A adrenergic receptorHomo sapiens (human)
fear responseAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of potassium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion-dependent exocytosisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2A adrenergic receptorHomo sapiens (human)
intestinal absorptionAlpha-2A adrenergic receptorHomo sapiens (human)
thermoceptionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of lipid catabolic processAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of uterine smooth muscle contractionAlpha-2A adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of wound healingAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transmembrane transporter activityAlpha-2A adrenergic receptorHomo sapiens (human)
inflammatory responseAdenosine receptor A3Homo sapiens (human)
signal transductionAdenosine receptor A3Homo sapiens (human)
activation of adenylate cyclase activityAdenosine receptor A3Homo sapiens (human)
regulation of heart contractionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A3Homo sapiens (human)
response to woundingAdenosine receptor A3Homo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell migrationAdenosine receptor A3Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityAdenosine receptor A3Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A3Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A3Homo sapiens (human)
positive regulation of monoatomic ion transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
neuromuscular synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M1Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M1Homo sapiens (human)
cognitionMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of postsynaptic membrane potentialMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of glial cell proliferationMuscarinic acetylcholine receptor M1Homo sapiens (human)
positive regulation of intracellular protein transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
negative regulation of chronic inflammatory responseAromataseHomo sapiens (human)
steroid biosynthetic processAromataseHomo sapiens (human)
estrogen biosynthetic processAromataseHomo sapiens (human)
androgen catabolic processAromataseHomo sapiens (human)
syncytium formationAromataseHomo sapiens (human)
negative regulation of macrophage chemotaxisAromataseHomo sapiens (human)
sterol metabolic processAromataseHomo sapiens (human)
female genitalia developmentAromataseHomo sapiens (human)
mammary gland developmentAromataseHomo sapiens (human)
uterus developmentAromataseHomo sapiens (human)
prostate gland growthAromataseHomo sapiens (human)
testosterone biosynthetic processAromataseHomo sapiens (human)
positive regulation of estradiol secretionAromataseHomo sapiens (human)
female gonad developmentAromataseHomo sapiens (human)
response to estradiolAromataseHomo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
receptor-mediated endocytosisBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-3 adrenergic receptorHomo sapiens (human)
carbohydrate metabolic processBeta-3 adrenergic receptorHomo sapiens (human)
generation of precursor metabolites and energyBeta-3 adrenergic receptorHomo sapiens (human)
energy reserve metabolic processBeta-3 adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerBeta-3 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
response to coldBeta-3 adrenergic receptorHomo sapiens (human)
heat generationBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-3 adrenergic receptorHomo sapiens (human)
eating behaviorBeta-3 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-3 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-3 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-3 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-3 adrenergic receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(2) dopamine receptorHomo sapiens (human)
response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein phosphorylationD(2) dopamine receptorHomo sapiens (human)
response to amphetamineD(2) dopamine receptorHomo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressureD(2) dopamine receptorHomo sapiens (human)
regulation of heart rateD(2) dopamine receptorHomo sapiens (human)
regulation of sodium ion transportD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(2) dopamine receptorHomo sapiens (human)
positive regulation of neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
positive regulation of receptor internalizationD(2) dopamine receptorHomo sapiens (human)
autophagyD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
neuron-neuron synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
axonogenesisD(2) dopamine receptorHomo sapiens (human)
synapse assemblyD(2) dopamine receptorHomo sapiens (human)
sensory perception of smellD(2) dopamine receptorHomo sapiens (human)
long-term memoryD(2) dopamine receptorHomo sapiens (human)
grooming behaviorD(2) dopamine receptorHomo sapiens (human)
locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
adult walking behaviorD(2) dopamine receptorHomo sapiens (human)
protein localizationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell population proliferationD(2) dopamine receptorHomo sapiens (human)
associative learningD(2) dopamine receptorHomo sapiens (human)
visual learningD(2) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(2) dopamine receptorHomo sapiens (human)
response to light stimulusD(2) dopamine receptorHomo sapiens (human)
response to toxic substanceD(2) dopamine receptorHomo sapiens (human)
response to iron ionD(2) dopamine receptorHomo sapiens (human)
response to inactivityD(2) dopamine receptorHomo sapiens (human)
Wnt signaling pathwayD(2) dopamine receptorHomo sapiens (human)
striatum developmentD(2) dopamine receptorHomo sapiens (human)
orbitofrontal cortex developmentD(2) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(2) dopamine receptorHomo sapiens (human)
adenohypophysis developmentD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell migrationD(2) dopamine receptorHomo sapiens (human)
peristalsisD(2) dopamine receptorHomo sapiens (human)
auditory behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of synaptic transmission, GABAergicD(2) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(2) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
response to histamineD(2) dopamine receptorHomo sapiens (human)
response to nicotineD(2) dopamine receptorHomo sapiens (human)
positive regulation of urine volumeD(2) dopamine receptorHomo sapiens (human)
positive regulation of renal sodium excretionD(2) dopamine receptorHomo sapiens (human)
positive regulation of multicellular organism growthD(2) dopamine receptorHomo sapiens (human)
response to cocaineD(2) dopamine receptorHomo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleepD(2) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(2) dopamine receptorHomo sapiens (human)
drinking behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(2) dopamine receptorHomo sapiens (human)
response to morphineD(2) dopamine receptorHomo sapiens (human)
pigmentationD(2) dopamine receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(2) dopamine receptorHomo sapiens (human)
negative regulation of innate immune responseD(2) dopamine receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IID(2) dopamine receptorHomo sapiens (human)
negative regulation of insulin secretionD(2) dopamine receptorHomo sapiens (human)
acid secretionD(2) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(2) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(2) dopamine receptorHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityD(2) dopamine receptorHomo sapiens (human)
response to axon injuryD(2) dopamine receptorHomo sapiens (human)
branching morphogenesis of a nerveD(2) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(2) dopamine receptorHomo sapiens (human)
epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(2) dopamine receptorHomo sapiens (human)
release of sequestered calcium ion into cytosolD(2) dopamine receptorHomo sapiens (human)
dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of synapse structural plasticityD(2) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(2) dopamine receptorHomo sapiens (human)
excitatory postsynaptic potentialD(2) dopamine receptorHomo sapiens (human)
positive regulation of growth hormone secretionD(2) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeD(2) dopamine receptorHomo sapiens (human)
regulation of locomotion involved in locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
negative regulation of cellular response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor productionD(2) dopamine receptorHomo sapiens (human)
positive regulation of long-term synaptic potentiationD(2) dopamine receptorHomo sapiens (human)
hyaloid vascular plexus regressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of neuron migrationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(2) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
angiogenesisAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of vascular associated smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2B adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2B adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of blood pressureAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
calcium-mediated signalingMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of monoatomic ion transmembrane transporter activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
synaptic transmission, cholinergicMuscarinic acetylcholine receptor M3Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of insulin secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein modification processMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ion channel modulating, G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ligand-gated ion channel signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M3Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M3Homo sapiens (human)
muscle contractionSubstance-K receptorHomo sapiens (human)
tachykinin receptor signaling pathwaySubstance-K receptorHomo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmissionSubstance-K receptorHomo sapiens (human)
intestine smooth muscle contractionSubstance-K receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionSubstance-K receptorHomo sapiens (human)
operant conditioningSubstance-K receptorHomo sapiens (human)
positive regulation of vascular permeabilitySubstance-K receptorHomo sapiens (human)
positive regulation of monoatomic ion transportSubstance-K receptorHomo sapiens (human)
positive regulation of smooth muscle contractionSubstance-K receptorHomo sapiens (human)
response to electrical stimulusSubstance-K receptorHomo sapiens (human)
prolactin secretionSubstance-K receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionSubstance-K receptorHomo sapiens (human)
positive regulation of flagellated sperm motilitySubstance-K receptorHomo sapiens (human)
temperature homeostasisD(1A) dopamine receptorHomo sapiens (human)
conditioned taste aversionD(1A) dopamine receptorHomo sapiens (human)
behavioral fear responseD(1A) dopamine receptorHomo sapiens (human)
regulation of protein phosphorylationD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(1A) dopamine receptorHomo sapiens (human)
response to amphetamineD(1A) dopamine receptorHomo sapiens (human)
protein import into nucleusD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
activation of adenylate cyclase activityD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
synapse assemblyD(1A) dopamine receptorHomo sapiens (human)
memoryD(1A) dopamine receptorHomo sapiens (human)
mating behaviorD(1A) dopamine receptorHomo sapiens (human)
grooming behaviorD(1A) dopamine receptorHomo sapiens (human)
adult walking behaviorD(1A) dopamine receptorHomo sapiens (human)
visual learningD(1A) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(1A) dopamine receptorHomo sapiens (human)
astrocyte developmentD(1A) dopamine receptorHomo sapiens (human)
dopamine transportD(1A) dopamine receptorHomo sapiens (human)
transmission of nerve impulseD(1A) dopamine receptorHomo sapiens (human)
neuronal action potentialD(1A) dopamine receptorHomo sapiens (human)
dentate gyrus developmentD(1A) dopamine receptorHomo sapiens (human)
striatum developmentD(1A) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of cell migrationD(1A) dopamine receptorHomo sapiens (human)
peristalsisD(1A) dopamine receptorHomo sapiens (human)
operant conditioningD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
vasodilationD(1A) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
maternal behaviorD(1A) dopamine receptorHomo sapiens (human)
positive regulation of potassium ion transportD(1A) dopamine receptorHomo sapiens (human)
glucose importD(1A) dopamine receptorHomo sapiens (human)
habituationD(1A) dopamine receptorHomo sapiens (human)
sensitizationD(1A) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(1A) dopamine receptorHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(1A) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic potentiationD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic depressionD(1A) dopamine receptorHomo sapiens (human)
cellular response to catecholamine stimulusD(1A) dopamine receptorHomo sapiens (human)
modification of postsynaptic structureD(1A) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of neuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
positive regulation of MAP kinase activityD(4) dopamine receptorHomo sapiens (human)
behavioral fear responseD(4) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(4) dopamine receptorHomo sapiens (human)
response to amphetamineD(4) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(4) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(4) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(4) dopamine receptorHomo sapiens (human)
adult locomotory behaviorD(4) dopamine receptorHomo sapiens (human)
positive regulation of sodium:proton antiporter activityD(4) dopamine receptorHomo sapiens (human)
positive regulation of kinase activityD(4) dopamine receptorHomo sapiens (human)
response to histamineD(4) dopamine receptorHomo sapiens (human)
social behaviorD(4) dopamine receptorHomo sapiens (human)
regulation of dopamine metabolic processD(4) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(4) dopamine receptorHomo sapiens (human)
fear responseD(4) dopamine receptorHomo sapiens (human)
regulation of circadian rhythmD(4) dopamine receptorHomo sapiens (human)
positive regulation of MAP kinase activityD(4) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(4) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(4) dopamine receptorHomo sapiens (human)
rhythmic processD(4) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(4) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(4) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(4) dopamine receptorHomo sapiens (human)
inhibitory postsynaptic potentialD(4) dopamine receptorHomo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationD(4) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(4) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathwayD(4) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerD(4) dopamine receptorHomo sapiens (human)
chemical synaptic transmissionD(4) dopamine receptorHomo sapiens (human)
potassium ion transportPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
optic nerve developmentPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
corpus callosum developmentPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
protein homooligomerizationPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
action potentialPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
prostaglandin biosynthetic processThromboxane-A synthase Homo sapiens (human)
icosanoid metabolic processThromboxane-A synthase Homo sapiens (human)
cyclooxygenase pathwayThromboxane-A synthase Homo sapiens (human)
intracellular chloride ion homeostasisThromboxane-A synthase Homo sapiens (human)
response to ethanolThromboxane-A synthase Homo sapiens (human)
positive regulation of vasoconstrictionThromboxane-A synthase Homo sapiens (human)
response to fatty acidThromboxane-A synthase Homo sapiens (human)
gastric acid secretionHistamine H2 receptorHomo sapiens (human)
immune responseHistamine H2 receptorHomo sapiens (human)
positive regulation of vasoconstrictionHistamine H2 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H2 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H2 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H2 receptorHomo sapiens (human)
dendritic cell chemotaxisC-X-C chemokine receptor type 1Homo sapiens (human)
cell surface receptor signaling pathwayC-X-C chemokine receptor type 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayC-X-C chemokine receptor type 1Homo sapiens (human)
receptor internalizationC-X-C chemokine receptor type 1Homo sapiens (human)
interleukin-8-mediated signaling pathwayC-X-C chemokine receptor type 1Homo sapiens (human)
chemokine-mediated signaling pathwayC-X-C chemokine receptor type 1Homo sapiens (human)
calcium-mediated signalingC-X-C chemokine receptor type 1Homo sapiens (human)
immune responseC-X-C chemokine receptor type 1Homo sapiens (human)
neutrophil chemotaxisC-X-C chemokine receptor type 1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-X-C chemokine receptor type 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-1D adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1D adrenergic receptorHomo sapiens (human)
aggressive behaviorSubstance-P receptorHomo sapiens (human)
positive regulation of leukocyte migrationSubstance-P receptorHomo sapiens (human)
angiotensin-mediated drinking behaviorSubstance-P receptorHomo sapiens (human)
inflammatory responseSubstance-P receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwaySubstance-P receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationSubstance-P receptorHomo sapiens (human)
tachykinin receptor signaling pathwaySubstance-P receptorHomo sapiens (human)
long-term memorySubstance-P receptorHomo sapiens (human)
associative learningSubstance-P receptorHomo sapiens (human)
detection of abiotic stimulusSubstance-P receptorHomo sapiens (human)
response to ozoneSubstance-P receptorHomo sapiens (human)
positive regulation of epithelial cell migrationSubstance-P receptorHomo sapiens (human)
response to auditory stimulusSubstance-P receptorHomo sapiens (human)
regulation of smooth muscle cell migrationSubstance-P receptorHomo sapiens (human)
positive regulation of synaptic transmission, cholinergicSubstance-P receptorHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicSubstance-P receptorHomo sapiens (human)
response to estradiolSubstance-P receptorHomo sapiens (human)
response to progesteroneSubstance-P receptorHomo sapiens (human)
response to nicotineSubstance-P receptorHomo sapiens (human)
operant conditioningSubstance-P receptorHomo sapiens (human)
sperm ejaculationSubstance-P receptorHomo sapiens (human)
eating behaviorSubstance-P receptorHomo sapiens (human)
positive regulation of vascular permeabilitySubstance-P receptorHomo sapiens (human)
response to ethanolSubstance-P receptorHomo sapiens (human)
positive regulation of action potentialSubstance-P receptorHomo sapiens (human)
positive regulation of blood pressureSubstance-P receptorHomo sapiens (human)
positive regulation of ossificationSubstance-P receptorHomo sapiens (human)
positive regulation of vasoconstrictionSubstance-P receptorHomo sapiens (human)
positive regulation of hormone secretionSubstance-P receptorHomo sapiens (human)
behavioral response to painSubstance-P receptorHomo sapiens (human)
regulation of smooth muscle cell proliferationSubstance-P receptorHomo sapiens (human)
positive regulation of lymphocyte proliferationSubstance-P receptorHomo sapiens (human)
positive regulation of epithelial cell proliferationSubstance-P receptorHomo sapiens (human)
positive regulation of stress fiber assemblySubstance-P receptorHomo sapiens (human)
response to electrical stimulusSubstance-P receptorHomo sapiens (human)
smooth muscle contraction involved in micturitionSubstance-P receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionSubstance-P receptorHomo sapiens (human)
positive regulation of flagellated sperm motilitySubstance-P receptorHomo sapiens (human)
positive regulation of cellular extravasationPlatelet-activating factor receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIPlatelet-activating factor receptorHomo sapiens (human)
chemotaxisPlatelet-activating factor receptorHomo sapiens (human)
inflammatory responsePlatelet-activating factor receptorHomo sapiens (human)
immune responsePlatelet-activating factor receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
parturitionPlatelet-activating factor receptorHomo sapiens (human)
response to symbiotic bacteriumPlatelet-activating factor receptorHomo sapiens (human)
lipopolysaccharide-mediated signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of interleukin-6 productionPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of tumor necrosis factor productionPlatelet-activating factor receptorHomo sapiens (human)
inositol trisphosphate biosynthetic processPlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of neutrophil degranulationPlatelet-activating factor receptorHomo sapiens (human)
transcytosisPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of translationPlatelet-activating factor receptorHomo sapiens (human)
negative regulation of blood pressurePlatelet-activating factor receptorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processPlatelet-activating factor receptorHomo sapiens (human)
cellular response to gravityPlatelet-activating factor receptorHomo sapiens (human)
cellular response to cAMPPlatelet-activating factor receptorHomo sapiens (human)
cellular response to fatty acidPlatelet-activating factor receptorHomo sapiens (human)
response to dexamethasonePlatelet-activating factor receptorHomo sapiens (human)
positive regulation of leukocyte tethering or rollingPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of transcytosisPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of maternal process involved in parturitionPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of gastro-intestinal system smooth muscle contractionPlatelet-activating factor receptorHomo sapiens (human)
cellular response to 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholinePlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
temperature homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytokine production involved in immune response5-hydroxytryptamine receptor 2AHomo sapiens (human)
glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytosolic calcium ion concentration5-hydroxytryptamine receptor 2AHomo sapiens (human)
memory5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 2AHomo sapiens (human)
artery smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
urinary bladder smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of heat generation5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of potassium ion transport5-hydroxytryptamine receptor 2AHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of neuron apoptotic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of vasoconstriction5-hydroxytryptamine receptor 2AHomo sapiens (human)
symbiont entry into host cell5-hydroxytryptamine receptor 2AHomo sapiens (human)
sensitization5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral response to cocaine5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of inflammatory response5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of execution phase of apoptosis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of platelet aggregation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of DNA biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2AHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 2CHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
locomotory behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
feeding behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2CHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of nervous system process5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of corticotropin-releasing hormone secretion5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of calcium-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2CHomo sapiens (human)
synaptic transmission, dopaminergicAdenosine receptor A2aHomo sapiens (human)
response to amphetamineAdenosine receptor A2aHomo sapiens (human)
regulation of DNA-templated transcriptionAdenosine receptor A2aHomo sapiens (human)
phagocytosisAdenosine receptor A2aHomo sapiens (human)
apoptotic processAdenosine receptor A2aHomo sapiens (human)
inflammatory responseAdenosine receptor A2aHomo sapiens (human)
cellular defense responseAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
cell-cell signalingAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, cholinergicAdenosine receptor A2aHomo sapiens (human)
central nervous system developmentAdenosine receptor A2aHomo sapiens (human)
blood coagulationAdenosine receptor A2aHomo sapiens (human)
sensory perceptionAdenosine receptor A2aHomo sapiens (human)
locomotory behaviorAdenosine receptor A2aHomo sapiens (human)
blood circulationAdenosine receptor A2aHomo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A2aHomo sapiens (human)
response to xenobiotic stimulusAdenosine receptor A2aHomo sapiens (human)
response to inorganic substanceAdenosine receptor A2aHomo sapiens (human)
positive regulation of glutamate secretionAdenosine receptor A2aHomo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmissionAdenosine receptor A2aHomo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A2aHomo sapiens (human)
response to purine-containing compoundAdenosine receptor A2aHomo sapiens (human)
response to caffeineAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
positive regulation of urine volumeAdenosine receptor A2aHomo sapiens (human)
vasodilationAdenosine receptor A2aHomo sapiens (human)
eating behaviorAdenosine receptor A2aHomo sapiens (human)
negative regulation of vascular permeabilityAdenosine receptor A2aHomo sapiens (human)
negative regulation of neuron apoptotic processAdenosine receptor A2aHomo sapiens (human)
positive regulation of circadian sleep/wake cycle, sleepAdenosine receptor A2aHomo sapiens (human)
negative regulation of alpha-beta T cell activationAdenosine receptor A2aHomo sapiens (human)
astrocyte activationAdenosine receptor A2aHomo sapiens (human)
neuron projection morphogenesisAdenosine receptor A2aHomo sapiens (human)
positive regulation of protein secretionAdenosine receptor A2aHomo sapiens (human)
negative regulation of inflammatory responseAdenosine receptor A2aHomo sapiens (human)
regulation of mitochondrial membrane potentialAdenosine receptor A2aHomo sapiens (human)
membrane depolarizationAdenosine receptor A2aHomo sapiens (human)
regulation of calcium ion transportAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
excitatory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
inhibitory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
prepulse inhibitionAdenosine receptor A2aHomo sapiens (human)
apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2aHomo sapiens (human)
positive regulation of long-term synaptic potentiationAdenosine receptor A2aHomo sapiens (human)
positive regulation of apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
positive regulation of systemic arterial blood pressureVasopressin V2 receptorHomo sapiens (human)
renal water retentionVasopressin V2 receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayVasopressin V2 receptorHomo sapiens (human)
activation of adenylate cyclase activityVasopressin V2 receptorHomo sapiens (human)
hemostasisVasopressin V2 receptorHomo sapiens (human)
positive regulation of cell population proliferationVasopressin V2 receptorHomo sapiens (human)
negative regulation of cell population proliferationVasopressin V2 receptorHomo sapiens (human)
positive regulation of gene expressionVasopressin V2 receptorHomo sapiens (human)
telencephalon developmentVasopressin V2 receptorHomo sapiens (human)
response to cytokineVasopressin V2 receptorHomo sapiens (human)
positive regulation of intracellular signal transductionVasopressin V2 receptorHomo sapiens (human)
cellular response to hormone stimulusVasopressin V2 receptorHomo sapiens (human)
positive regulation of vasoconstrictionVasopressin V2 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayVasopressin V2 receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by vasopressinVasopressin V2 receptorHomo sapiens (human)
temperature homeostasisAdenosine receptor A1Homo sapiens (human)
response to hypoxiaAdenosine receptor A1Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
regulation of respiratory gaseous exchange by nervous system processAdenosine receptor A1Homo sapiens (human)
negative regulation of acute inflammatory responseAdenosine receptor A1Homo sapiens (human)
negative regulation of leukocyte migrationAdenosine receptor A1Homo sapiens (human)
positive regulation of peptide secretionAdenosine receptor A1Homo sapiens (human)
positive regulation of systemic arterial blood pressureAdenosine receptor A1Homo sapiens (human)
negative regulation of systemic arterial blood pressureAdenosine receptor A1Homo sapiens (human)
regulation of glomerular filtrationAdenosine receptor A1Homo sapiens (human)
protein targeting to membraneAdenosine receptor A1Homo sapiens (human)
phagocytosisAdenosine receptor A1Homo sapiens (human)
inflammatory responseAdenosine receptor A1Homo sapiens (human)
signal transductionAdenosine receptor A1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
cell-cell signalingAdenosine receptor A1Homo sapiens (human)
nervous system developmentAdenosine receptor A1Homo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A1Homo sapiens (human)
response to inorganic substanceAdenosine receptor A1Homo sapiens (human)
negative regulation of glutamate secretionAdenosine receptor A1Homo sapiens (human)
response to purine-containing compoundAdenosine receptor A1Homo sapiens (human)
lipid catabolic processAdenosine receptor A1Homo sapiens (human)
negative regulation of synaptic transmission, GABAergicAdenosine receptor A1Homo sapiens (human)
positive regulation of nucleoside transportAdenosine receptor A1Homo sapiens (human)
negative regulation of neurotrophin productionAdenosine receptor A1Homo sapiens (human)
positive regulation of protein dephosphorylationAdenosine receptor A1Homo sapiens (human)
vasodilationAdenosine receptor A1Homo sapiens (human)
negative regulation of circadian sleep/wake cycle, non-REM sleepAdenosine receptor A1Homo sapiens (human)
negative regulation of apoptotic processAdenosine receptor A1Homo sapiens (human)
positive regulation of potassium ion transportAdenosine receptor A1Homo sapiens (human)
positive regulation of MAPK cascadeAdenosine receptor A1Homo sapiens (human)
negative regulation of hormone secretionAdenosine receptor A1Homo sapiens (human)
cognitionAdenosine receptor A1Homo sapiens (human)
leukocyte migrationAdenosine receptor A1Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of painAdenosine receptor A1Homo sapiens (human)
negative regulation of lipid catabolic processAdenosine receptor A1Homo sapiens (human)
positive regulation of lipid catabolic processAdenosine receptor A1Homo sapiens (human)
regulation of sensory perception of painAdenosine receptor A1Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergicAdenosine receptor A1Homo sapiens (human)
fatty acid homeostasisAdenosine receptor A1Homo sapiens (human)
excitatory postsynaptic potentialAdenosine receptor A1Homo sapiens (human)
long-term synaptic depressionAdenosine receptor A1Homo sapiens (human)
mucus secretionAdenosine receptor A1Homo sapiens (human)
negative regulation of mucus secretionAdenosine receptor A1Homo sapiens (human)
triglyceride homeostasisAdenosine receptor A1Homo sapiens (human)
regulation of cardiac muscle cell contractionAdenosine receptor A1Homo sapiens (human)
apoptotic signaling pathwayAdenosine receptor A1Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentrationAdenosine receptor A1Homo sapiens (human)
negative regulation of long-term synaptic potentiationAdenosine receptor A1Homo sapiens (human)
negative regulation of long-term synaptic depressionAdenosine receptor A1Homo sapiens (human)
G protein-coupled receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
monoamine transportSodium-dependent serotonin transporterHomo sapiens (human)
response to hypoxiaSodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transportSodium-dependent serotonin transporterHomo sapiens (human)
response to nutrientSodium-dependent serotonin transporterHomo sapiens (human)
memorySodium-dependent serotonin transporterHomo sapiens (human)
circadian rhythmSodium-dependent serotonin transporterHomo sapiens (human)
response to xenobiotic stimulusSodium-dependent serotonin transporterHomo sapiens (human)
response to toxic substanceSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of gene expressionSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of serotonin secretionSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of synaptic transmission, dopaminergicSodium-dependent serotonin transporterHomo sapiens (human)
response to estradiolSodium-dependent serotonin transporterHomo sapiens (human)
social behaviorSodium-dependent serotonin transporterHomo sapiens (human)
vasoconstrictionSodium-dependent serotonin transporterHomo sapiens (human)
sperm ejaculationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of neuron differentiationSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of cell cycleSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of organ growthSodium-dependent serotonin transporterHomo sapiens (human)
behavioral response to cocaineSodium-dependent serotonin transporterHomo sapiens (human)
enteric nervous system developmentSodium-dependent serotonin transporterHomo sapiens (human)
brain morphogenesisSodium-dependent serotonin transporterHomo sapiens (human)
serotonin uptakeSodium-dependent serotonin transporterHomo sapiens (human)
membrane depolarizationSodium-dependent serotonin transporterHomo sapiens (human)
platelet aggregationSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to retinoic acidSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to cGMPSodium-dependent serotonin transporterHomo sapiens (human)
regulation of thalamus sizeSodium-dependent serotonin transporterHomo sapiens (human)
conditioned place preferenceSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion transmembrane transportSodium-dependent serotonin transporterHomo sapiens (human)
amino acid transportSodium-dependent serotonin transporterHomo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 2Homo sapiens (human)
embryo implantationProstaglandin G/H synthase 2Homo sapiens (human)
learningProstaglandin G/H synthase 2Homo sapiens (human)
memoryProstaglandin G/H synthase 2Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell population proliferationProstaglandin G/H synthase 2Homo sapiens (human)
response to xenobiotic stimulusProstaglandin G/H synthase 2Homo sapiens (human)
response to nematodeProstaglandin G/H synthase 2Homo sapiens (human)
response to fructoseProstaglandin G/H synthase 2Homo sapiens (human)
response to manganese ionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 2Homo sapiens (human)
bone mineralizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fever generationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic plasticityProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergicProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin secretionProstaglandin G/H synthase 2Homo sapiens (human)
response to estradiolProstaglandin G/H synthase 2Homo sapiens (human)
response to lipopolysaccharideProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationProstaglandin G/H synthase 2Homo sapiens (human)
response to vitamin DProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to heatProstaglandin G/H synthase 2Homo sapiens (human)
response to tumor necrosis factorProstaglandin G/H synthase 2Homo sapiens (human)
maintenance of blood-brain barrierProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of protein import into nucleusProstaglandin G/H synthase 2Homo sapiens (human)
hair cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of apoptotic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vasoconstrictionProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
decidualizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle cell proliferationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of inflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
response to glucocorticoidProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of calcium ion transportProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProstaglandin G/H synthase 2Homo sapiens (human)
response to fatty acidProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to mechanical stimulusProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to lead ionProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to ATPProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to hypoxiaProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to non-ionic osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to fluid shear stressProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of transforming growth factor beta productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of platelet-derived growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to homocysteineProstaglandin G/H synthase 2Homo sapiens (human)
response to angiotensinProstaglandin G/H synthase 2Homo sapiens (human)
inflammatory responseHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
memoryHistamine H1 receptorHomo sapiens (human)
visual learningHistamine H1 receptorHomo sapiens (human)
regulation of vascular permeabilityHistamine H1 receptorHomo sapiens (human)
positive regulation of vasoconstrictionHistamine H1 receptorHomo sapiens (human)
regulation of synaptic plasticityHistamine H1 receptorHomo sapiens (human)
cellular response to histamineHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H1 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
response to ethanolD(3) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(3) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
learning or memoryD(3) dopamine receptorHomo sapiens (human)
learningD(3) dopamine receptorHomo sapiens (human)
locomotory behaviorD(3) dopamine receptorHomo sapiens (human)
visual learningD(3) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(3) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(3) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(3) dopamine receptorHomo sapiens (human)
response to histamineD(3) dopamine receptorHomo sapiens (human)
social behaviorD(3) dopamine receptorHomo sapiens (human)
response to cocaineD(3) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(3) dopamine receptorHomo sapiens (human)
response to morphineD(3) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(3) dopamine receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionD(3) dopamine receptorHomo sapiens (human)
acid secretionD(3) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(3) dopamine receptorHomo sapiens (human)
negative regulation of oligodendrocyte differentiationD(3) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(3) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(3) dopamine receptorHomo sapiens (human)
musculoskeletal movement, spinal reflex actionD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(3) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(3) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(3) dopamine receptorHomo sapiens (human)
positive regulation of dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(3) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(3) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(3) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(3) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(3) dopamine receptorHomo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
gluconeogenesisMalate dehydrogenase, cytoplasmicHomo sapiens (human)
NADH metabolic processMalate dehydrogenase, cytoplasmicHomo sapiens (human)
NADP metabolic processMalate dehydrogenase, cytoplasmicHomo sapiens (human)
malate metabolic processMalate dehydrogenase, cytoplasmicHomo sapiens (human)
oxaloacetate metabolic processMalate dehydrogenase, cytoplasmicHomo sapiens (human)
tricarboxylic acid cycleMalate dehydrogenase, cytoplasmicHomo sapiens (human)
malate-aspartate shuttleMalate dehydrogenase, cytoplasmicHomo sapiens (human)
immune responseDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerDelta-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
adult locomotory behaviorDelta-type opioid receptorHomo sapiens (human)
negative regulation of gene expressionDelta-type opioid receptorHomo sapiens (human)
negative regulation of protein-containing complex assemblyDelta-type opioid receptorHomo sapiens (human)
positive regulation of CREB transcription factor activityDelta-type opioid receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationDelta-type opioid receptorHomo sapiens (human)
response to nicotineDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
eating behaviorDelta-type opioid receptorHomo sapiens (human)
regulation of mitochondrial membrane potentialDelta-type opioid receptorHomo sapiens (human)
regulation of calcium ion transportDelta-type opioid receptorHomo sapiens (human)
cellular response to growth factor stimulusDelta-type opioid receptorHomo sapiens (human)
cellular response to hypoxiaDelta-type opioid receptorHomo sapiens (human)
cellular response to toxic substanceDelta-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayDelta-type opioid receptorHomo sapiens (human)
immune responseKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
chemical synaptic transmissionKappa-type opioid receptorHomo sapiens (human)
sensory perceptionKappa-type opioid receptorHomo sapiens (human)
locomotory behaviorKappa-type opioid receptorHomo sapiens (human)
sensory perception of painKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
response to insulinKappa-type opioid receptorHomo sapiens (human)
positive regulation of dopamine secretionKappa-type opioid receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionKappa-type opioid receptorHomo sapiens (human)
response to nicotineKappa-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
maternal behaviorKappa-type opioid receptorHomo sapiens (human)
eating behaviorKappa-type opioid receptorHomo sapiens (human)
response to estrogenKappa-type opioid receptorHomo sapiens (human)
estrous cycleKappa-type opioid receptorHomo sapiens (human)
response to ethanolKappa-type opioid receptorHomo sapiens (human)
regulation of saliva secretionKappa-type opioid receptorHomo sapiens (human)
behavioral response to cocaineKappa-type opioid receptorHomo sapiens (human)
sensory perception of temperature stimulusKappa-type opioid receptorHomo sapiens (human)
defense response to virusKappa-type opioid receptorHomo sapiens (human)
cellular response to lipopolysaccharideKappa-type opioid receptorHomo sapiens (human)
cellular response to glucose stimulusKappa-type opioid receptorHomo sapiens (human)
positive regulation of p38MAPK cascadeKappa-type opioid receptorHomo sapiens (human)
positive regulation of potassium ion transmembrane transportKappa-type opioid receptorHomo sapiens (human)
response to acrylamideKappa-type opioid receptorHomo sapiens (human)
positive regulation of eating behaviorKappa-type opioid receptorHomo sapiens (human)
conditioned place preferenceKappa-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayKappa-type opioid receptorHomo sapiens (human)
neural crest cell migration5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cytokine production5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of endothelial cell proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 2BHomo sapiens (human)
heart morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
cardiac muscle hypertrophy5-hydroxytryptamine receptor 2BHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
neural crest cell differentiation5-hydroxytryptamine receptor 2BHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphorylation5-hydroxytryptamine receptor 2BHomo sapiens (human)
calcium-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of apoptotic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of MAP kinase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
embryonic morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of nitric-oxide synthase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell division5-hydroxytryptamine receptor 2BHomo sapiens (human)
ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2BHomo sapiens (human)
cerebral cortex cell migration5-hydroxytryptamine receptor 6Homo sapiens (human)
positive regulation of TOR signaling5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 6Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 6Homo sapiens (human)
tolerance inductionC-C chemokine receptor type 4Homo sapiens (human)
chemotaxisC-C chemokine receptor type 4Homo sapiens (human)
inflammatory responseC-C chemokine receptor type 4Homo sapiens (human)
response to bacteriumC-C chemokine receptor type 4Homo sapiens (human)
homeostasis of number of cellsC-C chemokine receptor type 4Homo sapiens (human)
positive regulation of positive chemotaxisC-C chemokine receptor type 4Homo sapiens (human)
chemokine-mediated signaling pathwayC-C chemokine receptor type 4Homo sapiens (human)
interneuron migrationC-C chemokine receptor type 4Homo sapiens (human)
cell chemotaxisC-C chemokine receptor type 4Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-C chemokine receptor type 4Homo sapiens (human)
immune responseC-C chemokine receptor type 4Homo sapiens (human)
calcium-mediated signalingC-C chemokine receptor type 4Homo sapiens (human)
DNA repairTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
double-strand break repairTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
ubiquitin-dependent protein catabolic processTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
NADH metabolic processTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
endoplasmic reticulum to Golgi vesicle-mediated transportTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
autophagyTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
DNA damage responseTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
proteasomal protein catabolic processTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
positive regulation of mitochondrial membrane potentialTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
macroautophagyTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
protein ubiquitinationTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
viral genome replicationTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
translesion synthesisTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
endoplasmic reticulum unfolded protein responseTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
retrograde protein transport, ER to cytosolTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
positive regulation of protein-containing complex assemblyTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
endosome to lysosome transport via multivesicular body sorting pathwayTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
cellular response to heatTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
stress granule disassemblyTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
interstrand cross-link repairTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
ERAD pathwayTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
regulation of apoptotic processTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
establishment of protein localizationTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
positive regulation of protein catabolic processTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
negative regulation of smoothened signaling pathwayTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
ATP metabolic processTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
regulation of synapse organizationTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
endoplasmic reticulum stress-induced pre-emptive quality controlTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
aggresome assemblyTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
cellular response to misfolded proteinTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
flavin adenine dinucleotide catabolic processTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
autophagosome maturationTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
protein-DNA covalent cross-linking repairTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
negative regulation of protein localization to chromatinTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
positive regulation of protein K63-linked deubiquitinationTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
positive regulation of Lys63-specific deubiquitinase activityTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
regulation of aerobic respirationTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
cellular response to arsenite ionTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
positive regulation of oxidative phosphorylationTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
regulation of protein localization to chromatinTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
positive regulation of ATP biosynthetic processTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
mitotic spindle disassemblyTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to hypoxiaDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
neutrophil mediated immunityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
germinal center formationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of leukocyte chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch receptor processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell population proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to xenobiotic stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of T cell chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
signal releaseDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
B cell differentiationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell growthDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to lipopolysaccharideDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of chemokine productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
regulation of mast cell apoptotic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
T cell differentiation in thymusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesion mediated by integrinDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
wound healing, spreading of epidermal cellsDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
spleen developmentDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell motilityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
defense response to Gram-positive bacteriumDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cellular response to high density lipoprotein particle stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
commissural neuron axon guidanceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of cold-induced thermogenesisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
monoamine transportSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent dopamine transporter Homo sapiens (human)
lactationSodium-dependent dopamine transporter Homo sapiens (human)
sensory perception of smellSodium-dependent dopamine transporter Homo sapiens (human)
locomotory behaviorSodium-dependent dopamine transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent dopamine transporter Homo sapiens (human)
response to iron ionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine transportSodium-dependent dopamine transporter Homo sapiens (human)
adenohypophysis developmentSodium-dependent dopamine transporter Homo sapiens (human)
response to nicotineSodium-dependent dopamine transporter Homo sapiens (human)
positive regulation of multicellular organism growthSodium-dependent dopamine transporter Homo sapiens (human)
regulation of dopamine metabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to cocaineSodium-dependent dopamine transporter Homo sapiens (human)
dopamine biosynthetic processSodium-dependent dopamine transporter Homo sapiens (human)
dopamine catabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to ethanolSodium-dependent dopamine transporter Homo sapiens (human)
cognitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent dopamine transporter Homo sapiens (human)
response to cAMPSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
prepulse inhibitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
hyaloid vascular plexus regressionSodium-dependent dopamine transporter Homo sapiens (human)
amino acid transportSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine transportSodium-dependent dopamine transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent dopamine transporter Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
immune system developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
heart developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
embryonic forelimb morphogenesisVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
camera-type eye developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transport into cytosolVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transport via high voltage-gated calcium channelVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cell communication by electrical coupling involved in cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of ventricular cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
osteoblast differentiationNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
signal transductionNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
cell differentiationNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
steroid biosynthetic processLanosterol 14-alpha demethylaseHomo sapiens (human)
cholesterol biosynthetic processLanosterol 14-alpha demethylaseHomo sapiens (human)
sterol metabolic processLanosterol 14-alpha demethylaseHomo sapiens (human)
negative regulation of protein catabolic processLanosterol 14-alpha demethylaseHomo sapiens (human)
negative regulation of protein secretionLanosterol 14-alpha demethylaseHomo sapiens (human)
negative regulation of amyloid-beta clearanceLanosterol 14-alpha demethylaseHomo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
calcium-ion regulated exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
positive regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of synaptic vesicle cycleRap guanine nucleotide exchange factor 4Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of very-low-density lipoprotein particle remodelingBile acid receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionBile acid receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
nitrogen catabolite activation of transcription from RNA polymerase II promoterBile acid receptorHomo sapiens (human)
intracellular glucose homeostasisBile acid receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
inflammatory responseBile acid receptorHomo sapiens (human)
cell-cell junction assemblyBile acid receptorHomo sapiens (human)
Notch signaling pathwayBile acid receptorHomo sapiens (human)
bile acid metabolic processBile acid receptorHomo sapiens (human)
negative regulation of tumor necrosis factor-mediated signaling pathwayBile acid receptorHomo sapiens (human)
regulation of low-density lipoprotein particle clearanceBile acid receptorHomo sapiens (human)
intracellular receptor signaling pathwayBile acid receptorHomo sapiens (human)
negative regulation of type II interferon productionBile acid receptorHomo sapiens (human)
negative regulation of interleukin-1 productionBile acid receptorHomo sapiens (human)
negative regulation of interleukin-2 productionBile acid receptorHomo sapiens (human)
negative regulation of interleukin-6 productionBile acid receptorHomo sapiens (human)
negative regulation of tumor necrosis factor productionBile acid receptorHomo sapiens (human)
positive regulation of interleukin-17 productionBile acid receptorHomo sapiens (human)
toll-like receptor 9 signaling pathwayBile acid receptorHomo sapiens (human)
regulation of urea metabolic processBile acid receptorHomo sapiens (human)
intracellular triglyceride homeostasisBile acid receptorHomo sapiens (human)
positive regulation of insulin secretion involved in cellular response to glucose stimulusBile acid receptorHomo sapiens (human)
bile acid signaling pathwayBile acid receptorHomo sapiens (human)
intracellular bile acid receptor signaling pathwayBile acid receptorHomo sapiens (human)
cholesterol homeostasisBile acid receptorHomo sapiens (human)
defense response to bacteriumBile acid receptorHomo sapiens (human)
negative regulation of apoptotic processBile acid receptorHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionBile acid receptorHomo sapiens (human)
innate immune responseBile acid receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
positive regulation of insulin receptor signaling pathwayBile acid receptorHomo sapiens (human)
fatty acid homeostasisBile acid receptorHomo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulusBile acid receptorHomo sapiens (human)
regulation of bile acid biosynthetic processBile acid receptorHomo sapiens (human)
cellular response to lipopolysaccharideBile acid receptorHomo sapiens (human)
cellular response to fatty acidBile acid receptorHomo sapiens (human)
cellular response to organonitrogen compoundBile acid receptorHomo sapiens (human)
negative regulation of monocyte chemotactic protein-1 productionBile acid receptorHomo sapiens (human)
regulation of cholesterol metabolic processBile acid receptorHomo sapiens (human)
cellular response to bile acidBile acid receptorHomo sapiens (human)
positive regulation of adipose tissue developmentBile acid receptorHomo sapiens (human)
positive regulation of phosphatidic acid biosynthetic processBile acid receptorHomo sapiens (human)
positive regulation of glutamate metabolic processBile acid receptorHomo sapiens (human)
positive regulation of ammonia assimilation cycleBile acid receptorHomo sapiens (human)
cell differentiationBile acid receptorHomo sapiens (human)
negative regulation of inflammatory responseBile acid receptorHomo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
inflammatory response to antigenic stimulusCysteinyl leukotriene receptor 1Homo sapiens (human)
calcium ion transportCysteinyl leukotriene receptor 1Homo sapiens (human)
chemotaxisCysteinyl leukotriene receptor 1Homo sapiens (human)
defense responseCysteinyl leukotriene receptor 1Homo sapiens (human)
cell surface receptor signaling pathwayCysteinyl leukotriene receptor 1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationCysteinyl leukotriene receptor 1Homo sapiens (human)
respiratory gaseous exchange by respiratory systemCysteinyl leukotriene receptor 1Homo sapiens (human)
positive regulation of angiogenesisCysteinyl leukotriene receptor 1Homo sapiens (human)
positive regulation of vasoconstrictionCysteinyl leukotriene receptor 1Homo sapiens (human)
establishment of localization in cellCysteinyl leukotriene receptor 1Homo sapiens (human)
positive regulation of glial cell proliferationCysteinyl leukotriene receptor 1Homo sapiens (human)
leukotriene signaling pathwayCysteinyl leukotriene receptor 1Homo sapiens (human)
cellular response to hypoxiaCysteinyl leukotriene receptor 1Homo sapiens (human)
neuropeptide signaling pathwayCysteinyl leukotriene receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (355)

Processvia Protein(s)Taxonomy
acetylcholine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
dopamine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
secondary active organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
potassium channel activityIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
protein bindingIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
calcium-activated potassium channel activityIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
small conductance calcium-activated potassium channel activityIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
protein phosphatase bindingIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
calmodulin bindingIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
intermediate conductance calcium-activated potassium channel activityIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
hydrolase activityTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
ADP-ribose diphosphatase activityTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
monoatomic cation channel activityTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
calcium channel activityTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
sodium channel activityTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
manganese ion transmembrane transporter activityTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
calcium ion bindingTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
intracellularly gated calcium channel activityTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
mono-ADP-D-ribose bindingTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
ligand-gated calcium channel activityTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
virus receptor activityEpidermal growth factor receptorHomo sapiens (human)
chromatin bindingEpidermal growth factor receptorHomo sapiens (human)
double-stranded DNA bindingEpidermal growth factor receptorHomo sapiens (human)
MAP kinase kinase kinase activityEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane signaling receptor activityEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
integrin bindingEpidermal growth factor receptorHomo sapiens (human)
protein bindingEpidermal growth factor receptorHomo sapiens (human)
calmodulin bindingEpidermal growth factor receptorHomo sapiens (human)
ATP bindingEpidermal growth factor receptorHomo sapiens (human)
enzyme bindingEpidermal growth factor receptorHomo sapiens (human)
kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein phosphatase bindingEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
ubiquitin protein ligase bindingEpidermal growth factor receptorHomo sapiens (human)
identical protein bindingEpidermal growth factor receptorHomo sapiens (human)
cadherin bindingEpidermal growth factor receptorHomo sapiens (human)
actin filament bindingEpidermal growth factor receptorHomo sapiens (human)
ATPase bindingEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor bindingEpidermal growth factor receptorHomo sapiens (human)
protein bindingChymotrypsinogen ABos taurus (cattle)
serpin family protein bindingChymotrypsinogen ABos taurus (cattle)
beta-lactamase activityBeta-lactamaseEscherichia coli K-12
hydrolase activityBeta-lactamaseEscherichia coli K-12
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
core promoter sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription factor activityGlucocorticoid receptorHomo sapiens (human)
RNA bindingGlucocorticoid receptorHomo sapiens (human)
nuclear receptor activityGlucocorticoid receptorHomo sapiens (human)
nuclear glucocorticoid receptor activityGlucocorticoid receptorHomo sapiens (human)
steroid bindingGlucocorticoid receptorHomo sapiens (human)
protein bindingGlucocorticoid receptorHomo sapiens (human)
zinc ion bindingGlucocorticoid receptorHomo sapiens (human)
TBP-class protein bindingGlucocorticoid receptorHomo sapiens (human)
protein kinase bindingGlucocorticoid receptorHomo sapiens (human)
identical protein bindingGlucocorticoid receptorHomo sapiens (human)
Hsp90 protein bindingGlucocorticoid receptorHomo sapiens (human)
steroid hormone bindingGlucocorticoid receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingGlucocorticoid receptorHomo sapiens (human)
estrogen response element bindingGlucocorticoid receptorHomo sapiens (human)
growth factor bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
RNA polymerase I core bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein tyrosine kinase activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
transmembrane signaling receptor activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
signaling receptor bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ATP bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
coreceptor activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
receptor tyrosine kinase bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
identical protein bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ErbB-3 class receptor bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein heterodimerization activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
steroid 17-alpha-monooxygenase activitySteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
iron ion bindingSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
oxygen bindingSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
heme bindingSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
17-alpha-hydroxyprogesterone aldolase activitySteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase FynHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase FynHomo sapiens (human)
protein bindingTyrosine-protein kinase FynHomo sapiens (human)
ATP bindingTyrosine-protein kinase FynHomo sapiens (human)
phospholipase activator activityTyrosine-protein kinase FynHomo sapiens (human)
enzyme bindingTyrosine-protein kinase FynHomo sapiens (human)
type 5 metabotropic glutamate receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
identical protein bindingTyrosine-protein kinase FynHomo sapiens (human)
alpha-tubulin bindingTyrosine-protein kinase FynHomo sapiens (human)
phospholipase bindingTyrosine-protein kinase FynHomo sapiens (human)
transmembrane transporter bindingTyrosine-protein kinase FynHomo sapiens (human)
metal ion bindingTyrosine-protein kinase FynHomo sapiens (human)
ephrin receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
tau protein bindingTyrosine-protein kinase FynHomo sapiens (human)
tau-protein kinase activityTyrosine-protein kinase FynHomo sapiens (human)
growth factor receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
scaffold protein bindingTyrosine-protein kinase FynHomo sapiens (human)
disordered domain specific bindingTyrosine-protein kinase FynHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
arrestin family protein bindingMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M4Homo sapiens (human)
protein bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATP bindingATP-dependent translocase ABCB1Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
efflux transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ATP hydrolysis activityATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ubiquitin protein ligase bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylcholine floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylethanolamine flippase activityATP-dependent translocase ABCB1Homo sapiens (human)
ceramide floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
beta-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
beta1-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
protein bindingBeta-1 adrenergic receptorHomo sapiens (human)
PDZ domain bindingBeta-1 adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingBeta-1 adrenergic receptorHomo sapiens (human)
protein heterodimerization activityBeta-1 adrenergic receptorHomo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein kinase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-1B adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-2C adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
thioesterase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
heterotrimeric G-protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A3Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
iron ion bindingAromataseHomo sapiens (human)
steroid hydroxylase activityAromataseHomo sapiens (human)
electron transfer activityAromataseHomo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenAromataseHomo sapiens (human)
oxygen bindingAromataseHomo sapiens (human)
heme bindingAromataseHomo sapiens (human)
aromatase activityAromataseHomo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
norepinephrine bindingBeta-3 adrenergic receptorHomo sapiens (human)
beta-adrenergic receptor activityBeta-3 adrenergic receptorHomo sapiens (human)
protein bindingBeta-3 adrenergic receptorHomo sapiens (human)
beta3-adrenergic receptor activityBeta-3 adrenergic receptorHomo sapiens (human)
beta-3 adrenergic receptor bindingBeta-3 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-3 adrenergic receptorHomo sapiens (human)
epinephrine bindingBeta-3 adrenergic receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(2) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(2) dopamine receptorHomo sapiens (human)
protein bindingD(2) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(2) dopamine receptorHomo sapiens (human)
dopamine bindingD(2) dopamine receptorHomo sapiens (human)
ionotropic glutamate receptor bindingD(2) dopamine receptorHomo sapiens (human)
identical protein bindingD(2) dopamine receptorHomo sapiens (human)
heterocyclic compound bindingD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(2) dopamine receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2B adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2B adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2B adrenergic receptorHomo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
signaling receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-dependent translocase ABCB1Mus musculus (house mouse)
tachykinin receptor activitySubstance-K receptorHomo sapiens (human)
protein bindingSubstance-K receptorHomo sapiens (human)
substance K receptor activitySubstance-K receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via GsD(1A) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(1A) dopamine receptorHomo sapiens (human)
protein bindingD(1A) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine bindingD(1A) dopamine receptorHomo sapiens (human)
arrestin family protein bindingD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(1A) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(4) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(4) dopamine receptorHomo sapiens (human)
protein bindingD(4) dopamine receptorHomo sapiens (human)
potassium channel regulator activityD(4) dopamine receptorHomo sapiens (human)
SH3 domain bindingD(4) dopamine receptorHomo sapiens (human)
dopamine bindingD(4) dopamine receptorHomo sapiens (human)
identical protein bindingD(4) dopamine receptorHomo sapiens (human)
metal ion bindingD(4) dopamine receptorHomo sapiens (human)
epinephrine bindingD(4) dopamine receptorHomo sapiens (human)
norepinephrine bindingD(4) dopamine receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityD(4) dopamine receptorHomo sapiens (human)
neurotransmitter receptor activityD(4) dopamine receptorHomo sapiens (human)
serotonin bindingD(4) dopamine receptorHomo sapiens (human)
voltage-gated monoatomic ion channel activityPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
outward rectifier potassium channel activityPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monooxygenase activityThromboxane-A synthase Homo sapiens (human)
thromboxane-A synthase activityThromboxane-A synthase Homo sapiens (human)
iron ion bindingThromboxane-A synthase Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygenThromboxane-A synthase Homo sapiens (human)
heme bindingThromboxane-A synthase Homo sapiens (human)
12-hydroxyheptadecatrienoic acid synthase activityThromboxane-A synthase Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityThromboxane-A synthase Homo sapiens (human)
histamine receptor activityHistamine H2 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H2 receptorHomo sapiens (human)
neurotransmitter receptor activityHistamine H2 receptorHomo sapiens (human)
interleukin-8 receptor activityC-X-C chemokine receptor type 1Homo sapiens (human)
G protein-coupled receptor activityC-X-C chemokine receptor type 1Homo sapiens (human)
chemokine receptor activityC-X-C chemokine receptor type 1Homo sapiens (human)
protein bindingC-X-C chemokine receptor type 1Homo sapiens (human)
interleukin-8 bindingC-X-C chemokine receptor type 1Homo sapiens (human)
C-C chemokine receptor activityC-X-C chemokine receptor type 1Homo sapiens (human)
C-C chemokine bindingC-X-C chemokine receptor type 1Homo sapiens (human)
protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
identical protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1D adrenergic receptorHomo sapiens (human)
tachykinin receptor activitySubstance-P receptorHomo sapiens (human)
protein bindingSubstance-P receptorHomo sapiens (human)
substance P receptor activitySubstance-P receptorHomo sapiens (human)
lipopolysaccharide bindingPlatelet-activating factor receptorHomo sapiens (human)
lipopolysaccharide immune receptor activityPlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled receptor activityPlatelet-activating factor receptorHomo sapiens (human)
platelet activating factor receptor activityPlatelet-activating factor receptorHomo sapiens (human)
protein bindingPlatelet-activating factor receptorHomo sapiens (human)
phospholipid bindingPlatelet-activating factor receptorHomo sapiens (human)
mitogen-activated protein kinase bindingPlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled purinergic nucleotide receptor activityPlatelet-activating factor receptorHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
virus receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein-containing complex binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aHomo sapiens (human)
protein bindingAdenosine receptor A2aHomo sapiens (human)
calmodulin bindingAdenosine receptor A2aHomo sapiens (human)
lipid bindingAdenosine receptor A2aHomo sapiens (human)
enzyme bindingAdenosine receptor A2aHomo sapiens (human)
type 5 metabotropic glutamate receptor bindingAdenosine receptor A2aHomo sapiens (human)
identical protein bindingAdenosine receptor A2aHomo sapiens (human)
protein-containing complex bindingAdenosine receptor A2aHomo sapiens (human)
alpha-actinin bindingAdenosine receptor A2aHomo sapiens (human)
vasopressin receptor activityVasopressin V2 receptorHomo sapiens (human)
protein bindingVasopressin V2 receptorHomo sapiens (human)
peptide bindingVasopressin V2 receptorHomo sapiens (human)
G protein-coupled receptor bindingAdenosine receptor A1Homo sapiens (human)
purine nucleoside bindingAdenosine receptor A1Homo sapiens (human)
protein bindingAdenosine receptor A1Homo sapiens (human)
heat shock protein bindingAdenosine receptor A1Homo sapiens (human)
G-protein beta/gamma-subunit complex bindingAdenosine receptor A1Homo sapiens (human)
heterotrimeric G-protein bindingAdenosine receptor A1Homo sapiens (human)
protein heterodimerization activityAdenosine receptor A1Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A1Homo sapiens (human)
integrin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoatomic cation channel activitySodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activitySodium-dependent serotonin transporterHomo sapiens (human)
protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
antiporter activitySodium-dependent serotonin transporterHomo sapiens (human)
syntaxin-1 bindingSodium-dependent serotonin transporterHomo sapiens (human)
cocaine bindingSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion bindingSodium-dependent serotonin transporterHomo sapiens (human)
identical protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
nitric-oxide synthase bindingSodium-dependent serotonin transporterHomo sapiens (human)
actin filament bindingSodium-dependent serotonin transporterHomo sapiens (human)
serotonin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingProstaglandin G/H synthase 2Homo sapiens (human)
enzyme bindingProstaglandin G/H synthase 2Homo sapiens (human)
heme bindingProstaglandin G/H synthase 2Homo sapiens (human)
protein homodimerization activityProstaglandin G/H synthase 2Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 2Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 2Homo sapiens (human)
histamine receptor activityHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H1 receptorHomo sapiens (human)
neurotransmitter receptor activityHistamine H1 receptorHomo sapiens (human)
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(3) dopamine receptorHomo sapiens (human)
protein bindingD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(3) dopamine receptorHomo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
malic enzyme activityMalate dehydrogenase, cytoplasmicHomo sapiens (human)
protein bindingMalate dehydrogenase, cytoplasmicHomo sapiens (human)
L-malate dehydrogenase activityMalate dehydrogenase, cytoplasmicHomo sapiens (human)
diiodophenylpyruvate reductase activityMalate dehydrogenase, cytoplasmicHomo sapiens (human)
hydroxyphenylpyruvate reductase activityMalate dehydrogenase, cytoplasmicHomo sapiens (human)
G protein-coupled opioid receptor activityDelta-type opioid receptorHomo sapiens (human)
protein bindingDelta-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled enkephalin receptor activityDelta-type opioid receptorHomo sapiens (human)
neuropeptide bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityKappa-type opioid receptorHomo sapiens (human)
protein bindingKappa-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingKappa-type opioid receptorHomo sapiens (human)
dynorphin receptor activityKappa-type opioid receptorHomo sapiens (human)
neuropeptide bindingKappa-type opioid receptorHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G-protein alpha-subunit binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
GTPase activator activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
histamine receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 6Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
chemokine receptor activityC-C chemokine receptor type 4Homo sapiens (human)
protein bindingC-C chemokine receptor type 4Homo sapiens (human)
C-C chemokine receptor activityC-C chemokine receptor type 4Homo sapiens (human)
C-C chemokine bindingC-C chemokine receptor type 4Homo sapiens (human)
RNA bindingTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
protein bindingTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
ATP bindingTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
lipid bindingTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
ATP hydrolysis activityTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
protein phosphatase bindingTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
protein domain specific bindingTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
polyubiquitin modification-dependent protein bindingTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
ubiquitin protein ligase bindingTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
deubiquitinase activator activityTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
K48-linked polyubiquitin modification-dependent protein bindingTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
MHC class I protein bindingTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
identical protein bindingTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
ADP bindingTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
ubiquitin-like protein ligase bindingTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
ubiquitin-modified protein reader activityTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
BAT3 complex bindingTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
ubiquitin-specific protease bindingTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
endopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
interleukin-6 receptor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
integrin bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
peptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metallopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
SH3 domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytokine bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
PDZ domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
tumor necrosis factor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metal ion bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activity involved in amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protease bindingSodium-dependent dopamine transporter Homo sapiens (human)
signaling receptor bindingSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
protein bindingSodium-dependent dopamine transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine bindingSodium-dependent dopamine transporter Homo sapiens (human)
amine bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein-containing complex bindingSodium-dependent dopamine transporter Homo sapiens (human)
metal ion bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein phosphatase 2A bindingSodium-dependent dopamine transporter Homo sapiens (human)
heterocyclic compound bindingSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
DNA-binding transcription factor activityNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
nuclear receptor activityNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
protein bindingNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
zinc ion bindingNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
iron ion bindingLanosterol 14-alpha demethylaseHomo sapiens (human)
sterol 14-demethylase activityLanosterol 14-alpha demethylaseHomo sapiens (human)
heme bindingLanosterol 14-alpha demethylaseHomo sapiens (human)
oxidoreductase activityLanosterol 14-alpha demethylaseHomo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenLanosterol 14-alpha demethylaseHomo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein-macromolecule adaptor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
small GTPase bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingBile acid receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingBile acid receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificBile acid receptorHomo sapiens (human)
transcription coregulator bindingBile acid receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificBile acid receptorHomo sapiens (human)
DNA-binding transcription factor activityBile acid receptorHomo sapiens (human)
nuclear receptor activityBile acid receptorHomo sapiens (human)
protein bindingBile acid receptorHomo sapiens (human)
zinc ion bindingBile acid receptorHomo sapiens (human)
nuclear receptor bindingBile acid receptorHomo sapiens (human)
bile acid bindingBile acid receptorHomo sapiens (human)
bile acid receptor activityBile acid receptorHomo sapiens (human)
sequence-specific DNA bindingBile acid receptorHomo sapiens (human)
nuclear retinoid X receptor bindingBile acid receptorHomo sapiens (human)
chenodeoxycholic acid bindingBile acid receptorHomo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
leukotriene receptor activityCysteinyl leukotriene receptor 1Homo sapiens (human)
cysteinyl leukotriene receptor activityCysteinyl leukotriene receptor 1Homo sapiens (human)
G protein-coupled peptide receptor activityCysteinyl leukotriene receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (188)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
membraneSolute carrier family 22 member 1 Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
lateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
presynapseSolute carrier family 22 member 1 Homo sapiens (human)
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
plasma membraneIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
vesicleIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
voltage-gated potassium channel complexIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
plasma membraneIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
neuronal cell bodyIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
neuron projectionIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
lysosomeTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
lysosomal membraneTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
cytoplasmic vesicle membraneTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
specific granule membraneTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
cell projectionTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
perikaryonTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
tertiary granule membraneTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
ficolin-1-rich granule membraneTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
endosomeEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
ruffle membraneEpidermal growth factor receptorHomo sapiens (human)
Golgi membraneEpidermal growth factor receptorHomo sapiens (human)
extracellular spaceEpidermal growth factor receptorHomo sapiens (human)
nucleusEpidermal growth factor receptorHomo sapiens (human)
cytoplasmEpidermal growth factor receptorHomo sapiens (human)
endosomeEpidermal growth factor receptorHomo sapiens (human)
endoplasmic reticulum membraneEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
focal adhesionEpidermal growth factor receptorHomo sapiens (human)
cell surfaceEpidermal growth factor receptorHomo sapiens (human)
endosome membraneEpidermal growth factor receptorHomo sapiens (human)
membraneEpidermal growth factor receptorHomo sapiens (human)
basolateral plasma membraneEpidermal growth factor receptorHomo sapiens (human)
apical plasma membraneEpidermal growth factor receptorHomo sapiens (human)
cell junctionEpidermal growth factor receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneEpidermal growth factor receptorHomo sapiens (human)
early endosome membraneEpidermal growth factor receptorHomo sapiens (human)
nuclear membraneEpidermal growth factor receptorHomo sapiens (human)
membrane raftEpidermal growth factor receptorHomo sapiens (human)
perinuclear region of cytoplasmEpidermal growth factor receptorHomo sapiens (human)
multivesicular body, internal vesicle lumenEpidermal growth factor receptorHomo sapiens (human)
intracellular vesicleEpidermal growth factor receptorHomo sapiens (human)
protein-containing complexEpidermal growth factor receptorHomo sapiens (human)
receptor complexEpidermal growth factor receptorHomo sapiens (human)
Shc-EGFR complexEpidermal growth factor receptorHomo sapiens (human)
basal plasma membraneEpidermal growth factor receptorHomo sapiens (human)
extracellular regionChymotrypsinogen ABos taurus (cattle)
serine protease inhibitor complexChymotrypsinogen ABos taurus (cattle)
outer membrane-bounded periplasmic spaceBeta-lactamaseEscherichia coli K-12
periplasmic spaceBeta-lactamaseEscherichia coli K-12
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nucleusGlucocorticoid receptorHomo sapiens (human)
nucleusGlucocorticoid receptorHomo sapiens (human)
nucleoplasmGlucocorticoid receptorHomo sapiens (human)
cytoplasmGlucocorticoid receptorHomo sapiens (human)
mitochondrial matrixGlucocorticoid receptorHomo sapiens (human)
centrosomeGlucocorticoid receptorHomo sapiens (human)
spindleGlucocorticoid receptorHomo sapiens (human)
cytosolGlucocorticoid receptorHomo sapiens (human)
membraneGlucocorticoid receptorHomo sapiens (human)
nuclear speckGlucocorticoid receptorHomo sapiens (human)
synapseGlucocorticoid receptorHomo sapiens (human)
chromatinGlucocorticoid receptorHomo sapiens (human)
protein-containing complexGlucocorticoid receptorHomo sapiens (human)
semaphorin receptor complexReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
nucleusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
nucleoplasmReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
early endosomeReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cytosolReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
endosome membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
basolateral plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
apical plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neuromuscular junctionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ruffle membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
presynaptic membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
myelin sheathReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
perinuclear region of cytoplasmReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ERBB3:ERBB2 complexReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
receptor complexReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
basal plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
endoplasmic reticulum membraneSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
axonSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
neuronal cell bodySteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
membrane raftTyrosine-protein kinase FynHomo sapiens (human)
dendriteTyrosine-protein kinase FynHomo sapiens (human)
nucleusTyrosine-protein kinase FynHomo sapiens (human)
mitochondrionTyrosine-protein kinase FynHomo sapiens (human)
endosomeTyrosine-protein kinase FynHomo sapiens (human)
cytosolTyrosine-protein kinase FynHomo sapiens (human)
actin filamentTyrosine-protein kinase FynHomo sapiens (human)
plasma membraneTyrosine-protein kinase FynHomo sapiens (human)
postsynaptic densityTyrosine-protein kinase FynHomo sapiens (human)
dendriteTyrosine-protein kinase FynHomo sapiens (human)
perikaryonTyrosine-protein kinase FynHomo sapiens (human)
cell bodyTyrosine-protein kinase FynHomo sapiens (human)
membrane raftTyrosine-protein kinase FynHomo sapiens (human)
perinuclear region of cytoplasmTyrosine-protein kinase FynHomo sapiens (human)
perinuclear endoplasmic reticulumTyrosine-protein kinase FynHomo sapiens (human)
glial cell projectionTyrosine-protein kinase FynHomo sapiens (human)
Schaffer collateral - CA1 synapseTyrosine-protein kinase FynHomo sapiens (human)
plasma membraneTyrosine-protein kinase FynHomo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
clathrin-coated endocytic vesicle membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
asymmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
symmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
neuronal cell bodyMuscarinic acetylcholine receptor M2Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M2Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M4Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M4Homo sapiens (human)
cytoplasmATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cell surfaceATP-dependent translocase ABCB1Homo sapiens (human)
membraneATP-dependent translocase ABCB1Homo sapiens (human)
apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
extracellular exosomeATP-dependent translocase ABCB1Homo sapiens (human)
external side of apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
early endosomeBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
Schaffer collateral - CA1 synapseBeta-1 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
cytoplasmAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
basolateral plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
neuronal cell bodyAlpha-2A adrenergic receptorHomo sapiens (human)
axon terminusAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic active zone membraneAlpha-2A adrenergic receptorHomo sapiens (human)
dopaminergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
postsynaptic density membraneAlpha-2A adrenergic receptorHomo sapiens (human)
glutamatergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
GABA-ergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
receptor complexAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
presynaptic membraneAdenosine receptor A3Homo sapiens (human)
Schaffer collateral - CA1 synapseAdenosine receptor A3Homo sapiens (human)
dendriteAdenosine receptor A3Homo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
synapseAdenosine receptor A3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M1Homo sapiens (human)
Schaffer collateral - CA1 synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic density membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M1Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
endoplasmic reticulum membraneAromataseHomo sapiens (human)
membraneAromataseHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
plasma membraneBeta-3 adrenergic receptorHomo sapiens (human)
receptor complexBeta-3 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-3 adrenergic receptorHomo sapiens (human)
Golgi membraneD(2) dopamine receptorHomo sapiens (human)
acrosomal vesicleD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
ciliumD(2) dopamine receptorHomo sapiens (human)
lateral plasma membraneD(2) dopamine receptorHomo sapiens (human)
endocytic vesicleD(2) dopamine receptorHomo sapiens (human)
axonD(2) dopamine receptorHomo sapiens (human)
dendriteD(2) dopamine receptorHomo sapiens (human)
synaptic vesicle membraneD(2) dopamine receptorHomo sapiens (human)
sperm flagellumD(2) dopamine receptorHomo sapiens (human)
dendritic spineD(2) dopamine receptorHomo sapiens (human)
perikaryonD(2) dopamine receptorHomo sapiens (human)
axon terminusD(2) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(2) dopamine receptorHomo sapiens (human)
ciliary membraneD(2) dopamine receptorHomo sapiens (human)
non-motile ciliumD(2) dopamine receptorHomo sapiens (human)
dopaminergic synapseD(2) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(2) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(2) dopamine receptorHomo sapiens (human)
presynaptic membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
cytosolAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cell surfaceAlpha-2B adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basal plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basolateral plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneGlycine receptor subunit betaRattus norvegicus (Norway rat)
plasma membraneATP-dependent translocase ABCB1Mus musculus (house mouse)
plasma membraneSubstance-K receptorHomo sapiens (human)
sperm flagellumSubstance-K receptorHomo sapiens (human)
sperm headSubstance-K receptorHomo sapiens (human)
sperm midpieceSubstance-K receptorHomo sapiens (human)
sperm midpieceSubstance-K receptorHomo sapiens (human)
plasma membraneSubstance-K receptorHomo sapiens (human)
nucleusD(1A) dopamine receptorHomo sapiens (human)
endoplasmic reticulum membraneD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
ciliumD(1A) dopamine receptorHomo sapiens (human)
presynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
dendritic spineD(1A) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
ciliary membraneD(1A) dopamine receptorHomo sapiens (human)
non-motile ciliumD(1A) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(1A) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
centrosomeD(4) dopamine receptorHomo sapiens (human)
plasma membraneD(4) dopamine receptorHomo sapiens (human)
membraneD(4) dopamine receptorHomo sapiens (human)
postsynapseD(4) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(4) dopamine receptorHomo sapiens (human)
plasma membraneD(4) dopamine receptorHomo sapiens (human)
dendriteD(4) dopamine receptorHomo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
presynaptic membranePotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
calyx of HeldPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
membrane raftPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
postsynaptic membranePotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
glutamatergic synapsePotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
axonPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
membranePotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
endoplasmic reticulumThromboxane-A synthase Homo sapiens (human)
endoplasmic reticulum membraneThromboxane-A synthase Homo sapiens (human)
cytosolThromboxane-A synthase Homo sapiens (human)
plasma membraneHistamine H2 receptorHomo sapiens (human)
synapseHistamine H2 receptorHomo sapiens (human)
plasma membraneHistamine H2 receptorHomo sapiens (human)
dendriteHistamine H2 receptorHomo sapiens (human)
plasma membraneC-X-C chemokine receptor type 1Homo sapiens (human)
secretory granule membraneC-X-C chemokine receptor type 1Homo sapiens (human)
external side of plasma membraneC-X-C chemokine receptor type 1Homo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
plasma membraneSubstance-P receptorHomo sapiens (human)
cell surfaceSubstance-P receptorHomo sapiens (human)
dendriteSubstance-P receptorHomo sapiens (human)
sperm flagellumSubstance-P receptorHomo sapiens (human)
cell bodySubstance-P receptorHomo sapiens (human)
sperm headSubstance-P receptorHomo sapiens (human)
sperm midpieceSubstance-P receptorHomo sapiens (human)
plasma membraneSubstance-P receptorHomo sapiens (human)
sperm midpieceSubstance-P receptorHomo sapiens (human)
plasma membranePlatelet-activating factor receptorHomo sapiens (human)
membranePlatelet-activating factor receptorHomo sapiens (human)
secretory granule membranePlatelet-activating factor receptorHomo sapiens (human)
tertiary granule membranePlatelet-activating factor receptorHomo sapiens (human)
neurofilament5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
caveola5-hydroxytryptamine receptor 2AHomo sapiens (human)
axon5-hydroxytryptamine receptor 2AHomo sapiens (human)
cytoplasmic vesicle5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
neuronal cell body5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendritic shaft5-hydroxytryptamine receptor 2AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
cell body fiber5-hydroxytryptamine receptor 2AHomo sapiens (human)
glutamatergic synapse5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
intermediate filamentAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
membraneAdenosine receptor A2aHomo sapiens (human)
dendriteAdenosine receptor A2aHomo sapiens (human)
axolemmaAdenosine receptor A2aHomo sapiens (human)
asymmetric synapseAdenosine receptor A2aHomo sapiens (human)
presynaptic membraneAdenosine receptor A2aHomo sapiens (human)
neuronal cell bodyAdenosine receptor A2aHomo sapiens (human)
postsynaptic membraneAdenosine receptor A2aHomo sapiens (human)
presynaptic active zoneAdenosine receptor A2aHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2aHomo sapiens (human)
endosomeVasopressin V2 receptorHomo sapiens (human)
endoplasmic reticulumVasopressin V2 receptorHomo sapiens (human)
Golgi apparatusVasopressin V2 receptorHomo sapiens (human)
plasma membraneVasopressin V2 receptorHomo sapiens (human)
membraneVasopressin V2 receptorHomo sapiens (human)
endocytic vesicleVasopressin V2 receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneVasopressin V2 receptorHomo sapiens (human)
perinuclear region of cytoplasmVasopressin V2 receptorHomo sapiens (human)
plasma membraneVasopressin V2 receptorHomo sapiens (human)
plasma membraneAdenosine receptor A1Homo sapiens (human)
plasma membraneAdenosine receptor A1Homo sapiens (human)
basolateral plasma membraneAdenosine receptor A1Homo sapiens (human)
axolemmaAdenosine receptor A1Homo sapiens (human)
asymmetric synapseAdenosine receptor A1Homo sapiens (human)
presynaptic membraneAdenosine receptor A1Homo sapiens (human)
neuronal cell bodyAdenosine receptor A1Homo sapiens (human)
terminal boutonAdenosine receptor A1Homo sapiens (human)
dendritic spineAdenosine receptor A1Homo sapiens (human)
calyx of HeldAdenosine receptor A1Homo sapiens (human)
postsynaptic membraneAdenosine receptor A1Homo sapiens (human)
presynaptic active zoneAdenosine receptor A1Homo sapiens (human)
synapseAdenosine receptor A1Homo sapiens (human)
dendriteAdenosine receptor A1Homo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
focal adhesionSodium-dependent serotonin transporterHomo sapiens (human)
endosome membraneSodium-dependent serotonin transporterHomo sapiens (human)
endomembrane systemSodium-dependent serotonin transporterHomo sapiens (human)
presynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
membrane raftSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
postsynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
serotonergic synapseSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
neuron projectionSodium-dependent serotonin transporterHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
nuclear inner membraneProstaglandin G/H synthase 2Homo sapiens (human)
nuclear outer membraneProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulumProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum lumenProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 2Homo sapiens (human)
caveolaProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
protein-containing complexProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
cytosolHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
synapseHistamine H1 receptorHomo sapiens (human)
dendriteHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
synapseD(3) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
extracellular spaceMalate dehydrogenase, cytoplasmicHomo sapiens (human)
cytoplasmMalate dehydrogenase, cytoplasmicHomo sapiens (human)
centrosomeMalate dehydrogenase, cytoplasmicHomo sapiens (human)
cytosolMalate dehydrogenase, cytoplasmicHomo sapiens (human)
extracellular exosomeMalate dehydrogenase, cytoplasmicHomo sapiens (human)
cytosolMalate dehydrogenase, cytoplasmicHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneDelta-type opioid receptorHomo sapiens (human)
dendrite membraneDelta-type opioid receptorHomo sapiens (human)
presynaptic membraneDelta-type opioid receptorHomo sapiens (human)
axon terminusDelta-type opioid receptorHomo sapiens (human)
spine apparatusDelta-type opioid receptorHomo sapiens (human)
postsynaptic density membraneDelta-type opioid receptorHomo sapiens (human)
neuronal dense core vesicleDelta-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
neuron projectionDelta-type opioid receptorHomo sapiens (human)
nucleoplasmKappa-type opioid receptorHomo sapiens (human)
mitochondrionKappa-type opioid receptorHomo sapiens (human)
cytosolKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
membraneKappa-type opioid receptorHomo sapiens (human)
sarcoplasmic reticulumKappa-type opioid receptorHomo sapiens (human)
T-tubuleKappa-type opioid receptorHomo sapiens (human)
dendriteKappa-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneKappa-type opioid receptorHomo sapiens (human)
presynaptic membraneKappa-type opioid receptorHomo sapiens (human)
perikaryonKappa-type opioid receptorHomo sapiens (human)
axon terminusKappa-type opioid receptorHomo sapiens (human)
postsynaptic membraneKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
neuron projectionKappa-type opioid receptorHomo sapiens (human)
nucleoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
cilium5-hydroxytryptamine receptor 6Homo sapiens (human)
synapse5-hydroxytryptamine receptor 6Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 6Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
plasma membraneC-C chemokine receptor type 4Homo sapiens (human)
neuronal cell bodyC-C chemokine receptor type 4Homo sapiens (human)
external side of plasma membraneC-C chemokine receptor type 4Homo sapiens (human)
endoplasmic reticulum membraneTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
extracellular regionTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
nucleusTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
nucleoplasmTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
cytoplasmTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
endoplasmic reticulumTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
endoplasmic reticulum membraneTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
lipid dropletTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
cytosolTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
cytoplasmic stress granuleTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
VCP-NPL4-UFD1 AAA ATPase complexTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
secretory granule lumenTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
azurophil granule lumenTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
site of double-strand breakTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
intracellular membrane-bounded organelleTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
perinuclear region of cytoplasmTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
extracellular exosomeTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
glutamatergic synapseTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
ficolin-1-rich granule lumenTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
VCP-NSFL1C complexTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
proteasome complexTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
protein-containing complexTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
Derlin-1 retrotranslocation complexTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
ATPase complexTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
cytosolTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
nucleusTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cell-cell junctionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
focal adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
ruffle membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Golgi membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytoplasmDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
endoplasmic reticulum lumenDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytosolDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell surfaceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
actin cytoskeletonDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
apical plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane raftDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytoplasmSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
cell surfaceSodium-dependent dopamine transporter Homo sapiens (human)
membraneSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
neuron projectionSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell bodySodium-dependent dopamine transporter Homo sapiens (human)
axon terminusSodium-dependent dopamine transporter Homo sapiens (human)
membrane raftSodium-dependent dopamine transporter Homo sapiens (human)
postsynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
dopaminergic synapseSodium-dependent dopamine transporter Homo sapiens (human)
flotillin complexSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
presynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic densityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
dendriteVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic density membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
nucleusNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
nucleoplasmNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
cytoplasmNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
cytosolNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
cytoskeletonNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
chromatinNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
nucleusNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
endoplasmic reticulum membraneLanosterol 14-alpha demethylaseHomo sapiens (human)
membraneLanosterol 14-alpha demethylaseHomo sapiens (human)
cytosolRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleoplasmBile acid receptorHomo sapiens (human)
chromatinBile acid receptorHomo sapiens (human)
euchromatinBile acid receptorHomo sapiens (human)
receptor complexBile acid receptorHomo sapiens (human)
RNA polymerase II transcription regulator complexBile acid receptorHomo sapiens (human)
nucleusBile acid receptorHomo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
plasma membraneCysteinyl leukotriene receptor 1Homo sapiens (human)
membraneCysteinyl leukotriene receptor 1Homo sapiens (human)
plasma membraneCysteinyl leukotriene receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (988)

Assay IDTitleYearJournalArticle
AID1799791Binding Assay from Article 10.1074/jbc.M110.164293: \\Structural and biochemical characterization of Mycobacterium tuberculosis CYP142: evidence for multiple cholesterol 27-hydroxylase activities in a human pathogen.\\2010The Journal of biological chemistry, Dec-03, Volume: 285, Issue:49
Structural and biochemical characterization of Mycobacterium tuberculosis CYP142: evidence for multiple cholesterol 27-hydroxylase activities in a human pathogen.
AID1799801Binding Assay from Article 10.1074/jbc.M109.017632: \\Interaction of Mycobacterium tuberculosis CYP130 with heterocyclic arylamines.\\2009The Journal of biological chemistry, Sep-11, Volume: 284, Issue:37
Interaction of Mycobacterium tuberculosis CYP130 with heterocyclic arylamines.
AID1799166In Vitro HO Activity Assay from Article 10.1124/jpet.106.102699: \\Inhibition of the enzymatic activity of heme oxygenases by azole-based antifungal drugs.\\2006The Journal of pharmacology and experimental therapeutics, Oct, Volume: 319, Issue:1
Inhibition of the enzymatic activity of heme oxygenases by azole-based antifungal drugs.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745850Viability Counterscreen for Confirmatory qHTS for Inhibitors of ATXN expression
AID1745848Confirmatory qHTS for Inhibitors of ATXN expression
AID1745849Viability Counterscreen for CMV-Luciferase Assay of Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745847CMV-Luciferase Counterscreen for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1210013Inhibition of recombinant CYP2J2 (unknown origin)-mediated terfenadine hydroxylation assessed as remaining activity at 30 uM after 5 mins by LC-MS analysis relative to control2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID318207Antifungal activity against Aspergillus fumigatus2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Clotrimazole scaffold as an innovative pharmacophore towards potent antimalarial agents: design, synthesis, and biological and structure-activity relationship studies.
AID1442001Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of ASP+ after 2 mins by fluorescence assay2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1).
AID50858Antibacterial activity against Clostridium novyi, activity expressed as inhibitory zone(mm, diameter)1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID143824Mitogen-induced cell proliferation assay to evaluate the antiproliferative effect in NIH 3T3 cells2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
Triaryl methane derivatives as antiproliferative agents.
AID1636360Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 40.5 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of N2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID729307Inhibition of vasopressin-stimulated vasopressin V2 receptor in human HTLA cells pre-incubated for 20 mins with Tween-80-treated compound solution measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
Colloidal aggregation causes inhibition of G protein-coupled receptors.
AID322753Inhibition of human CYP51 expressed in Topp 3 cells by lanosterol demethylase assay2007Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3
Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors.
AID755446Agonist activity at PXR (unknown origin) expressed in human HepG2 cells assessed as induction of CYP3A4 transactivation at 10 uM after 16 hrs by luciferase reporter gene assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.
AID416041Fungicidal activity against tebuconazole-adapted wild type Colletotrichum graminicola CgM2 assessed as inhibition of radial growth rate at 23 degC in darkness2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Treatment of a clinically relevant plant-pathogenic fungus with an agricultural azole causes cross-resistance to medical azoles and potentiates caspofungin efficacy.
AID583000Antimicrobial activity against Saccharomyces cerevisiae YUG37 transformed with plasmid carrying cyp51A gene in reverse orientation without doxycycline-regulatable promoter by broth dilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Complementation of a Saccharomyces cerevisiae ERG11/CYP51 (sterol 14α-demethylase) doxycycline-regulated mutant and screening of the azole sensitivity of Aspergillus fumigatus isoenzymes CYP51A and CYP51B.
AID106798Fold increase in IC50 vs malate dehydrogenase (MDH) with 1 mg/ml saponin2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID1557075Antifungal activity against Candida albicans ATCC 90028 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID481665Antifungal activity against Candida zeylanoides NRRL Y-1774 after 24 hrs by broth microdilution assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and the selective antifungal activity of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives.
AID1605079Inhibition of rabbit kidney Sodium/potassium-transporting ATPase by PK/LDH method2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
Sarco/Endoplasmic Reticulum Calcium ATPase Inhibitors: Beyond Anticancer Perspective.
AID1890487Antifungal activity against Trichophyton rubrum assessed as fungal growth inhibition incubated for 72 hrs by microplate reader analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Antimicrobial Prenylated Isoflavones from the Leaves of the Amazonian Medicinal Plant
AID1379943Selectivity index, ratio of CC50 for human Hep2 cells to MIC for Candida albicans clinical isolates2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis, biological evaluation and quantitative structure-active relationships of 1,3-thiazolidin-4-one derivatives. A promising chemical scaffold endowed with high antifungal potency and low cytotoxicity.
AID755455Antagonist activity at human GTS-tagged FXR at 15 uM after 20 mins by TR-FRET assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.
AID208343Enhanced styrene oxide hydrolase activity pH 8.71985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Structural features of imidazole derivatives that enhance styrene oxide hydrolase activity in rat hepatic microsomes.
AID537736Antifungal activity against yeast AD1-8u expressing Candida albicans CaCdr1p by agar disk diffusion assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID665137Antiproliferative activity against human Hep2 cells assessed as cell survival fraction at 50 ug/mL after 24 hrs by MTT assay2012European journal of medicinal chemistry, Jul, Volume: 53Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
AID536086Antimicrobial activity against Candida albicans IFO 0583 at 100 ug/8 mm disk after 48 hrs by agar disk diffusion method2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis, antimicrobial and anti-inflammatory activities of novel 5-(1-adamantyl)-1,3,4-thiadiazole derivatives.
AID1156864Antimicrobial activity against Cryptococcus neoformans after 72 hrs by microbroth dilution method2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis of 2,3,6-trideoxy sugar triazole hybrids as potential new broad spectrum antimicrobial agents.
AID277613Antifungal activity against Aspergillus fumigatus2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Design and synthesis of potent antimalarial agents based on clotrimazole scaffold: exploring an innovative pharmacophore.
AID204340Antifungal activity against Sporothrix schenck ii was determined by twofold Micro-broth dilution assay2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
Bile acid amides derived from chiral amino alcohols: novel antimicrobials and antifungals.
AID1276957Inverse agonist activity at human CAR-LBD transfected in CV-1 cells after 24 hrs by luciferase reporter gene assay2016European journal of medicinal chemistry, Jan-27, Volume: 108Development of CINPA1 analogs as novel and potent inverse agonists of constitutive androstane receptor.
AID1287120Antiinflammatory activity in antibiotic resistant Candida albicans clinical isolate 08030809 induced mouse vaginitis model assessed as reduction in IL-6 secretion in vaginal tissue at 10 mg/ml administered as intravaginal instillation measured on day 10 b2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
A Designed Tryptophan- and Lysine/Arginine-Rich Antimicrobial Peptide with Therapeutic Potential for Clinical Antibiotic-Resistant Candida albicans Vaginitis.
AID1557087Antifungal activity against Candida glabrata ATCC 66032 assessed as reduction in fungal cell growth incubated for 48 hrs by MTT based broth double dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID48603Concentration for complete inhibition of growth of Candida tropicalis1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Antimycotic azoles. 6. Synthesis and antifungal properties of terconazole, a novel triazole ketal.
AID1287040Antimicrobial activity against antibiotic resistant Candida albicans clinical isolate 08030809 assessed as clone count at 10 mg/ml after 30 mins by colony counting assay (Rvb = 156 +/- 16 CFU)2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
A Designed Tryptophan- and Lysine/Arginine-Rich Antimicrobial Peptide with Therapeutic Potential for Clinical Antibiotic-Resistant Candida albicans Vaginitis.
AID681166TP_TRANSPORTER: Western blot, LS180 cell1996Molecular pharmacology, Feb, Volume: 49, Issue:2
Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells.
AID503336Effect on cofilin1 expressed in HEK293 cells assessed as effect on cofilin1; Limk2 interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID412377Antimalarial activity as reduced parasitaemia against Plasmodium berghei ANKA infected CD1 mice (Mus musculus) at 150 mg/kg/day intraperitoneal dose over 4 days2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Combining 4-aminoquinoline- and clotrimazole-based pharmacophores toward innovative and potent hybrid antimalarials.
AID729310Inhibition of CX3CL1-stimulated CX3CR1 in human HTLA cells pre-incubated for 20 mins with Tween-80-treated compound solution measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
Colloidal aggregation causes inhibition of G protein-coupled receptors.
AID536090Antimicrobial activity against Escherichia coli IFO 3301 after 24 hrs2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis, antimicrobial and anti-inflammatory activities of novel 5-(1-adamantyl)-1,3,4-thiadiazole derivatives.
AID731775Antifungal activity against Aspergillus flavus AUMC 3214 assessed as growth inhibition at 28 degC after 7 days2013European journal of medicinal chemistry, Apr, Volume: 62First synthesis and biological evaluation of indeno[2,1-e]pyrazolo[3,4-b]pyrazin-5-one and related derivatives.
AID245309Minimum inhibitory concentration required for antibacterial activity against Escherichia coli ATCC 13607; Not tested2004Bioorganic & medicinal chemistry letters, Aug-16, Volume: 14, Issue:16
Synthesis and QSAR studies of pyrimido[4,5-d]pyrimidine-2,5-dione derivatives as potential antimicrobial agents.
AID665133Antifungal activity against 4 strains of Candida glabrata after 24 hrs by EUCAST broth microdilution method2012European journal of medicinal chemistry, Jul, Volume: 53Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
AID1265650Cytotoxicity against human Hep2 cells assessed as cell survival at 0.05 ug/ml after 24 hrs by trypan blue exclusion test (Rvb = 87 to 94%)2016European journal of medicinal chemistry, Jan-01, Volume: 107Anti-Candida activity and cytotoxicity of a large library of new N-substituted-1,3-thiazolidin-4-one derivatives.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID410911Antiproliferative activity against human A549 cells by SRB assay2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
11-Phenyl-[b,e]-dibenzazepine compounds: novel antitumor agents.
AID1373217Antifungal activity against Geotrichum candidum AUMC 226 by microdilution method2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Fusarithioamide B, a new benzamide derivative from the endophytic fungus Fusarium chlamydosporium with potent cytotoxic and antimicrobial activities.
AID287241Antimicrobial activity against Escherichia coli IFO 3301 after 24 hrs2007European journal of medicinal chemistry, Feb, Volume: 42, Issue:2
Synthesis, antimicrobial, and anti-inflammatory activities of novel 2-(1-adamantyl)-5-substituted-1,3,4-oxadiazoles and 2-(1-adamantylamino)-5-substituted-1,3,4-thiadiazoles.
AID345649Decrease in nuclear co-repressor receptor binding to mouse CAR L253F mutant expressed in HEK293 cells at 2 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID755454Antagonist activity at human GTS-tagged FXR after 20 mins by TR-FRET assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.
AID352802Antimicrobial activity against Bacillus subtilis NCIM 2063 at 10 ug/disk after 24 hrs by disk diffusion method2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID345633Decrease in nuclear co-repressor receptor binding to mouse CAR S251L mutant expressed in HEK293 cells at 2 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID1287048Antimicrobial activity against antibiotic resistant Candida albicans clinical isolate 08030809 assessed as clone count at 10 mg/ml after 12 hrs by colony counting assay (Rvb = 54153 +/- 8769 CFU)2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
A Designed Tryptophan- and Lysine/Arginine-Rich Antimicrobial Peptide with Therapeutic Potential for Clinical Antibiotic-Resistant Candida albicans Vaginitis.
AID426143Antifungal activity against Aspergillus fumigatus after 72 hrs by agar well diffusion method2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Synthesis and antimicrobial studies of novel methylene bridged benzisoxazolyl imidazo[2,1-b][1,3,4]thiadiazole derivatives.
AID568441Antimicrobial activity against Aspergillus niger MTCC 1344 at 30 ug/ml after 24 to 96 hrs by agar cup method2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Stereoselective first total synthesis, confirmation of the absolute configuration and bioevaluation of botryolide-E.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1184402Antibacterial activity against Bacillus subtilis ATCC 6633 after 24 hrs by two fold serial dilution method2014European journal of medicinal chemistry, Sep-12, Volume: 84Ultrasound-assisted synthesis of novel 1,2,3-triazoles coupled diaryl sulfone moieties by the CuAAC reaction, and biological evaluation of them as antioxidant and antimicrobial agents.
AID1443987Inhibition of recombinant human BSEP expressed in baculovirus infected sf21 cell membrane vesicles assessed as reduction in ATP-dependent [3H]-taurocholate uptake in to vesicles after 5 mins by TopCount method2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID345657Decrease in steroid receptor coactivator 1 binding to mouse CAR Y336A mutant expressed in HEK293 cells at 2 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID318197Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 by [3H]hypoxanthine incorporation2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Clotrimazole scaffold as an innovative pharmacophore towards potent antimalarial agents: design, synthesis, and biological and structure-activity relationship studies.
AID412364Antimalarial activity after 24 hrs against chloroquine-resistant synchronous Plasmodium falciparum K1 infected human A+ erythrocytes by [3H]hypoxanthine uptake2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Combining 4-aminoquinoline- and clotrimazole-based pharmacophores toward innovative and potent hybrid antimalarials.
AID1402900Induction of apoptosis in Candida parapsilosis ATCC 22019 assessed as late apoptotic cells at antifungal MIC90 after 24 hrs by Annexin V/propidium iodide staining based flow cytometry (Rvb = 0.9%)2018European journal of medicinal chemistry, Jan-20, Volume: 144The synthesis, antifungal and apoptotic effects of triazole-oxadiazoles against Candida species.
AID481659Antifungal activity against Candida albicans clinical isolate after 24 hrs by broth microdilution assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and the selective antifungal activity of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives.
AID1184408Antifungal activity against Candida albicans NRRL Y-477 after 48 hrs by two fold serial dilution method2014European journal of medicinal chemistry, Sep-12, Volume: 84Ultrasound-assisted synthesis of novel 1,2,3-triazoles coupled diaryl sulfone moieties by the CuAAC reaction, and biological evaluation of them as antioxidant and antimicrobial agents.
AID1557076Antifungal activity against Candida albicans P-87 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID681586TP_TRANSPORTER: quantitative PCR in vivo, liver of mouse2003Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 31, Issue:11
Induction of ABCC3 (MRP3) by pregnane X receptor activators.
AID1330315Antagonist activity at rat TRPV1 expressed in HEK293 cells assessed as inhibition of capsaicin-stimulated Ca2+ flux up to 100 uM after 30 mins by calcium-4 dye based FLIPR assay2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Evaluation of known and novel inhibitors of Orai1-mediated store operated Ca
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID345559Activation of mouse CAR L212A mutant expressed in HEK293 cells at 2 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID620354Antifungal activity against Aspergillus fumigatus RCMB 002003 at 30 ug/ml after 3 to 4 days by agar well diffusion method2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and anti-microbial activity of some 1- substituted amino-4,6-dimethyl-2-oxo-pyridine-3-carbonitrile derivatives.
AID288611Inhibition of Bacillus subtilis NAD synthetase in presence of 0.01% Triton X-100 by fluorescence based assay2007Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
Antibacterial nicotinamide adenine dinucleotide synthetase inhibitors: amide- and ether-linked tethered dimers with alpha-amino acid end groups.
AID729308Inhibition of vasopressin-stimulated vasopressin V2 receptor in human HTLA cells pre-incubated for 20 mins with centrifuged compound solution measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
Colloidal aggregation causes inhibition of G protein-coupled receptors.
AID1636416Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 44.4 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of N2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID562244Antimycobacterial activity against Mycobacterium smegmatis grown in carbon-limited broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID757543Cytotoxicity against human Hep2 cells assessed as cell survival fraction at 10 ug/ml after 24 hrs by trypan blue exclusion assay (Rvb = 97 to 98%)2013European journal of medicinal chemistry, Jul, Volume: 65Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents.
AID481672Cytotoxicity against african green monkey Vero cells up to 25 ug/ml after 48 hrs by neutral red assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and the selective antifungal activity of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives.
AID395381Antifungal activity against Candida albicans ATCC 10231 at 10 ug after 72 hrs by disk diffusion method2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Synthesis, Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of mixed aza-oxo-thia macrocyclic compounds.
AID19468Partition coefficient (logP)2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID397433Cytotoxicity against human effector memory T cells of PBMC2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants.
AID564272Antifungal activity against Candida albicans isolate 108 harboring erg11 and erg5 double mutant after 48 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B.
AID731776Antifungal activity against Trichophyton rubrum AUMC 1804 assessed as growth inhibition at 28 degC after 7 days2013European journal of medicinal chemistry, Apr, Volume: 62First synthesis and biological evaluation of indeno[2,1-e]pyrazolo[3,4-b]pyrazin-5-one and related derivatives.
AID295133Antifungal activity against Kluyveromyces fragilis NRRL 2415 at 10 ug after 72 hrs by disk diffusion method2007European journal of medicinal chemistry, Aug, Volume: 42, Issue:8
Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of bis[micro2-(benzimidazol-2-yl)-2-ethanethiolato-N,S,S-chloro-palladium(II)] dimer, [(micro2-CH2CH2NHNCC6H4)PdCl]2.C2H5OH complex.
AID349544Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 21 to 28 days by two fold agar dilution method2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Synthesis and biological evaluation of new enantiomerically pure azole derivatives as inhibitors of Mycobacterium tuberculosis.
AID46931Concentration for complete inhibition of growth of Candida albicans1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Antimycotic azoles. 6. Synthesis and antifungal properties of terconazole, a novel triazole ketal.
AID770911Antibacterial activity against Escherichia coli IFO 3301 assessed as growth inhibition at 100 ug/disc after 24 hrs by agar disc-diffusion method2013European journal of medicinal chemistry, Oct, Volume: 68Synthesis and antimicrobial activity of novel 5-(1-adamantyl)-2-aminomethyl-4-substituted-1,2,4-triazoline-3-thiones.
AID681120TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in Caco-2 cells2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID75519Evaluated for cure against trichophytosis after topical treatment with 1% of compound in a group of 6 guinea pigs1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Antimycotic azoles. 6. Synthesis and antifungal properties of terconazole, a novel triazole ketal.
AID1379936Antifungal activity against Candida albicans clinical isolates assessed as inhibition of microbial growth incubated for 24 hrs by broth microdilution method2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis, biological evaluation and quantitative structure-active relationships of 1,3-thiazolidin-4-one derivatives. A promising chemical scaffold endowed with high antifungal potency and low cytotoxicity.
AID566727Antifungal activity against Candida tropicalis after 24 hrs by MTT assay2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and biological evaluation of novel 2,4-disubstituted-1,3-thiazoles as anti-Candida spp. agents.
AID1595107Antifungal activity against Candida albicans assessed as reduction in fungal cell growth incubated for 48 hrs by broth microdilution susceptibility method2019European journal of medicinal chemistry, May-15, Volume: 170Tetrazole hybrids and their antifungal activities.
AID318212Cytotoxicity against human KB cells by MTT assay2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Clotrimazole scaffold as an innovative pharmacophore towards potent antimalarial agents: design, synthesis, and biological and structure-activity relationship studies.
AID1605087Inhibition of pig gastric mucosa Potassium-transporting ATPase by malachite green based colorimetric method2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
Sarco/Endoplasmic Reticulum Calcium ATPase Inhibitors: Beyond Anticancer Perspective.
AID547636Antimicrobial activity against Candida albicans after 24 to 48 hrs by micro dilution susceptibility test2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Synthesis and biological evaluation of some thiazolylpyrazole derivatives as dual anti-inflammatory antimicrobial agents.
AID537733Binding affinity to Candida albicans CaCdr1p expressed in yeast AD1-8u2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID362120Antifungal activity against Candida albicans ATCC 2091 by NCCLS M27-A2 method2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Studies on the antifungal properties of N-thiolated beta-lactams.
AID1557088Antifungal activity against Candida glabrata 192 assessed as reduction in fungal cell growth incubated for 48 hrs by MTT based broth double dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID1866103Inhibition of Mycobacterium tuberculosis CYP121A1 mediated cYY conversion to mycocyclosin assessed as mycocyclosin level at 100 uM incubated for 2 hrs in the presence of NADPH by LC-MS activity assay relative to clotrimazole2022European journal of medicinal chemistry, Feb-15, Volume: 230A new strategy for hit generation: Novel in cellulo active inhibitors of CYP121A1 from Mycobacterium tuberculosis via a combined X-ray crystallographic and phenotypic screening approach (XP screen).
AID1402889Induction of apoptosis in Candida albicans ATCC 90028 assessed as necrotic cells at antifungal MIC90 after 24 hrs by Annexin V/propidium iodide staining based flow cytometry (Rvb = 0.2%)2018European journal of medicinal chemistry, Jan-20, Volume: 144The synthesis, antifungal and apoptotic effects of triazole-oxadiazoles against Candida species.
AID1287118Antiinflammatory activity in antibiotic resistant Candida albicans clinical isolate 08030809 induced mouse vaginitis model assessed as microabscess number in vaginal tissue at 200 ug administered as intravaginal instillation measured after 16 days by hema2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
A Designed Tryptophan- and Lysine/Arginine-Rich Antimicrobial Peptide with Therapeutic Potential for Clinical Antibiotic-Resistant Candida albicans Vaginitis.
AID1636478Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 36.8 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of N2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID665132Antifungal activity against 2 strains of Candida sake after 24 hrs by EUCAST broth microdilution method2012European journal of medicinal chemistry, Jul, Volume: 53Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
AID345543Enhancement of steroid receptor coactivator 1 binding to wild type mouse CAR expressed in HEK293 cells at 10 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID1753910Antifungal activity against Microsporum gypseum assessed as fungal growth inhibition incubated for 4 days by CLSI protocol based agar microdilution method
AID70075Antifungal activity against Epidermophyton floccosum, activity expressed as minimum inhibitory concentration (ug/mL)1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID54857Concentration for complete inhibition of growth of Cryptococcus neo formans1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Antimycotic azoles. 6. Synthesis and antifungal properties of terconazole, a novel triazole ketal.
AID731782Antifungal activity against Candida albicans AUMC 418 assessed as diameter of growth inhibition zone at 20 mg/ml at 28 degC after 7 days2013European journal of medicinal chemistry, Apr, Volume: 62First synthesis and biological evaluation of indeno[2,1-e]pyrazolo[3,4-b]pyrazin-5-one and related derivatives.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID277603Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D102007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Design and synthesis of potent antimalarial agents based on clotrimazole scaffold: exploring an innovative pharmacophore.
AID345662Decrease in nuclear co-repressor receptor binding to mouse CAR T350A mutant expressed in HEK293 cells at 2 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID205796Fungicidal concentration on sterol 14-alpha-demethylase2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID1193499Thermodynamic equilibrium solubility, log S of the compound simulated intestinal fluid at pH 6.8 at RT after 24 hrs by shake-flask method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1184395Antibacterial activity against Klebsiella pneumoniae ATCC 13883 at 50 mg/mL after 24 hrs by agar well diffusion method2014European journal of medicinal chemistry, Sep-12, Volume: 84Ultrasound-assisted synthesis of novel 1,2,3-triazoles coupled diaryl sulfone moieties by the CuAAC reaction, and biological evaluation of them as antioxidant and antimicrobial agents.
AID1184394Antibacterial activity against Sarcina lutea at 50 mg/mL after 24 hrs by agar well diffusion method2014European journal of medicinal chemistry, Sep-12, Volume: 84Ultrasound-assisted synthesis of novel 1,2,3-triazoles coupled diaryl sulfone moieties by the CuAAC reaction, and biological evaluation of them as antioxidant and antimicrobial agents.
AID318203Antifungal activity against Candida krusei ATCC 62582008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Clotrimazole scaffold as an innovative pharmacophore towards potent antimalarial agents: design, synthesis, and biological and structure-activity relationship studies.
AID286783Inhibition of Escherichia coli AmpC beta lactamase using relaxed assay conditions in presence of 0.00001% Triton X-100 detergent2007Journal of medicinal chemistry, May-17, Volume: 50, Issue:10
A high-throughput screen for aggregation-based inhibition in a large compound library.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID762010Fungicidal activity against Trichophyton mentagrophytes after 6 hrs2013European journal of medicinal chemistry, Aug, Volume: 66Antimicrobial activity of imidazo[1,5-a]quinoxaline derivatives with pyridinium moiety.
AID481660Antifungal activity against Candida albicans ATCC 90028 after 24 hrs by broth microdilution assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and the selective antifungal activity of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives.
AID1184398Antifungal activity against Candida albicans NRRL Y-477 at 50 mg/mL after 48 hrs by agar well diffusion method2014European journal of medicinal chemistry, Sep-12, Volume: 84Ultrasound-assisted synthesis of novel 1,2,3-triazoles coupled diaryl sulfone moieties by the CuAAC reaction, and biological evaluation of them as antioxidant and antimicrobial agents.
AID503332Effect on Cdc2 expressed in HEK293 cells assessed as effect on Cdc2:Cdc25C interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID52772Fold increase in IC50 vs chymotrypsinogen with 0.1 mg/ml saponin2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID1184409Antifungal activity against Saccharomyces cerevisiae after 48 hrs by two fold serial dilution method2014European journal of medicinal chemistry, Sep-12, Volume: 84Ultrasound-assisted synthesis of novel 1,2,3-triazoles coupled diaryl sulfone moieties by the CuAAC reaction, and biological evaluation of them as antioxidant and antimicrobial agents.
AID1193494Thermodynamic equilibrium solubility, log S of the compound in simulated gastric fluid at pH 1.2 at RT after 4 hrs by 96 well plate method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID352850Antimicrobial activity against Lipomyces lipofer NCIM 3252 at 10 ug/disk after 72 hrs by disk diffusion method2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID345548Activation of mouse CAR F171A mutant expressed in HEK293 cells at 2 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID352628Antimicrobial activity against Pseudomonas aeruginosa NCIM 2200 at 10 ug/disk after 24 hrs by disk diffusion method2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID1184410Antifungal activity against Aspergillus niger after 48 hrs by two fold serial dilution method2014European journal of medicinal chemistry, Sep-12, Volume: 84Ultrasound-assisted synthesis of novel 1,2,3-triazoles coupled diaryl sulfone moieties by the CuAAC reaction, and biological evaluation of them as antioxidant and antimicrobial agents.
AID563614Effect on sterol composition in Candida albicans isolate 14 expressing wild type erg11 and erg5 assessed as lanosterol level after 2 hrs by gas chromatography2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B.
AID449704NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID536088Antimicrobial activity against Bacillus subtilis IFO 3007 after 24 hrs2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis, antimicrobial and anti-inflammatory activities of novel 5-(1-adamantyl)-1,3,4-thiadiazole derivatives.
AID1207632Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID566623Antifungal activity against Candida glabrata after 24 hrs by MTT assay2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and biological evaluation of novel 2,4-disubstituted-1,3-thiazoles as anti-Candida spp. agents.
AID481673Cytotoxicity against african pig LLC-PK11 up to 25 ug/ml after 48 hrs by neutral red assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and the selective antifungal activity of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives.
AID318208Antifungal activity against itraconazole resistant Aspergillus fumigatus2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Clotrimazole scaffold as an innovative pharmacophore towards potent antimalarial agents: design, synthesis, and biological and structure-activity relationship studies.
AID1428258Antifungal activity against Syncephalastrum racemosum 005004 assessed as zone of inhibition at 30 ug/ml2017European journal of medicinal chemistry, Jan-27, Volume: 126An insight on synthetic and medicinal aspects of pyrazolo[1,5-a]pyrimidine scaffold.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID562240Antimycobacterial activity against Mycobacterium smegmatis grown in Luria-Bertani broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID582798Antifungal activity against Candida albicans isolate 177 by broth dilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Identification and characterization of four azole-resistant erg3 mutants of Candida albicans.
AID582800Antifungal activity against Candida albicans isolate 488 harboring ERG3 H243N, T330A, A351V and ERG11 D225G, E266D, E391G, V488I mutant genes by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Identification and characterization of four azole-resistant erg3 mutants of Candida albicans.
AID1402883Antifungal activity against Candida krusei ATCC 6258 by broth microdilution assay2018European journal of medicinal chemistry, Jan-20, Volume: 144The synthesis, antifungal and apoptotic effects of triazole-oxadiazoles against Candida species.
AID564268Effect on sterol composition in Candida albicans isolate 108 harboring erg11 and erg5 double mutant eburicol level after 2 hrs by gas chromatography2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B.
AID731780Antifungal activity against Aspergillus flavus AUMC 1276 assessed as diameter of growth inhibition zone at 20 mg/ml at 28 degC after 7 days2013European journal of medicinal chemistry, Apr, Volume: 62First synthesis and biological evaluation of indeno[2,1-e]pyrazolo[3,4-b]pyrazin-5-one and related derivatives.
AID345918Activation of human CAR Phe234Ala mutant expressed in human C3A cells at 4 uM after 24 hrs by GAL4-dependent luciferase reporter gene assay relative to control2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Insights into ligand-elicited activation of human constitutive androstane receptor based on novel agonists and three-dimensional quantitative structure-activity relationship.
AID277614Antifungal activity against itraconazole resistant Aspergillus fumigatus2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Design and synthesis of potent antimalarial agents based on clotrimazole scaffold: exploring an innovative pharmacophore.
AID770917Antibacterial activity against Bacillus subtilis IFO 3007 assessed as growth inhibition at 100 ug/disc after 24 hrs by agar disc-diffusion method2013European journal of medicinal chemistry, Oct, Volume: 68Synthesis and antimicrobial activity of novel 5-(1-adamantyl)-2-aminomethyl-4-substituted-1,2,4-triazoline-3-thiones.
AID757546Anticandida activity against Candida sake clinical isolate assessed as growth inhibition after 24 hrs by broth microdilution method2013European journal of medicinal chemistry, Jul, Volume: 65Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents.
AID67516Antiprotozoal activity measured as the conc for 100% inhibition of Entamoeba histolytica,1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID295134Antifungal activity against Rhodotorula rubra DSM 70403 at 10 ug after 72 hrs by disk diffusion method2007European journal of medicinal chemistry, Aug, Volume: 42, Issue:8
Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of bis[micro2-(benzimidazol-2-yl)-2-ethanethiolato-N,S,S-chloro-palladium(II)] dimer, [(micro2-CH2CH2NHNCC6H4)PdCl]2.C2H5OH complex.
AID572692Binding affinity to Mycobacterium smegmatis ATCC 700084 CYP51 at pH7.52009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Identification, characterization, and azole-binding properties of Mycobacterium smegmatis CYP164A2, a homolog of ML2088, the sole cytochrome P450 gene of Mycobacterium leprae.
AID214619In vitro antifungal activity against Trichophyton asteroides1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Synthesis and in vitro antimicrobial property of o-carborane derivatives.
AID665146Cytotoxicity against human Hep2 cells assessed as cell survival fraction at 5 ug/mL after 24 hrs by trypan blue exclusion method2012European journal of medicinal chemistry, Jul, Volume: 53Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
AID729311Inhibition of CX3CL1-stimulated CX3CR1 in human HTLA cells pre-incubated for 20 mins with centrifuged compound solution measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
Colloidal aggregation causes inhibition of G protein-coupled receptors.
AID1156865Antimicrobial activity against Sporothrix schenckii after 72 hrs by microbroth dilution method2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis of 2,3,6-trideoxy sugar triazole hybrids as potential new broad spectrum antimicrobial agents.
AID536087Antimicrobial activity against Staphylococcus aureus IFO 3060 after 24 hrs2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis, antimicrobial and anti-inflammatory activities of novel 5-(1-adamantyl)-1,3,4-thiadiazole derivatives.
AID1300320Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by BACTEC method2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Fragment-Based Approaches to the Development of Mycobacterium tuberculosis CYP121 Inhibitors.
AID1300889Cytotoxicity against human Hep2 cells assessed as reduction in cell viability after 24 hrs by trypan blue exclusion assay2016European journal of medicinal chemistry, Jul-19, Volume: 117Novel 1,3-thiazolidin-4-one derivatives as promising anti-Candida agents endowed with anti-oxidant and chelating properties.
AID1330317Antagonist activity at Cav2.2 in human SH-SY5Y cells assessed as inhibition of KCl/CaCl2-stimulated Ca2+ flux up to 100 uM after 30 mins in presence of nifedipine by Fuo-4 dye based FLIPR assay2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Evaluation of known and novel inhibitors of Orai1-mediated store operated Ca
AID294967Antifungal activity against Candida albicans after 48 hrs by serial dilution method2007European journal of medicinal chemistry, Oct, Volume: 42, Issue:10
Synthesis and in vitro antimicrobial activity of new 2-[p-substituted-benzyl]-5-[substituted-carbonylamino]benzoxazoles.
AID681143TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation in MDR1-expressing LLC-PK1 cells2002Molecular pharmacology, May, Volume: 61, Issue:5
Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein.
AID379711Antifungal activity against Saccharomyces cerevisiae by modified microtiter plate assay2006Journal of natural products, Feb, Volume: 69, Issue:2
Bioactive natural and semisynthetic latrunculins.
AID1428257Antifungal activity against Geotrichum candidum 052008 assessed as zone of inhibition at 30 ug/ml2017European journal of medicinal chemistry, Jan-27, Volume: 126An insight on synthetic and medicinal aspects of pyrazolo[1,5-a]pyrimidine scaffold.
AID214090Concentration for complete inhibition of growth of Trichophyton mentagrophytes1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Antimycotic azoles. 6. Synthesis and antifungal properties of terconazole, a novel triazole ketal.
AID1478062Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 7 days by resazurin microtiter assay
AID729315Inhibition of CCL22-stimulated CCR4 in human HTLA cells pre-incubated for 20 mins measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
Colloidal aggregation causes inhibition of G protein-coupled receptors.
AID717846Inhibition of mouse Ido1 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID1713876Antifungal activity against Candida albicans CEMTC 34 assessed as fungal growth inhibition by CLSI protocol based serial microdilution method2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Biological evaluation of tetracationic compounds based on two 1,4-diazabicyclo[2.2.2]octane moieties connected by different linkers.
AID572693Binding affinity to Mycobacterium smegmatis ATCC 700084 CYP51 in presence of 0.5 M NaCl at pH7.52009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Identification, characterization, and azole-binding properties of Mycobacterium smegmatis CYP164A2, a homolog of ML2088, the sole cytochrome P450 gene of Mycobacterium leprae.
AID1184392Antibacterial activity against Bacillus subtilis ATCC 6633 at 50 mg/mL after 24 hrs by agar well diffusion method2014European journal of medicinal chemistry, Sep-12, Volume: 84Ultrasound-assisted synthesis of novel 1,2,3-triazoles coupled diaryl sulfone moieties by the CuAAC reaction, and biological evaluation of them as antioxidant and antimicrobial agents.
AID562242Antimycobacterial activity against Mycobacterium smegmatis grown in nitrogen -limited broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID481662Antifungal activity against Candida utilis NRRL Y-900 after 24 hrs by broth microdilution assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and the selective antifungal activity of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID397422Antiinflammatory activity against oxazolone-induced delayed type hypersensitivity in mouse assessed as reduction in ear swelling at 1%, topically applied 30 mins post oxazolone challenge2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants.
AID1287119Antiinflammatory activity in antibiotic resistant Candida albicans clinical isolate 08030809 induced mouse vaginitis model assessed as reduction in TNF-alpha secretion in vaginal tissue at 10 mg/ml administered as intravaginal instillation measured on day2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
A Designed Tryptophan- and Lysine/Arginine-Rich Antimicrobial Peptide with Therapeutic Potential for Clinical Antibiotic-Resistant Candida albicans Vaginitis.
AID249984Minimum inhibitory concentration against Candida albicans2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Studies on synthesis and evaluation of quantitative structure-activity relationship of 5-[(3'-chloro-4',4'-disubstituted-2-oxoazetidinyl)(N-nitro)amino]-6-hydroxy-3-alkyl/aryl[1,3]azaphospholo[1,5-a]pyridin-1-yl-phosphorus dichlorides.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID412371Antimalarial activity as reduced parasitaemia against Plasmodium chabaudi AS infected CD1 mice (Mus musculus) at 50 mg/kg/day peroral dose2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Combining 4-aminoquinoline- and clotrimazole-based pharmacophores toward innovative and potent hybrid antimalarials.
AID106802Fold decrease in IC50 vs malate dehydrogenase (MDH) on pre-incubation2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID277610Antifungal activity against Candida parapsilosis ATCC 220192007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Design and synthesis of potent antimalarial agents based on clotrimazole scaffold: exploring an innovative pharmacophore.
AID352810Antimicrobial activity against Vibrio fischeri NCIM 2154 at 10 ug/disk after 24 hrs by disk diffusion method2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID777329Antifungal activity against Aspergillus fumigatus isolated from patient assessed as growth inhibition after 72 to 96 hrs by microbroth dilution method2013ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10
Identification of 1-[4-Benzyloxyphenyl)-but-3-enyl]-1H-azoles as New Class of Antitubercular and Antimicrobial Agents.
AID283196Susceptibility of polyene-resistant Candida glabrata 21229 isolate at 10 ug by disk diffusion method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Reduced susceptibility to polyenes associated with a missense mutation in the ERG6 gene in a clinical isolate of Candida glabrata with pseudohyphal growth.
AID532559Antifungal activity against Saccharomyces cerevisiae BY4741 assessed as growth rate at 2 ug/ml (Rvb = 0.144%)2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus.
AID1854171Antimicrobial activity against Aspergillus niger NCIM 20812022European journal of medicinal chemistry, Aug-05, Volume: 238Cascade synthetic strategies opening access to medicinal-relevant aliphatic 3- and 4-membered N-heterocyclic scaffolds.
AID682797Antifungal activity against Trichophyton mentagrophytes after 96 hrs by broth microdilution method2012European journal of medicinal chemistry, Oct, Volume: 56Micelles catalyzed chemo- and regio-selective one pot and one step synthesis of 2,3,5,6-tetrakis(alkyl and arylsulfanyl)-1,4-benzoquinones and 2,5-diaminosubstituted-1,4-benzoquinones "In-Water" and their biological evaluation as antibacterial and antifun
AID345571Activation of mouse CAR I252L mutant expressed in HEK293 cells at 2 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID447231Antifungal activity against Rhodotorula rubra DSM 70403 at 10 ug after 72 hrs by agar disk diffusion assay2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, Raman, FT-IR, NMR spectroscopic characterization, antimicrobial activity, cytotoxicity and DNA binding of new mixed aza-oxo-thia macrocyclic compounds.
AID345556Decrease in mouse CAR N175A mutant activation expressed in HEK293 cells at 2 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID609165Antibacterial activity against Staphylococcus equorum assessed as zone of inhibition at 5 uL and 32 degC after 36 hrs at by disk diffusion method2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Cytotoxic ring A-modified steroid analogues derived from Grundmann's ketone.
AID536089Antimicrobial activity against Micrococcus luteus IFO 3232 after 24 hrs2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis, antimicrobial and anti-inflammatory activities of novel 5-(1-adamantyl)-1,3,4-thiadiazole derivatives.
AID1402892Induction of apoptosis in Candida glabrata ATCC 90030 assessed as late apoptotic cells at antifungal MIC90 after 24 hrs by Annexin V/propidium iodide staining based flow cytometry (Rvb = 0.2%)2018European journal of medicinal chemistry, Jan-20, Volume: 144The synthesis, antifungal and apoptotic effects of triazole-oxadiazoles against Candida species.
AID1557086Antifungal activity against Candida albicans SN152 assessed as reduction in fungal cell growth incubated for 48 hrs by MTT based broth double dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID412367Cytotoxicity against mouse NSO cells by MTT assay2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Combining 4-aminoquinoline- and clotrimazole-based pharmacophores toward innovative and potent hybrid antimalarials.
AID757541Cytotoxicity against human Hep2 cells assessed as cell survival fraction at 0.5 ug/ml after 24 hrs by trypan blue exclusion assay (Rvb = 97 to 98%)2013European journal of medicinal chemistry, Jul, Volume: 65Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents.
AID569327Antifungal activity against Geotrichum candidum at 50 uL/well by well diffusion assay2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Synthesis and biological activity of pyrazolothienotetrahydroisoquinoline and [1,2,4]triazolo[3,4-a]thienotetrahydroisoquinoline derivatives.
AID517141Antifungal activity against Rhizopus oryzae MTCC 262 at 100 ug/ml2010Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20
Synthesis, antimicrobial, and mosquito larvicidal activity of 1-aryl-4-methyl-3,6-bis-(5-methylisoxazol-3-yl)-2-thioxo-2,3,6,10b-tetrahydro-1H-pyrimido[5,4-c]quinolin-5-ones.
AID680517TP_TRANSPORTER: inhibition of Doxorubicin efflux (Doxorubicin: 50 uM, Clotrimazole: 100 uM) in MDR1-expressing B16/F10 cells1996Toxicology and applied pharmacology, Nov, Volume: 141, Issue:1
Interaction of structurally diverse pesticides with the human MDR1 gene product P-glycoprotein.
AID39384Antifungal activity against Aspergillus flavus was determined by twofold Micro-broth dilution assay2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
Bile acid amides derived from chiral amino alcohols: novel antimicrobials and antifungals.
AID620356Antifungal activity against Candida albicans RCMB 005002 at 30 ug/ml after 3 to 4 days by agar well diffusion method2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and anti-microbial activity of some 1- substituted amino-4,6-dimethyl-2-oxo-pyridine-3-carbonitrile derivatives.
AID770914Antibacterial activity against Micrococcus luteus IFO 3232 assessed as growth inhibition at 100 ug/disc after 24 hrs by agar disc-diffusion method2013European journal of medicinal chemistry, Oct, Volume: 68Synthesis and antimicrobial activity of novel 5-(1-adamantyl)-2-aminomethyl-4-substituted-1,2,4-triazoline-3-thiones.
AID395384Antifungal activity against Hanseniaspora guilliermondii DSM 3432 at 10 ug after 72 hrs by disk diffusion method2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Synthesis, Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of mixed aza-oxo-thia macrocyclic compounds.
AID1321217Antimicrobial activity against Pseudomonas aeruginosa IFO 3448 at 200 ug/disc measured after 24 hrs by agar disc-diffusion method2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Synthesis, biological evaluation and molecular modeling study of some new methoxylated 2-benzylthio-quinazoline-4(3H)-ones as nonclassical antifolates.
AID1265647Cytotoxicity against human Hep2 cells assessed as cell survival at 50 ug/ml after 24 hrs by trypan blue exclusion test (Rvb = 87 to 94%)2016European journal of medicinal chemistry, Jan-01, Volume: 107Anti-Candida activity and cytotoxicity of a large library of new N-substituted-1,3-thiazolidin-4-one derivatives.
AID568443Antimicrobial activity against Candida albicans MTCC 227 at 30 ug/ml after 24 to 96 hrs by agar cup method2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Stereoselective first total synthesis, confirmation of the absolute configuration and bioevaluation of botryolide-E.
AID777046Inhibition of human Alexa 488 labeled Arno Sec7 domain-mediated promiscuous aggregator activity in delta17 Arf1 (17 to 181) at >20 uM by fluorescence anisotropy assay2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Fragment-based identification of a locus in the Sec7 domain of Arno for the design of protein-protein interaction inhibitors.
AID1287039Antimicrobial activity against antibiotic resistant Candida albicans clinical isolate 08030809 assessed as clone count at 10 mg/ml after 10 mins by colony counting assay (Rvb = 102 +/- 11 CFU)2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
A Designed Tryptophan- and Lysine/Arginine-Rich Antimicrobial Peptide with Therapeutic Potential for Clinical Antibiotic-Resistant Candida albicans Vaginitis.
AID1402891Induction of apoptosis in Candida glabrata ATCC 90030 assessed as early apoptotic cells at antifungal MIC90 after 24 hrs by Annexin V/propidium iodide staining based flow cytometry (Rvb = 0%)2018European journal of medicinal chemistry, Jan-20, Volume: 144The synthesis, antifungal and apoptotic effects of triazole-oxadiazoles against Candida species.
AID1546162Antifungal activity against Fusarium oxysporum2019European journal of medicinal chemistry, Dec-15, Volume: 184Current scenario of tetrazole hybrids for antibacterial activity.
AID264079Antifungal activity against Aspergillus niger ATCC 164042006Bioorganic & medicinal chemistry letters, May-01, Volume: 16, Issue:9
Studies on synthesis and evaluation of quantitative structure-activity relationship of 10-methyl-6-oxo-5-arylazo-6,7-dihydro-5H-[1,3]azaphospholo[1,5-d][1,4]benzodiazepin-2-phospha-3-ethoxycarbonyl-1-phosphorus dichlorides.
AID1300321Binding affinity to Mycobacterium tuberculosis H37Rv wild type CYP121 by titration assay2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Fragment-Based Approaches to the Development of Mycobacterium tuberculosis CYP121 Inhibitors.
AID412361Antimalarial activity after 72 hrs against chloroquine-sensitive Plasmodium falciparum D10 infected human A+ erythrocytes in Makler LDH reporter assay2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Combining 4-aminoquinoline- and clotrimazole-based pharmacophores toward innovative and potent hybrid antimalarials.
AID1557085Antifungal activity against Candida albicans ATCC 90028 assessed as reduction in fungal cell growth incubated for 48 hrs by MTT based broth double dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID729309Inhibition of vasopressin-stimulated vasopressin V2 receptor in human HTLA cells pre-incubated for 20 mins measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
Colloidal aggregation causes inhibition of G protein-coupled receptors.
AID30562Antibacterial activity against Actinomyces israelii, activity expressed as inhibitory zone(mm, diameter)1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID397440Cytotoxicity against human HaCaT cells2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants.
AID572700Binding affinity to Mycobacterium tuberculosis CYP1302009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Identification, characterization, and azole-binding properties of Mycobacterium smegmatis CYP164A2, a homolog of ML2088, the sole cytochrome P450 gene of Mycobacterium leprae.
AID682798Antifungal activity against Aspergillus fumigatus after 72 hrs by broth microdilution method2012European journal of medicinal chemistry, Oct, Volume: 56Micelles catalyzed chemo- and regio-selective one pot and one step synthesis of 2,3,5,6-tetrakis(alkyl and arylsulfanyl)-1,4-benzoquinones and 2,5-diaminosubstituted-1,4-benzoquinones "In-Water" and their biological evaluation as antibacterial and antifun
AID1402885Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 24 hrs by MTT assay2018European journal of medicinal chemistry, Jan-20, Volume: 144The synthesis, antifungal and apoptotic effects of triazole-oxadiazoles against Candida species.
AID174695Evaluated for cure against vaginal candidosis after topical treatment with 1% of compound in a group of 10 rats1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Antimycotic azoles. 6. Synthesis and antifungal properties of terconazole, a novel triazole ketal.
AID308421Antifungal activity against Candida albicans after 24 hrs by broth microdilution method2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Synthesis and in vitro activity of 2-thiazolylhydrazone derivatives compared with the activity of clotrimazole against clinical isolates of Candida spp.
AID1330310Inhibition of Orai1-mediated store operated Ca2+ entry in human MDA-MB-231 cells assessed as reduction of SERCA inhibition-induced ER release at 100 uM preincubated for 15 mins followed by CPA addition by PBX-based FLIPR assay2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Evaluation of known and novel inhibitors of Orai1-mediated store operated Ca
AID287238Antimicrobial activity against Candida albicans IFO 0583 at 100 ug/disc after 48 hrs2007European journal of medicinal chemistry, Feb, Volume: 42, Issue:2
Synthesis, antimicrobial, and anti-inflammatory activities of novel 2-(1-adamantyl)-5-substituted-1,3,4-oxadiazoles and 2-(1-adamantylamino)-5-substituted-1,3,4-thiadiazoles.
AID609164Antibacterial activity against Pseudomonas antimicrobica assessed as zone of inhibition at 5 uL and 32 degC after 36 hrs by disk diffusion method2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Cytotoxic ring A-modified steroid analogues derived from Grundmann's ketone.
AID649718Antifungal activity against Candida albicans2012Bioorganic & medicinal chemistry letters, Mar-15, Volume: 22, Issue:6
Novel N'-benzylidene benzofuran-3-carbohydrazide derivatives as antitubercular and antifungal agents.
AID287384Antifungal activity against Debaryomyces hansenii after 24 hrs by disk diffusion method2007European journal of medicinal chemistry, Feb, Volume: 42, Issue:2
Synthesis, characterization and antimicrobial activity of Fe(II), Zn(II), Cd(II) and Hg(II) complexes with 2,6-bis(benzimidazol-2-yl) pyridine ligand.
AID270271Antifungal activity against Cryptococcus neoformans2006Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17
Antifungal anthraquinones from Saprosma fragrans.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID532553Antifungal activity against Saccharomyces cerevisiae BY4741 harboring human CYP51 assessed as growth rate at 0.5 ug/ml (Rvb = 0.157%)2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus.
AID665140Antiproliferative activity against human Hep2 cells assessed as cell survival fraction at 0.5 ug/mL after 24 hrs by MTT assay2012European journal of medicinal chemistry, Jul, Volume: 53Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
AID315276Inhibition of Gardos channel in human RBC assessed as inhibition of ionomycin-stimulated [86Rb] efflux2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Novel inhibitors of the Gardos channel for the treatment of sickle cell disease.
AID1577815Inhibition of Cys5-LDEETGEFL-NH2 binding to recombinant human KEAP1 Kelch domain (321 to 609 residues) expressed in Escherichia coli BL21 (DE3) measured after 10 to 15 mins by fluorescence polarization assay2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
A Comparative Assessment Study of Known Small-Molecule Keap1-Nrf2 Protein-Protein Interaction Inhibitors: Chemical Synthesis, Binding Properties, and Cellular Activity.
AID515300Antifungal activity against Saccharomyces cerevisiae MTCC 171 at 30 ug/ml after 24 to 96 hrs by agar cup diffusion method2010European journal of medicinal chemistry, Oct, Volume: 45, Issue:10
Stereoselective synthesis and biological evaluation of (R)-rugulactone, (6R)-((4R)-hydroxy-6-phenyl-hex-2-enyl)-5,6-dihydro-pyran-2-one and its 4S epimer.
AID562243Antimycobacterial activity against Mycobacterium smegmatis grown in Luria-Bertani broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID681137TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation in mdr1a-expressing LLC-PK1 cells2002The Journal of pharmacology and experimental therapeutics, Oct, Volume: 303, Issue:1
Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
AID481663Antifungal activity against Candida tropicalis NRRL Y-12968 after 24 hrs by broth microdilution assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and the selective antifungal activity of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID675139Antifungal activity against Pythium aphanidermatum after 72 to 96 hrs by agar cup method2012European journal of medicinal chemistry, Sep, Volume: 55Design, synthesis, antimicrobial, anti-inflammatory and analgesic activity of novel isoxazolyl pyrimido[4,5-b]quinolines and isoxazolyl chromeno[2,3-d]pyrimidin-4-ones.
AID734202Antifungal activity against Candida glabrata assessed as inhibition of fungal growth2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Stereoselective synthesis of a new class of potent and selective inhibitors of human Δ8,7-sterol isomerase.
AID569329Antifungal activity against Scopulariopsis brevicaulis at 50 uL/well by well diffusion assay2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Synthesis and biological activity of pyrazolothienotetrahydroisoquinoline and [1,2,4]triazolo[3,4-a]thienotetrahydroisoquinoline derivatives.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID609166Antibacterial activity against Streptococcus entericus assessed as zone of inhibition at 5 uL and 32 degC after 36 hrs by disk diffusion method2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Cytotoxic ring A-modified steroid analogues derived from Grundmann's ketone.
AID89686In vitro anticancer activity against human lung cancer cell line2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
3,3-diaryl-1,3-dihydroindol-2-ones as antiproliferatives mediated by translation initiation inhibition.
AID67521Antiprotozoal activity measured as the conc for >95% inhibition of Entamoeba histolytica,1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID770920Antibacterial activity against Staphylococcus aureus IFO 3060 assessed as growth inhibition at 100 ug/disc after 24 hrs by agar disc-diffusion method2013European journal of medicinal chemistry, Oct, Volume: 68Synthesis and antimicrobial activity of novel 5-(1-adamantyl)-2-aminomethyl-4-substituted-1,2,4-triazoline-3-thiones.
AID560138Antifungal activity against Candida glabrata isolate 22852 at 10 ug after 48 hrs by disk diffusion method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Hypersusceptibility to azole antifungals in a clinical isolate of Candida glabrata with reduced aerobic growth.
AID397426Inhibition of human cloned IK1 expressed in african green monkey COS7 cells by whole cell patch clamp assay2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants.
AID270273Antifungal activity against Trichophyton mentagrophytes2006Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17
Antifungal anthraquinones from Saprosma fragrans.
AID214102Antifungal activity against Trichophyton mentagrophytes, activity expressed as minimum inhibitory concentration (ug/mL).1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID537734Antifungal activity against yeast AD1-8u expressing Candida albicans CaMdr1p by agar disk diffusion assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID277608Antifungal activity against Candida albicans2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Design and synthesis of potent antimalarial agents based on clotrimazole scaffold: exploring an innovative pharmacophore.
AID352806Antimicrobial activity against Bacillus cereus NCIM 2155 at 10 ug/disk after 24 hrs by disk diffusion method2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID1808022Inhibition of porcine heart malate dehydrogenase assessed as critical aggregation concentration preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec by spectrophotometric method2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID345551Decrease in mouse CAR F171L mutant activation expressed in HEK293 cells at 2 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID1557083Antifungal activity against Candida guilliermondii T-47 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID210259Antibacterial activity against Streptococcus pyogenes C, activity expressed as inhibitory zone(mm, diameter)1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID204337Concentration for complete inhibition of growth of Sporo thrix schenck ii1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Antimycotic azoles. 6. Synthesis and antifungal properties of terconazole, a novel triazole ketal.
AID479369Inhibition of human placental microsome CYP192010Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10
Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19).
AID763991Antifungal activity against Candida albicans ATCC 2091 after 48 hrs by two-fold serial dilution method2013European journal of medicinal chemistry, Aug, Volume: 66Synthesis, biological evaluation and molecular docking studies of some pyrimidine derivatives.
AID366423Antibacterial activity against Klebsiella pneumoniae ATCC 10032 assessed as inhibition zone diameter after 24 hrs by agar diffusion method2008Journal of natural products, Aug, Volume: 71, Issue:8
Bioactive brominated metabolites from the red sea sponge Suberea mollis.
AID564270Antifungal activity against Candida albicans isolate 14 after 48 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B.
AID762016Antifungal activity against Candida albicans 885-653 measured every 24 hrs for 14 days by conventional dilution method2013European journal of medicinal chemistry, Aug, Volume: 66Antimicrobial activity of imidazo[1,5-a]quinoxaline derivatives with pyridinium moiety.
AID1598718Binding affinity to Triton-X 100 assessed as change in chemical shift at 150 uM by 1H-NMR spectra analysis2019Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10
Mechanisms of Specific versus Nonspecific Interactions of Aggregation-Prone Inhibitors and Attenuators.
AID264080Antifungal activity against Candida albicans ATCC 102312006Bioorganic & medicinal chemistry letters, May-01, Volume: 16, Issue:9
Studies on synthesis and evaluation of quantitative structure-activity relationship of 10-methyl-6-oxo-5-arylazo-6,7-dihydro-5H-[1,3]azaphospholo[1,5-d][1,4]benzodiazepin-2-phospha-3-ethoxycarbonyl-1-phosphorus dichlorides.
AID1265646Cytotoxicity against human Hep2 cells assessed as cell survival at 100 ug/ml after 24 hrs by trypan blue exclusion test (Rvb = 87 to 94%)2016European journal of medicinal chemistry, Jan-01, Volume: 107Anti-Candida activity and cytotoxicity of a large library of new N-substituted-1,3-thiazolidin-4-one derivatives.
AID55013Antifungal activity against Cryptococcus neoformans Cr-1 strain1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and quantitative structure-activity relationship analysis of N-triiodoallyl- and N-iodopropargylazoles. New antifungal agents.
AID345922Activation of human CAR Tyr326Ala mutant expressed in human C3A cells at 4 uM after 24 hrs by GAL4-dependent luciferase reporter gene assay relative to control2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Insights into ligand-elicited activation of human constitutive androstane receptor based on novel agonists and three-dimensional quantitative structure-activity relationship.
AID572701Selectivity ratio, ratio of Kd for Mycobacterium smegmatis ATCC 700084 CYP164A2 to Kd for Mycobacterium tuberculosis CYP1212009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Identification, characterization, and azole-binding properties of Mycobacterium smegmatis CYP164A2, a homolog of ML2088, the sole cytochrome P450 gene of Mycobacterium leprae.
AID1373235Antibacterial activity against Escherichia coli AUMC B-53 assessed as diameter of inhibition zone at 5 ug/disc after 24 hrs by agar disc diffusion method2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Fusarithioamide B, a new benzamide derivative from the endophytic fungus Fusarium chlamydosporium with potent cytotoxic and antimicrobial activities.
AID682978Antifungal activity against Candida parapsilosis ATCC 22019 after 48 hrs by broth microdilution method2012European journal of medicinal chemistry, Oct, Volume: 56Micelles catalyzed chemo- and regio-selective one pot and one step synthesis of 2,3,5,6-tetrakis(alkyl and arylsulfanyl)-1,4-benzoquinones and 2,5-diaminosubstituted-1,4-benzoquinones "In-Water" and their biological evaluation as antibacterial and antifun
AID345613Enhancement of steroid receptor co-activator 1 binding to mouse CAR N175A mutant expressed in HEK293 cells at 2 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID77076Effect of topical administration (1% w/v) on course of expt. Ringworm infections in guinea pig by Trichophyton mentagrophytes1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Synthesis of (E)-1-(5-chlorothien-2-yl)-2-(1H-imidazol-1-yl)ethanone 2,6-dichlorophenylhydrazone hydrochloride, a novel, orally active antifungal agent.
AID39670Antifungal activity against Aspergillus fumigatus was determined in vitro1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and antifungal activity of a series of novel 1,2-disubstituted propenones.
AID283195Susceptibility of Candida glabrata 21231 isolate at 10 ug by disk diffusion method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Reduced susceptibility to polyenes associated with a missense mutation in the ERG6 gene in a clinical isolate of Candida glabrata with pseudohyphal growth.
AID1193497Thermodynamic equilibrium solubility, log S of the compound PBS at pH 7.4 at RT after 24 hrs by shake-flask method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1402895Induction of apoptosis in Candida krusei ATCC 6258 assessed as early apoptotic cells at antifungal MIC90 after 24 hrs by Annexin V/propidium iodide staining based flow cytometry (Rvb = 0.5%)2018European journal of medicinal chemistry, Jan-20, Volume: 144The synthesis, antifungal and apoptotic effects of triazole-oxadiazoles against Candida species.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID318213Antimalarial activity against Plasmodium chabaudi AS infected CD1 mice (Mus musculus) assessed as suppression of parasitaemia at 50mg/kg, perorally after 4 days2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Clotrimazole scaffold as an innovative pharmacophore towards potent antimalarial agents: design, synthesis, and biological and structure-activity relationship studies.
AID1193492Thermodynamic equilibrium solubility, log S of the compound in water at RT after 4 hrs by 96 well plate method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID609169Antifungal activity against Aspergillus niger assessed as zone of inhibition at 5 uL and 28 degC after 36 hrs by disk diffusion method2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Cytotoxic ring A-modified steroid analogues derived from Grundmann's ketone.
AID582999Antimicrobial activity against Saccharomyces cerevisiae YUG37 transformed with plasmid carrying cyp51B gene with doxycycline-regulatable promoter by broth dilution method in presence of doxycycline2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Complementation of a Saccharomyces cerevisiae ERG11/CYP51 (sterol 14α-demethylase) doxycycline-regulated mutant and screening of the azole sensitivity of Aspergillus fumigatus isoenzymes CYP51A and CYP51B.
AID352798Antimicrobial activity against Salmonella Typhimurium NCIM 2501 at 10 ug/disk after 24 hrs by disk diffusion method2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID1557084Antifungal activity against Candida dubliniensis T-99 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID1265651Cytotoxicity against human Hep2 cells assessed as cell survival after 24 hrs by trypan blue exclusion method2016European journal of medicinal chemistry, Jan-01, Volume: 107Anti-Candida activity and cytotoxicity of a large library of new N-substituted-1,3-thiazolidin-4-one derivatives.
AID37575Antifungal activity against Aspergillus niger was determined by twofold Micro-broth dilution assay2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
Bile acid amides derived from chiral amino alcohols: novel antimicrobials and antifungals.
AID125953Antifungal activity against Microsporum gypseum was determined by twofold Micro-broth dilution assay2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
Bile acid amides derived from chiral amino alcohols: novel antimicrobials and antifungals.
AID287380Antifungal activity against Candida albicans after 24 hrs by disk diffusion method2007European journal of medicinal chemistry, Feb, Volume: 42, Issue:2
Synthesis, characterization and antimicrobial activity of Fe(II), Zn(II), Cd(II) and Hg(II) complexes with 2,6-bis(benzimidazol-2-yl) pyridine ligand.
AID681122TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing LLC-PK1 cells2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID729306Inhibition of vasopressin V2 receptor (unknown origin) assessed as change in intracellular calcium levels treated with centrifuged compound solution by fluorometric analysis2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
Colloidal aggregation causes inhibition of G protein-coupled receptors.
AID214099Antifungal activity towards Trichophyton mentagrophytes 530324 strain1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and quantitative structure-activity relationship analysis of N-triiodoallyl- and N-iodopropargylazoles. New antifungal agents.
AID602118NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence.2011Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
AID299297Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D102007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Development of piperazine-tethered heterodimers as potent antimalarials against chloroquine-resistant P. falciparum strains. Synthesis and molecular modeling.
AID582802Antifungal activity against Candida albicans isolate 1008 harboring ERG3 K97E, L193P, V237A, A351V, A353T and ERG11 E266D mutant genes by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Identification and characterization of four azole-resistant erg3 mutants of Candida albicans.
AID517139Antifungal activity against Chrysosporium tropicum MTCC 2821 at 100 ug/ml2010Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20
Synthesis, antimicrobial, and mosquito larvicidal activity of 1-aryl-4-methyl-3,6-bis-(5-methylisoxazol-3-yl)-2-thioxo-2,3,6,10b-tetrahydro-1H-pyrimido[5,4-c]quinolin-5-ones.
AID201547Concentration for complete inhibition of growth of Saprolegnia sp.1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Antimycotic azoles. 6. Synthesis and antifungal properties of terconazole, a novel triazole ketal.
AID125802Concentration for complete inhibition of growth of Microsporum canis1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Antimycotic azoles. 6. Synthesis and antifungal properties of terconazole, a novel triazole ketal.
AID211173Minimum inhibitory concentration against Trichophyton mentagrophyte IFO 58101987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and antifungal activity of new 1-vinylimidazoles.
AID1558384Inhibition of p97 in human HeLa cells assessed as reduction in p97-dependent UbG76V-GFP degradation incubated for 1 hr by luciferase reporter gene assay2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
p97: An Emerging Target for Cancer, Neurodegenerative Diseases, and Viral Infections.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID774657Antitrypanosomal activity against amastigote stage of Trypanosoma cruzi infected in mouse NIH/3T3 cells after 48 hrs by Hoechst staining assay2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Approaches to protozoan drug discovery: phenotypic screening.
AID1402899Induction of apoptosis in Candida parapsilosis ATCC 22019 assessed as early apoptotic cells at antifungal MIC90 after 24 hrs by Annexin V/propidium iodide staining based flow cytometry (Rvb = 0.1%)2018European journal of medicinal chemistry, Jan-20, Volume: 144The synthesis, antifungal and apoptotic effects of triazole-oxadiazoles against Candida species.
AID757533Cytotoxicity against human Hep2 cells assessed as appearance of finely granular cytoplasm at 5 ug/ml after 24 hrs by transmission electron microscopic analysis2013European journal of medicinal chemistry, Jul, Volume: 65Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID532561Antifungal activity against Saccharomyces cerevisiae BY4741 assessed as growth rate at 0.5 ug/ml (Rvb = 0.144%)2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus.
AID665142Cytotoxicity against human Hep2 cells assessed as cell survival fraction after 24 hrs by trypan blue exclusion method2012European journal of medicinal chemistry, Jul, Volume: 53Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
AID1283270Inhibition of CYP51 in Dhcr7-deficient mouse Neuro2a cells assessed as decrease in 7-DHC levels at 1 uM by LC-MS/GC-MS analysis2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
AID90843Antifungal activity against Histoplasma capsulatum was determined by twofold Micro-broth dilution assay; No data2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
Bile acid amides derived from chiral amino alcohols: novel antimicrobials and antifungals.
AID1184397Antibacterial activity against Escherichia coli ATCC 25922 at 50 mg/mL after 24 hrs by agar well diffusion method2014European journal of medicinal chemistry, Sep-12, Volume: 84Ultrasound-assisted synthesis of novel 1,2,3-triazoles coupled diaryl sulfone moieties by the CuAAC reaction, and biological evaluation of them as antioxidant and antimicrobial agents.
AID762017Antifungal activity against Trichophyton mentagrophytes measured every 24 hrs for 14 days by conventional dilution method2013European journal of medicinal chemistry, Aug, Volume: 66Antimicrobial activity of imidazo[1,5-a]quinoxaline derivatives with pyridinium moiety.
AID763669Antibacterial activity against Pseudomonas aeruginosa at 200 ug/disc after 24 hrs by agar disc-diffusion method2013European journal of medicinal chemistry, Aug, Volume: 66Nonclassical antifolates, part 4. 5-(2-aminothiazol-4-yl)-4-phenyl-4H-1,2,4-triazole-3-thiols as a new class of DHFR inhibitors: synthesis, biological evaluation and molecular modeling study.
AID1184401Antibacterial activity against Staphylococcus aureus ATCC 29213 after 24 hrs by two fold serial dilution method2014European journal of medicinal chemistry, Sep-12, Volume: 84Ultrasound-assisted synthesis of novel 1,2,3-triazoles coupled diaryl sulfone moieties by the CuAAC reaction, and biological evaluation of them as antioxidant and antimicrobial agents.
AID757544Cytotoxicity against human Hep2 cells assessed as cell survival fraction at 50 ug/ml after 24 hrs by trypan blue exclusion assay (Rvb = 97 to 98%)2013European journal of medicinal chemistry, Jul, Volume: 65Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents.
AID503333Effect on Cdc2 expressed in HEK293 cells assessed as effect on Cdc2:Cdc25A interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID1265640Antifungal activity against Candida albicans clinical isolate after 24 hrs by sabouraud dextrose broth based microdilution method2016European journal of medicinal chemistry, Jan-01, Volume: 107Anti-Candida activity and cytotoxicity of a large library of new N-substituted-1,3-thiazolidin-4-one derivatives.
AID536084Antimicrobial activity against Pseudomonas aeruginosa IFO 3448 at 100 ug/8 mm disk after 24 hrs by agar disk diffusion method2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis, antimicrobial and anti-inflammatory activities of novel 5-(1-adamantyl)-1,3,4-thiadiazole derivatives.
AID345622Enhancement of steroid receptor co-activator 1 binding to mouse CAR L212A mutant expressed in HEK293 cells at 2 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID731781Antifungal activity against Trichophyton rubrum AUMC 1804 assessed as diameter of growth inhibition zone at 20 mg/ml at 28 degC after 7 days2013European journal of medicinal chemistry, Apr, Volume: 62First synthesis and biological evaluation of indeno[2,1-e]pyrazolo[3,4-b]pyrazin-5-one and related derivatives.
AID426142Antifungal activity against Candida albicans after 72 hrs by agar well diffusion method2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Synthesis and antimicrobial studies of novel methylene bridged benzisoxazolyl imidazo[2,1-b][1,3,4]thiadiazole derivatives.
AID245359Minimum inhibitory concentration required for antibacterial activity against Staphylococcus aureus ATCC 2943; Not tested2004Bioorganic & medicinal chemistry letters, Aug-16, Volume: 14, Issue:16
Synthesis and QSAR studies of pyrimido[4,5-d]pyrimidine-2,5-dione derivatives as potential antimicrobial agents.
AID774655Selectivity ratio of cytotoxic activity against mouse NIH/3T3 cells to antitrypanosomal activity against amastigote stage of Trypanosoma cruzi2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Approaches to protozoan drug discovery: phenotypic screening.
AID183631Evaluated for marked improvement against vaginal candidosis after topical treatment with 0.5% of compound in a group of 10 rats1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Antimycotic azoles. 6. Synthesis and antifungal properties of terconazole, a novel triazole ketal.
AID208226Effective concentration that inhibits growth of Trypanosoma cruzi by 50% was reported1993Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14
Toward a novel metal-based chemotherapy against tropical diseases. 1. Enhancement of the efficacy of clotrimazole against Trypanosoma cruzi by complexation to ruthenium in RuCl2(clotrimazole)2.
AID452944Antifungal activity against Candida albicans at 50 ug/disk by agar plate disk diffusion method2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
In vitro antitubercular and antimicrobial activities of 1-substituted quinoxaline-2,3(1H,4H)-diones.
AID1558383Inhibition of p97 (unknown origin) assessed as reduction in ATPase activity2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
p97: An Emerging Target for Cancer, Neurodegenerative Diseases, and Viral Infections.
AID44957Antifungal activity against Candida albicans, activity expressed as minimum inhibitory concentration (ug/mL)1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID318196Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 by [3H]hypoxanthine incorporation2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Clotrimazole scaffold as an innovative pharmacophore towards potent antimalarial agents: design, synthesis, and biological and structure-activity relationship studies.
AID287243Antimicrobial activity against Candida albicans IFO 0583 after 48 hrs2007European journal of medicinal chemistry, Feb, Volume: 42, Issue:2
Synthesis, antimicrobial, and anti-inflammatory activities of novel 2-(1-adamantyl)-5-substituted-1,3,4-oxadiazoles and 2-(1-adamantylamino)-5-substituted-1,3,4-thiadiazoles.
AID1373212Antibacterial activity against Pseudomonas aeruginosa AUMC B-73 by microdilution method2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Fusarithioamide B, a new benzamide derivative from the endophytic fungus Fusarium chlamydosporium with potent cytotoxic and antimicrobial activities.
AID143835Percent inhibition at 10 uM determined against mouse NIH 3T3 cells2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
Triaryl methane derivatives as antiproliferative agents.
AID77139Evaluated for marked improvement against microsporosis after topical treatment with 0.5% of compound in a group of 8 guinea pigs1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Antimycotic azoles. 6. Synthesis and antifungal properties of terconazole, a novel triazole ketal.
AID665135Antiproliferative activity against human Hep2 cells assessed as cell survival fraction after 24 hrs by MTT assay2012European journal of medicinal chemistry, Jul, Volume: 53Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
AID1321215Antimicrobial activity against Bacillus subtilis IFO 3007 at 200 ug/disc measured after 24 hrs by agar disc-diffusion method2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Synthesis, biological evaluation and molecular modeling study of some new methoxylated 2-benzylthio-quinazoline-4(3H)-ones as nonclassical antifolates.
AID78118In vivo inhibition of topical Trichophyton infection in Guinea Pig after drug administration1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Isobenzofurans as conformationally constrained miconazole analogues with improved antifungal potency.
AID345924Increase in human nuclear co-repressor receptor binding to human CAR-LBD expressed in HEK293 cells by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Insights into ligand-elicited activation of human constitutive androstane receptor based on novel agonists and three-dimensional quantitative structure-activity relationship.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID218567Fold increase in IC50 vs beta-lactamase with 0.1 mg/mL saponin2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID295135Antifungal activity against Hanseniaspora guilliermondii DSM 3432 at 10 ug after 72 hrs by disk diffusion method2007European journal of medicinal chemistry, Aug, Volume: 42, Issue:8
Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of bis[micro2-(benzimidazol-2-yl)-2-ethanethiolato-N,S,S-chloro-palladium(II)] dimer, [(micro2-CH2CH2NHNCC6H4)PdCl]2.C2H5OH complex.
AID1678799Antimalarial activity against chloroquine resistant Plasmodium falciparum2020RSC medicinal chemistry, Feb-01, Volume: 11, Issue:2
An epigrammatic status of the '
AID428421Antifungal activity against Trichophyton rubrum after 48 hrs by agar dilution method2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Design, synthesis, and antifungal activity of triazole and benzotriazole derivatives.
AID757547Anticandida activity against Candida parapsilosis clinical isolate assessed as growth inhibition after 24 hrs by broth microdilution method2013European journal of medicinal chemistry, Jul, Volume: 65Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents.
AID299298Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W22007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Development of piperazine-tethered heterodimers as potent antimalarials against chloroquine-resistant P. falciparum strains. Synthesis and molecular modeling.
AID39402Concentration for complete inhibition of growth of Aspergillus fumigatus1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Antimycotic azoles. 6. Synthesis and antifungal properties of terconazole, a novel triazole ketal.
AID1300886Cytotoxicity against human Hep2 cells assessed as cell survival at 5 ug/ml after 24 hrs by trypan blue exclusion assay2016European journal of medicinal chemistry, Jul-19, Volume: 117Novel 1,3-thiazolidin-4-one derivatives as promising anti-Candida agents endowed with anti-oxidant and chelating properties.
AID345675Decrease in nuclear co-repressor receptor binding to mouse CAR L353A mutant expressed in HEK293 cells at 2 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID416040Fungicidal activity against tebuconazole-nonadapted wild type Colletotrichum graminicola CgM2 assessed as inhibition of radial growth rate at 23 degC in darkness2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Treatment of a clinically relevant plant-pathogenic fungus with an agricultural azole causes cross-resistance to medical azoles and potentiates caspofungin efficacy.
AID345640Enhancement of steroid receptor coactivator 1 binding to mouse CAR I252L mutant expressed in HEK293 cells at 2 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID532528Antifungal activity against Saccharomyces cerevisiae BY4741 harboring human CYP51 assessed as growth rate at 2 ug/ml (Rvb = 0.157%)2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus.
AID1321214Antimicrobial activity against Staphylococcus aureus IFO 3060 at 200 ug/disc measured after 24 hrs by agar disc-diffusion method2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Synthesis, biological evaluation and molecular modeling study of some new methoxylated 2-benzylthio-quinazoline-4(3H)-ones as nonclassical antifolates.
AID665145Cytotoxicity against human Hep2 cells assessed as cell survival fraction at 10 ug/mL after 24 hrs by trypan blue exclusion method2012European journal of medicinal chemistry, Jul, Volume: 53Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
AID1484691Antileishmanial activity against Leishmania infantum chagasi MHOM/BR/1972/LD promastigote forms infected in golden hamster after 48 hrs by Alamar Blue assay2017European journal of medicinal chemistry, Jul-28, Volume: 135An overview of azoles targeting sterol 14α-demethylase for antileishmanial therapy.
AID52779Fold decrease in IC50 vs chymotrypsinogen on pre-incubation; increase2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID395385Antifungal activity against Debaryomyces hansenii DSM 70238 at 10 ug after 72 hrs by disk diffusion method2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Synthesis, Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of mixed aza-oxo-thia macrocyclic compounds.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID562241Antimycobacterial activity against Mycobacterium smegmatis grown in carbon-limited broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID575755Binding affinity to Aspergillus fumigatus AF293 sterol 14-alpha demethylase isoenzyme B expressed in Escherichia coli assessed as tight binding affinity constant2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Expression, purification, and characterization of Aspergillus fumigatus sterol 14-alpha demethylase (CYP51) isoenzymes A and B.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID572694Binding affinity to Mycobacterium smegmatis ATCC 700084 CYP51 in presence of 0.1% triton X-100 at pH7.52009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Identification, characterization, and azole-binding properties of Mycobacterium smegmatis CYP164A2, a homolog of ML2088, the sole cytochrome P450 gene of Mycobacterium leprae.
AID1402881Antifungal activity against Candida albicans ATCC 90028 by broth microdilution assay2018European journal of medicinal chemistry, Jan-20, Volume: 144The synthesis, antifungal and apoptotic effects of triazole-oxadiazoles against Candida species.
AID345583Decrease in mouse CAR T350A mutant activation expressed in HEK293 cells at 2 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID757548Anticandida activity against Candida krusei clinical isolate assessed as growth inhibition after 24 hrs by broth microdilution method2013European journal of medicinal chemistry, Jul, Volume: 65Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents.
AID731777Antifungal activity against Geotrichum candidum AUMC 226 assessed as diameter of growth inhibition zone at 20 mg/ml at 28 degC after 7 days2013European journal of medicinal chemistry, Apr, Volume: 62First synthesis and biological evaluation of indeno[2,1-e]pyrazolo[3,4-b]pyrazin-5-one and related derivatives.
AID1713875Antifungal activity against Candida albicans CEMTC 34 assessed as concentration required to inhibit visible growth by CLSI protocol based serial microdilution method2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Biological evaluation of tetracationic compounds based on two 1,4-diazabicyclo[2.2.2]octane moieties connected by different linkers.
AID345826Activation of human CAR-LBD expressed in human C3A cells at 4 uM after 24 hrs by GAL4-dependent luciferase reporter gene assay relative to control2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Insights into ligand-elicited activation of human constitutive androstane receptor based on novel agonists and three-dimensional quantitative structure-activity relationship.
AID1300882Antifungal activity against Candida parapsilosis clinical isolate after 24 hrs by broth microdilution method2016European journal of medicinal chemistry, Jul-19, Volume: 117Novel 1,3-thiazolidin-4-one derivatives as promising anti-Candida agents endowed with anti-oxidant and chelating properties.
AID214428Minimum inhibitory concentration against Trichophyton rubrum IFO 58071987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and antifungal activity of new 1-vinylimidazoles.
AID560137Antifungal activity against Candida glabrata isolate 21231 at 10 ug after 48 hrs by disk diffusion method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Hypersusceptibility to azole antifungals in a clinical isolate of Candida glabrata with reduced aerobic growth.
AID1443995Hepatotoxicity in human assessed as drug-induced liver injury2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID564269Antifungal activity against Candida albicans isolate 6 after 48 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B.
AID155485Concentration for complete inhibition of growth of Phialophora uerrucosa1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Antimycotic azoles. 6. Synthesis and antifungal properties of terconazole, a novel triazole ketal.
AID277609Antifungal activity against Candida krusei ATCC 62582007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Design and synthesis of potent antimalarial agents based on clotrimazole scaffold: exploring an innovative pharmacophore.
AID211166Antifungal activity towards Trichophyton interdigitale1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and quantitative structure-activity relationship analysis of N-triiodoallyl- and N-iodopropargylazoles. New antifungal agents.
AID1300887Cytotoxicity against human Hep2 cells assessed as cell survival at 10 ug/ml after 24 hrs by trypan blue exclusion assay2016European journal of medicinal chemistry, Jul-19, Volume: 117Novel 1,3-thiazolidin-4-one derivatives as promising anti-Candida agents endowed with anti-oxidant and chelating properties.
AID211172Minimum inhibitory concentration against Trichophyton mentagrophyte IFO 58091987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and antifungal activity of new 1-vinylimidazoles.
AID757550Anticandida activity against Candida glabrata clinical isolate assessed as growth inhibition after 24 hrs by broth microdilution method2013European journal of medicinal chemistry, Jul, Volume: 65Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents.
AID397429Inhibition of human HaCaT cell proliferation after 48 hrs2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants.
AID762009Fungicidal activity against Candida albicans 885-653 after 6 hrs2013European journal of medicinal chemistry, Aug, Volume: 66Antimicrobial activity of imidazo[1,5-a]quinoxaline derivatives with pyridinium moiety.
AID568439Antimicrobial activity against Rhizopus oryzae MTCC 262 at 30 ug/ml after 24 to 96 hrs by agar cup method2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Stereoselective first total synthesis, confirmation of the absolute configuration and bioevaluation of botryolide-E.
AID1193496Thermodynamic equilibrium solubility, log S of the compound in water at RT after 24 hrs by shake-flask method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1577841Inhibition of Cys5-LDEETGEFL-NH2 binding to recombinant human KEAP1 Kelch domain (321 to 609 residues) expressed in Escherichia coli BL21 (DE3) measured after 10 to 15 mins in presence of 0.01% Triton X-100 by fluorescence polarization assay2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
A Comparative Assessment Study of Known Small-Molecule Keap1-Nrf2 Protein-Protein Interaction Inhibitors: Chemical Synthesis, Binding Properties, and Cellular Activity.
AID288610Inhibition of Bacillus subtilis NAD synthetase in presence of 0.001% Triton X-100 by fluorescence based assay2007Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
Antibacterial nicotinamide adenine dinucleotide synthetase inhibitors: amide- and ether-linked tethered dimers with alpha-amino acid end groups.
AID1265642Antifungal activity against Candida tropicalis clinical isolate after 24 hrs by sabouraud dextrose broth based microdilution method2016European journal of medicinal chemistry, Jan-01, Volume: 107Anti-Candida activity and cytotoxicity of a large library of new N-substituted-1,3-thiazolidin-4-one derivatives.
AID1639192Antibacterial activity against Mycobacterium tuberculosis H37Rv after 7 days by resazurin dye-based fluorescence assay2019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Synthesis and biological evaluation of novel cYY analogues targeting Mycobacterium tuberculosis CYP121A1.
AID609168Antifungal activity against Candida glabrata assessed as zone of inhibition at 5 uL and 28 degC after 36 hrs by disk diffusion method2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Cytotoxic ring A-modified steroid analogues derived from Grundmann's ketone.
AID315278Solubility by shake-flask method2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Novel inhibitors of the Gardos channel for the treatment of sickle cell disease.
AID428420Antifungal activity against Candida albicans after 48 hrs by agar dilution method2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Design, synthesis, and antifungal activity of triazole and benzotriazole derivatives.
AID428423Antifungal activity against Epidermophyton floccosum after 48 hrs by agar dilution method2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Design, synthesis, and antifungal activity of triazole and benzotriazole derivatives.
AID67519Antiprotozoal activity measured as the conc for <25% inhibition of Entamoeba histolytica,1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID734201Antifungal activity against Saccharomyces cerevisiae assessed as inhibition of fungal growth2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Stereoselective synthesis of a new class of potent and selective inhibitors of human Δ8,7-sterol isomerase.
AID277606Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K12007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Design and synthesis of potent antimalarial agents based on clotrimazole scaffold: exploring an innovative pharmacophore.
AID1557078Antifungal activity against Candida glabrata ATCC 66032 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID755445Agonist activity at PXR (unknown origin) expressed in human HepG2 cells assessed as induction of CYP3A4 transactivation after 16 hrs by luciferase reporter gene assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.
AID462893Blockade of protein farnesyltransferase at 100 uM by aggregate-based inhibition assay2010Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
Prediction and evaluation of protein farnesyltransferase inhibition by commercial drugs.
AID665144Cytotoxicity against human Hep2 cells assessed as cell survival fraction at 50 ug/mL after 24 hrs by trypan blue exclusion method2012European journal of medicinal chemistry, Jul, Volume: 53Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
AID277611Antifungal activity against Cryptococcus neoformans2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Design and synthesis of potent antimalarial agents based on clotrimazole scaffold: exploring an innovative pharmacophore.
AID1557080Antifungal activity against Candida glabrata 192 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID1300878Antifungal activity against Candida albicans clinical isolate after 24 hrs by broth microdilution method2016European journal of medicinal chemistry, Jul-19, Volume: 117Novel 1,3-thiazolidin-4-one derivatives as promising anti-Candida agents endowed with anti-oxidant and chelating properties.
AID717840Inhibition of mouse Tdo2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation at 100 uM after 45 mins by spectrophotometric analysis relative to control2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID497654Inhibition of dynamic light scattering at 25 uM by thioflavin T fluorescence assay relative to untreated control2008Nature chemical biology, Mar, Volume: 4, Issue:3
Small-molecule aggregates inhibit amyloid polymerization.
AID345610Decrease in nuclear co-repressor receptor binding to mouse CAR N175A mutant expressed in HEK293 cells at 2 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID503335Inhibition of of c-Jun expressed in HEK293 cells assessed as induction of protein interaction in presence of camptothecin with Pin1 by EYFP based reporter gene assay2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID277604Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W22007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Design and synthesis of potent antimalarial agents based on clotrimazole scaffold: exploring an innovative pharmacophore.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1678800Antimalarial activity against chloroquine sensitive Plasmodium falciparum2020RSC medicinal chemistry, Feb-01, Volume: 11, Issue:2
An epigrammatic status of the '
AID1373240Antifungal activity against Trichophyton rubrum AUMC 1804 assessed as diameter of inhibition zone at 5 ug/disc after 48 hrs by agar disc diffusion method2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Fusarithioamide B, a new benzamide derivative from the endophytic fungus Fusarium chlamydosporium with potent cytotoxic and antimicrobial activities.
AID569331Antifungal activity against Aspergillus flavus at 50 uL/well by well diffusion assay2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Synthesis and biological activity of pyrazolothienotetrahydroisoquinoline and [1,2,4]triazolo[3,4-a]thienotetrahydroisoquinoline derivatives.
AID345541Enhancement of steroid receptor coactivator 1 binding to wild type mouse CAR expressed in HEK293 cells at 1 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID1866102Inhibition of Mycobacterium tuberculosis CYP121A1 mediated cYY conversion to mycocyclosin assessed as fold change in cYY level at 100 uM incubated for 2 hrs in the presence of NADPH by LC-MS activity assay relative to clotrimazole2022European journal of medicinal chemistry, Feb-15, Volume: 230A new strategy for hit generation: Novel in cellulo active inhibitors of CYP121A1 from Mycobacterium tuberculosis via a combined X-ray crystallographic and phenotypic screening approach (XP screen).
AID763672Antibacterial activity against Bacillus subtilis at 200 ug/disc after 24 hrs by agar disc-diffusion method2013European journal of medicinal chemistry, Aug, Volume: 66Nonclassical antifolates, part 4. 5-(2-aminothiazol-4-yl)-4-phenyl-4H-1,2,4-triazole-3-thiols as a new class of DHFR inhibitors: synthesis, biological evaluation and molecular modeling study.
AID1156866Antimicrobial activity against Trichophyton mentagrophytes after 96 hrs by microbroth dilution method2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis of 2,3,6-trideoxy sugar triazole hybrids as potential new broad spectrum antimicrobial agents.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID352830Antimicrobial activity against Aspergillus flavus NCIM 902 at 10 ug/disk after 72 hrs by disk diffusion method2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID564266Effect on sterol composition in Candida albicans isolate 108 harboring erg11 and erg5 double mutant assessed as obtusifoliol level after 2 hrs by gas chromatography2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B.
AID536078Antimicrobial activity against Bacillus subtilis IFO 3007 at 100 ug/8 mm disk after 24 hrs by agar disk diffusion method2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis, antimicrobial and anti-inflammatory activities of novel 5-(1-adamantyl)-1,3,4-thiadiazole derivatives.
AID318198Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 by [3H]hypoxanthine incorporation2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Clotrimazole scaffold as an innovative pharmacophore towards potent antimalarial agents: design, synthesis, and biological and structure-activity relationship studies.
AID563611Effect on sterol composition in Candida albicans isolate 108 harboring erg11 and erg5 double mutant assessed as ergosta 5,7-dienol level after 2 hrs by gas chromatography2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B.
AID734200Antifungal activity against Yarrowia lipolytica assessed as inhibition of fungal growth2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Stereoselective synthesis of a new class of potent and selective inhibitors of human Δ8,7-sterol isomerase.
AID757532Cytotoxicity against human Hep2 cells assessed as induction of vacuolization in proximity of mitochondria at 5 ug/ml after 24 hrs by transmission electron microscopic analysis2013European journal of medicinal chemistry, Jul, Volume: 65Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents.
AID1373239Antifungal activity against Geotrichum candidum AUMC 226 assessed as diameter of inhibition zone at 5 ug/disc after 48 hrs by agar disc diffusion method2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Fusarithioamide B, a new benzamide derivative from the endophytic fungus Fusarium chlamydosporium with potent cytotoxic and antimicrobial activities.
AID1355481Antifungal activity against Saccharomyces cerevisiae ATCC 9763 after 48 hrs by bromocresol green dye based assay2018Journal of natural products, 07-27, Volume: 81, Issue:7
Banksialactones and Banksiamarins: Isochromanones and Isocoumarins from an Australian Fungus, Aspergillus banksianus.
AID1300879Antifungal activity against Candida glabrata clinical isolate after 24 hrs by broth microdilution method2016European journal of medicinal chemistry, Jul-19, Volume: 117Novel 1,3-thiazolidin-4-one derivatives as promising anti-Candida agents endowed with anti-oxidant and chelating properties.
AID345665Decrease in steroid receptor coactivator 1 binding to mouse CAR T350A mutant expressed in HEK293 cells at 2 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID29421Partition coefficient (logP) (HPLC)2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
ElogPoct: a tool for lipophilicity determination in drug discovery.
AID361270Binding affinity to recombinant CYP3A4 expressed in Escherichia coli assessed as spectral dissociation constant by spectrophotometric equilibrium binding titration method2007The Journal of biological chemistry, Mar-02, Volume: 282, Issue:9
Multiple sequential steps involved in the binding of inhibitors to cytochrome P450 3A4.
AID336893Antifungal activity against Trichophyton rubrum after 2 to 4 days
AID299300Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K12007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Development of piperazine-tethered heterodimers as potent antimalarials against chloroquine-resistant P. falciparum strains. Synthesis and molecular modeling.
AID620357Antifungal activity against Syncephalastrum racemosum RCMB 005003 at 30 ug/ml after 3 to 4 days by agar well diffusion method2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and anti-microbial activity of some 1- substituted amino-4,6-dimethyl-2-oxo-pyridine-3-carbonitrile derivatives.
AID449706NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID481669Cytotoxicity against human SK-MEL cells up to 25 ug/ml after 48 hrs by neutral red assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and the selective antifungal activity of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives.
AID245308Minimum inhibitory concentration required for antibacterial activity against Bacillus subtilis ATCC 6633; Not tested2004Bioorganic & medicinal chemistry letters, Aug-16, Volume: 14, Issue:16
Synthesis and QSAR studies of pyrimido[4,5-d]pyrimidine-2,5-dione derivatives as potential antimicrobial agents.
AID352814Antimicrobial activity against Corynebacterium rubrum NCIM 2252 at 10 ug/disk after 24 hrs by disk diffusion method2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID1184407Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by two fold serial dilution method2014European journal of medicinal chemistry, Sep-12, Volume: 84Ultrasound-assisted synthesis of novel 1,2,3-triazoles coupled diaryl sulfone moieties by the CuAAC reaction, and biological evaluation of them as antioxidant and antimicrobial agents.
AID1210015Inhibition of CYP1A2 in human liver microsomes using phenacetin as substrate after 8 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID564265Effect on sterol composition in Candida albicans isolate 14 expressing wild type erg11 and erg5 assessed as obtusifoliol level after 2 hrs by gas chromatography2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID447232Antifungal activity against Candida albicans ATCC 10231 at 10 ug after 72 hrs by agar disk diffusion assay2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, Raman, FT-IR, NMR spectroscopic characterization, antimicrobial activity, cytotoxicity and DNA binding of new mixed aza-oxo-thia macrocyclic compounds.
AID665129Antifungal activity against 10 strains of Candida albicans after 24 hrs by EUCAST broth microdilution method2012European journal of medicinal chemistry, Jul, Volume: 53Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
AID1854173Antimicrobial activity against Aspergillus fumigatus NCIM 20812022European journal of medicinal chemistry, Aug-05, Volume: 238Cascade synthetic strategies opening access to medicinal-relevant aliphatic 3- and 4-membered N-heterocyclic scaffolds.
AID318210Cytotoxicity against human Daudi cells after 48 hrs by MTT assay2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Clotrimazole scaffold as an innovative pharmacophore towards potent antimalarial agents: design, synthesis, and biological and structure-activity relationship studies.
AID1287049Antimicrobial activity against antibiotic resistant Candida albicans clinical isolate 08030809 assessed as clone count at 10 mg/ml after 24 hrs by colony counting assay (Rvb > 10'5 CFU)2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
A Designed Tryptophan- and Lysine/Arginine-Rich Antimicrobial Peptide with Therapeutic Potential for Clinical Antibiotic-Resistant Candida albicans Vaginitis.
AID1372810Antimicrobial activity against Candida albicans ATCC 10231 by two-fold serial dilution assay2018Bioorganic & medicinal chemistry, 01-15, Volume: 26, Issue:2
An appraisal on synthetic and pharmaceutical perspectives of pyrazolo[4,3-d]pyrimidine scaffold.
AID150755Inhibition of P-glycoprotein using calcein-AM assay transfected in porcine PBCEC2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID287242Antimicrobial activity against Pseudomonas aeruginosa IFO 3448 at 200 ug/disc2007European journal of medicinal chemistry, Feb, Volume: 42, Issue:2
Synthesis, antimicrobial, and anti-inflammatory activities of novel 2-(1-adamantyl)-5-substituted-1,3,4-oxadiazoles and 2-(1-adamantylamino)-5-substituted-1,3,4-thiadiazoles.
AID757545Cytotoxicity against human Hep2 cells assessed as cell survival fraction at 100 ug/ml after 24 hrs by trypan blue exclusion assay (Rvb = 97 to 98%)2013European journal of medicinal chemistry, Jul, Volume: 65Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents.
AID318209Cytotoxicity against mouse NSO cells after 48 hrs by MTT assay2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Clotrimazole scaffold as an innovative pharmacophore towards potent antimalarial agents: design, synthesis, and biological and structure-activity relationship studies.
AID1373213Antibacterial activity against Staphylococcus aureus AUMC B-54 by microdilution method2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Fusarithioamide B, a new benzamide derivative from the endophytic fungus Fusarium chlamydosporium with potent cytotoxic and antimicrobial activities.
AID211151Antiprotozoal activity measured as the conc for <25% inhibition of Trichomonas vaginalis1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID1373211Antibacterial activity against Escherichia coli AUMC B-53 by microdilution method2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Fusarithioamide B, a new benzamide derivative from the endophytic fungus Fusarium chlamydosporium with potent cytotoxic and antimicrobial activities.
AID563608Effect on sterol composition in Candida albicans isolate 14 expressing wild type erg11 and erg5 assessed as ergosterol level after 2 hrs by gas chromatography2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B.
AID1184405Antibacterial activity against Klebsiella pneumoniae ATCC 13883 after 24 hrs by two fold serial dilution method2014European journal of medicinal chemistry, Sep-12, Volume: 84Ultrasound-assisted synthesis of novel 1,2,3-triazoles coupled diaryl sulfone moieties by the CuAAC reaction, and biological evaluation of them as antioxidant and antimicrobial agents.
AID515298Antifungal activity against Aspergillus niger MTCC 1344 at 30 ug/ml after 24 to 96 hrs by agar cup diffusion method2010European journal of medicinal chemistry, Oct, Volume: 45, Issue:10
Stereoselective synthesis and biological evaluation of (R)-rugulactone, (6R)-((4R)-hydroxy-6-phenyl-hex-2-enyl)-5,6-dihydro-pyran-2-one and its 4S epimer.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1484693Cytotoxicity against mouse NCTC-929 cells assessed as reduction in cell viability after 48 hrs by Alamar Blue assay2017European journal of medicinal chemistry, Jul-28, Volume: 135An overview of azoles targeting sterol 14α-demethylase for antileishmanial therapy.
AID1402886Induction of apoptosis in Candida albicans ATCC 90028 assessed as live cells at antifungal MIC90 after 24 hrs by Annexin V/propidium iodide staining based flow cytometry (Rvb = 99.8%)2018European journal of medicinal chemistry, Jan-20, Volume: 144The synthesis, antifungal and apoptotic effects of triazole-oxadiazoles against Candida species.
AID619763Antifungal activity against Aspergillus fumigatus RCMB 002003 at 30 mg/ml after 3 to 4 days by agar well diffusion method2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Design and synthesis of some new thiophene, thienopyrimidine and thienothiadiazine derivatives of antipyrine as potential antimicrobial agents.
AID214818Concentration for complete inhibition of growth of Trichophyton rubrum1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Antimycotic azoles. 6. Synthesis and antifungal properties of terconazole, a novel triazole ketal.
AID345828Activation of human CAR Phe161Ala mutant expressed in human C3A cells at 4 uM after 24 hrs by GAL4-dependent luciferase reporter gene assay relative to control2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Insights into ligand-elicited activation of human constitutive androstane receptor based on novel agonists and three-dimensional quantitative structure-activity relationship.
AID19424Partition coefficient (logD7.4)2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
AID1276953Binding affinity to biotinylated human CAR LBD after 1 hr by Scintillation Proximity Assay2016European journal of medicinal chemistry, Jan-27, Volume: 108Development of CINPA1 analogs as novel and potent inverse agonists of constitutive androstane receptor.
AID227351Compound was evaluated for ability to release [Ca2+] from internal stores using FURA-2AM loaded cells assayed in Ca2+ free media; Yes2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
3,3-diaryl-1,3-dihydroindol-2-ones as antiproliferatives mediated by translation initiation inhibition.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID345618Decrease in nuclear co-repressor receptor binding to mouse CAR L212A mutant expressed in HEK293 cells at 2 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID1265644Antifungal activity against Candida parapsilosis clinical isolate after 24 hrs by sabouraud dextrose broth based microdilution method2016European journal of medicinal chemistry, Jan-01, Volume: 107Anti-Candida activity and cytotoxicity of a large library of new N-substituted-1,3-thiazolidin-4-one derivatives.
AID211150Antiprotozoal activity measured as the conc for 95-25% inhibition of Trichomonas vaginalis1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID54923Inhibition of human cytochrome P450 3A42003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID564271Antifungal activity against Candida albicans isolate 177 after 48 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B.
AID703615Antimicrobial activity against Saccharomyces cerevisiae DSM 1333 after 48 hrs2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
A new class of selective and potent 7-dehydrocholesterol reductase inhibitors.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1330314Solubility of compound2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Evaluation of known and novel inhibitors of Orai1-mediated store operated Ca
AID287237Antimicrobial activity against Pseudomonas aeruginosa IFO 3448 at 100 ug/disc2007European journal of medicinal chemistry, Feb, Volume: 42, Issue:2
Synthesis, antimicrobial, and anti-inflammatory activities of novel 2-(1-adamantyl)-5-substituted-1,3,4-oxadiazoles and 2-(1-adamantylamino)-5-substituted-1,3,4-thiadiazoles.
AID665148Cytotoxicity against human Hep2 cells assessed as cell survival fraction at 0.05 ug/mL after 24 hrs by trypan blue exclusion method2012European journal of medicinal chemistry, Jul, Volume: 53Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
AID150751Inhibition of P-glycoprotein using ATPase in MDR1 membranes2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID449703NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay 2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID1373215Antibacterial activity against Serratia marcescens AUMC B-55 by microdilution method2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Fusarithioamide B, a new benzamide derivative from the endophytic fungus Fusarium chlamydosporium with potent cytotoxic and antimicrobial activities.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID757542Cytotoxicity against human Hep2 cells assessed as cell survival fraction at 5 ug/ml after 24 hrs by trypan blue exclusion assay (Rvb = 97 to 98%)2013European journal of medicinal chemistry, Jul, Volume: 65Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents.
AID1428259Antifungal activity against Candida albicans RCMB 0005003 assessed as zone of inhibition at 30 ug/ml2017European journal of medicinal chemistry, Jan-27, Volume: 126An insight on synthetic and medicinal aspects of pyrazolo[1,5-a]pyrimidine scaffold.
AID717845Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID39703In vitro antifungal activity against Aspergillus fumigatus1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Synthesis and in vitro antimicrobial property of o-carborane derivatives.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1287117Antimicrobial activity against antibiotic resistant Candida albicans clinical isolate 08030809 in mouse vaginitis model assessed as colony count in lavage liquid of vagina at 10 mg/ml administered as intravaginal instillation measured on day 162016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
A Designed Tryptophan- and Lysine/Arginine-Rich Antimicrobial Peptide with Therapeutic Potential for Clinical Antibiotic-Resistant Candida albicans Vaginitis.
AID532565Antifungal activity against wild-type Saccharomyces cerevisiae BY4741 by broth microdilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus.
AID497825Inhibition of polyhistidine tagged yeast prion protein Sup35 expressed in Escherichia coli BL21 (DE3) assessed as inhibition of amyloid polymerization at 100 uM by thioflavin T fluorescence assay relative to untreated control2008Nature chemical biology, Mar, Volume: 4, Issue:3
Small-molecule aggregates inhibit amyloid polymerization.
AID1065914Inhibition of TRPM2 (unknown origin)2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Structure-activity relationship of adenosine 5'-diphosphoribose at the transient receptor potential melastatin 2 (TRPM2) channel: rational design of antagonists.
AID1287121Antiinflammatory activity in antibiotic resistant Candida albicans clinical isolate 08030809 induced mouse vaginitis model assessed as reduction in IL-1beta secretion in vaginal tissue at 10 mg/ml administered as intravaginal instillation measured on day 2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
A Designed Tryptophan- and Lysine/Arginine-Rich Antimicrobial Peptide with Therapeutic Potential for Clinical Antibiotic-Resistant Candida albicans Vaginitis.
AID572695Binding affinity to Mycobacterium smegmatis ATCC 700084 CYP164A2 at pH7.52009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Identification, characterization, and azole-binding properties of Mycobacterium smegmatis CYP164A2, a homolog of ML2088, the sole cytochrome P450 gene of Mycobacterium leprae.
AID1713950Cytotoxicity against HEK293T cells assessed as reduction in cell viability measured after 24 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Biological evaluation of tetracationic compounds based on two 1,4-diazabicyclo[2.2.2]octane moieties connected by different linkers.
AID366421Antibacterial activity against Staphylococcus aureus ATCC 6538P assessed as inhibition zone diameter after 24 hrs by agar diffusion method2008Journal of natural products, Aug, Volume: 71, Issue:8
Bioactive brominated metabolites from the red sea sponge Suberea mollis.
AID569326Antifungal activity against Candida albicans at 50 uL/well by well diffusion assay2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Synthesis and biological activity of pyrazolothienotetrahydroisoquinoline and [1,2,4]triazolo[3,4-a]thienotetrahydroisoquinoline derivatives.
AID1373216Antifungal activity against Candida albicans AUMC 418 by microdilution method2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Fusarithioamide B, a new benzamide derivative from the endophytic fungus Fusarium chlamydosporium with potent cytotoxic and antimicrobial activities.
AID569330Antifungal activity against Fusarium oxysporum at 50 uL/well by well diffusion assay2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Synthesis and biological activity of pyrazolothienotetrahydroisoquinoline and [1,2,4]triazolo[3,4-a]thienotetrahydroisoquinoline derivatives.
AID678721Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID665143Cytotoxicity against human Hep2 cells assessed as cell survival fraction at 100 ug/mL after 24 hrs by trypan blue exclusion method2012European journal of medicinal chemistry, Jul, Volume: 53Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
AID1557077Antifungal activity against Candida albicans SN152 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID1373234Antibacterial activity against Bacillus cereus AUMC B-5 assessed as diameter of inhibition zone at 5 ug/disc after 24 hrs by agar disc diffusion method2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Fusarithioamide B, a new benzamide derivative from the endophytic fungus Fusarium chlamydosporium with potent cytotoxic and antimicrobial activities.
AID1557079Antifungal activity against Candida glabrata ATCC 2001 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID582801Antifungal activity against Candida albicans isolate 490 harboring ERG3 D147G, T330A, A351V and ERG11 F72S, T229A, E266D, N440S, V488I, R523G mutant genes by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Identification and characterization of four azole-resistant erg3 mutants of Candida albicans.
AID1428256Antifungal activity against Aspergillus fumigatus RCMB 002006 assessed as zone of inhibition at 30 ug/ml2017European journal of medicinal chemistry, Jan-27, Volume: 126An insight on synthetic and medicinal aspects of pyrazolo[1,5-a]pyrimidine scaffold.
AID1287047Antimicrobial activity against antibiotic resistant Candida albicans clinical isolate 08030809 assessed as clone count at 10 mg/ml after 6 hrs by colony counting assay (Rvb = 14536 +/- 2467 CFU)2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
A Designed Tryptophan- and Lysine/Arginine-Rich Antimicrobial Peptide with Therapeutic Potential for Clinical Antibiotic-Resistant Candida albicans Vaginitis.
AID1634152Lipophilicity, log D of compound at pH 7.42019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Strategies for the development of highly selective cytochrome P450 inhibitors: Several CYP targets in current research.
AID572698Selectivity ratio, ratio of Kd for Mycobacterium smegmatis ATCC 700084 CYP164A2 to Kd for Mycobacterium smegmatis ATCC 700084 CYP512009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Identification, characterization, and azole-binding properties of Mycobacterium smegmatis CYP164A2, a homolog of ML2088, the sole cytochrome P450 gene of Mycobacterium leprae.
AID562245Antimycobacterial activity against Mycobacterium smegmatis grown in nitrogen -limited broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID1379939Antifungal activity against Candida krusei clinical isolates assessed as inhibition of microbial growth incubated for 24 hrs by broth microdilution method2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis, biological evaluation and quantitative structure-active relationships of 1,3-thiazolidin-4-one derivatives. A promising chemical scaffold endowed with high antifungal potency and low cytotoxicity.
AID1300880Antifungal activity against Candida tropicalis clinical isolate after 24 hrs by broth microdilution method2016European journal of medicinal chemistry, Jul-19, Volume: 117Novel 1,3-thiazolidin-4-one derivatives as promising anti-Candida agents endowed with anti-oxidant and chelating properties.
AID1383232Antimalarial activity against Plasmodium falciparum2018European journal of medicinal chemistry, Apr-10, Volume: 149Pyrazole-pyrazoline as promising novel antimalarial agents: A mechanistic study.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID345668Decrease in nuclear co-repressor receptor binding to mouse CAR T350M mutant expressed in HEK293 cells at 2 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID1373238Antifungal activity against Candida albicans AUMC 418 assessed as diameter of inhibition zone at 5 ug/disc after 48 hrs by agar disc diffusion method2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Fusarithioamide B, a new benzamide derivative from the endophytic fungus Fusarium chlamydosporium with potent cytotoxic and antimicrobial activities.
AID569328Antifungal activity against Trichophyton rubrum at 50 uL/well by well diffusion assay2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Synthesis and biological activity of pyrazolothienotetrahydroisoquinoline and [1,2,4]triazolo[3,4-a]thienotetrahydroisoquinoline derivatives.
AID1265641Antifungal activity against Candida glabrata clinical isolate after 24 hrs by sabouraud dextrose broth based microdilution method2016European journal of medicinal chemistry, Jan-01, Volume: 107Anti-Candida activity and cytotoxicity of a large library of new N-substituted-1,3-thiazolidin-4-one derivatives.
AID763671Antibacterial activity against Escherichia coli at 200 ug/disc after 24 hrs by agar disc-diffusion method2013European journal of medicinal chemistry, Aug, Volume: 66Nonclassical antifolates, part 4. 5-(2-aminothiazol-4-yl)-4-phenyl-4H-1,2,4-triazole-3-thiols as a new class of DHFR inhibitors: synthesis, biological evaluation and molecular modeling study.
AID681128TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1b-expressing LLC-PK1 cells2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID335822Antimicrobial activity against Trichophyton mentagrophytes UPCC 4193 assessed as clearing zone at 30 ug after 72 hrs2002Journal of natural products, Aug, Volume: 65, Issue:8
New furanoid diterpenes from Caesalpinia pulcherrima.
AID1546107Antifungal activity against Aspergillus flavus2019European journal of medicinal chemistry, Dec-15, Volume: 184Current scenario of tetrazole hybrids for antibacterial activity.
AID517137Antifungal activity against Aspergillus niger MTCC 282 at 100 ug/ml2010Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20
Synthesis, antimicrobial, and mosquito larvicidal activity of 1-aryl-4-methyl-3,6-bis-(5-methylisoxazol-3-yl)-2-thioxo-2,3,6,10b-tetrahydro-1H-pyrimido[5,4-c]quinolin-5-ones.
AID1379942Cytotoxicity against human Hep2 cells assessed as reduction in cell viability incubated for 24 hrs by trypan blue dye exclusion assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis, biological evaluation and quantitative structure-active relationships of 1,3-thiazolidin-4-one derivatives. A promising chemical scaffold endowed with high antifungal potency and low cytotoxicity.
AID352632Antimicrobial activity against Escherichia coli NCIM 2065 at 10 ug/disk after 24 hrs by disk diffusion method2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID397428Inhibition of IK12009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants.
AID517145Antifungal activity against Curvularia lunata MTCC 2030 at 100 ug/ml2010Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20
Synthesis, antimicrobial, and mosquito larvicidal activity of 1-aryl-4-methyl-3,6-bis-(5-methylisoxazol-3-yl)-2-thioxo-2,3,6,10b-tetrahydro-1H-pyrimido[5,4-c]quinolin-5-ones.
AID352834Antimicrobial activity against Rhodotorula rubra NCIM 3174 at 10 ug/disk after 72 hrs by disk diffusion method2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID1287041Antimicrobial activity against antibiotic resistant Candida albicans clinical isolate 08030809 assessed as clone count at 10 mg/ml after 1 hr by colony counting assay (Rvb = 228 +/- 23 CFU)2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
A Designed Tryptophan- and Lysine/Arginine-Rich Antimicrobial Peptide with Therapeutic Potential for Clinical Antibiotic-Resistant Candida albicans Vaginitis.
AID1076972Antifungal activity against Candida albicans ATCC 10231 assessed as growth inhibition after 48 hrs by two-fold serial dilution assay2014European journal of medicinal chemistry, Apr-09, Volume: 76Bifunctional ethyl 2-amino-4-methylthiazole-5-carboxylate derivatives: synthesis and in vitro biological evaluation as antimicrobial and anticancer agents.
AID1402887Induction of apoptosis in Candida albicans ATCC 90028 assessed as early apoptotic cells at antifungal MIC90 after 24 hrs by Annexin V/propidium iodide staining based flow cytometry (Rvb = 0%)2018European journal of medicinal chemistry, Jan-20, Volume: 144The synthesis, antifungal and apoptotic effects of triazole-oxadiazoles against Candida species.
AID335827Antimicrobial activity against Candida albicans UPCC 2168 assessed as antimicrobial index at 30 ug after 48 hrs2002Journal of natural products, Aug, Volume: 65, Issue:8
New furanoid diterpenes from Caesalpinia pulcherrima.
AID572697Binding affinity to Mycobacterium smegmatis ATCC 700084 CYP164A2 in presence of 0.1% triton X-100 at pH7.52009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Identification, characterization, and azole-binding properties of Mycobacterium smegmatis CYP164A2, a homolog of ML2088, the sole cytochrome P450 gene of Mycobacterium leprae.
AID345916Activation of human CAR His203Ala mutant expressed in human C3A cells at 4 uM after 24 hrs by GAL4-dependent luciferase reporter gene assay relative to control2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Insights into ligand-elicited activation of human constitutive androstane receptor based on novel agonists and three-dimensional quantitative structure-activity relationship.
AID566725Antifungal activity against Candida krusei after 24 hrs by MTT assay2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and biological evaluation of novel 2,4-disubstituted-1,3-thiazoles as anti-Candida spp. agents.
AID1265645Antifungal activity against Candida sake clinical isolate after 24 hrs by sabouraud dextrose broth based microdilution method2016European journal of medicinal chemistry, Jan-01, Volume: 107Anti-Candida activity and cytotoxicity of a large library of new N-substituted-1,3-thiazolidin-4-one derivatives.
AID345644Effect on steroid receptor coactivator 1 binding to mouse CAR I252L mutant expressed in HEK293 cells at 2 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345920Activation of human CAR Phe243Ala mutant expressed in human C3A cells at 4 uM after 24 hrs by GAL4-dependent luciferase reporter gene assay relative to control2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Insights into ligand-elicited activation of human constitutive androstane receptor based on novel agonists and three-dimensional quantitative structure-activity relationship.
AID1184406Antibacterial activity against Pseudomonas aeruginosa ATCC 27953 after 24 hrs by two fold serial dilution method2014European journal of medicinal chemistry, Sep-12, Volume: 84Ultrasound-assisted synthesis of novel 1,2,3-triazoles coupled diaryl sulfone moieties by the CuAAC reaction, and biological evaluation of them as antioxidant and antimicrobial agents.
AID345914Activation of human CAR Asn165Ala mutant expressed in human C3A cells at 4 uM after 24 hrs by GAL4-dependent luciferase reporter gene assay relative to control2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Insights into ligand-elicited activation of human constitutive androstane receptor based on novel agonists and three-dimensional quantitative structure-activity relationship.
AID1265649Cytotoxicity against human Hep2 cells assessed as cell survival at 0.5 ug/ml after 24 hrs by trypan blue exclusion test (Rvb = 87 to 94%)2016European journal of medicinal chemistry, Jan-01, Volume: 107Anti-Candida activity and cytotoxicity of a large library of new N-substituted-1,3-thiazolidin-4-one derivatives.
AID345595Effect on nuclear co-repressor receptor binding to mouse CAR F171A mutant expressed in HEK293 cells at 2 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID665138Antiproliferative activity against human Hep2 cells assessed as cell survival fraction at 10 ug/mL after 24 hrs by MTT assay2012European journal of medicinal chemistry, Jul, Volume: 53Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
AID295136Antifungal activity against Debaryomyces hansenii DSM 70238 at 10 ug after 72 hrs by disk diffusion method2007European journal of medicinal chemistry, Aug, Volume: 42, Issue:8
Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of bis[micro2-(benzimidazol-2-yl)-2-ethanethiolato-N,S,S-chloro-palladium(II)] dimer, [(micro2-CH2CH2NHNCC6H4)PdCl]2.C2H5OH complex.
AID211149Antiprotozoal activity measured as the conc for 100% inhibition of Trichomonas vaginalis1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID221126Inhibition of Vaginal Candida (C-60 strain) infection in Hamsters, estimated as Percent Area under curve at 0.05 % concentration after 8 days of administration1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Isobenzofurans as conformationally constrained miconazole analogues with improved antifungal potency.
AID1598717Binding affinity to Triton-X 100 assessed as peak intensity loss at 150 uM by 1H-NMR spectra analysis2019Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10
Mechanisms of Specific versus Nonspecific Interactions of Aggregation-Prone Inhibitors and Attenuators.
AID318211Cytotoxicity against human lymphocytes after 48 hrs by MTT assay2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Clotrimazole scaffold as an innovative pharmacophore towards potent antimalarial agents: design, synthesis, and biological and structure-activity relationship studies.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID150753Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID1373218Antifungal activity against Trichophyton rubrum AUMC 1804 by microdilution method2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Fusarithioamide B, a new benzamide derivative from the endophytic fungus Fusarium chlamydosporium with potent cytotoxic and antimicrobial activities.
AID1147016Antifungal activity against Candida albicans infected in mouse assessed as noninfected animals at 1% formulation in neat PEG 400 solution administered vaginally bid for 4 days measured on day 7 relative to placebo1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
1-[4-(4-Chlorophenyl)-2-(2,6-dichlorophenylthio)-n-butyl]-1H-imidazole nitrate, a new potent antifungal agent.
AID141785Concentration for complete inhibition of growth of Mucor sp.1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Antimycotic azoles. 6. Synthesis and antifungal properties of terconazole, a novel triazole ketal.
AID619767Antifungal activity against Syncephalastrum racemosum RCMB 052003 at 30 mg/ml after 3 to 4 days by agar well diffusion method2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Design and synthesis of some new thiophene, thienopyrimidine and thienothiadiazine derivatives of antipyrine as potential antimicrobial agents.
AID1276954Inverse agonist activity at GST tagged-human CAR-LBD assessed as reduction in fluorescein-PGC1 alpha coactivator recruitment after 1 hr by TR-FRET assay2016European journal of medicinal chemistry, Jan-27, Volume: 108Development of CINPA1 analogs as novel and potent inverse agonists of constitutive androstane receptor.
AID1287069Effect on cell membrane integrity in antibiotic resistant Candida albicans clinical isolate 08030809 at 20 ug/ml measured every 2 mins upto 20 mins by SYTOX green nucleic acid staining-based fluorescence assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
A Designed Tryptophan- and Lysine/Arginine-Rich Antimicrobial Peptide with Therapeutic Potential for Clinical Antibiotic-Resistant Candida albicans Vaginitis.
AID665131Antifungal activity against 4 strains of Candida parapsilosis after 24 hrs by EUCAST broth microdilution method2012European journal of medicinal chemistry, Jul, Volume: 53Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
AID1300883Antifungal activity against Candida sake clinical isolate after 24 hrs by broth microdilution method2016European journal of medicinal chemistry, Jul-19, Volume: 117Novel 1,3-thiazolidin-4-one derivatives as promising anti-Candida agents endowed with anti-oxidant and chelating properties.
AID481664Antifungal activity against Candida krusei NRRL Y-7179 after 24 hrs by broth microdilution assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and the selective antifungal activity of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives.
AID318202Antifungal activity against Candida albicans2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Clotrimazole scaffold as an innovative pharmacophore towards potent antimalarial agents: design, synthesis, and biological and structure-activity relationship studies.
AID1193495Thermodynamic equilibrium solubility, log S of the compound in simulated intestinal fluid at pH 6.8 at RT after 4 hrs by 96 well plate method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID395382Antifungal activity against Kluyveromyces fragilis NRRL 2415 at 10 ug after 72 hrs by disk diffusion method2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Synthesis, Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of mixed aza-oxo-thia macrocyclic compounds.
AID77140Evaluated for marked improvement against trichophytosis after topical treatment with 0.5% of compound in a group of 6 guinea pigs1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Antimycotic azoles. 6. Synthesis and antifungal properties of terconazole, a novel triazole ketal.
AID503311Antiproliferative activity against human PC3 cells at 10 uM after 120 hrs by MTT assay relative to DMSO2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID1330313Inhibition of Orai1-mediated store operated Ca2+ entry in human MDA-MB-231 cells assessed as reduction in BAPTA-induced Ca2+ depletion-stimulated SOCE activity at 30 uM preincubated for 15 mins followed by BAPTA addition in presence of extracellular Ca2+ 2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Evaluation of known and novel inhibitors of Orai1-mediated store operated Ca
AID582796Antifungal activity against Candida albicans isolate 6 by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Identification and characterization of four azole-resistant erg3 mutants of Candida albicans.
AID1321216Antimicrobial activity against Escherichia coli IFO 3301 at 200 ug/disc measured after 24 hrs by agar disc-diffusion method2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Synthesis, biological evaluation and molecular modeling study of some new methoxylated 2-benzylthio-quinazoline-4(3H)-ones as nonclassical antifolates.
AID777333Antifungal activity against Candida albicans isolated from patient assessed as growth inhibition after 24 to 48 hrs by microbroth dilution method2013ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10
Identification of 1-[4-Benzyloxyphenyl)-but-3-enyl]-1H-azoles as New Class of Antitubercular and Antimicrobial Agents.
AID1443992Total Cmax in human administered as single dose2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID665136Antiproliferative activity against human Hep2 cells assessed as cell survival fraction at 100 ug/mL after 24 hrs by MTT assay2012European journal of medicinal chemistry, Jul, Volume: 53Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID569332Antifungal activity against Aspergillus niger at 50 uL/well by well diffusion assay2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Synthesis and biological activity of pyrazolothienotetrahydroisoquinoline and [1,2,4]triazolo[3,4-a]thienotetrahydroisoquinoline derivatives.
AID777331Antifungal activity against Sporothrix schenckii isolated from patient assessed as growth inhibition after 72 to 96 hrs by microbroth dilution method2013ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10
Identification of 1-[4-Benzyloxyphenyl)-but-3-enyl]-1H-azoles as New Class of Antitubercular and Antimicrobial Agents.
AID770904Antifungal activity against Candida albicans IFO 0583 after 24 hrs by two fold dilution method2013European journal of medicinal chemistry, Oct, Volume: 68Synthesis and antimicrobial activity of novel 5-(1-adamantyl)-2-aminomethyl-4-substituted-1,2,4-triazoline-3-thiones.
AID1184403Antibacterial activity against Bacillus megaterium ATCC 9885 after 24 hrs by two fold serial dilution method2014European journal of medicinal chemistry, Sep-12, Volume: 84Ultrasound-assisted synthesis of novel 1,2,3-triazoles coupled diaryl sulfone moieties by the CuAAC reaction, and biological evaluation of them as antioxidant and antimicrobial agents.
AID1333868Antifungal activity against Aspergillus niger after 24 hrs by two fold dilution method2017Bioorganic & medicinal chemistry letters, 01-01, Volume: 27, Issue:1
Synthesis of new morpholine-connected pyrazolidine derivatives and their antimicrobial, antioxidant, and cytotoxic activities.
AID1546161Antifungal activity against Aspergillus niger2019European journal of medicinal chemistry, Dec-15, Volume: 184Current scenario of tetrazole hybrids for antibacterial activity.
AID1184393Antibacterial activity against Bacillus megaterium ATCC 9885 at 50 mg/mL after 24 hrs by agar well diffusion method2014European journal of medicinal chemistry, Sep-12, Volume: 84Ultrasound-assisted synthesis of novel 1,2,3-triazoles coupled diaryl sulfone moieties by the CuAAC reaction, and biological evaluation of them as antioxidant and antimicrobial agents.
AID1204384Antimicrobial activity against Candida albicans assessed as diameter of inhibition zone after 1 day by agar diffusion assay2015European journal of medicinal chemistry, Jun-05, Volume: 97Organoselenocyanates and symmetrical diselenides redox modulators: Design, synthesis and biological evaluation.
AID48588Minimum inhibitory concentration against Candida albicans IFO 13881987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and antifungal activity of new 1-vinylimidazoles.
AID603972Antifungal activity against Candida albicans after 48 hrs by agar well diffusion assay2011European journal of medicinal chemistry, Jul, Volume: 46, Issue:7
Synthesis and antimicrobial activity of some novel dicationic sulphonophanes.
AID481671Cytotoxicity against human SKOV3 cells up to 25 ug/ml after 48 hrs by neutral red assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and the selective antifungal activity of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives.
AID576612Inhibition of human ERG2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID299299Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D72007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Development of piperazine-tethered heterodimers as potent antimalarials against chloroquine-resistant P. falciparum strains. Synthesis and molecular modeling.
AID1333869Antifungal activity against Candida albicans after 24 hrs by two fold dilution method2017Bioorganic & medicinal chemistry letters, 01-01, Volume: 27, Issue:1
Synthesis of new morpholine-connected pyrazolidine derivatives and their antimicrobial, antioxidant, and cytotoxic activities.
AID1210014Inhibition of recombinant CYP2J2 (unknown origin)-mediated astemizole O-demethylation assessed as remaining activity at 30 uM after 5 mins by LC-MS/MS analysis relative to control2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID515299Antifungal activity against Candida albicans MTCC 227 at 30 ug/ml after 24 to 96 hrs by agar cup diffusion method2010European journal of medicinal chemistry, Oct, Volume: 45, Issue:10
Stereoselective synthesis and biological evaluation of (R)-rugulactone, (6R)-((4R)-hydroxy-6-phenyl-hex-2-enyl)-5,6-dihydro-pyran-2-one and its 4S epimer.
AID1186788Antifungal activity against Candida glabrata MTCC3019 at 30 ug/ml after 48 hrs by agar well diffusion method2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Indolylmethylene benzo[h]thiazolo[2,3-b]quinazolinones: synthesis, characterization and evaluation of anticancer and antimicrobial activities.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1321218Antimicrobial activity against Candida albicans IFO 0583 at 200 ug/disc measured after 48 hrs by agar disc-diffusion method2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Synthesis, biological evaluation and molecular modeling study of some new methoxylated 2-benzylthio-quinazoline-4(3H)-ones as nonclassical antifolates.
AID481667Antifungal activity against Candida albicans NRRL Y-12983 after 24 hrs by broth microdilution assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and the selective antifungal activity of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives.
AID681167TP_TRANSPORTER: Northern blot from LS174T cell2001The Journal of biological chemistry, May-04, Volume: 276, Issue:18
Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin.
AID1402888Induction of apoptosis in Candida albicans ATCC 90028 assessed as late apoptotic cells at antifungal MIC90 after 24 hrs by Annexin V/propidium iodide staining based flow cytometry (Rvb = 0%)2018European journal of medicinal chemistry, Jan-20, Volume: 144The synthesis, antifungal and apoptotic effects of triazole-oxadiazoles against Candida species.
AID70214Enhancement of epoxide hydrolase activity1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Structural features of imidazole derivatives that enhance styrene oxide hydrolase activity in rat hepatic microsomes.
AID352624Antimicrobial activity against Klebsiella aerogenes NCIM 2239 at 10 ug/disk after 24 hrs by disk diffusion method2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID620132Antifungal activity against Candida albicans IFO 0583 at 100 ug/disc after 48 hrs by agar disc diffusion method2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis of novel 6-phenyl-2,4-disubstituted pyrimidine-5-carbonitriles as potential antimicrobial agents.
AID345602Enhancement of nuclear co-repressor receptor binding to mouse CAR F171L mutant expressed in HEK293 cells at 2 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID1713957Selectivity index, ratio of CC50 for HEK293T cells assessed as reduction in cell viability measured after 24 hrs by MTT assay to MIC for Candida albicans CEMTC 34 assessed as bacterial growth inhibition by CLSI protocol based serial microdilution method2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Biological evaluation of tetracationic compounds based on two 1,4-diazabicyclo[2.2.2]octane moieties connected by different linkers.
AID481670Cytotoxicity against human BT549 cells up to 25 ug/ml after 48 hrs by neutral red assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and the selective antifungal activity of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1300885Cytotoxicity against human Hep2 cells assessed as cell survival at 0.5 ug/ml after 24 hrs by trypan blue exclusion assay2016European journal of medicinal chemistry, Jul-19, Volume: 117Novel 1,3-thiazolidin-4-one derivatives as promising anti-Candida agents endowed with anti-oxidant and chelating properties.
AID729298Inverse agonist activity at CCR4 in human HTLA cells assessed as depression of basal activity incubated for 20 mins by beta arrestin-recruitment mediated luciferase reporter gene assay in absence of CCL222013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
Colloidal aggregation causes inhibition of G protein-coupled receptors.
AID1333870Antifungal activity against Cryptococcus neoformans after 24 hrs by two fold dilution method2017Bioorganic & medicinal chemistry letters, 01-01, Volume: 27, Issue:1
Synthesis of new morpholine-connected pyrazolidine derivatives and their antimicrobial, antioxidant, and cytotoxic activities.
AID189042Percent reduction in recovery of Candida albicans (experimental vaginitis) in rats by topical administration at 1% w/v1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Synthesis of (E)-1-(5-chlorothien-2-yl)-2-(1H-imidazol-1-yl)ethanone 2,6-dichlorophenylhydrazone hydrochloride, a novel, orally active antifungal agent.
AID287239Antimicrobial activity against Staphylococcus aureus IFO 3060 after 24 hrs2007European journal of medicinal chemistry, Feb, Volume: 42, Issue:2
Synthesis, antimicrobial, and anti-inflammatory activities of novel 2-(1-adamantyl)-5-substituted-1,3,4-oxadiazoles and 2-(1-adamantylamino)-5-substituted-1,3,4-thiadiazoles.
AID287383Antifungal activity against Hanseniaspora guilliermondii after 24 hrs by disk diffusion method2007European journal of medicinal chemistry, Feb, Volume: 42, Issue:2
Synthesis, characterization and antimicrobial activity of Fe(II), Zn(II), Cd(II) and Hg(II) complexes with 2,6-bis(benzimidazol-2-yl) pyridine ligand.
AID1557081Antifungal activity against Candida parapsilosis ATCC 90018 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID1634151Partition coefficient, log P of the compound2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Strategies for the development of highly selective cytochrome P450 inhibitors: Several CYP targets in current research.
AID1184399Antifungal activity against Saccharomyces cerevisiae at 50 mg/mL after 48 hrs by agar well diffusion method2014European journal of medicinal chemistry, Sep-12, Volume: 84Ultrasound-assisted synthesis of novel 1,2,3-triazoles coupled diaryl sulfone moieties by the CuAAC reaction, and biological evaluation of them as antioxidant and antimicrobial agents.
AID295132Antifungal activity against Candida albicans ATCC 10231 at 10 ug after 72 hrs by disk diffusion method2007European journal of medicinal chemistry, Aug, Volume: 42, Issue:8
Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of bis[micro2-(benzimidazol-2-yl)-2-ethanethiolato-N,S,S-chloro-palladium(II)] dimer, [(micro2-CH2CH2NHNCC6H4)PdCl]2.C2H5OH complex.
AID39669Antifungal activity against Aspergillus fumigatus Saito strain1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and quantitative structure-activity relationship analysis of N-triiodoallyl- and N-iodopropargylazoles. New antifungal agents.
AID345912Effect on steroid receptor coactivator 1 binding to mouse CAR L353A mutant expressed in HEK293 cells at 2 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID150754Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID1207633Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID665139Antiproliferative activity against human Hep2 cells assessed as cell survival fraction at 5 ug/mL after 24 hrs by MTT assay2012European journal of medicinal chemistry, Jul, Volume: 53Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
AID1605086Inhibition of rabbit kidney Sodium/potassium-transporting ATPase by malachite green based colorimetric method2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
Sarco/Endoplasmic Reticulum Calcium ATPase Inhibitors: Beyond Anticancer Perspective.
AID678983TP_TRANSPORTER: Western blot, HepG2 cells2002Toxicology, Feb-28, Volume: 171, Issue:2-3
Influence of redox-active compounds and PXR-activators on human MRP1 and MRP2 gene expression.
AID395111Antifungal activity against Candida albicans isolate after 72 hrs by twofold serial dilution method2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Azole antimicrobial pharmacophore-based tetrazoles: synthesis and biological evaluation as potential antimicrobial and anticonvulsant agents.
AID345652Decrease in steroid receptor coactivator 1 binding to mouse CAR L253F mutant expressed in HEK293 cells at 2 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID1634153Antifungal activity against Candida albicans2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Strategies for the development of highly selective cytochrome P450 inhibitors: Several CYP targets in current research.
AID1713949Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Biological evaluation of tetracationic compounds based on two 1,4-diazabicyclo[2.2.2]octane moieties connected by different linkers.
AID582799Antifungal activity against Candida albicans isolate 12 harboring ERG3 W332R mutant gene by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Identification and characterization of four azole-resistant erg3 mutants of Candida albicans.
AID366422Antibacterial activity against Pseudomonas aeruginosa ATCC 9027 assessed as inhibition zone diameter after 24 hrs by agar diffusion method2008Journal of natural products, Aug, Volume: 71, Issue:8
Bioactive brominated metabolites from the red sea sponge Suberea mollis.
AID287234Antimicrobial activity against Staphylococcus aureus IFO 3060 at 100 ug/disc after 24 hrs2007European journal of medicinal chemistry, Feb, Volume: 42, Issue:2
Synthesis, antimicrobial, and anti-inflammatory activities of novel 2-(1-adamantyl)-5-substituted-1,3,4-oxadiazoles and 2-(1-adamantylamino)-5-substituted-1,3,4-thiadiazoles.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID287236Antimicrobial activity against Escherichia coli IFO 3301 at 100 ug/disc after 24 hrs2007European journal of medicinal chemistry, Feb, Volume: 42, Issue:2
Synthesis, antimicrobial, and anti-inflammatory activities of novel 2-(1-adamantyl)-5-substituted-1,3,4-oxadiazoles and 2-(1-adamantylamino)-5-substituted-1,3,4-thiadiazoles.
AID1605036Inhibition of rabbit skeletal muscle microsomes SERCA1a2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
Sarco/Endoplasmic Reticulum Calcium ATPase Inhibitors: Beyond Anticancer Perspective.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID729312Inhibition of CX3CL1-stimulated CX3CR1 in human HTLA cells pre-incubated for 20 mins measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
Colloidal aggregation causes inhibition of G protein-coupled receptors.
AID77935Lession score which is determined as number of animals minus days to become negative1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Isobenzofurans as conformationally constrained miconazole analogues with improved antifungal potency.
AID1379937Antifungal activity against Candida glabrata clinical isolates assessed as inhibition of microbial growth incubated for 24 hrs by broth microdilution method2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis, biological evaluation and quantitative structure-active relationships of 1,3-thiazolidin-4-one derivatives. A promising chemical scaffold endowed with high antifungal potency and low cytotoxicity.
AID345574Decrease in mouse CAR L253F mutant activation expressed in HEK293 cells at 2 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID703736Cytotoxicity against human HepG2 cells after 24 hrs by neutral red dye uptake assay2012Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
Optimization of 4-aminoquinoline/clotrimazole-based hybrid antimalarials: further structure-activity relationships, in vivo studies, and preliminary toxicity profiling.
AID345654Decrease in nuclear co-repressor receptor binding to mouse CAR Y336A mutant expressed in HEK293 cells at 2 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID27580Partition coefficient (logP)2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
ElogPoct: a tool for lipophilicity determination in drug discovery.
AID681142TP_TRANSPORTER: increase in Vinblastine intracellular accumulation in MDR1-expressing LLC-PK1 cells2002Molecular pharmacology, May, Volume: 61, Issue:5
Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein.
AID54864Antifungal activity against Cryptococcus neoformans was determined by twofold Micro-broth dilution assay; No data2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
Bile acid amides derived from chiral amino alcohols: novel antimicrobials and antifungals.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID45486In vitro antifungal activity against Candida albicans1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Synthesis and in vitro antimicrobial property of o-carborane derivatives.
AID1808020Inhibition of porcine heart malate dehydrogenase preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec by spectrophotometric method2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID1055629Antifungal activity against Candida albicans assessed as growth inhibition after 48 hrs by broth microdilution method2013European journal of medicinal chemistry, , Volume: 70Synthesis and antimicrobial activity of some novel hydrazide, benzochromenone, dihydropyridine, pyrrole, thiazole and thiophene derivatives.
AID1209974Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID566726Antifungal activity against Candida sake after 24 hrs by MTT assay2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and biological evaluation of novel 2,4-disubstituted-1,3-thiazoles as anti-Candida spp. agents.
AID1557082Antifungal activity against Candida parapsilosis ATCC 22019 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID412370Cytotoxicity against human KB cells by MTT assay2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Combining 4-aminoquinoline- and clotrimazole-based pharmacophores toward innovative and potent hybrid antimalarials.
AID763670Antifungal activity against Candida albicans at 200 ug/disc after 48 hrs by agar disc-diffusion method2013European journal of medicinal chemistry, Aug, Volume: 66Nonclassical antifolates, part 4. 5-(2-aminothiazol-4-yl)-4-phenyl-4H-1,2,4-triazole-3-thiols as a new class of DHFR inhibitors: synthesis, biological evaluation and molecular modeling study.
AID497649Inhibition of polyhistidine tagged yeast prion protein Sup35 expressed in Escherichia coli BL21 (DE3) assessed as inhibition of amyloid polymerization at 50 uM in presence of 5 mg/ml BSA by thioflavin T fluorescence assay relative to untreated control2008Nature chemical biology, Mar, Volume: 4, Issue:3
Small-molecule aggregates inhibit amyloid polymerization.
AID1442006Ratio of Kii for human OCT1-ASP+-inhibitor complex to Kis for human OCT1-inhibitor complex by Lineweaver-Burk plot analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1).
AID345563Effect on mouse CAR H213A mutant expressed in HEK293 cells at 2 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID665147Cytotoxicity against human Hep2 cells assessed as cell survival fraction at 0.5 ug/mL after 24 hrs by trypan blue exclusion method2012European journal of medicinal chemistry, Jul, Volume: 53Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
AID1186792Antifungal activity against Aspergillus parasiticus MTCC 8850 at 30 ug/ml after 48 hrs by agar well diffusion method2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Indolylmethylene benzo[h]thiazolo[2,3-b]quinazolinones: synthesis, characterization and evaluation of anticancer and antimicrobial activities.
AID675134Antifungal activity against Fusarium oxysporum after 72 to 96 hrs by agar cup method2012European journal of medicinal chemistry, Sep, Volume: 55Design, synthesis, antimicrobial, anti-inflammatory and analgesic activity of novel isoxazolyl pyrimido[4,5-b]quinolines and isoxazolyl chromeno[2,3-d]pyrimidin-4-ones.
AID665130Antifungal activity against 3 strains of Candida krusei after 24 hrs by EUCAST broth microdilution method2012European journal of medicinal chemistry, Jul, Volume: 53Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
AID1808019Inhibition of SARS CoV2 C-terminal His6-tagged 3CL protease (3264 to 3569 residues) expressed in Escherichia coli BL21 DE3 using rr-K(MCA)-ATLQAIAS-K(DNP)-COOH preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 0.02021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID286782Aggregate based-inhibition of Escherichia coli AmpC beta lactamase using stringent assay conditions in presence of 0.01% Triton X-100 detergent2007Journal of medicinal chemistry, May-17, Volume: 50, Issue:10
A high-throughput screen for aggregation-based inhibition in a large compound library.
AID729314Inhibition of CCL22-stimulated CCR4 in human HTLA cells pre-incubated for 20 mins with centrifuged compound solution measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
Colloidal aggregation causes inhibition of G protein-coupled receptors.
AID345626Enhancement of nuclear co-repressor receptor binding to mouse CAR H213A mutant expressed in HEK293 cells at 2 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345538Activation of wild type mouse CAR expressed in HEK293 cells at 2 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID609163Antibacterial activity against Escherichia coli assessed as zone of inhibition at 5 uL and 32 degC after 36 hrs by disk diffusion method2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Cytotoxic ring A-modified steroid analogues derived from Grundmann's ketone.
AID497826Inhibition of polyhistidine tagged yeast prion protein Sup35 expressed in Escherichia coli BL21 (DE3) assessed as inhibition of amyloid polymerization preincubation of seed fibers and compound for 5 mins at 100 uM by thioflavin T fluorescence assay relati2008Nature chemical biology, Mar, Volume: 4, Issue:3
Small-molecule aggregates inhibit amyloid polymerization.
AID619761Antifungal activity against Candida albicans RCMB 052002 at 30 mg/ml after 3 to 4 days by agar well diffusion method2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Design and synthesis of some new thiophene, thienopyrimidine and thienothiadiazine derivatives of antipyrine as potential antimicrobial agents.
AID1402890Induction of apoptosis in Candida glabrata ATCC 90030 assessed as live cells at antifungal MIC90 after 24 hrs by Annexin V/propidium iodide staining based flow cytometry (Rvb = 99.5%)2018European journal of medicinal chemistry, Jan-20, Volume: 144The synthesis, antifungal and apoptotic effects of triazole-oxadiazoles against Candida species.
AID426137Antifungal activity against Aspergillus fumigatus at 100 ug/ml after 72 hrs by agar well diffusion method2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Synthesis and antimicrobial studies of novel methylene bridged benzisoxazolyl imidazo[2,1-b][1,3,4]thiadiazole derivatives.
AID572696Binding affinity to Mycobacterium smegmatis ATCC 700084 CYP164A2 in presence of 0.5 M NaCl at pH7.52009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Identification, characterization, and azole-binding properties of Mycobacterium smegmatis CYP164A2, a homolog of ML2088, the sole cytochrome P450 gene of Mycobacterium leprae.
AID47569Antifungal activity against Candida albicans, activity expressed as minimum inhibitory zone(mm, diameter)1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID315277Intrinsic clearance in rat liver microsome S9 fraction as % compound remaining after incubation2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Novel inhibitors of the Gardos channel for the treatment of sickle cell disease.
AID568445Antimicrobial activity against Saccharomyces cerevisiae MTCC 171 at 30 ug/ml after 24 to 96 hrs by agar cup method2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Stereoselective first total synthesis, confirmation of the absolute configuration and bioevaluation of botryolide-E.
AID497644Inhibition of polyhistidine tagged yeast prion protein Sup35 expressed in Escherichia coli BL21 (DE3) assessed as inhibition of amyloid polymerization at 50 uM by thioflavin T fluorescence assay relative to untreated control2008Nature chemical biology, Mar, Volume: 4, Issue:3
Small-molecule aggregates inhibit amyloid polymerization.
AID481661Antifungal activity against Candida glabrata clinical isolate 1 after 24 hrs by broth microdilution assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and the selective antifungal activity of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives.
AID1402894Induction of apoptosis in Candida krusei ATCC 6258 assessed as live cells at antifungal MIC90 after 24 hrs by Annexin V/propidium iodide staining based flow cytometry (Rvb = 97.3%)2018European journal of medicinal chemistry, Jan-20, Volume: 144The synthesis, antifungal and apoptotic effects of triazole-oxadiazoles against Candida species.
AID681138TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation in mdr1b-expressing LLC-PK1 cells2002The Journal of pharmacology and experimental therapeutics, Oct, Volume: 303, Issue:1
Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
AID609170Antifungal activity against Hyphopichia burtonii assessed as zone of inhibition at 5 uL and 28 degC after 36 hrs by disk diffusion method2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Cytotoxic ring A-modified steroid analogues derived from Grundmann's ketone.
AID270272Antifungal activity against Sporothrix schenckii2006Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17
Antifungal anthraquinones from Saprosma fragrans.
AID412368Cytotoxicity against human Daudi cells by MTT assay2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Combining 4-aminoquinoline- and clotrimazole-based pharmacophores toward innovative and potent hybrid antimalarials.
AID625277FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID412380Inhibition of beta-hematin assessed as molar equivalents at pH 2.7 after 18 hrs by spectrophotometric microassay relative to hemin2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Combining 4-aminoquinoline- and clotrimazole-based pharmacophores toward innovative and potent hybrid antimalarials.
AID1651558Antifungal activity against Candida albicans ATCC 10231 assessed as reduction in microbial growth after incubated for 48 hrs by bromocresol green dye based assay2020Journal of natural products, 04-24, Volume: 83, Issue:4
Talauxins: Hybrid Phenalenone Dimers from
AID1156862Antimicrobial activity against Candida albicans after 48 hrs by microbroth dilution method2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis of 2,3,6-trideoxy sugar triazole hybrids as potential new broad spectrum antimicrobial agents.
AID318205Antifungal activity against Cryptococcus neoformans2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Clotrimazole scaffold as an innovative pharmacophore towards potent antimalarial agents: design, synthesis, and biological and structure-activity relationship studies.
AID1265648Cytotoxicity against human Hep2 cells assessed as cell survival at 5 ug/ml after 24 hrs by trypan blue exclusion test (Rvb = 87 to 94%)2016European journal of medicinal chemistry, Jan-01, Volume: 107Anti-Candida activity and cytotoxicity of a large library of new N-substituted-1,3-thiazolidin-4-one derivatives.
AID1156863Antimicrobial activity against Aspergillus fumigatus after 72 hrs by microbroth dilution method2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis of 2,3,6-trideoxy sugar triazole hybrids as potential new broad spectrum antimicrobial agents.
AID208353Maximum enhancement of styrene oxide hydrolase activity was reported at compound concentration of 1e-4M1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Structural features of imidazole derivatives that enhance styrene oxide hydrolase activity in rat hepatic microsomes.
AID1598719Binding affinity to Triton-X 100 assessed as line broadening at 150 uM by 1H-NMR spectra analysis2019Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10
Mechanisms of Specific versus Nonspecific Interactions of Aggregation-Prone Inhibitors and Attenuators.
AID345671Effect on steroid receptor coactivator 1 binding to mouse CAR T350M mutant expressed in HEK293 cells at 2 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID703616Antifungal activity against Candida glabrata DSM 11226 after 48 hrs2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
A new class of selective and potent 7-dehydrocholesterol reductase inhibitors.
AID1402898Induction of apoptosis in Candida parapsilosis ATCC 22019 assessed as live cells at antifungal MIC90 after 24 hrs by Annexin V/propidium iodide staining based flow cytometry (Rvb = 97.6%)2018European journal of medicinal chemistry, Jan-20, Volume: 144The synthesis, antifungal and apoptotic effects of triazole-oxadiazoles against Candida species.
AID681119TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1a-expressing LLC-PK1 cells2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID447230Antifungal activity against Kluyveromyces fragilis NRRL 2415 at 10 ug after 72 hrs by agar disk diffusion assay2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, Raman, FT-IR, NMR spectroscopic characterization, antimicrobial activity, cytotoxicity and DNA binding of new mixed aza-oxo-thia macrocyclic compounds.
AID270270Antifungal activity against Candida albicans2006Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17
Antifungal anthraquinones from Saprosma fragrans.
AID497657Inhibition of polyhistidine tagged yeast prion protein Sup35 expressed in Escherichia coli BL21 (DE3) assessed as inhibition of amyloid polymerization at 50 uM in presence of 0.5% seed fibres by thioflavin T fluorescence assay relative to untreated contro2008Nature chemical biology, Mar, Volume: 4, Issue:3
Small-molecule aggregates inhibit amyloid polymerization.
AID703614Antifungal activity against Yarrowia lipolytica DSM 1345 after 48 hrs2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
A new class of selective and potent 7-dehydrocholesterol reductase inhibitors.
AID308424Antifungal activity against Candida krusei after 24 hrs by broth microdilution method2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Synthesis and in vitro activity of 2-thiazolylhydrazone derivatives compared with the activity of clotrimazole against clinical isolates of Candida spp.
AID452942Antifungal activity against Aspergillus niger at 50 ug/disk by agar plate disk diffusion method2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
In vitro antitubercular and antimicrobial activities of 1-substituted quinoxaline-2,3(1H,4H)-diones.
AID560139Antifungal activity against Candida glabrata isolate 22853 at 10 ug after 48 hrs by disk diffusion method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Hypersusceptibility to azole antifungals in a clinical isolate of Candida glabrata with reduced aerobic growth.
AID1287060Antimicrobial activity against antibiotic resistant Candida albicans clinical isolate 08030809 in mouse vaginitis model assessed as decrease in colony count in lavage liquid of vagina at 10 mg/ml administered as intravaginal instillation measured on day 12016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
A Designed Tryptophan- and Lysine/Arginine-Rich Antimicrobial Peptide with Therapeutic Potential for Clinical Antibiotic-Resistant Candida albicans Vaginitis.
AID412369Cytotoxicity against PHA-stimulated human lymphocytes by MTT assay2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Combining 4-aminoquinoline- and clotrimazole-based pharmacophores toward innovative and potent hybrid antimalarials.
AID288612Inhibition of yeast alcohol dehydrogenase by fluorescence based assay2007Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
Antibacterial nicotinamide adenine dinucleotide synthetase inhibitors: amide- and ether-linked tethered dimers with alpha-amino acid end groups.
AID345923Increase in human steroid receptor coactivator 1 binding to human CAR-LBD expressed in human C3A cells by mammalian two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Insights into ligand-elicited activation of human constitutive androstane receptor based on novel agonists and three-dimensional quantitative structure-activity relationship.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID352854Antimicrobial activity against Trichoderma viride NCIM 1195 at 10 ug/disk after 72 hrs by disk diffusion method2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID214296Antifungal activity against Trichophyton rubrum was determined by twofold Micro-broth dilution assay2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
Bile acid amides derived from chiral amino alcohols: novel antimicrobials and antifungals.
AID497667Toxicity in PSI yeast spheroplast cells infected with yeast prion protein Sup352008Nature chemical biology, Mar, Volume: 4, Issue:3
Small-molecule aggregates inhibit amyloid polymerization.
AID536076Antimicrobial activity against Staphylococcus aureus IFO 3060 at 100 ug/8 mm disk after 24 hrs by agar disk diffusion method2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis, antimicrobial and anti-inflammatory activities of novel 5-(1-adamantyl)-1,3,4-thiadiazole derivatives.
AID536080Antimicrobial activity against Micrococcus luteus IFO 3232 at 100 ug/8 mm disk after 24 hrs by agar disk diffusion method2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis, antimicrobial and anti-inflammatory activities of novel 5-(1-adamantyl)-1,3,4-thiadiazole derivatives.
AID536092Antimicrobial activity against Candida albicans IFO 0583 after 48 hrs2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis, antimicrobial and anti-inflammatory activities of novel 5-(1-adamantyl)-1,3,4-thiadiazole derivatives.
AID1287038Antimicrobial activity against antibiotic resistant Candida albicans clinical isolate 08030809 assessed as clone count at 10 mg/ml after 1 min by colony counting assay (Rvb = 62 +/- 7 CFU)2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
A Designed Tryptophan- and Lysine/Arginine-Rich Antimicrobial Peptide with Therapeutic Potential for Clinical Antibiotic-Resistant Candida albicans Vaginitis.
AID1184396Antibacterial activity against Pseudomonas aeruginosa ATCC 27953 at 50 mg/mL after 24 hrs by agar well diffusion method2014European journal of medicinal chemistry, Sep-12, Volume: 84Ultrasound-assisted synthesis of novel 1,2,3-triazoles coupled diaryl sulfone moieties by the CuAAC reaction, and biological evaluation of them as antioxidant and antimicrobial agents.
AID277612Antifungal activity against Aspergillus flavus ATCC 2043042007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Design and synthesis of potent antimalarial agents based on clotrimazole scaffold: exploring an innovative pharmacophore.
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID48828Antifungal activity against Candida albicans was determined by twofold Micro-broth dilution assay2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
Bile acid amides derived from chiral amino alcohols: novel antimicrobials and antifungals.
AID665134Antifungal activity against 4 strains of Candida tropicalis after 24 hrs by EUCAST broth microdilution method2012European journal of medicinal chemistry, Jul, Volume: 53Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
AID532552Antifungal activity against Saccharomyces cerevisiae BY4741 harboring human CYP51 assessed as growth rate at 1 ug/ml (Rvb = 0.157%)2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus.
AID497659Inhibition of polyhistidine tagged yeast prion protein Sup35 expressed in Escherichia coli BL21 (DE3) assessed as inhibition of amyloid polymerization at 50 uM in presence of 5% seed fibres by thioflavin T fluorescence assay relative to untreated control2008Nature chemical biology, Mar, Volume: 4, Issue:3
Small-molecule aggregates inhibit amyloid polymerization.
AID26810Partition coefficient (logP)1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Structural features of imidazole derivatives that enhance styrene oxide hydrolase activity in rat hepatic microsomes.
AID345683Cytotoxicity against HEK293 cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID397423Inhibition of cloned Kv1.3 channel expressed in mammalian cells by whole cell patch clamp assay2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants.
AID777328Antifungal activity against Candida parapsilosis ATCC 22019 assessed as growth inhibition after 24 to 48 hrs by microbroth dilution method2013ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10
Identification of 1-[4-Benzyloxyphenyl)-but-3-enyl]-1H-azoles as New Class of Antitubercular and Antimicrobial Agents.
AID1330316Antagonist activity at rat TRPM8 expressed in HEK293 cells assessed as inhibition of menthol-stimulated Ca2+ flux up to 100 uM after 30 mins by calcium-4 dye based FLIPR assay2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Evaluation of known and novel inhibitors of Orai1-mediated store operated Ca
AID318204Antifungal activity against Candida parapsilosis ATCC 220192008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Clotrimazole scaffold as an innovative pharmacophore towards potent antimalarial agents: design, synthesis, and biological and structure-activity relationship studies.
AID345606Effect on steroid receptor co-activator 1 binding to mouse CAR F171L mutant expressed in HEK293 cells at 2 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID245122Minimum inhibitory concentration required for antifungal activity against Aspergillus niger ATCC 164042004Bioorganic & medicinal chemistry letters, Aug-16, Volume: 14, Issue:16
Synthesis and QSAR studies of pyrimido[4,5-d]pyrimidine-2,5-dione derivatives as potential antimicrobial agents.
AID757549Anticandida activity against Candida tropicalis clinical isolate assessed as growth inhibition after 24 hrs by broth microdilution method2013European journal of medicinal chemistry, Jul, Volume: 65Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents.
AID1287028Antiinflammatory activity in antibiotic resistant Candida albicans clinical isolate 08030809 induced mouse vaginitis model assessed as microabscess number in vaginal tissue at 200 ug administered as intravaginal instillation measured on day 6 by hematoxyl2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
A Designed Tryptophan- and Lysine/Arginine-Rich Antimicrobial Peptide with Therapeutic Potential for Clinical Antibiotic-Resistant Candida albicans Vaginitis.
AID1147015Antifungal activity against Candida albicans infected in mouse assessed as noninfected animals at 1% formulation in neat PEG 400 solution administered vaginally bid for 4 days measured 6 hrs post last dose relative to placebo1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
1-[4-(4-Chlorophenyl)-2-(2,6-dichlorophenylthio)-n-butyl]-1H-imidazole nitrate, a new potent antifungal agent.
AID1184404Antibacterial activity against Sarcina lutea after 24 hrs by two fold serial dilution method2014European journal of medicinal chemistry, Sep-12, Volume: 84Ultrasound-assisted synthesis of novel 1,2,3-triazoles coupled diaryl sulfone moieties by the CuAAC reaction, and biological evaluation of them as antioxidant and antimicrobial agents.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1193493Thermodynamic equilibrium solubility, log S of the compound in PBS at pH 7.4 at RT after 4 hrs by 96 well plate method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID572699Binding affinity to Mycobacterium tuberculosis CYP512009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Identification, characterization, and azole-binding properties of Mycobacterium smegmatis CYP164A2, a homolog of ML2088, the sole cytochrome P450 gene of Mycobacterium leprae.
AID1402884Antifungal activity against Candida parapsilosis ATCC 22019 by broth microdilution assay2018European journal of medicinal chemistry, Jan-20, Volume: 144The synthesis, antifungal and apoptotic effects of triazole-oxadiazoles against Candida species.
AID412363Antimalarial activity after 24 hrs against chloroquine-sensitive Plasmodium falciparum 3D7 infected human A+ erythrocytes by [3H]hypoxanthine uptake2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Combining 4-aminoquinoline- and clotrimazole-based pharmacophores toward innovative and potent hybrid antimalarials.
AID1402901Induction of apoptosis in Candida parapsilosis ATCC 22019 assessed as necrotic cells at antifungal MIC90 after 24 hrs by Annexin V/propidium iodide staining based flow cytometry (Rvb = 1.4%)2018European journal of medicinal chemistry, Jan-20, Volume: 144The synthesis, antifungal and apoptotic effects of triazole-oxadiazoles against Candida species.
AID517143Antifungal activity against Fusarium moniliforme MTCC 1848 at 100 ug/ml2010Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20
Synthesis, antimicrobial, and mosquito larvicidal activity of 1-aryl-4-methyl-3,6-bis-(5-methylisoxazol-3-yl)-2-thioxo-2,3,6,10b-tetrahydro-1H-pyrimido[5,4-c]quinolin-5-ones.
AID536082Antimicrobial activity against Escherichia coli IFO 3301 at 100 ug/8 mm disk after 24 hrs by agar disk diffusion method2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis, antimicrobial and anti-inflammatory activities of novel 5-(1-adamantyl)-1,3,4-thiadiazole derivatives.
AID532550Antifungal activity against Saccharomyces cerevisiae BY4741 harboring human CYP51 by broth microdilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus.
AID318216Reduced parasitemia in Plasmodium berghei ANKA infected CD1 mice (Mus musculus) at 150 mg/kg peroral dose after 4 days2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Clotrimazole scaffold as an innovative pharmacophore towards potent antimalarial agents: design, synthesis, and biological and structure-activity relationship studies.
AID352826Antimicrobial activity against Aspergillus niger NCIM 902 at 10 ug/disk after 72 hrs by disk diffusion method2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID729313Inhibition of CCL22-stimulated CCR4 in human HTLA cells pre-incubated for 20 mins with Tween-80-treated compound solution measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
Colloidal aggregation causes inhibition of G protein-coupled receptors.
AID41120Antibacterial activity against Bacteroides fragilis, activity expressed as minimum inhibitory zone(mm, diameter)1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID426136Antifungal activity against Candida albicans at 100 ug/ml after 72 hrs by agar well diffusion method2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Synthesis and antimicrobial studies of novel methylene bridged benzisoxazolyl imidazo[2,1-b][1,3,4]thiadiazole derivatives.
AID49467Antifungal activity against Candida albicans ATCC 26278 strain in YNB medium after incorporation of 10 ug per disk.1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Synthesis and biological properties of N3-(4-methoxyfumaroyl)-L-2,3-diaminopropanoic acid dipeptides, a novel group of antimicrobial agents.
AID44953Antifungal activity against Candida albicans C-A-24 strain1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and quantitative structure-activity relationship analysis of N-triiodoallyl- and N-iodopropargylazoles. New antifungal agents.
AID277605Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D72007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Design and synthesis of potent antimalarial agents based on clotrimazole scaffold: exploring an innovative pharmacophore.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1209973Inhibition of CYP2D6 in human liver microsomes using dextromethorphan as substrate after 8 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID287381Antifungal activity against Kluyveromyces fragilis after 24 hrs by disk diffusion method2007European journal of medicinal chemistry, Feb, Volume: 42, Issue:2
Synthesis, characterization and antimicrobial activity of Fe(II), Zn(II), Cd(II) and Hg(II) complexes with 2,6-bis(benzimidazol-2-yl) pyridine ligand.
AID678984TP_TRANSPORTER: RT-PCR in HepG2 cells2002Toxicology, Feb-28, Volume: 171, Issue:2-3
Influence of redox-active compounds and PXR-activators on human MRP1 and MRP2 gene expression.
AID288613Inhibition of yeast alcohol dehydrogenase in presence of 0.001% Triton X-100 by fluorescence based assay2007Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
Antibacterial nicotinamide adenine dinucleotide synthetase inhibitors: amide- and ether-linked tethered dimers with alpha-amino acid end groups.
AID43563Fold decrease in IC50 vs beta-lactamase on pre-incubation2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID1265643Antifungal activity against Candida krusei clinical isolate after 24 hrs by sabouraud dextrose broth based microdilution method2016European journal of medicinal chemistry, Jan-01, Volume: 107Anti-Candida activity and cytotoxicity of a large library of new N-substituted-1,3-thiazolidin-4-one derivatives.
AID1210016Inhibition of CYP2C8 in human liver microsomes using paclitaxel as substrate after 8 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID1651557Antifungal activity against Saccharomyces cerevisiae ATCC 9763 assessed as reduction in microbial growth after incubated for 48 hrs by bromocresol green dye based assay2020Journal of natural products, 04-24, Volume: 83, Issue:4
Talauxins: Hybrid Phenalenone Dimers from
AID623636Antifungal activity against Candida albicans ATCC 90028 assessed as zone of inhibition at 10 ug/disc after 48 hrs by agar disc diffusion method2011European journal of medicinal chemistry, Nov, Volume: 46, Issue:11
A facile synthesis of carbocycle-fused mono and bis-1,2,3-selenadiazoles and their antimicrobial and antimycobacterial studies.
AID345638Decrease in steroid receptor coactivator 1 binding to mouse CAR S251L mutant expressed in HEK293 cells at 2 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID91481Binding constant against human serum albumin (HSA)2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
Cheminformatic models to predict binding affinities to human serum albumin.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1379938Antifungal activity against Candida tropicalis clinical isolates assessed as inhibition of microbial growth incubated for 24 hrs by broth microdilution method2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis, biological evaluation and quantitative structure-active relationships of 1,3-thiazolidin-4-one derivatives. A promising chemical scaffold endowed with high antifungal potency and low cytotoxicity.
AID352822Antimicrobial activity against Proteus vulgaris NCIM 2027 at 10 ug/disk after 24 hrs by disk diffusion method2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1210017Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 8 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID1287042Antimicrobial activity against antibiotic resistant Candida albicans clinical isolate 08030809 assessed as clone count at 10 mg/ml after 3 hrs by colony counting assay (Rvb = 3687 +/- 543 CFU)2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
A Designed Tryptophan- and Lysine/Arginine-Rich Antimicrobial Peptide with Therapeutic Potential for Clinical Antibiotic-Resistant Candida albicans Vaginitis.
AID1184400Antifungal activity against Aspergillus niger at 50 mg/mL after 48 hrs by agar well diffusion method2014European journal of medicinal chemistry, Sep-12, Volume: 84Ultrasound-assisted synthesis of novel 1,2,3-triazoles coupled diaryl sulfone moieties by the CuAAC reaction, and biological evaluation of them as antioxidant and antimicrobial agents.
AID1373214Antibacterial activity against Bacillus cereus AUMC B-5 by microdilution method2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Fusarithioamide B, a new benzamide derivative from the endophytic fungus Fusarium chlamydosporium with potent cytotoxic and antimicrobial activities.
AID731779Antifungal activity against Fusarium oxysporum AUMC 5119 assessed as diameter of growth inhibition zone at 20 mg/ml at 28 degC after 7 days2013European journal of medicinal chemistry, Apr, Volume: 62First synthesis and biological evaluation of indeno[2,1-e]pyrazolo[3,4-b]pyrazin-5-one and related derivatives.
AID675135Antifungal activity against Verticillium dahliae after 72 to 96 hrs by agar cup method2012European journal of medicinal chemistry, Sep, Volume: 55Design, synthesis, antimicrobial, anti-inflammatory and analgesic activity of novel isoxazolyl pyrimido[4,5-b]quinolines and isoxazolyl chromeno[2,3-d]pyrimidin-4-ones.
AID345567Decrease in mouse CAR S251L mutant activation expressed in HEK293 cells at 2 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID449705NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID757538Cytotoxicity against human Hep2 cells assessed as reduction of cell viability after 24 hrs by trypan blue exclusion assay2013European journal of medicinal chemistry, Jul, Volume: 65Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents.
AID44954Antifungal activity against Candida albicans was determined in vitro1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and antifungal activity of a series of novel 1,2-disubstituted propenones.
AID217559Effective concentration to inhibit the proliferation of amastigote form of the parasite grown on mammalian (Vero) cells1993Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14
Toward a novel metal-based chemotherapy against tropical diseases. 1. Enhancement of the efficacy of clotrimazole against Trypanosoma cruzi by complexation to ruthenium in RuCl2(clotrimazole)2.
AID1379940Antifungal activity against Candida parapsilosis clinical isolates assessed as inhibition of microbial growth incubated for 24 hrs by broth microdilution method2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis, biological evaluation and quantitative structure-active relationships of 1,3-thiazolidin-4-one derivatives. A promising chemical scaffold endowed with high antifungal potency and low cytotoxicity.
AID1193498Thermodynamic equilibrium solubility, log S of the compound simulated gastric fluid at pH 1.2 at RT after 24 hrs by shake-flask method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID43431Compound was tested for the inhibition of beta-lactamase2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID287382Antifungal activity against Rhodotorula rubra after 24 hrs by disk diffusion method2007European journal of medicinal chemistry, Feb, Volume: 42, Issue:2
Synthesis, characterization and antimicrobial activity of Fe(II), Zn(II), Cd(II) and Hg(II) complexes with 2,6-bis(benzimidazol-2-yl) pyridine ligand.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID288614Inhibition of yeast alcohol dehydrogenase in presence of 0.01% Triton X-100 by fluorescence based assay2007Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
Antibacterial nicotinamide adenine dinucleotide synthetase inhibitors: amide- and ether-linked tethered dimers with alpha-amino acid end groups.
AID675137Antifungal activity against Rhizoctonia solani after 72 to 96 hrs by agar cup method2012European journal of medicinal chemistry, Sep, Volume: 55Design, synthesis, antimicrobial, anti-inflammatory and analgesic activity of novel isoxazolyl pyrimido[4,5-b]quinolines and isoxazolyl chromeno[2,3-d]pyrimidin-4-ones.
AID270274Antifungal activity against Aspergillus fumigatus2006Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17
Antifungal anthraquinones from Saprosma fragrans.
AID352818Antimicrobial activity against Staphylococcus albus NCIM 2178 at 10 ug/disk after 24 hrs by disk diffusion method2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID1402897Induction of apoptosis in Candida krusei ATCC 6258 assessed as necrotic cells at antifungal MIC90 after 24 hrs by Annexin V/propidium iodide staining based flow cytometry (Rvb = 0.9%)2018European journal of medicinal chemistry, Jan-20, Volume: 144The synthesis, antifungal and apoptotic effects of triazole-oxadiazoles against Candida species.
AID1186786Antifungal activity against Candida albicans MTCC 183 at 30 ug/ml after 48 hrs by agar well diffusion method2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Indolylmethylene benzo[h]thiazolo[2,3-b]quinazolinones: synthesis, characterization and evaluation of anticancer and antimicrobial activities.
AID1478060Binding affinity to Mycobacterium tuberculosis CYP121A1 expressed in Escherichia coli TG1 (DE3) by UV-visible scanning spectrophotometric analysis
AID345598Effect on steroid receptor co-activator 1 binding to mouse CAR F171A mutant expressed in HEK293 cells at 2 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID777330Antifungal activity against Trichophyton mentagrophytes isolated from patient assessed as growth inhibition after 72 to 96 hrs by microbroth dilution method2013ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10
Identification of 1-[4-Benzyloxyphenyl)-but-3-enyl]-1H-azoles as New Class of Antitubercular and Antimicrobial Agents.
AID1402896Induction of apoptosis in Candida krusei ATCC 6258 assessed as late apoptotic cells at antifungal MIC90 after 24 hrs by Annexin V/propidium iodide staining based flow cytometry (Rvb = 1.4%)2018European journal of medicinal chemistry, Jan-20, Volume: 144The synthesis, antifungal and apoptotic effects of triazole-oxadiazoles against Candida species.
AID532560Antifungal activity against Saccharomyces cerevisiae BY4741 assessed as growth rate at 1 ug/ml (Rvb = 0.144%)2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus.
AID336891Antifungal activity against Aspergillus fumigatus MSU-SM 920 after 2 to 4 days
AID428564Inhibition of CYP3A42009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.
AID70071Antifungal activity against Epidermophyton floccosum, activity expressed as inhibitory zone(mm, diameter)1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID447234Antifungal activity against Debaryomyces hansenii DSM 70238 at 10 ug after 72 hrs by agar disk diffusion assay2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, Raman, FT-IR, NMR spectroscopic characterization, antimicrobial activity, cytotoxicity and DNA binding of new mixed aza-oxo-thia macrocyclic compounds.
AID763673Antibacterial activity against Staphylococcus aureus at 200 ug/disc after 24 hrs by agar disc-diffusion method2013European journal of medicinal chemistry, Aug, Volume: 66Nonclassical antifolates, part 4. 5-(2-aminothiazol-4-yl)-4-phenyl-4H-1,2,4-triazole-3-thiols as a new class of DHFR inhibitors: synthesis, biological evaluation and molecular modeling study.
AID563612Effect on sterol composition in Candida albicans isolate 14 expressing wild type erg11 and erg5 assessed as 14 -Methylergosta-8,24(28)-dien-3beta,6alpha-diol level after 2 hrs by gas chromatography2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B.
AID379708Antifungal activity against Candida albicans ATCC 10231 by modified microtiter plate assay2006Journal of natural products, Feb, Volume: 69, Issue:2
Bioactive natural and semisynthetic latrunculins.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID729305Inhibition of vasopressin V2 receptor (unknown origin) assessed as change in intracellular calcium levels incubated with compound treated with Tween-80 by fluorometric analysis2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
Colloidal aggregation causes inhibition of G protein-coupled receptors.
AID620355Antifungal activity against Geotrichum candidum RCMB 052006 at 30 ug/ml after 3 to 4 days by agar well diffusion method2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and anti-microbial activity of some 1- substituted amino-4,6-dimethyl-2-oxo-pyridine-3-carbonitrile derivatives.
AID75517Evaluated for cure against microsporosis after topical treatment with 1% of compound in a group of 8 guinea pigs1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Antimycotic azoles. 6. Synthesis and antifungal properties of terconazole, a novel triazole ketal.
AID582998Antimicrobial activity against Saccharomyces cerevisiae YUG37 transformed with plasmid carrying cyp51A gene with doxycycline-regulatable promoter by broth dilution method in presence of doxycycline2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Complementation of a Saccharomyces cerevisiae ERG11/CYP51 (sterol 14α-demethylase) doxycycline-regulated mutant and screening of the azole sensitivity of Aspergillus fumigatus isoenzymes CYP51A and CYP51B.
AID609167Antifungal activity against Yarrowia lipolytica assessed as zone of inhibition at 5 uL and 28 degC after 36 hrs by disk diffusion method2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Cytotoxic ring A-modified steroid analogues derived from Grundmann's ketone.
AID757539Cytotoxicity against human Hep2 cells assessed as cell survival fraction at 0.005 ug/ml after 24 hrs by trypan blue exclusion assay (Rvb = 97 to 98%)2013European journal of medicinal chemistry, Jul, Volume: 65Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents.
AID481668Antifungal activity against Candida glabrata clinical isolate 2 after 24 hrs by broth microdilution assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and the selective antifungal activity of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives.
AID1055633Antifungal activity against Candida albicans assessed as growth inhibition at 1 mg/mL after 48 hrs by two-fold serial dilution method2013European journal of medicinal chemistry, , Volume: 70Synthesis and antimicrobial activity of some novel hydrazide, benzochromenone, dihydropyridine, pyrrole, thiazole and thiophene derivatives.
AID1557089Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method2019European journal of medicinal chemistry, Oct-01, Volume: 179Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID277607Inhibition of beta-hematin formation2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Design and synthesis of potent antimalarial agents based on clotrimazole scaffold: exploring an innovative pharmacophore.
AID52776Compound was tested for the inhibition of Chymotrypsinogen2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID218572Fold increase in IC50 vs beta-lactamase with 10x increased enzyme2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID582797Antifungal activity against Candida albicans isolate 14 by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Identification and characterization of four azole-resistant erg3 mutants of Candida albicans.
AID763996Antifungal activity against Candida albicans ATCC 2091 assessed as diameter of inhibition zone at 1 mg/ml after 48 hrs by cup diffusion method (Rvb = 22 mm)2013European journal of medicinal chemistry, Aug, Volume: 66Synthesis, biological evaluation and molecular docking studies of some pyrimidine derivatives.
AID563615Effect on sterol composition in Candida albicans isolate 108 harboring erg11 and erg5 double mutant assessed as lanosterol level after 2 hrs by gas chromatography2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B.
AID428422Antifungal activity against Microsporum canis after 48 hrs by agar dilution method2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Design, synthesis, and antifungal activity of triazole and benzotriazole derivatives.
AID202867Antifungal activity against Saccharomyces cerevisiae, activity expressed as minimum inhibitory concentration (ug/mL).1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID1808025Inhibition of SARS-Cov2 N-terminal full-length MBP-tagged 3CL protease expressed in Escherichia coli using DABCYL-KTSAVLQSGFRKME-EDANS as substrate preincubated for 30 mins followed by substrate addition and measured after 3 hrs by fluorescence assay2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID1209972Inhibition of CYP2C19 in human liver microsomes using S-mephenytoin as substrate after 8 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID1276956Inverse agonist activity at GST tagged-human CAR-LBD assessed as reduction in fluorescein-SRC1 coactivator recruitment after 1 hr by TR-FRET assay2016European journal of medicinal chemistry, Jan-27, Volume: 108Development of CINPA1 analogs as novel and potent inverse agonists of constitutive androstane receptor.
AID481666Antifungal activity against Candida parapsilosis NRRL Y-12696 after 24 hrs by broth microdilution assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and the selective antifungal activity of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives.
AID211162Antifungal activity against Trichophyton asteroides was determined in vitro1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and antifungal activity of a series of novel 1,2-disubstituted propenones.
AID67517Antiprotozoal activity measured as the conc for 95-25% inhibition of Entamoeba histolytica1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID515297Antifungal activity against Rhizopus oryzae MTCC 262 at 30 ug/ml after 24 to 96 hrs by agar cup diffusion method2010European journal of medicinal chemistry, Oct, Volume: 45, Issue:10
Stereoselective synthesis and biological evaluation of (R)-rugulactone, (6R)-((4R)-hydroxy-6-phenyl-hex-2-enyl)-5,6-dihydro-pyran-2-one and its 4S epimer.
AID19427HPLC capacity factor (k)2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
ElogPoct: a tool for lipophilicity determination in drug discovery.
AID536091Antimicrobial activity against Pseudomonas aeruginosa IFO 3448 after 24 hrs2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Synthesis, antimicrobial and anti-inflammatory activities of novel 5-(1-adamantyl)-1,3,4-thiadiazole derivatives.
AID682603Antifungal activity against Cryptococcus neoformans after 72 hrs by broth microdilution method2012European journal of medicinal chemistry, Oct, Volume: 56Micelles catalyzed chemo- and regio-selective one pot and one step synthesis of 2,3,5,6-tetrakis(alkyl and arylsulfanyl)-1,4-benzoquinones and 2,5-diaminosubstituted-1,4-benzoquinones "In-Water" and their biological evaluation as antibacterial and antifun
AID682796Antifungal activity against Sporothrix schenckii after 72 hrs by broth microdilution method2012European journal of medicinal chemistry, Oct, Volume: 56Micelles catalyzed chemo- and regio-selective one pot and one step synthesis of 2,3,5,6-tetrakis(alkyl and arylsulfanyl)-1,4-benzoquinones and 2,5-diaminosubstituted-1,4-benzoquinones "In-Water" and their biological evaluation as antibacterial and antifun
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID619765Antifungal activity against Geotrichum candidum RCMB 052006 at 30 mg/ml after 3 to 4 days by agar well diffusion method2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Design and synthesis of some new thiophene, thienopyrimidine and thienothiadiazine derivatives of antipyrine as potential antimicrobial agents.
AID335829Antimicrobial activity against Trichophyton mentagrophytes UPCC 4193 assessed as antimicrobial index at 30 ug after 72 hrs2002Journal of natural products, Aug, Volume: 65, Issue:8
New furanoid diterpenes from Caesalpinia pulcherrima.
AID503334Effect on p53 expressed in HEK293 cells assessed as effect on p53-p53 interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID575747Binding affinity to Aspergillus fumigatus AF293 sterol 14-alpha demethylase isoenzyme A expressed in Escherichia coli2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Expression, purification, and characterization of Aspergillus fumigatus sterol 14-alpha demethylase (CYP51) isoenzymes A and B.
AID1808021Inhibition of porcine heart malate dehydrogenase assessed as reduction in enzyme inhibition at 3 times IC50 preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec in presence of 0.01% Triton-X100 by spectrop2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID287240Antimicrobial activity against Bacillus subtilis IFO 3007 after 24 hrs2007European journal of medicinal chemistry, Feb, Volume: 42, Issue:2
Synthesis, antimicrobial, and anti-inflammatory activities of novel 2-(1-adamantyl)-5-substituted-1,3,4-oxadiazoles and 2-(1-adamantylamino)-5-substituted-1,3,4-thiadiazoles.
AID345830Activation of human CAR Ile164Ala mutant expressed in human C3A cells at 4 uM after 24 hrs by GAL4-dependent luciferase reporter gene assay relative to control2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Insights into ligand-elicited activation of human constitutive androstane receptor based on novel agonists and three-dimensional quantitative structure-activity relationship.
AID355710Antifungal activity against Candida albicans MSU-SM 543 after 2 to 4 days
AID395112Antifungal activity against Aspergillus fumigatus isolate after 72 hrs by twofold serial dilution method2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Azole antimicrobial pharmacophore-based tetrazoles: synthesis and biological evaluation as potential antimicrobial and anticonvulsant agents.
AID1300881Antifungal activity against Candida krusei clinical isolate after 24 hrs by broth microdilution method2016European journal of medicinal chemistry, Jul-19, Volume: 117Novel 1,3-thiazolidin-4-one derivatives as promising anti-Candida agents endowed with anti-oxidant and chelating properties.
AID288609Inhibition of Bacillus subtilis NAD synthetase by fluorescence based assay2007Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
Antibacterial nicotinamide adenine dinucleotide synthetase inhibitors: amide- and ether-linked tethered dimers with alpha-amino acid end groups.
AID106801Inhibition of malate dehydrogenase (MDH)2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID757551Anticandida activity against Candida albicans clinical isolate assessed as growth inhibition after 24 hrs by broth microdilution method2013European journal of medicinal chemistry, Jul, Volume: 65Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents.
AID308422Antifungal activity against Candida glabrata after 24 hrs by broth microdilution method2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Synthesis and in vitro activity of 2-thiazolylhydrazone derivatives compared with the activity of clotrimazole against clinical isolates of Candida spp.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID703735Cytotoxicity against mouse NIH3T3 cells after 24 hrs by neutral red dye uptake assay2012Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
Optimization of 4-aminoquinoline/clotrimazole-based hybrid antimalarials: further structure-activity relationships, in vivo studies, and preliminary toxicity profiling.
AID757531Cytotoxicity against human Hep2 cells assessed as cell survival at 100 ug/ml after 24 hrs by transmission electron microscopic analysis2013European journal of medicinal chemistry, Jul, Volume: 65Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents.
AID428419Antifungal activity against Trichophyton mentagrophytes after 48 hrs by agar dilution method2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Design, synthesis, and antifungal activity of triazole and benzotriazole derivatives.
AID1186790Antifungal activity against Aspergillus niger MTCC 282 at 30 ug/ml after 48 hrs by agar well diffusion method2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Indolylmethylene benzo[h]thiazolo[2,3-b]quinazolinones: synthesis, characterization and evaluation of anticancer and antimicrobial activities.
AID770905Antifungal activity against Candida albicans IFO 0583 assessed as growth inhibition at 100 ug/disc after 48 hrs by agar disc-diffusion method2013European journal of medicinal chemistry, Oct, Volume: 68Synthesis and antimicrobial activity of novel 5-(1-adamantyl)-2-aminomethyl-4-substituted-1,2,4-triazoline-3-thiones.
AID53377In vitro inhibition of human Cytochrome P450 17A1 activity2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy.
AID345588Activation of mouse CAR T350M mutant expressed in HEK293 cells at 2 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID308425Antifungal activity against Candida parapsilosis after 24 hrs by broth microdilution method2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Synthesis and in vitro activity of 2-thiazolylhydrazone derivatives compared with the activity of clotrimazole against clinical isolates of Candida spp.
AID318195Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D10 by [3H]hypoxanthine incorporation2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Clotrimazole scaffold as an innovative pharmacophore towards potent antimalarial agents: design, synthesis, and biological and structure-activity relationship studies.
AID497656Inhibition of mouse prion protein (89-230) assessed as inhibition of amyloid polymerization at 25 uM by thioflavin T fluorescence assay relative to untreated control2008Nature chemical biology, Mar, Volume: 4, Issue:3
Small-molecule aggregates inhibit amyloid polymerization.
AID308423Antifungal activity against Candida tropicalis after 24 hrs by broth microdilution method2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Synthesis and in vitro activity of 2-thiazolylhydrazone derivatives compared with the activity of clotrimazole against clinical isolates of Candida spp.
AID675136Antifungal activity against Alternaria solani after 72 to 96 hrs by agar cup method2012European journal of medicinal chemistry, Sep, Volume: 55Design, synthesis, antimicrobial, anti-inflammatory and analgesic activity of novel isoxazolyl pyrimido[4,5-b]quinolines and isoxazolyl chromeno[2,3-d]pyrimidin-4-ones.
AID345545Increase in nuclear co-repressor receptor binding to wild type mouse CAR expressed in HEK293 cells at 2 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID318206Antifungal activity against Aspergillus flavus ATCC 2043042008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Clotrimazole scaffold as an innovative pharmacophore towards potent antimalarial agents: design, synthesis, and biological and structure-activity relationship studies.
AID202859Antifungal activity against Saccharomyces cerevisiae, activity expressed as inhibitory zone(mm, diameter)1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID352846Antimicrobial activity against Penicillium chrysogenum NCIM 707 at 10 ug/disk after 72 hrs by disk diffusion method2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID48587Minimum inhibitory concentration against Candida albicans IFO 10601987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and antifungal activity of new 1-vinylimidazoles.
AID675138Antifungal activity against Colletotrichum capsici after 72 to 96 hrs by agar cup method2012European journal of medicinal chemistry, Sep, Volume: 55Design, synthesis, antimicrobial, anti-inflammatory and analgesic activity of novel isoxazolyl pyrimido[4,5-b]quinolines and isoxazolyl chromeno[2,3-d]pyrimidin-4-ones.
AID1287122Antiinflammatory activity in antibiotic resistant Candida albicans clinical isolate 08030809 induced mouse vaginitis model assessed as reduction in IL-10 secretion in vaginal tissue at 10 mg/ml administered as intravaginal instillation measured on day 10 2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
A Designed Tryptophan- and Lysine/Arginine-Rich Antimicrobial Peptide with Therapeutic Potential for Clinical Antibiotic-Resistant Candida albicans Vaginitis.
AID214427Minimum inhibitory concentration against Trichophyton rubrum IFO 54671987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and antifungal activity of new 1-vinylimidazoles.
AID1333871Antifungal activity against Microsporum audouinii after 24 hrs by two fold dilution method2017Bioorganic & medicinal chemistry letters, 01-01, Volume: 27, Issue:1
Synthesis of new morpholine-connected pyrazolidine derivatives and their antimicrobial, antioxidant, and cytotoxic activities.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID150752Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID447233Antifungal activity against Hanseniaspora guilliermondii DSM 3432 at 10 ug after 72 hrs by agar disk diffusion assay2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, Raman, FT-IR, NMR spectroscopic characterization, antimicrobial activity, cytotoxicity and DNA binding of new mixed aza-oxo-thia macrocyclic compounds.
AID1854172Antimicrobial activity against Candida albicans NCIM 20872022European journal of medicinal chemistry, Aug-05, Volume: 238Cascade synthetic strategies opening access to medicinal-relevant aliphatic 3- and 4-membered N-heterocyclic scaffolds.
AID777332Antifungal activity against Cryptococcus neoformans CDRI isolate assessed as growth inhibition after 24 to 48 hrs by microbroth dilution method2013ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10
Identification of 1-[4-Benzyloxyphenyl)-but-3-enyl]-1H-azoles as New Class of Antitubercular and Antimicrobial Agents.
AID49468Antifungal activity against Candida albicans ATCC 26278 strain in YNB medium after incorporation of 20 ug per disk.1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Synthesis and biological properties of N3-(4-methoxyfumaroyl)-L-2,3-diaminopropanoic acid dipeptides, a novel group of antimicrobial agents.
AID352842Antimicrobial activity against Aspergillus parasiticus NCIM 904 at 10 ug/disk after 72 hrs by disk diffusion method2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID214095Antifungal activity against Trichophyton mentagrophytes, activity expressed as inhibitory zone(mm, diameter)1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID1300884Cytotoxicity against human Hep2 cells assessed as cell survival at 0.05 ug/ml after 24 hrs by trypan blue exclusion assay2016European journal of medicinal chemistry, Jul-19, Volume: 117Novel 1,3-thiazolidin-4-one derivatives as promising anti-Candida agents endowed with anti-oxidant and chelating properties.
AID1184391Antibacterial activity against Staphylococcus aureus ATCC 29213 at 50 mg/mL after 24 hrs by agar well diffusion method2014European journal of medicinal chemistry, Sep-12, Volume: 84Ultrasound-assisted synthesis of novel 1,2,3-triazoles coupled diaryl sulfone moieties by the CuAAC reaction, and biological evaluation of them as antioxidant and antimicrobial agents.
AID345630Effect on steroid receptor co-activator 1 binding to mouse CAR H213A mutant expressed in HEK293 cells at 2 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID1372811Fungicidal activity against Candida albicans ATCC 10231 by two-fold serial dilution assay2018Bioorganic & medicinal chemistry, 01-15, Volume: 26, Issue:2
An appraisal on synthetic and pharmaceutical perspectives of pyrazolo[4,3-d]pyrimidine scaffold.
AID245101Minimum inhibitory concentration required for antifungal activity against Candida albicans ATCC 103212004Bioorganic & medicinal chemistry letters, Aug-16, Volume: 14, Issue:16
Synthesis and QSAR studies of pyrimido[4,5-d]pyrimidine-2,5-dione derivatives as potential antimicrobial agents.
AID395383Antifungal activity against Rhodotorula rubra DSM 70403 at 10 ug after 72 hrs by disk diffusion method2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Synthesis, Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of mixed aza-oxo-thia macrocyclic compounds.
AID770908Antibacterial activity against Pseudomonas aeruginosa IFO 3448 assessed as growth inhibition at 100 ug/disc after 24 hrs by agar disc-diffusion method2013European journal of medicinal chemistry, Oct, Volume: 68Synthesis and antimicrobial activity of novel 5-(1-adamantyl)-2-aminomethyl-4-substituted-1,2,4-triazoline-3-thiones.
AID160374Antibacterial activity against Propionibacterium acnes, activity expressed as inhibitory zone(mm, diameter)1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID1402893Induction of apoptosis in Candida glabrata ATCC 90030 assessed as necrotic cells at antifungal MIC90 after 24 hrs by Annexin V/propidium iodide staining based flow cytometry (Rvb = 0.3%)2018European journal of medicinal chemistry, Jan-20, Volume: 144The synthesis, antifungal and apoptotic effects of triazole-oxadiazoles against Candida species.
AID1373237Antibacterial activity against Serratia marcescens AUMC B-55 assessed as diameter of inhibition zone at 5 ug/disc after 24 hrs by agar disc diffusion method2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Fusarithioamide B, a new benzamide derivative from the endophytic fungus Fusarium chlamydosporium with potent cytotoxic and antimicrobial activities.
AID497658Inhibition of polyhistidine tagged yeast prion protein Sup35 expressed in Escherichia coli BL21 (DE3) assessed as inhibition of amyloid polymerization at 50 uM in presence of 1% seed fibres by thioflavin T fluorescence assay relative to untreated control2008Nature chemical biology, Mar, Volume: 4, Issue:3
Small-molecule aggregates inhibit amyloid polymerization.
AID1300888Cytotoxicity against human Hep2 cells assessed as cell survival at 50 ug/ml after 24 hrs by trypan blue exclusion assay2016European journal of medicinal chemistry, Jul-19, Volume: 117Novel 1,3-thiazolidin-4-one derivatives as promising anti-Candida agents endowed with anti-oxidant and chelating properties.
AID78119In vivo inhibition of topical Trichophyton infection in Guinea Pig during drug administration1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Isobenzofurans as conformationally constrained miconazole analogues with improved antifungal potency.
AID287235Antimicrobial activity against Bacillus subtilis IFO 3007 at 100 ug/disc after 24 hrs2007European journal of medicinal chemistry, Feb, Volume: 42, Issue:2
Synthesis, antimicrobial, and anti-inflammatory activities of novel 2-(1-adamantyl)-5-substituted-1,3,4-oxadiazoles and 2-(1-adamantylamino)-5-substituted-1,3,4-thiadiazoles.
AID757540Cytotoxicity against human Hep2 cells assessed as cell survival fraction at 0.05 ug/ml after 24 hrs by trypan blue exclusion assay (Rvb = 97 to 98%)2013European journal of medicinal chemistry, Jul, Volume: 65Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents.
AID1402882Antifungal activity against Candida glabrata ATCC 90030 by broth microdilution assay2018European journal of medicinal chemistry, Jan-20, Volume: 144The synthesis, antifungal and apoptotic effects of triazole-oxadiazoles against Candida species.
AID563613Effect on sterol composition in Candida albicans isolate 108 harboring erg11 and erg5 double mutant assessed as 14 -Methylergosta-8,24(28)-dien-3beta,6alpha-diol level after 2 hrs by gas chromatography2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B.
AID1443991Induction of mitochondrial dysfunction in Sprague-Dawley rat liver mitochondria assessed as inhibition of mitochondrial respiration per mg mitochondrial protein measured for 20 mins by A65N-1 oxygen probe based fluorescence assay2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID352838Antimicrobial activity against Aspergillus fumigatus NCIM 902 at 10 ug/disk after 72 hrs by disk diffusion method2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID335820Antimicrobial activity against Candida albicans UPCC 2168 assessed as clearing zone at 30 ug after 48 hrs2002Journal of natural products, Aug, Volume: 65, Issue:8
New furanoid diterpenes from Caesalpinia pulcherrima.
AID345542Enhancement of steroid receptor coactivator 1 binding to wild type mouse CAR expressed in HEK293 cells at 2 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID386877Antifungal activity against Candida albicans at 10 ug/disc after 24 to 48 hrs2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
DNA binding and biological studies of some novel water-soluble polymer-copper(II)-phenanthroline complexes.
AID308426Antifungal activity against Candida sake after 24 hrs by broth microdilution method2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Synthesis and in vitro activity of 2-thiazolylhydrazone derivatives compared with the activity of clotrimazole against clinical isolates of Candida spp.
AID1373236Antibacterial activity against Pseudomonas aeruginosa AUMC B-73 assessed as diameter of inhibition zone at 5 ug/disc after 24 hrs by agar disc diffusion method2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Fusarithioamide B, a new benzamide derivative from the endophytic fungus Fusarium chlamydosporium with potent cytotoxic and antimicrobial activities.
AID1634154Inhibition of CYP3A4 (unknown origin)2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Strategies for the development of highly selective cytochrome P450 inhibitors: Several CYP targets in current research.
AID412362Antimalarial activity after 72 hrs against chloroquine-resistant Plasmodium falciparum W2 infected human A+ erythrocytes by Makler LDH reporter assay2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Combining 4-aminoquinoline- and clotrimazole-based pharmacophores toward innovative and potent hybrid antimalarials.
AID623631Antifungal activity against Candida albicans ATCC 90028 after 18 to 24 hrs by NCCLS M7-A5 based agar dilution method2011European journal of medicinal chemistry, Nov, Volume: 46, Issue:11
A facile synthesis of carbocycle-fused mono and bis-1,2,3-selenadiazoles and their antimicrobial and antimycobacterial studies.
AID610798Antifungal activity against Candida albicans ATCC 2091 at 10 mg/mL after 24 hrs by agar diffusion method2011Journal of natural products, Jun-24, Volume: 74, Issue:6
Brominated arginine-derived alkaloids from the red sea sponge Suberea mollis.
AID665141Antiproliferative activity against human Hep2 cells assessed as cell survival fraction at 0.05 ug/mL after 24 hrs by MTT assay2012European journal of medicinal chemistry, Jul, Volume: 53Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
AID1775861Inhibition of human TRPM2 expressed in HEK293T cells assessed as suppression of H2O2-induced calcium flux at 30 uM measured after 30 mins by Fluo-3/AM assay2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
The Discovery of Novel ACA Derivatives as Specific TRPM2 Inhibitors that Reduce Ischemic Injury Both In Vitro and In Vivo.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID537735Binding affinity to Candida albicans CaMdr1p expressed in yeast AD1-8u2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID1775860Inhibition of human TRPM2 expressed in HEK293T cells assessed as blocked of ADPR-activated current by whole cell patch clamp electrophysiology2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
The Discovery of Novel ACA Derivatives as Specific TRPM2 Inhibitors that Reduce Ischemic Injury Both In Vitro and In Vivo.
AID245340Minimum inhibitory concentration required for antibacterial activity against Pseudomonas diminuta MTCC 3361; Not tested2004Bioorganic & medicinal chemistry letters, Aug-16, Volume: 14, Issue:16
Synthesis and QSAR studies of pyrimido[4,5-d]pyrimidine-2,5-dione derivatives as potential antimicrobial agents.
AID1639191Binding affinity to Mycobacterium tuberculosis H37Rv CYP121A1 by UV-visible scanning spectrophotometric analysis2019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Synthesis and biological evaluation of novel cYY analogues targeting Mycobacterium tuberculosis CYP121A1.
AID566724Antifungal activity against Candida albicans after 24 hrs by MTT assay2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and biological evaluation of novel 2,4-disubstituted-1,3-thiazoles as anti-Candida spp. agents.
AID1373233Antibacterial activity against Staphylococcus aureus AUMC B-54 assessed as diameter of inhibition zone at 5 ug/disc after 24 hrs by agar disc diffusion method2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Fusarithioamide B, a new benzamide derivative from the endophytic fungus Fusarium chlamydosporium with potent cytotoxic and antimicrobial activities.
AID150756Inhibition of P-gp was determined using rhodamine-assay in human CaCo-2 cells2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID336892Antifungal activity against Microsporum canis after 2 to 4 days
AID731778Antifungal activity against Scopulariopsis brevicaulis AUMC 729 assessed as diameter of growth inhibition zone at 20 mg/ml at 28 degC after 7 days2013European journal of medicinal chemistry, Apr, Volume: 62First synthesis and biological evaluation of indeno[2,1-e]pyrazolo[3,4-b]pyrazin-5-one and related derivatives.
AID1379941Antifungal activity against Candida sake clinical isolates assessed as inhibition of microbial growth incubated for 24 hrs by broth microdilution method2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis, biological evaluation and quantitative structure-active relationships of 1,3-thiazolidin-4-one derivatives. A promising chemical scaffold endowed with high antifungal potency and low cytotoxicity.
AID685358Antifungal activity against Candida albicans after 48 hrs by broth microdilution method2012European journal of medicinal chemistry, Oct, Volume: 56Micelles catalyzed chemo- and regio-selective one pot and one step synthesis of 2,3,5,6-tetrakis(alkyl and arylsulfanyl)-1,4-benzoquinones and 2,5-diaminosubstituted-1,4-benzoquinones "In-Water" and their biological evaluation as antibacterial and antifun
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1346741Human Pregnane X receptor (1I. Vitamin D receptor-like receptors)1998Proceedings of the National Academy of Sciences of the United States of America, Oct-13, Volume: 95, Issue:21
Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction.
AID1346444Human KCa3.1 (Calcium- and sodium-activated potassium channels)1998Genomics, Jul-01, Volume: 51, Issue:1
Human calcium-activated potassium channel gene KCNN4 maps to chromosome 19q13.2 in the region deleted in diamond-blackfan anemia.
AID1346746Human Constitutive androstane receptor (1I. Vitamin D receptor-like receptors)2000The Journal of biological chemistry, May-19, Volume: 275, Issue:20
Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands.
AID1346444Human KCa3.1 (Calcium- and sodium-activated potassium channels)1997The Journal of biological chemistry, Dec-26, Volume: 272, Issue:52
A novel gene, hKCa4, encodes the calcium-activated potassium channel in human T lymphocytes.
AID1346628Human TRPM2 (Transient Receptor Potential channels)2004Naunyn-Schmiedeberg's archives of pharmacology, Oct, Volume: 370, Issue:4
Inhibition of TRPM2 channels by the antifungal agents clotrimazole and econazole.
AID1346444Human KCa3.1 (Calcium- and sodium-activated potassium channels)2000Proceedings of the National Academy of Sciences of the United States of America, 07-05, Volume: 97, Issue:14
Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: a potential immunosuppressant.
AID1346444Human KCa3.1 (Calcium- and sodium-activated potassium channels)1997Proceedings of the National Academy of Sciences of the United States of America, Oct-14, Volume: 94, Issue:21
A human intermediate conductance calcium-activated potassium channel.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID602156Novartis GNF Liver Stage Dataset: Malariabox Annotation2011Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,868)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990566 (30.30)18.7374
1990's315 (16.86)18.2507
2000's433 (23.18)29.6817
2010's439 (23.50)24.3611
2020's115 (6.16)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 81.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index81.07 (24.57)
Research Supply Index7.74 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index254.61 (26.88)
Search Engine Supply Index3.45 (0.95)

This Compound (81.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials299 (14.91%)5.53%
Reviews79 (3.94%)6.00%
Case Studies158 (7.88%)4.05%
Observational2 (0.10%)0.25%
Other1,467 (73.17%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (87)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Prospective, Case-controlled Randomized Study of Human Reproductive Tract Active Lactobacillus in Adjuvant Treatment of Recurrent Vulvovaginal Candidiasis. [NCT04699240]Phase 4140 participants (Anticipated)Interventional2020-07-01Recruiting
The First Affiliated Hospital of Guangxi Medical University [NCT03819348]1,200 participants (Actual)Observational2003-01-01Active, not recruiting
Posaconazole Oral Suspension and Itraconazole Oral Solution in Preventing Invasive Fungal Disease (IFD) in Patients With Hematopoietic Stem Cell Transplantation [NCT03631602]Phase 2/Phase 3120 participants (Anticipated)Interventional2017-10-01Recruiting
Efflux Pump Mediated Azole Resistance in Candida Albicans Among Neutropenic Patients With Haematological Malignancies [NCT03659162]100 participants (Anticipated)Observational2019-02-17Not yet recruiting
Atavistic Chemotherapy and Immunotherapy in Advanced, Metastatic, and Otherwise Incurable and Lethal Cancers Under Conventional Treatments [NCT02366884]Phase 2250 participants (Anticipated)Interventional2011-07-26Recruiting
Effects of Antimicrobials on the Altered Skin Flora in Patients With Palmar Arsenical Keratosis [NCT03632733]Phase 230 participants (Anticipated)Interventional2018-01-21Recruiting
HT201309- Human Photoallergy Test [NCT04532164]Phase 3137 participants (Actual)Interventional2013-06-10Completed
B-Lymphocyte Immunotherapy in Islet Transplantation: Single Subject Modification to Calcineurin-Inhibitor Based Immunosuppression for Initial Islet Graft (CIT-0501) [NCT01049633]0 participants Expanded AccessNo longer available
A Prospective Randomized, Blinded Parallel Group Study of Clotrimazole Troches vs. Mycelex® Troches (10 mg Troche Five Times a Day for 14 Days) in Patients With Human Insufficiency Virus (HIV) Infection for the Treatment of Oropharyngeal Candidiasis [NCT02184351]Phase 3187 participants (Actual)Interventional2001-05-31Completed
Clinical Study to Evaluate System Safety and Clinical Performance of the SecuraTM ICD [NCT00526227]81 participants (Actual)Interventional2007-10-31Completed
International Pediatric Fungal Network: Multi-Center Studies to Improve Diagnosis and Treatment of Pediatric Candidiasis [NCT01869829]750 participants (Actual)Observational [Patient Registry]2015-01-31Completed
"Study Clinical, Multicenter, Phase III, to Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections Like Tinea Foot, Tinea and Tinea Crural Body" [NCT01105013]Phase 390 participants (Anticipated)Interventional2012-04-30Not yet recruiting
Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study [NCT05653193]Phase 250 participants (Anticipated)Interventional2024-01-31Not yet recruiting
A Phase II Trial of Allogeneic Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Antifungal Prophylaxis With Posaconazole. [NCT03434704]Phase 210 participants (Actual)Interventional2018-06-18Completed
An Investigator-blinded, Active-controlled Phase 3 Study to Prove the Non-inferior Efficacy of a Clotrimazole Ovule (500 mg) Versus a Clotrimazole Vaginal Tablet (500 mg) in Vaginal Candidiasis [NCT00755053]Phase 3466 participants (Actual)Interventional2008-09-30Completed
Randomized Comparison of β-D-Glucan Surveillance With Preemptive Anidulafungin Versus Standard Care for the Management of Invasive Candidiasis in Surgical Intensive Care Unit Patients [NCT00672841]64 participants (Actual)Interventional2008-06-30Completed
Randomized, Double-blind, Phase III Study of the Efficacy and Safety of Miconazole Oil, Active Versus Placebo in the Treatment of Otomycosis [NCT05660382]Phase 3100 participants (Anticipated)Interventional2023-05-31Not yet recruiting
Prospective 2-Year Longitudinal Study to Assess for Miconazole Resistance in Candida Spp. With Repeated Treatment Courses of 0.25% Miconazole Nitrate Ointment in Neonates and Infants up to 1 Year of Age With Recurrent Moderate-Severe Diaper Dermatitis Com [NCT00702507]Phase 4200 participants (Actual)Interventional2007-05-31Completed
"Dynamic Thoracic Impedance as a Marker for Heart Failure Decompensation: A Pilot Trial of the Dynamic Thoracic Impedance Bed Rest Test" [NCT02134379]11 participants (Actual)Observational2014-04-30Completed
REperfusion With Cooling in CerebraL Acute IscheMia II [NCT02411877]Phase 20 participants (Actual)Interventional2016-02-29Withdrawn(stopped due to It was decided that it was not feasible to continue this study.)
A Phase 2, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Efficacy and Safety of Miconazole Nitrate 2% + Domiphen Bromide Vaginal Cream in the Treatment of Subjects With Acute Vulvovaginal Candidiasis [NCT04813822]Phase 290 participants (Anticipated)Interventional2021-09-13Recruiting
A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of a Generic Butenafine Hydrochloride Cream, 1% and Reference Listed Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) and Compa [NCT01580878]Phase 1707 participants (Actual)Interventional2012-01-31Completed
An Individualized Administration Research of Voriconazole Based on CYP2C19 Gene Polymorphism and Therapeutic Drug Monitoring in Chinese Patients With Invasive Pulmonary Infection [NCT04004078]314 participants (Actual)Observational2018-03-01Completed
Uptake of the Antifungal Miconazole and Effect on Estrogen Metabolizing Enzymes in Humans [NCT00668538]20 participants (Actual)Interventional2008-04-30Completed
Analysis of the Outcomes of Photoactivated Chromophore for Keratitis Cross _linking for Treatment of Infectious Keratitis [NCT05881187]60 participants (Anticipated)Interventional2023-06-15Not yet recruiting
Fluconazole Versus Micafungin in Neonates With Suspected or Culture-proven Candidiasis: a Randomized Pharmacokinetic and Safety Study (TINN Project - Treat Infections iN Neonates) [NCT02145832]Phase 2/Phase 3100 participants (Anticipated)Interventional2014-06-30Not yet recruiting
A Multicentre, Randomized, Controlled Study of the Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer Alone for the Trea [NCT01014637]Phase 4260 participants (Anticipated)Interventional2009-08-31Recruiting
A Randomized, Parallel-Group, Multicentre, Open-Labelled, Active-Controlled Study to Assess the Efficacy, Safety and Tolerability of RV4104A Ointment Versus Bifonazole-Urea Ointment for the Complete Removal of the Clinically Infected Nail Plate Area in Pa [NCT00808366]228 participants (Anticipated)Interventional2008-10-31Recruiting
AN OPEN-LABEL, RANDOMISED TRIAL, WITH A THREE-PERIOD CROSSOVER PART IN HEALTHY HIV-NEGATIVE WOMEN TO ASSESS THE DRUG-DRUG INTERACTION POTENTIAL BETWEEN DAPIVIRINE VAGINAL RING-004, CONTAINING 25 MG OF DAPIVIRINE, AND CLOTRIMAZOLE 10 mg/g (1%) ADMINISTERED [NCT02847286]Phase 136 participants (Actual)Interventional2015-09-01Completed
Comparative Study of the Efficacy of 10.0 mg Dequalinium Chloride (Fluomizin®) and 100 mg Clotrimazole (Canesten®) for the Treatment of Vulvovaginal Candidiasis [NCT02242695]Phase 4150 participants (Actual)Interventional2014-11-30Completed
An Open Label Study in Healthy Volunteers to Evaluate the Potential for Drug/Drug Interactions Between F901318 and Fluconazole [NCT02730442]Phase 120 participants (Actual)Interventional2016-02-29Completed
Efficacy of Slow Release Clotrimazole Varnish Treating Denture Stomatitis [NCT00835029]Phase 213 participants (Actual)Interventional2009-03-31Completed
Phase 3 Study, Randomized, Double-blind, Parallel to Evaluate Ketoconazole and Betamethasone Dipropionate(Candicort®) Compared to Clotrimazole and Dexamethasone Acetate(Baycuten N®) in Relief of Fungal Infections/Dermatophytosis Symptoms. [NCT02582177]Phase 3125 participants (Actual)Interventional2019-06-11Completed
Empirical Antifungal Treatment in Neutropenic Patients Stratified by Risk: Prospective Validation of an Algorithm Based on the D-index [NCT00982540]28 participants (Actual)Interventional2010-02-28Terminated(stopped due to Low accrual)
F901318 - A Phase I, Double-Blind, Placebo Controlled, Multiple Ascending Oral Dose Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects [NCT02737371]Phase 140 participants (Actual)Interventional2016-05-31Completed
Dr. Bill Antifungal Nail Gel Study [NCT04341402]Phase 230 participants (Anticipated)Interventional2020-05-01Recruiting
ANTIVORIFUNGOL:Strategy of Antifungal Use in Oncohematological Neutropenic Patients. Use of Voriconazole as Early Treatment. [NCT00386802]Phase 4115 participants (Anticipated)Interventional2006-08-31Completed
Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081) [NCT00000676]Phase 3500 participants InterventionalCompleted
[NCT00004492]Phase 1/Phase 220 participants (Anticipated)Interventional1999-10-31Completed
A Comparative Randomized, Double-blind, Double-Dummy, Multicenter Study of the Efficacy and Safety of Miconazole Lauriad 50mg Administered Once a Day and Mycelex Troches (Clotrimazole 10mg) Administered Five Times a Day in the Treatment of Oropharyngeal C [NCT00390780]Phase 3578 participants (Actual)Interventional2006-07-31Completed
Vaginal Imaging Study to Evaluate the Effect of Exercise on the Distribution of Miconozole Nitrate OVULE [NCT00194324]Phase 412 participants Interventional2004-07-31Completed
An Open Label, Multi-Center Study to Determine the Safety and Pharmacokinetics of Intravenous and Oral APX001 in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia With Neutropenia [NCT03333005]Phase 120 participants (Actual)Interventional2017-11-27Completed
Observational Prospective Multicenter Study to Evaluate the Infective Risk in Myelodysplastic Syndrome Patients: Antimicrobial Prophylaxis and Granulocyte Growth Factors. [NCT01951430]229 participants (Actual)Observational2014-03-31Completed
Phase III, Multicenter, Randomized, Parallel, Open Label, Controlled and Comparative Study to Evaluate the Efficacy and Safety of the Association of Clotrimazole 200mg and Metronidazole 0,75% (Colpistatin 5DT®) Compared to Gynecological Flagyl®(Metronidaz [NCT02713139]Phase 30 participants (Actual)Interventional2013-09-30Withdrawn(stopped due to Due to budget limitations, the company decided to withdraw this study.)
Clotrimazole Enemas for Pouchitis in Children and Adults [NCT00061282]Phase 1/Phase 211 participants (Actual)Interventional2002-09-30Terminated(stopped due to Funding Horizon)
The Role of Fractional CO2 Laser in Consolidation Treatment of Recurrent Vulvovaginal Candidiasis (RVVC) :a Study Protocol for a Randomized Controlled Trial [NCT04292704]205 participants (Anticipated)Interventional2019-12-13Recruiting
Comparative Study of the Efficacy and Safety of LactiSal 1% Vaginal Gel and LactSal 50 mg Vaginal Tablet Versus Clotrimazole 100 mg Vaginal Tablet in the Treatment of Vulvovaginal Candidiasis (VVC) [NCT02907307]Phase 30 participants (Actual)Interventional2018-12-31Withdrawn(stopped due to Development project stopped)
Detection of Bloodstream Pathogens in Hematological Malignancies [NCT03896880]139 participants (Actual)Observational2020-01-01Completed
Empirical Steroids and/or Antifungals in Immunocompromised Patients With Acute Respiratory Failure From Undetermined Etiology: a Multicenter Double-blind Randomized Controlled Trial [NCT04680884]Phase 3420 participants (Anticipated)Interventional2020-12-21Not yet recruiting
The Incidence of Invasive Aspergillosis in Acute Myeloid Leukemia [NCT02900430]246 participants (Actual)Observational2009-01-31Completed
[NCT00004404]20 participants (Anticipated)Interventional1997-04-30Completed
Epidemiological Study About the Clinical and Microbiological Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis. [NCT02248506]Phase 456 participants (Actual)Interventional2013-06-30Completed
Isolation and Comparative Efficacy of the Combination of beclometasona0, 025% + Gentamicin 0.1% + Clotrimazole 1% Topical Dermatological Cream of GLENMARK PHARMACEUTICALS, in Patients Infected With Acne [NCT01244256]Phase 2/Phase 380 participants (Anticipated)Interventional2007-04-30Suspended
A Double-Blind, Randomized Trial of Monthly Treatment With Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories Versus Placebo for Preventing Vaginal Infections in HIV-seronegative Women [NCT01230814]Phase 2234 participants (Actual)Interventional2011-04-30Completed
Prospective Multicentre Randomized Double-blind Study Comparing Caspofungin to Placebo for the Treatment of ICU Intra-abdominal Candidiasis [NCT03580733]Phase 3448 participants (Anticipated)Interventional2019-01-01Recruiting
Multicenter Pilot Study to Compare the Efficacy of a Combination of Vaginal Capsules With Acid Boric, L.Gasseri and L.Rhamnosus Versus the Reference Medication in Patients With Vaginal Candidiasis or Bacterial Vaginosis [NCT02860845]Phase 448 participants (Actual)Interventional2016-07-12Completed
Phase III Study in Hygienic Socks With Antifungal Agent-loaded Microcapsules for Patients With Tinea Pedis [NCT01524432]Phase 142 participants (Actual)Interventional2012-01-31Completed
A Randomized Multicenter Study of the Efficacy, Safety, and Toleration of Fluconazole or Clotrimazole Troches in the Treatment of Patients With Oropharyngeal Candidiasis in Association With the Acquired Immunodeficiency Syndrome [NCT00002282]0 participants InterventionalCompleted
Effectiveness of 3% Boric Acid in 70% Alcohol Versus 1% Clotrimazole Solution in Otomycosis Patients: a Randomized Controlled Trial [NCT01547221]120 participants (Actual)Interventional2012-03-31Completed
Double-blind Evaluation of the Safety and Efficacy of Quadriderme® (Betamethasone Diproprionate, Clotrimazole and Gentamicin) Compared With Betamethasone Diproprionate Combined With Gentamicin Sulfate and With Betamethasone Diproprionate in the Treatment [NCT00671528]Phase 43 participants (Actual)Interventional2009-07-31Terminated(stopped due to terminated early due to lack of recruitment [only 3 of 207 subjects were enrolled])
A Multicenter Cohort Study of the Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents [NCT01686607]40,110 participants (Actual)Observational2012-10-01Completed
A Randomised Controlled Trial of Single Dose Tinidazole+Fluconazole Versus Longer Courses of Metronidazole+Clotrimazole in the Management of West African Women With Vaginal Discharge [NCT00313131]Phase 31,524 participants Interventional2004-01-31Completed
Factors on Therapeutic Drug Monitoring and Safety of Voriconazole in Critically Ill Elderly Patients: A Prospective Observational Study [NCT06137690]550 participants (Anticipated)Observational2018-07-01Recruiting
A Comparative Open Labeled Clinical Study to Evaluate the Efficacy and Tolerability of Two Different Intravaginal Formulations Containing a Combination of Clindamycin and Clotrimazole in Vaginal Infections [NCT01697826]Phase 473 participants (Actual)Interventional2011-04-30Completed
An Open-Label Clinical Case Series to Demonstrate Efficacy of the Kendall Skin Wellness System [NCT01724229]20 participants (Actual)Interventional2012-11-30Completed
Therapeutic Drug Monitoring of Antifungals in Patients From Intensive Care Units: a Retrospective Study [NCT04502771]200 participants (Actual)Observational2018-01-01Completed
Dose-Ranging Study of the Efficacy and Safety of Miconazole Oil Used for 7 or 14 Days Compared With Vehicle in the Treatment of Otomycosis [NCT03130738]Phase 265 participants (Actual)Interventional2017-04-20Completed
The Use of Campath-1H, Tacrolimus, and Sirolimus Followed by Sirolimus Withdrawal in Renal Transplant Patients [NCT00078559]Phase 1/Phase 210 participants (Actual)Interventional2003-11-30Completed
Efficacy of Combined Blood Clot and Platelet Rich Fibrin Scaffolds in Regeneration of Necrotic Immature Permanent Teeth (A Randomized Controlled Clinical Trial) [NCT04390854]Phase 230 participants (Actual)Interventional2018-07-06Completed
Comparative Evaluation of Two PRF Formulations on Quality of Life and 2D and 3D Assessment of Healing Outcome of Apicomarginal Defects. [NCT04396743]32 participants (Anticipated)Interventional2019-12-11Recruiting
A Phase II, Multicenter, Randomized, Open-label, Active Controlled Study to Evaluate the Safety and Efficacy of Micafungin Salvage Mono-therapy Versus Active Control Intravenous Salvage Mono-therapy in Patients With Invasive Aspergillosis [NCT00376337]Phase 217 participants (Actual)Interventional2006-06-30Terminated(stopped due to Study was stopped due to difficulties in recruitment and changes in standard care for invasive aspergillosis)
Effect of Blue Light Emitting Diode Therapy on Recurrent Vulvovaginal Candidiasis [NCT05795491]60 participants (Anticipated)Interventional2023-04-30Enrolling by invitation
Effectiveness of 4% Boric Acid in Distilled Water Versus Clotrimazole Solution in Otomycosis Patients. [NCT04824261]100 participants (Anticipated)Interventional2021-06-01Not yet recruiting
Phenotypic and Genotypic Characterization of Malassezia Species Isolated From Malassezia Associated Skin Diseases [NCT05476731]100 participants (Anticipated)Observational2022-08-31Not yet recruiting
A Phase IIa Randomized, Active-controlled, Double-blind, Dose-escalation Study in Patients With Vulvovaginal Candidiasis to Evaluate Dose Response Relationship of Clinical Efficacy, Safety and Tolerability of Topically Administered ProF-001 [NCT03115073]Phase 2/Phase 384 participants (Actual)Interventional2017-04-04Completed
Clinical & Visual Outcomes of Collagen Cross Linking for Fungal Keratitis [NCT02328053]20 participants (Anticipated)Interventional2014-02-28Recruiting
(1-3)-Beta-D-Glucan Driven vs. Empirical Antifungal Therapy in High Risk Critically Ill Patients A Randomized Study [NCT03117439]120 participants (Actual)Interventional2016-07-31Completed
An Case-controlled Randomized Study to the Efficacy of Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis [NCT02180828]Phase 4240 participants (Actual)Interventional2014-07-31Completed
Randomized Clinical Trial of a Mucoadhesive Gel Containing EPP-AF in Patients Diagnosed With Vulvovaginal Candidiasis [NCT03024502]Phase 1/Phase 290 participants (Anticipated)Interventional2018-01-30Recruiting
Pharmacokinetic Evaluation of Sublingual Versus Oral Tacrolimus Administration in Patients Awaiting Kidney Transplantation [NCT00629122]Phase 45 participants (Actual)Interventional2008-02-29Completed
A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multiple-Site Study to Evaluate the Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis [NCT00835510]Phase 1548 participants (Actual)Interventional2008-06-30Completed
Randomized Multicenter Crossover Study to Compare the Plasmat® Futura Heparin Induced Extracorporeal Lower Density Lipo-Protein (LDL) Precipitation (H.E.L.P.) Apheresis System to the Approved Secura System in the Reduction of LDL-c in Patients With Hyperc [NCT00526058]18 participants (Actual)Interventional2007-08-31Completed
Prospective Evaluation of the Effects of Topical Therapy With Sulfamylon® For 5% Topical Solution on Autograft Healing in Subjects With Thermal Injuries Requiring Meshed Autografts: A Comparison to a Historical Control Group [NCT00634166]Phase 4220 participants (Actual)Interventional2007-09-30Terminated(stopped due to FDA request as study could not serve as the confirmatory trial.)
Randomized Clinical Trial for Treatment of Candidal Vulvovaginitis Using Cumin Seed Extract Vaginal Suppositories. [NCT03005353]Phase 2/Phase 3100 participants (Actual)Interventional2018-03-01Completed
A Phase III, Multicenter, Randomized, Double-blind, Parallel Group, Active Treatment-controlled Study Assessing the Safety and Efficacy of G238 Compared to Clotrimazole 1% Otic Solution in Patients With Otomycosis [NCT01993823]Phase 3190 participants (Actual)Interventional2013-05-31Completed
Clinical Study of Non-inferiority (Phase 2), Comparing Dapaconazole (BL123 - Biolab Sanus Farmacêutica Ltda.) Versus Miconazole Nitrate (União Química) in Patients With a Single Lesion of Tinea Cruris. [NCT03359070]Phase 251 participants (Actual)Interventional2014-01-29Completed
Prospective, Non-interventional, Post-marketing, Multi-center, Single-cohort, Safety (Questionnaire) Investigation of Empecid L Cream (Clotrimazole 1%) [NCT03599323]1,033 participants (Actual)Observational2018-07-10Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00078559 (14) [back to overview]Number of Sirolimus Associated Adverse Events, Stratified by Sirolimus Withdrawal Status
NCT00078559 (14) [back to overview]Number of Severe Acute Rejections Stratified by Sirolimus Withdrawal Status
NCT00078559 (14) [back to overview]Number of Participants Who Experienced Graft Loss Stratified by Sirolimus Withdrawal Status
NCT00078559 (14) [back to overview]Number of Participants Requiring Anti-lymphocyte Therapy for an Acute Rejection, Stratified by Sirolimus Withdrawal Status
NCT00078559 (14) [back to overview]Number of Deaths Stratified by Sirolimus Withdrawal Status
NCT00078559 (14) [back to overview]Number of Alemtuzumab Associated Adverse Events, Stratified by Sirolimus Withdrawal Status
NCT00078559 (14) [back to overview]Number of Acute Rejections in All Enrolled Participants Following Sirolimus Withdrawal
NCT00078559 (14) [back to overview]Number of Side Effects of Conventional Immunosuppression, Stratified by Withdrawal Status
NCT00078559 (14) [back to overview]Number of Tacrolimus Associated Adverse Events, Stratified by Sirolimus Withdrawal Status
NCT00078559 (14) [back to overview]Time From Transplantation to Acute Rejection in Participants for Whom Acute Rejection Occurred During the 1 Year Post-transplant Period
NCT00078559 (14) [back to overview]Time From Transplantation to Acute Rejection in Participants for Whom Sirolimus Withdrawal Was Not Initiated
NCT00078559 (14) [back to overview]Number of Acute Rejections in All Enrolled Participants
NCT00078559 (14) [back to overview]Number of Acute Rejections Between Initiation of Sirolimus Withdrawal and End of Study
NCT00078559 (14) [back to overview]Change in Renal Function as Measured by Serum Creatinine, Stratified by Withdrawal Status
NCT00390780 (13) [back to overview]Susceptibility of Candida Species by Microdilution Test
NCT00390780 (13) [back to overview]Relapse at the Late Post-Therapy Visit (Day 35-38)
NCT00390780 (13) [back to overview]Duration of Adhesion of Miconazole Lauriad 50 mg Mucoadhesive Buccal Tablet
NCT00390780 (13) [back to overview]Oral Discomfort Using Visual Analog Scale (VAS)
NCT00390780 (13) [back to overview]Systemic Exposure of Miconazole Lauriad 50 mg Bioadhesive Buccal Tablet
NCT00390780 (13) [back to overview]Treatment Compliance
NCT00390780 (13) [back to overview]Clinical Cure (Defined as a Complete Resolution of Signs and Symptoms) After 14 Days of Treatment at the Test of Cure Visit (Day 17-Day 22) Using Murray Scoring Scale
NCT00390780 (13) [back to overview]Clinical Cure at Day 7 (Using Murray Scoring Scale)
NCT00390780 (13) [back to overview]Clinical Success at Day 7 (Using Murray Scoring Scale)
NCT00390780 (13) [back to overview]Clinical Success at Test-of-cure Visit (Day 17-22) (Using Murray Scoring Scale)
NCT00390780 (13) [back to overview]General and Local Tolerability and Oral Discomfort
NCT00390780 (13) [back to overview]Mycological Cure at the Test of Cure Visit (Day 17-22)
NCT00390780 (13) [back to overview]Partial Response at Test of Cure Visit (Days 17-22) Using Murray Scoring Scale
NCT00526058 (4) [back to overview]Percent Change of the Pre and Post Treatment Value
NCT00526058 (4) [back to overview]Device Parameters
NCT00526058 (4) [back to overview]Clinical Lab Profiles (Pre- and Post-Treatment)
NCT00526058 (4) [back to overview]Percent Change in Pre- and Post-treatment Reductions of Low-density Lipoprotein Cholesterol (LDL-C) Levels Between the Approved H.E.L.P. System and the Modified H.E.L.P. System.
NCT00526227 (5) [back to overview]Adverse Events
NCT00526227 (5) [back to overview]System Performance Assessed by Technical Observations
NCT00526227 (5) [back to overview]System Performance Assessed by Holter Records
NCT00526227 (5) [back to overview]Freedom From Unanticipated Serious Adverse Device Effects at 1-month Post Implant.
NCT00526227 (5) [back to overview]System Performance Assessed by Save to Disk Files
NCT00629122 (5) [back to overview]Tacrolimus Powder Dissolution Time
NCT00629122 (5) [back to overview]C0 (ng/mL)
NCT00629122 (5) [back to overview]Cmax
NCT00629122 (5) [back to overview]Estimated AUC 0-6
NCT00629122 (5) [back to overview]Tmax
NCT00634166 (7) [back to overview]Percentage of Participants With Graft Loss After Initial Meshed Autograft Procedure on Days 5-7.
NCT00634166 (7) [back to overview]Percentage of Participants With All-cause Graft Loss at Days 12 to 14 in the FAS Population
NCT00634166 (7) [back to overview]Percentage of Participants With All-cause Graft Loss at Days 18 to 21 in the FAS Population
NCT00634166 (7) [back to overview]Percentage of Participants With Infectious Graft Loss at Days 12 to 14 in the FAS Population
NCT00634166 (7) [back to overview]Percentage of Participants With Infectious Graft Loss at Days 18 to 21 in the FAS Population
NCT00634166 (7) [back to overview]Percentage of Participants With Infectious Graft Loss at Days 5 to 7 in the FAS Population
NCT00634166 (7) [back to overview]Percentage of Participants With Treatment Failure at Days 5 to 7 in the FAS Population
NCT00671528 (1) [back to overview]Number of Days Required to Achieve Total Remission
NCT00672841 (3) [back to overview]Incidence of Proven or Probable Invasive Fungal Infection (IFI)
NCT00672841 (3) [back to overview]Safety and Tolerability of Preemptive Anidulafungin
NCT00672841 (3) [back to overview]Clinical Utility of Biweekly β-D-glucan (BDG) Testing in At-risk Intensive Care Unit (ICU) Patients.
NCT00702507 (8) [back to overview]Number of Participants With Overall Cure (OC)
NCT00702507 (8) [back to overview]Number of Participants With Clinical Cure
NCT00702507 (8) [back to overview]Number of Participants With Overall Cure (OC) of First to Third Recurrent Episodes (RE)
NCT00702507 (8) [back to overview]Number of Participants With Clinical Cure of First to Third Recurrent Episodes
NCT00702507 (8) [back to overview]Number of Participants With Mycological Cure of First to Third Recurrent Episodes
NCT00702507 (8) [back to overview]Number of Participants With Mycological Cure
NCT00702507 (8) [back to overview]Clinical Evaluations Using the Diaper Dermatitis Severity Index Score for Initial Treatment Episode
NCT00702507 (8) [back to overview]Clinical Evaluations Using Change From Baseline in the Dermatitis Severity Index Score at Day 14 of the Initial Treatment Episode
NCT00835510 (5) [back to overview]Therapeutic Cure Non-Inferiority Comparison of Butenafine Cream and Lotrimin Ultra
NCT00835510 (5) [back to overview]Therapeutic Cure - Superiority Analysis
NCT00835510 (5) [back to overview]Therapeutic Cure
NCT00835510 (5) [back to overview]Mycologic Cure
NCT00835510 (5) [back to overview]Clinical Cure
NCT01230814 (4) [back to overview]Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Matching Placebo Nightly for Five Nights Each Month for Preventing Vulvovaginal Candidiasis (VVC).
NCT01230814 (4) [back to overview]Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Placebo for Preventing Any Vaginal Infection (a Combined Endpoint Including BV, VVC, and Trichomonas Vaginalis Infection).
NCT01230814 (4) [back to overview]Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Matching Placebo Nightly for Five Nights Each Month for Preventing BV by Clinical Criteria (Amsel's Criteria).
NCT01230814 (4) [back to overview]Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Matching Placebo Nightly for Five Nights Each Month for Preventing Bacterial Vaginosis (BV).
NCT01993823 (2) [back to overview]Changes in Signs/ Symptoms
NCT01993823 (2) [back to overview]Proportion of Subjects With a Complete Response to Treatment
NCT02180828 (9) [back to overview]Adverse Events 2
NCT02180828 (9) [back to overview]Adverse Events 3
NCT02180828 (9) [back to overview]Adverse Events 4
NCT02180828 (9) [back to overview]Therapeutic Efficacy 1
NCT02180828 (9) [back to overview]Therapeutic Efficacy 2
NCT02180828 (9) [back to overview]Therapeutic Efficacy 3
NCT02180828 (9) [back to overview]Therapeutic Efficacy 4
NCT02180828 (9) [back to overview]Total Adverse Events
NCT02180828 (9) [back to overview]Adverse Events 1
NCT02860845 (3) [back to overview]Number of Participants With Recurrent Infections
NCT02860845 (3) [back to overview]Change in the Presence of Vaginitis Clinical Symptoms Determined by Sobel Score.
NCT02860845 (3) [back to overview]Change in the Level of Lactobacillus in Vaginal Flora Determined by Vaginal Cultures.
NCT03130738 (2) [back to overview]Primary Efficacy Endpoint
NCT03130738 (2) [back to overview]Secondary Efficacy Endpoints
NCT04532164 (8) [back to overview]Development of Erythema on the Treated Non-irradiated Test Sites During Challenge Phase Reported as Number of Test Site With Different Erythema Score - All Treated Subjects
NCT04532164 (8) [back to overview]Development of Erythema on the Treated Non-irradiated Test Sites During Challenge Phase Reported as Number of Test Site With Different Erythema Score - All Evaluable Subjects
NCT04532164 (8) [back to overview]Development of Erythema on the Treated Non-irradiated Test Sites During Induction Phase - All Evaluable Subjects
NCT04532164 (8) [back to overview]Development of Erythema on the Treated Non-irradiated Test Sites During Induction Phase - All Treated Subjects
NCT04532164 (8) [back to overview]Photoallergic Reaction Evaluation Reported as Number of Test Site With Different Erythema Score During Challenge Phase - All Treated Subjects
NCT04532164 (8) [back to overview]Photoallergic Reaction Evaluation Reported as Number of Test Site With Different Erythema Score During Challenge Phase - All Evaluable Subjects
NCT04532164 (8) [back to overview]Development of Erythema on Treated Irradiated Test Sites During Induction Phase - All Treated Subjects
NCT04532164 (8) [back to overview]Development of Erythema on Treated Irradiated Test Sites During Induction Phase - All Evaluable Subjects

Number of Sirolimus Associated Adverse Events, Stratified by Sirolimus Withdrawal Status

(NCT00078559)
Timeframe: Transplantation to end of study (up to four years post-transplant)

Interventionadverse events (Number)
Alemtuzumab (Withdrawn From Sirolimus)2
Alemtuzumab (Not Withdrawn From Sirolimus)7

[back to top]

Number of Severe Acute Rejections Stratified by Sirolimus Withdrawal Status

"Participants who experienced severe acute rejections[1] during study~Severe acute rejection is defined as that which requires treatment with anti-lymphocyte antibody or is histologically evaluated as Type IIA or greater using the Banff 1997 criteria[2]~Reference: Racusen LC, Solez K, Colvin RB et al,The Banff 97 working classification of renal allograft pathology. Kidney Int,55: 713-723, 1999" (NCT00078559)
Timeframe: Transplantation to severe acute rejection (up to four years post-transplantation)

InterventionRejection Events (Number)
Alemtuzumab (Withdrawn From Sirolimus)0
Alemtuzumab (Not Withdrawn From Sirolimus)0

[back to top]

Number of Participants Who Experienced Graft Loss Stratified by Sirolimus Withdrawal Status

"Participants who experienced graft loss[1] during study~[1]Graft loss is defined as the institution of chronic dialysis (at least 6 consecutive weeks, excluding participants with delayed graft function), transplant nephrectomy, or retransplantation" (NCT00078559)
Timeframe: Transplantation to Graft Loss (up to four years post-transplantation)

Interventionparticipants (Number)
Alemtuzumab (Withdrawn From Sirolimus)0
Alemtuzumab (Not Withdrawn From Sirolimus)0

[back to top]

Number of Participants Requiring Anti-lymphocyte Therapy for an Acute Rejection, Stratified by Sirolimus Withdrawal Status

"Participants who experienced acute rejection[1] during study which required anti-lymphocyte (OKT3, ATG) therapy~1] Acute rejection is defined as a biopsy-prove rejection: a renal biopsy demonstrates acute cellular or humoral rejection of Banff[2] Grade 1B or greater; or presumed rejection in the absence of biopsy-proven rejection, the participant is treated for an unexplained 20% increase in serum creatinine.~[2] Reference: Racusen LC, Solez K, Colvin RB et al,The Banff 97 working classification of renal allograft pathology. Kidney Int,55: 713-723, 1999" (NCT00078559)
Timeframe: Transplantation to acute rejection (up to four years post-transplantation)

Interventionparticipants (Number)
Alemtuzumab (Withdrawn From Sirolimus)0
Alemtuzumab (Not Withdrawn From Sirolimus)0

[back to top]

Number of Deaths Stratified by Sirolimus Withdrawal Status

Participants who died during the study, all cause(s) (NCT00078559)
Timeframe: Transplantation to Death (up to four years post-transplant)

Interventiondeaths (Number)
Alemtuzumab (Withdrawn From Sirolimus)0
Alemtuzumab (Not Withdrawn From Sirolimus)0

[back to top]

Number of Alemtuzumab Associated Adverse Events, Stratified by Sirolimus Withdrawal Status

(NCT00078559)
Timeframe: Transplantation to end of study (up to four years post-transplant)

Interventionadverse events (Number)
Alemtuzumab (Withdrawn From Sirolimus)2
Alemtuzumab (Not Withdrawn From Sirolimus)8

[back to top]

Number of Acute Rejections in All Enrolled Participants Following Sirolimus Withdrawal

"Following sirolimus withdrawal, the number of acute rejections[1] in all enrolled participants~1] Acute rejection is defined as a biopsy-proven rejection: a renal biopsy demonstrates acute cellular or humoral rejection of Banff[2] Grade 1B or greater; or presumed rejection in the absence of biopsy-proven rejection, the participant is treated for an unexplained 20% increase in serum creatinine.~[2] Reference: Racusen LC, Solez K, Colvin RB et al,The Banff 97 working classification of renal allograft pathology. Kidney Int,55: 713-723, 1999" (NCT00078559)
Timeframe: Transplantation to end of study (up to four years post-transplant)

InterventionRejection Events (Number)
Alemtuzumab0

[back to top]

Number of Side Effects of Conventional Immunosuppression, Stratified by Withdrawal Status

Side effects of conventional immunosuppression include increased body weight and hypertension (NCT00078559)
Timeframe: Transplantation to end of study (up to four years post-transplant)

Interventionside effects (Number)
Alemtuzumab (Withdrawn From Sirolimus)2
Alemtuzumab (Not Withdrawn From Sirolimus)6

[back to top]

Number of Tacrolimus Associated Adverse Events, Stratified by Sirolimus Withdrawal Status

(NCT00078559)
Timeframe: Transplantation to end of study (up to four years post-transplant)

Interventionadverse events (Number)
Alemtuzumab (Withdrawn From Sirolimus)0
Alemtuzumab (Not Withdrawn From Sirolimus)2

[back to top]

Time From Transplantation to Acute Rejection in Participants for Whom Acute Rejection Occurred During the 1 Year Post-transplant Period

"Time (days) to acute rejection[1] for participants occurring during the year following transplantation~1] Acute rejection is defined as a biopsy-proven rejection: a renal biopsy demonstrates acute cellular or humoral rejection of Banff[2] Grade 1B or greater; or presumed rejection in the absence of biopsy-proven rejection, the participant is treated for an unexplained 20% increase in serum creatinine.~[2] Reference: Racusen LC, Solez K, Colvin RB et al,The Banff 97 working classification of renal allograft pathology. Kidney Int,55: 713-723, 1999" (NCT00078559)
Timeframe: Transplantation to acute rejection (up to one year post-transplant)

InterventionDays (Number)
Alemtuzumab274

[back to top]

Time From Transplantation to Acute Rejection in Participants for Whom Sirolimus Withdrawal Was Not Initiated

"Time (days) to acute rejection[1] for participants where sirolimus was not initiated~1] Acute rejection is defined as a biopsy-proven rejection: a renal biopsy demonstrates acute cellular or humoral rejection of Banff[2] Grade 1B or greater; or presumed rejection in the absence of biopsy-proven rejection, the participant is treated for an unexplained 20% increase in serum creatinine.~[2] Reference: Racusen LC, Solez K, Colvin RB et al,The Banff 97 working classification of renal allograft pathology. Kidney Int,55: 713-723, 1999" (NCT00078559)
Timeframe: Transplantation to acute rejection (up to four years post-transplantation)

InterventionDays (Number)
Alemtuzumab274

[back to top]

Number of Acute Rejections in All Enrolled Participants

"Number of acute rejections[1] in all enrolled subjects from the time of transplantation to the end of the trial (four years post-transplant)~Acute rejection is defined as a biopsy-proven rejection: a renal biopsy demonstrates acute cellular or humoral rejection of Banff[2] Grade 1B or greater; or presumed rejection in the absence of biopsy-proven rejection, the participant is treated for an unexplained 20% increase in serum creatinine.~Reference: Racusen LC, Solez K, Colvin RB et al,The Banff 97 working classification of renal allograft pathology. Kidney Int,55: 713-723, 1999" (NCT00078559)
Timeframe: Four years post-transplant

InterventionRejection Events (Number)
Alemtuzumab1

[back to top]

Number of Acute Rejections Between Initiation of Sirolimus Withdrawal and End of Study

"Acute rejections[1] between initiation of sirolimus withdrawal and end of study~1] Acute rejection is defined as a biopsy-proven rejection: a renal biopsy demonstrates acute cellular or humoral rejection of Banff[2] Grade 1B or greater; or presumed rejection in the absence of biopsy-proven rejection, the participant is treated for an unexplained 20% increase in serum creatinine.~[2] Reference: Racusen LC, Solez K, Colvin RB et al,The Banff 97 working classification of renal allograft pathology. Kidney Int,55: 713-723, 1999" (NCT00078559)
Timeframe: Initiation of sirolimus to end of study (up to four years post-transplant)

InterventionRejection Events (Number)
Alemtuzumab0

[back to top]

Change in Renal Function as Measured by Serum Creatinine, Stratified by Withdrawal Status

Mean change from transplantation to Month 48 in serum creatinine. Normal serum creatinine range is from 0.7 - 1.4 mg/dL. In a transplant population, starting serum creatinine is higher than normal range. A negative change indicates better renal function (NCT00078559)
Timeframe: Transplantation to end of study (up to four years post-transplant)

Interventionmg/dL (Mean)
Alemtuzumab (Withdrawn From Sirolimus)-4.2
Alemtuzumab (Not Withdrawn From Sirolimus)-5.4

[back to top]

Susceptibility of Candida Species by Microdilution Test

minimum inhibitory concentration (MIC) in nonresponders at test-of-cure visit (NCT00390780)
Timeframe: Initiation of treatment to Day 17 to 22

,
Interventionmcg/ml (Mean)
Clotrimazole MIC for C. albicans (n=9, 7)Miconazole MIC for C. albicans (n=9, 7)
Clotrimazole Troches0.00730.1664
Miconazole Lauriad Buccal Tablet0.00990.0764

[back to top]

Relapse at the Late Post-Therapy Visit (Day 35-38)

"Number of patients represents the number of participants who completed visit 6 (the late post-therapy visit on Days 35-38) and had been a clinical success at test-of-cure visit (visit 5). For this subset of participants, relapse was defined as a patient who responded to treatment by clinical cure or improvement (i.e., clinical success) on Days 17-22 at the test-of-cure visit (visit 5) and subsequently had an increase in the extent of oral lesions or symptoms, as assessed at the late post-therapy visit on Days 35-38 (visit 6). No relapse indicates participants who were considered a clinical success at visit 5 and did not have a subsequent increase in the extent of oral lesions or symptoms, as assessed at the late post-therapy visit (visit 6). The remaining number of participants in the Intent-to-Treat population who did not meet the criteria for relapse assessment at visit 6 is listed under Not Analyzed-ITT." (NCT00390780)
Timeframe: 35 to 38 days

,
Interventionparticipants (Number)
Number of patients-ITTRelapse-ITTNo relapse-ITTNot Analyzed-ITTNumber of patients-PPRelapse-PPNo relapse-PP
Clotrimazole Troches197531449018449135
Miconazole Lauriad Buccal Tablet1835113210716845123

[back to top]

Duration of Adhesion of Miconazole Lauriad 50 mg Mucoadhesive Buccal Tablet

The mean durations of adhesion from initiation of treatment to Day 14 of miconazole Lauriad 50 mg mucoadhesive buccal tablet (or, in the case of the Clotrimazole troches treatment arm, the placebo mucoadhesive buccal tablet) were rounded to the nearest hour (NCT00390780)
Timeframe: 14 days

Interventionhours (Mean)
Miconazole Lauriad Buccal Tablet13
Clotrimazole Troches13

[back to top]

Oral Discomfort Using Visual Analog Scale (VAS)

Visual analog scale was used by the patient in the patient diary. The scale ranged from 0 (no oral discomfort) to 10 (maximum oral discomfort) (NCT00390780)
Timeframe: 14 days

Interventionunits on a scale (Mean)
Miconazole Lauriad Buccal Tablet0.8
Clotrimazole Troches0.4

[back to top]

Systemic Exposure of Miconazole Lauriad 50 mg Bioadhesive Buccal Tablet

Number of patients with detectable plasma concentration at Visit 3 (day 7) (NCT00390780)
Timeframe: 7 days

Interventionparticipants (Number)
Miconazole Lauriad Buccal Tablet0
Clotrimazole Troches0

[back to top]

Treatment Compliance

Number of patients who were 100% compliant with the treatment regimen (NCT00390780)
Timeframe: Initiation of treatment to Day 14

Interventionparticipants compliant (Number)
Miconazole Lauriad Buccal Tablet253
Clotrimazole Troches250

[back to top]

Clinical Cure (Defined as a Complete Resolution of Signs and Symptoms) After 14 Days of Treatment at the Test of Cure Visit (Day 17-Day 22) Using Murray Scoring Scale

Murray scoring scale range: extent of oral lesions (signs) 0 (none) to 3 (extensive or confluent), ordinal; symptoms (soreness/burning) 0 (absent) to 3 (severe), ordinal. Clinical cure was defined as a complete resolution of signs and symptoms (extent of oral lesions score = 0, symptoms score = 0). Clinical failure was defined as any patient who failed to be clinically cured by the treatment. (NCT00390780)
Timeframe: 17 to 22 days

,
Interventionparticipants (Number)
Clinical Cure-ITTClinical Failure-ITTClinical Cure-PPClinical Failure-PP
Clotrimazole Troches18710017561
Miconazole Lauriad Buccal Tablet17611416476

[back to top]

Clinical Cure at Day 7 (Using Murray Scoring Scale)

Murray scoring scale range: extent of oral lesions (signs) 0 (none) to 3 (extensive or confluent), ordinal; symptoms (soreness/burning) 0 (absent) to 3 (severe), ordinal. Clinical cure was defined as a complete resolution of signs and symptoms (extent of oral lesions score = 0, symptoms score = 0). Clinical failure was defined as any patient who failed to be clinically cured by the treatment. (NCT00390780)
Timeframe: 7 days

,
Interventionparticipants (Number)
Clinical Cure-ITTClinical Failure-ITTData Missing-ITTClinical Cure-PPClinical Failure-PP
Clotrimazole Troches712021463173
Miconazole Lauriad Buccal Tablet672101360180

[back to top]

Clinical Success at Day 7 (Using Murray Scoring Scale)

Murray scoring scale range: extent of oral lesions (signs) 0 (none) to 3 (extensive or confluent), ordinal; symptoms (soreness/burning) 0 (absent) to 3 (severe), ordinal. Clinical success was defined as clinical cure or clinical improvement. Clinical cure was defined as a complete resolution of signs and symptoms (extent of oral lesions score = 0, symptoms score = 0). Clinical improvement was defined as having no visible lesion (extent of lesions score = 0) and minimal symptoms (soreness/burning score <2). Clinical failure was defined as any patient who failed to be clinically cured by the treatment. (NCT00390780)
Timeframe: 7 days

,
Interventionparticipants (Number)
Clinical Success-ITTClinical Failure-ITTData Missing-ITTClinical Success-PPClinical Failure-PP
Clotrimazole Troches891841478158
Miconazole Lauriad Buccal Tablet921851382158

[back to top]

Clinical Success at Test-of-cure Visit (Day 17-22) (Using Murray Scoring Scale)

Murray scoring scale range: extent of oral lesions (signs) 0 (none) to 3 (extensive or confluent), ordinal; symptoms (soreness/burning) 0 (absent) to 3 (severe), ordinal. Clinical success was defined as clinical cure or clinical improvement. Clinical cure was defined as a complete resolution of signs and symptoms (extent of oral lesions score = 0, symptoms score = 0). Clinical improvement was defined as having no visible lesion (extent of lesions score = 0) and minimal symptoms (soreness/burning score <2). Clinical failure was defined as any patient who failed to be clinically cured by the treatment. (NCT00390780)
Timeframe: 17 to 22 days

,
Interventionparticipants (Number)
Clinical Success-ITTClinical Failure-ITTData Missing-ITTClinical Failure-PPClinical Success-PP
Clotrimazole Troches199612751185
Miconazole Lauriad Buccal Tablet188802267173

[back to top]

General and Local Tolerability and Oral Discomfort

Overall local adverse reactions, including gingival inflammation, gum pain, alterations in taste of food when eating, alterations in taste when not eating, and dry mouth. Visit 4 occurred on Day 14. (NCT00390780)
Timeframe: 14 days

,
Interventionparticipants (Number)
Gingival Inflammation-Visit 4 (R canine fossa)No Gingival Inflammation-Visit 4 (R canine fossa)Data Missing (Inflammation)-Visit 4 (R fossa)Gingival Inflammation-Visit 4 (L canine fossa)No Gingival Inflammation-Visit 4 (L canine fossa)Data Missing (Inflammation)-Visit 4 (L fossa)Gum Pain-Visit 4No Gum Pain-Visit 4Data Missing (Gum Pain)-Visit 4Taste of Food Alteration-Visit 4No Taste of Food Alteration-Visit 4Data Missing (Taste of Food Alteration)-Visit 4Taste When Not Eating Alteration-Visit 4No Taste When Not Eating Alteration-Visit 4Data Missing (Taste When Not Eating)-Visit 4Dry Mouth-Visit 4No Dry Mouth-Visit 4Data Missing (Dry Mouth)-Visit 4
Clotrimazole Troches262332824236272423627542062752208276719327
Miconazole Lauriad Buccal Tablet342352130239213224018632091863209185721518

[back to top]

Mycological Cure at the Test of Cure Visit (Day 17-22)

"Mycological cure was defined as a patient who had no yeast isolated when oral specimens were cultured for fungi." (NCT00390780)
Timeframe: 17 to 22 days

,
Interventionparticipants (Number)
Mycological Cure-ITTMycological Failure-ITTData Missing-ITTMycological Cure-PPMycological Failure-PP
Clotrimazole Troches711853164168
Miconazole Lauriad Buccal Tablet791852673164

[back to top]

Partial Response at Test of Cure Visit (Days 17-22) Using Murray Scoring Scale

Murray scoring scale range: extent of oral lesions (signs) 0 (none) to 3 (extensive or confluent), ordinal; symptoms (soreness/burning) 0 (absent) to 3 (severe), ordinal. Clinical success was defined as clinical cure or clinical improvement. Partial response is having decrease in Murray extent of oral lesions score by at least 1 level and a stable Murray symptoms score, with partial symptom response defined as having a decrease in the Murray symptoms (soreness/burning) score by at least 1 level and a stable Murray extent of oral lesions score, and partial clinical/symptom response defined as decrease in Murray extent of oral lesions score by at least 1 level and a decrease in the Murray symptoms (soreness/burning) score by at least 1 level (NCT00390780)
Timeframe: 17 to 22 days

,
Interventionparticipants (Number)
Partial response-ITTPartial response-PP
Clotrimazole Troches140123
Miconazole Lauriad Buccal Tablet139120

[back to top]

Percent Change of the Pre and Post Treatment Value

The primary study endpoint is the change in percent measurements of the pre-to-post apheresis LDL measurements. Blood samples for LDL-cholesterol determination will be obtained before and after each treatment. The pooled difference between the pre- and post-treatment LDL level for each apheresis machine will be reported as the primary endpoint for the system performance. (NCT00526058)
Timeframe: Assessment based on LDL-C values obtained pre-and post-treatment, analyzed from week 0 to week 24.

Interventionpercent change (Mean)
Secura55.28
Futura52.89

[back to top]

Device Parameters

Comparison of plasma flow rate recorded with both systems before treatment, after 500 mL of plasma treated, and at the end of each treatment session. (NCT00526058)
Timeframe: Analyzed at specific time points throughout the study from week 0 to week 24.

,
Interventionflow rate (mL/min) (Mean)
Start of Session; Session 1Start of Session; Session 2Start of Session; Session 3Start of Session; Session 4Start of Session; Session 5Start of Session; Session 6After 500mL; Session 1After 500mL; Session 2After 500mL; Session 3After 500mL; Session 4After 500mL; Session 5After 500mL; Session 6End of session; Session 1End of session; Session 2End of session; Session 3End of session; Session 4End of session; Session 5End of session; Session 6
Futura12.398.899.679.1710.128.3923.4422.5022.7123.1121.4123.7232.2428.4426.4423.2921.5029.06
Secura27.1123.4128.0026.3526.2927.6133.6732.5931.6132.1134.6732.7226.2427.8719.1728.0030.2828.59

[back to top]

Clinical Lab Profiles (Pre- and Post-Treatment)

Changes in pre- and post-treatment levels of total cholesterol, high-density lipoprotein cholesterol (HDL-C), total triglycerides, lipoprotein (a), fibrinogen, and C-reactive protein. (NCT00526058)
Timeframe: Analyzed at specific time points throughout the study from week 0 to week 24.

,
Interventionpercent change (Mean)
Total TriglyceridesTotal CholesterolHDL-CVLDL-CLipoprotein (a)FibrinogenC-Reactive Protein
Futura71.4648.127.4162.6549.6852.0048.88
Secura63.1750.2311.8262.1459.2554.8158.59

[back to top]

Percent Change in Pre- and Post-treatment Reductions of Low-density Lipoprotein Cholesterol (LDL-C) Levels Between the Approved H.E.L.P. System and the Modified H.E.L.P. System.

(NCT00526058)
Timeframe: Blood samples for LDL-cholesterol determination will be obtained before and after each treatment from week 0 to week 24..

Interventionpercent change (Mean)
Secura55.28
Futura52.89

[back to top]

Adverse Events

Number of Adverse Events reported in the implanted subjects. (NCT00526227)
Timeframe: 1 Month

Interventionadverse events (Number)
Secura Implant62

[back to top]

System Performance Assessed by Technical Observations

Reported technical observations will be reviewed to determine if there are any device performance issues. (NCT00526227)
Timeframe: 1 month follow-up

Interventiondevice performance issues (Number)
Secura ICD Implant0

[back to top]

System Performance Assessed by Holter Records

The first 21 digital Holter records that were successfully collected in the total of 80 implanted participants will summarize any anomalous or unintended operation and describe device features, ventricular arrhythmia detection times and device classification of ventricular arrhythmias. (NCT00526227)
Timeframe: 1 month

Interventionanomalous or unintended operation (Number)
Secura Implant0

[back to top]

Freedom From Unanticipated Serious Adverse Device Effects at 1-month Post Implant.

"Criteria to assess the results of the primary objective safety analysis is to demonstrate that the percentage of subjects experiencing an Unanticipated Serious Adverse Device Effect (USADE) is lower than 10% at one-month post-implant, with one month considered to be the same as 28 days.~A pre-specified interim analysis is included in the study which, if the primary objective was met, is to also be considered the final analysis." (NCT00526227)
Timeframe: 1 month

Interventionpercentage of patients (Number)
Secura Implant0

[back to top]

System Performance Assessed by Save to Disk Files

The Save to Disk files from 79 implanted participants collected after implant and 1 month follow up were reviewed to identify any anomolous or unintended device operation, examine device features, observe ventricular arrhythmia detection times and device classification of ventricular arrhythmias. (NCT00526227)
Timeframe: 1 month follow-up

Interventionanomolous or unintended device operation (Number)
Secura ICD Implant0

[back to top]

Tacrolimus Powder Dissolution Time

Tacrolimus Powder Dissolution Time during Sublingual Administration (minutes) (NCT00629122)
Timeframe: Day 3, minutes to powder dissolution

Interventionminutes (Median)
Arm A (Tacrolimus and Nystatin)2.25
Arm B (Tacrolimus and Clotrimazole)2.0

[back to top]

C0 (ng/mL)

Trough concentration (NCT00629122)
Timeframe: Day 3 and Day 8, time 0 (before tacrolimus dose)

,
Interventionng/mL (Median)
Day 3 (Sublingual)Day 8 (Oral)
Arm A (Tacrolimus and Nystatin)1.451.25
Arm B (Tacrolimus and Clotrimazole)6.26.5

[back to top]

Cmax

Maximum concentration (ng/mL) (NCT00629122)
Timeframe: Day 3 and Day 8, at time of maximum concentration

,
Interventionng/mL (Median)
Day 3 (Sublingual)Day 8 (Oral)
Arm A (Tacrolimus and Nystatin)9.64.6
Arm B (Tacrolimus and Clotrimazole)14.019.5

[back to top]

Estimated AUC 0-6

Area Under the Concentration-Time Curve from 0-6 hours (mg-hr/L) (NCT00629122)
Timeframe: Day 3 and Day 8, calculated based on concentrations measured between hours 0 and 6

,
Interventionmg-hr/L (Number)
Patient 1 Sublingual (day 3)Patient 1 Oral (day 8)Patient 2 Sublingual (day 3)Patient 2 Oral (day 8)Patient 3 Sublingual (day 3)Patient 3 Oral (day 8)Patient 4 Sublingual (day 3)Patient 4 Oral (day 8)Patient 5 Sublingual (day 3)Patient 5 Oral (day 8)
Arm A (Tacrolimus and Nystatin)9.34.9NANANANANANA63.023.2
Arm B (Tacrolimus and Clotrimazole)NANA27.232.466.076.063.752.5NANA

[back to top]

Tmax

Time to Maximum concentration (hours) (NCT00629122)
Timeframe: Day 3 and Day 8, time of maximum concentration

,
Interventionhours (Median)
Day 3 (Sublingual)Day 8 (Oral)
Arm A (Tacrolimus and Nystatin)1.750.875
Arm B (Tacrolimus and Clotrimazole)3.02.0

[back to top]

Percentage of Participants With Graft Loss After Initial Meshed Autograft Procedure on Days 5-7.

(NCT00634166)
Timeframe: The primary analysis will compare the percent of subjects with All Cause Graft Loss of the initial meshed autograft procedure at Days 5-7.

InterventionPercentage of Participants (Number)
Historical Control4.9
Prospective Patients/Active Drug4.3

[back to top]

Percentage of Participants With All-cause Graft Loss at Days 12 to 14 in the FAS Population

All cause graft loss is defined as graft adhesion of < 85% for the initial meshed autograft procedure. (NCT00634166)
Timeframe: Secondary analyses will include the percent of subjects with All Cause Graft Loss at Days 12-14

InterventionPercentage of participants (Number)
Historical Control20.3
Prospective Patients/Active Drug2.7

[back to top]

Percentage of Participants With All-cause Graft Loss at Days 18 to 21 in the FAS Population

All cause graft loss is defined as graft adhesion of < 85% for the initial meshed autograft procedure. (NCT00634166)
Timeframe: Days 18 to 21

InterventionPercentage of participants (Number)
Historical Control4.5
Prospective Patients/Active Drug6

[back to top]

Percentage of Participants With Infectious Graft Loss at Days 12 to 14 in the FAS Population

Graft adhesion of < 85% for the initial meshed autograft procedure due to infection. (NCT00634166)
Timeframe: Days 12-14

InterventionPercentage of participants (Number)
Historical Control3.4
Prospective Patients/Active Drug0.0

[back to top]

Percentage of Participants With Infectious Graft Loss at Days 18 to 21 in the FAS Population

Graft adhesion of < 85% for the initial meshed autograft procedure due to infection. (NCT00634166)
Timeframe: Days 18-21

InterventionPercentage of participants (Number)
Historical Control0.0
Prospective Patients/Active Drug1.3

[back to top]

Percentage of Participants With Infectious Graft Loss at Days 5 to 7 in the FAS Population

Graft adhesion of < 85% for the initial meshed autograft procedure due to infection. (NCT00634166)
Timeframe: Days 5-7

InterventionPercentage of participants (Number)
Historical Control2.4
Prospective Patients/Active Drug0.7

[back to top]

Percentage of Participants With Treatment Failure at Days 5 to 7 in the FAS Population

Treatment failure is defined as a change in topical antimicrobial therapy of initial meshed autograft due to suspected infection within the first 7 days or infectious graft loss. (NCT00634166)
Timeframe: Days 5-7

InterventionPercentage of participants (Number)
Historical Control13.4
Prospective Patients/Active Drug1.4

[back to top]

Number of Days Required to Achieve Total Remission

The speed of action, measured as the number of days required to achieve total remission of all signs and symptoms of the disease. (NCT00671528)
Timeframe: Up to 28 days

InterventionDays (Number)
Quadriderme® Cream15
Betamethasone Diproprionate and Gentamicin Sulfate Cream15
Betamethasone Diproprionate Cream8

[back to top]

Incidence of Proven or Probable Invasive Fungal Infection (IFI)

Institution specific criteria were used to establish a diagnosis of proven or probable invasive candidiasis. Other IFIs were classified according to the European Organization for Research and Treatment of Cancer/Mycosis Study Group (EORTC/MSG) criteria. However, BDG results were not factored into the EORTC/MSG criteria. (NCT00672841)
Timeframe: Participants were followed until ICU discharge, an average of 17 days

Interventionparticipants (Number)
Standard Care, Empiric Treatment3
Active Surveillance, Preemptive Therapy3

[back to top]

Safety and Tolerability of Preemptive Anidulafungin

reported as the Number of Adverse Events Possibly Related to Study Drug (NCT00672841)
Timeframe: weekly until ICU discharge

Interventionevents (Number)
Standard Care, Empiric Treatment0
Active Surveillance, Preemptive Therapy10

[back to top]

Clinical Utility of Biweekly β-D-glucan (BDG) Testing in At-risk Intensive Care Unit (ICU) Patients.

Clinical utility was defined as β-D-glucan test performance. Biweekly βDG testing used a threshold of ≥ 60 pg/ml to indicate a positive test for invasive candidiasis. True and false positives, and true and false negatives were confirmed using a composite clinical definition of invasive candidiasis that combines physical symptom/signs and microbiology. Cases of proven/probable invasive fungal infection (IFI) were adjudicated by a single reviewer blinded to group assignment and BDG results. (NCT00672841)
Timeframe: Participants were followed until ICU discharge, an average of 17 days

,
Interventionparticipants (Number)
True BDG PositivesTrue BDG NegativeFalse BDG PositivesFalse BGD Negatives
Active Surveillance, Preemptive Therapy319230
Standard Care, Empiric Treatment3950

[back to top]

Number of Participants With Overall Cure (OC)

"OC was defined as both clinical (therapeutic) cure with total resolution of signs/symptoms (no clinical signs of infection) and microbiological cure with mycological eradication (both negative potassium hydroxide [KOH] and culture results). Participants who had OC were categorized as Successes; those without OC were categorized as Failures. Any discontinued or lost to follow-up participant was also considered a failure." (NCT00702507)
Timeframe: Test-of-cure visit (Day 14) of initial treatment episode

Interventionparticipants (Number)
SuccessFailure
Vusion Treatment49119

[back to top]

Number of Participants With Clinical Cure

"Participants were evaluated for clinical cure, which was defined as therapeutic cure with total resolution of signs and symptoms (i.e., no clinical signs of infection). Participants who had clinical cure were categorized as Successes; those without clianical cure were categorized as Failures. Any discontinued or lost to follow-up participant was also considered a failure." (NCT00702507)
Timeframe: Test-of-cure visit (Day 14) of initial treatment episode

Interventionparticipants (Number)
SuccessFailure
Vusion Treatment8385

[back to top]

Number of Participants With Overall Cure (OC) of First to Third Recurrent Episodes (RE)

"OC was defined as both clinical (therapeutic) cure with total resolution of signs/symptoms (no clinical signs of infection) and microbiological cure with mycological eradication (both negative potassium hydroxide and culture results) at TOC visit for initial episode (ep.) to third ep. Participants (par) who had OC were categorized as Successes; those without OC were categorized as Failures (discontinued/lost to follow-up par were also failures). A RE is not temporally associated with a prior episode (PE) irrespective of whether the PE involves continuing treatment with study medication." (NCT00702507)
Timeframe: Test-of-cure (TOC) visit (Day 14) of first to third recurrent episodes (up to approximately 1 year and 7 months)

Interventionparticipants (Number)
First Recurrence, Success; n=35First Recurrence, Failure; n=35Second Recurrence, Success; n=10Second Recurrence, Failure; n=10Third Recurrence, Success; n=4Third Recurrence Failure; n=4
Vusion Treatment11245522

[back to top]

Number of Participants With Clinical Cure of First to Third Recurrent Episodes

"Participants were evaluated for clinical cure, which was defined as therapeutic cure with total resolution of signs and symptoms (i.e., no clinical signs of infection). Participants who had clinical cure were categorized as Successes; those without clinical cure were categorized as Failures. Any discontinued or lost to follow-up participant was also considered a failure." (NCT00702507)
Timeframe: Test-of-cure visit (Day 14) of first to third recurrent episodes (up to approximately 1 year and 7 months)

Interventionparticipants (Number)
First Recurrence, Success; n=35First Recurrence, Failure; n=35Second Recurrence, Success; n=10Second Recurrence, Failure; n=10Third Recurrence, Success; n=4Third Recurrence Failure; n=4
Vusion Treatment20155531

[back to top]

Number of Participants With Mycological Cure of First to Third Recurrent Episodes

"Participants were evaluated for mycological cure, which was defined as mycological eradication with negative KOH and culture results. Participants who had mycological cure were categorized as Successes; those without mycological cure were categorized as Failures. Any discontinued or lost to follow-up participant was also considered a failure." (NCT00702507)
Timeframe: Test-of-cure visit (Day 14) of first to third recurrent episodes (up to approximately 1 year and 7 months)

Interventionparticipants (Number)
First Recurrence, Success; n=35First Recurrence, Failure; n=35Second Recurrence, Success; n=10Second Recurrence, Failure; n=10Third Recurrence, Success; n=4Third Recurrence Failure; n=4
Vusion Treatment16197331

[back to top]

Number of Participants With Mycological Cure

"Participants were evaluated for mycological cure, which was defined as mycological eradication with negative KOH and culture results. Participants who had mycological cure were categorized as Successes; those without mycological cure were categorized as Failures. Any discontinued or lost to follow-up participant was also considered a failure." (NCT00702507)
Timeframe: Test-of-cure visit (Day 14) of initial treatment episode

Interventionparticipants (Number)
SuccessFailure
Vusion Treatment7791

[back to top]

Clinical Evaluations Using the Diaper Dermatitis Severity Index Score for Initial Treatment Episode

The diaper dermatitis severity index score was calculated as the sum of severity grades for each parameter evaluated (erythema, papules or pustules, and erosions) for the initial treatment episode. The maximum score possible for the diaper dermatitis severity index is 8. Rating scale for Erythema: 0 (none to trace), 1 (mild [pink]), 2 (moderate [red]), 3 (severe [beefy red]). Rating scale for Papules or Pustules: 0 (none to trace [0]), 1 (few [1-10]), 2 (multiple [11-20]), 3 (many [21-40]), 4 (abundant [more than 40]. Rating scale for Erosions: 0 (absent), 1 (present). (NCT00702507)
Timeframe: Test-of-cure visit (Day 14) of initial treatment episode

Interventionscores on a scale (Median)
Vusion Treatment0.0

[back to top]

Clinical Evaluations Using Change From Baseline in the Dermatitis Severity Index Score at Day 14 of the Initial Treatment Episode

The diaper dermatitis severity index score was calculated as the sum of severity grades for each parameter evaluated (erythema, papules or pustules, and erosions). Change from baseline=baseline value minus Day 14 value. The maximum score possible for the diaper dermatitis severity index is 8. Rating scale for Erythema: 0 (none to trace), 1 (mild [pink]), 2 (moderate [red]), 3 (severe [beefy red]). Rating scale for Papules or Pustules: 0 (none to trace [0]), 1 (few [1-10]), 2 (multiple [11-20]), 3 (many [21-40]), 4 (abundant [more than 40]. Rating scale for Erosions: 0 (absent), 1 (present). (NCT00702507)
Timeframe: Test-of-cure visit (Day 14) of initial treatment episode

Interventionscores on a scale (Median)
Vusion Treatment-5.0

[back to top]

Therapeutic Cure Non-Inferiority Comparison of Butenafine Cream and Lotrimin Ultra

Patient was cured both by symptoms (Clinical Cure) and by the results of fungal testing (Mycological Cure). (NCT00835510)
Timeframe: 42 days

InterventionParticipants (Number)
Butenafine Cream 1% (Taro)63
Lotrimin Ultra (Butenafine) 1%97

[back to top]

Therapeutic Cure - Superiority Analysis

"Therapeutic Cure requires both Clinical Cure and Mycological Cure.~Clinical Cure was based on the following signs and symptoms: fissuring, erythema, maceration, vesiculation, scaling, exudation, pruritus, burning. Each clinical symptom was evaluated using a 0-3 point rating scale: none=0, mild=1, moderate=2 or severe=3. If the score for erythema was ≤ 2 and the sum for all of the other 7 signs and symptoms was <2 then the patient was considered a Clinical Cure.~Mycological Cure: The potassium hydroxide (KOH) and the fungal culture were both negative." (NCT00835510)
Timeframe: 42 days

InterventionParticipants (Number)
Butenafine Cream 1% (Taro)76
Lotrimin Ultra (Butenafine) 1%108
Vehicle24

[back to top]

Therapeutic Cure

Subject with clinical and mycological cure at day 7 (NCT00835510)
Timeframe: 7 days

InterventionParticipants (Number)
Butenafine Cream 1% (Taro)30
Lotrimin Ultra (Butenafine) 1%38
Vehicle11

[back to top]

Mycologic Cure

Negative KOH and fungal culture at day 42 (NCT00835510)
Timeframe: 42 days

InterventionParticipants (Number)
Butenafine Cream 1% (Taro)101
Lotrimin Ultra (Butenafine) 1%128
Vehicle33

[back to top]

Clinical Cure

"The following 8 signs and symptoms are rated at each visit:~Erythema Fissuring Maceration Vesiculation Desquamation/scaling Exudation Pruritus Stinging/Burning~Each symptom is evaluated using the following scale:~0 = None- Complete absence of any sign or symptom~= Mild - obvious but minimal involvement~= Moderate - something that is easily noted~= Severe - quite marked~Clinical cure is defined as a score of 2 (moderate) or less for erythema and a total score for seven other signs and symptoms less than 2." (NCT00835510)
Timeframe: 42 days

InterventionParticipants (Number)
Butenafine Cream 1% (Taro)83
Lotrimin Ultra (Butenafine) 1%111
Vehicle27

[back to top]

Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Matching Placebo Nightly for Five Nights Each Month for Preventing Vulvovaginal Candidiasis (VVC).

Percentage of follow-up visits (Months 2, 4, 6, 8, 10, 12) positive for VVC based on the presence of fungal elements (pseudohyphae, blastoconidia, or both) on vaginal saline wet mount plus a positive culture showing yeast on Sabouraud's agar. (NCT01230814)
Timeframe: Months 2, 4, 6, 8, 10, and 12.

Interventionpercentage of follow-up visits (Number)
Arm 1: Metronidazole Plus Miconazole10.4
Arm 2: Placebo11.3

[back to top]

Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Placebo for Preventing Any Vaginal Infection (a Combined Endpoint Including BV, VVC, and Trichomonas Vaginalis Infection).

Percentage of follow-up visits (Months 2, 4, 6, 8, 10, 12) positive for any of three vaginal infections (BV, VVC, Trichomonas vaginalis infection). (NCT01230814)
Timeframe: Months 2, 4, 6, 8, 10, and 12.

Interventionpercentage of follow-up visits (Number)
Arm 1: Metronidazole Plus Miconazole32.6
Arm 2: Placebo46.5

[back to top]

Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Matching Placebo Nightly for Five Nights Each Month for Preventing BV by Clinical Criteria (Amsel's Criteria).

Percentage of follow-up visits (Months 2, 4, 6, 8, 10, 12) positive for BV by clinical criteria (Amsel's criteria). (NCT01230814)
Timeframe: Months 2, 4, 6, 8, 10, and 12.

Interventionpercentage of follow-up visits (Number)
Arm 1: Metronidazole Plus Miconazole14.4
Arm 2: Placebo18.2

[back to top]

Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Matching Placebo Nightly for Five Nights Each Month for Preventing Bacterial Vaginosis (BV).

Percentage of follow-up visits (Months 2, 4, 6, 8, 10, 12) positive for BV as determined by applying standard microscopic scoring criteria (Nugent's criteria) to vaginal Gram stained slides. BV is diagnosed when the score is greater than or equal to 7. (NCT01230814)
Timeframe: Months 2, 4, 6, 8, 10, and 12.

Interventionpercentage of follow-up visits (Number)
Arm 1: Metronidazole Plus Miconazole21.2
Arm 2: Placebo32.5

[back to top]

Changes in Signs/ Symptoms

"The secondary efficacy variables include:~Proportion of subjects with signs and symptoms score of 0 at Day 15~Proportion of subjects with signs and symptoms score of 0 at Day 24~Proportion of subjects with a negative culture for fungus or presumed eradication (mycological cure) on Day 24." (NCT01993823)
Timeframe: 2 weeks and 4 weeks

,
Interventionpercentage of patient (Number)
Signs and symptoms score 0 at Day 15Signs and symptoms score 0 at Day 24Mycological cure at Day 24
Clotrimazole77.6586.0897.65
G23859.5585.8396.63

[back to top]

Proportion of Subjects With a Complete Response to Treatment

"Efficacy will be assessed primarily by evaluation of the fungal culture, and the sum of signs and symptom scores (pruritus, otalgia, otorrhea and aural fullness obstruction to be scored as 0=absent; 1= mild; 2=moderate; 3=severe). The primary efficacy variable is the proportion of subjects with a negative culture for fungus, AND a signs and symptom score of 0 on Day 24.~Response to the study treatment was classed according to the following definitions:~Complete response: Negative fungal culture or presumed eradication on day 24, and sum score for signs and symptoms = 0 on day 24.~Partial response: Negative culture or presumed eradication on day 24, and sum score for signs and symptoms = 1 or 2 on day 24.~No response: Positive culture on day 24 or negative culture or presumed eradication and sum score for signs and symptoms > 2 on day 24." (NCT01993823)
Timeframe: Day 24

,
Interventionparticipants (Number)
Complete ResponsePartial ResponseNo-responseMissing data
Clotrimazole661126
G238721151

[back to top]

Adverse Events 2

Vulvovaginal pruritus, burning, irritation, and bleeding (NCT02180828)
Timeframe: at day 7-14 follow up

Interventionparticipants (Number)
Clotrimazole Vaginal Tablet12
Fluconazole1

[back to top]

Adverse Events 3

Gastrointestinal tract: abdominal pain, diarrhoea, nausea (NCT02180828)
Timeframe: at day 7-14 follow up

Interventionparticipants (Number)
Clotrimazole Vaginal Tablet3
Fluconazole3

[back to top]

Adverse Events 4

Skin sensitivity, urticaria rash, erythematous rash, irritation (NCT02180828)
Timeframe: at day 7-14 follow up

Interventionparticipants (Number)
Clotrimazole Vaginal Tablet0
Fluconazole3

[back to top]

Therapeutic Efficacy 1

The clinical cure rates of clotrimazole and fluconazol: Clinical cure was defined as the resolution of symptoms present at baseline with a total severity score of ≤2. Improvement was defined as considerable reduction in the severity of baseline signs and symptoms with a decrease in the total score by ≥50%.Patients not clinically cured or showing improvement were considered clinical failures. (NCT02180828)
Timeframe: 7-14 days after treatment (=visit 2)

Interventionparticipants (Number)
Clotrimazole Vaginal Tablet102
Fluconazole98

[back to top]

Therapeutic Efficacy 2

The clinical cure rates of clotrimazole and fluconazol (NCT02180828)
Timeframe: at days 30-35 follow-up

Interventionparticipants (Number)
Clotrimazole Vaginal Tablet82
Fluconazole85

[back to top]

Therapeutic Efficacy 3

Mycological cure of clotrimazole group and fluconazole group (NCT02180828)
Timeframe: at days 7-14 follow-up

Interventionparticipants (Number)
Clotrimazole Vaginal Tablet90
Fluconazole81

[back to top]

Therapeutic Efficacy 4

Mycological cure of clotrimazole group and fluconazole group: Mycological cure or failure was referred to as Candida negative or positive,respectively, on Candida culture at follow-up visits. (NCT02180828)
Timeframe: at days30-35 follow-up

Interventionparticipants (Number)
Clotrimazole Vaginal Tablet62
Fluconazole61

[back to top]

Total Adverse Events

Total adverse events(cases) (NCT02180828)
Timeframe: at day 7-14 follow up

Interventionparticipants (Number)
Clotrimazole Vaginal Tablet16
Fluconazole12

[back to top]

Adverse Events 1

Systemic: weak, palpitation, tachycardia, migraine, headache, dizzy, rhinorrhea, numb, dizziness, fatigue. (NCT02180828)
Timeframe: at day 7-14 follow up

Interventionparticipants (Number)
Clotrimazole Vaginal Tablet1
Fluconazole9

[back to top]

Number of Participants With Recurrent Infections

Descriptive of the proportion of patients with vulvovaginitis recurrence (NCT02860845)
Timeframe: At 3 months after recruitment

,
InterventionParticipants (Count of Participants)
No recurrenceRecurrence
Antibiotic/Antifungal149
Boric Acid and Probiotics175

[back to top]

Change in the Presence of Vaginitis Clinical Symptoms Determined by Sobel Score.

Semi-quantitative scale where itching, erythema, edema, stinging and abnormal vaginal discharge are scored from 0 to 3: absent (0), mild (1), moderate (2), severe (3). Worse result is 3 (severe) (NCT02860845)
Timeframe: Baseline and at 2 weeks after treatment finalization

,,,
Interventionscore on a scale (Mean)
Stinging sobel scoreItching Sobel ScoreErythema Sobel ScoreEdema Sobel Scoreabnormal vaginal discharge
Antibiotic/Antifungal Baseline1.211.580.960.421.96
Antibiotic/Antifungal Visit 10.220.570.1700.35
Boric Acid and Probiotics Baseline1.131.630.920.51.67
Boric Acid and Probiotics Visit 10.180.410.140.050.23

[back to top]

Change in the Level of Lactobacillus in Vaginal Flora Determined by Vaginal Cultures.

Lactobacillus spp count. in vaginal discharge at baseline and at visit 1, determined by vaginal cultures. (NCT02860845)
Timeframe: Baseline and 2 weeks after treatment finalization

InterventionCount of Organism/counting chamber (Mean)
Boric Acid and Probiotics Baseline51.59
Antibiotic/Antifungal Baseline49.30
Boric Acid and Probiotics Visit 181.82
Antibiotic/Antifungal Visit 166.09

[back to top]

Primary Efficacy Endpoint

"Percentage of subjects in MITT population, at the Test of Cure visit with Therapeutic cure, defined as a negative fungal culture plus clinical cure defined as the absence of all otomycosis signs and symptoms for pruritus, debris, fungal elements, and pain." (NCT03130738)
Timeframe: At Test of Cure visit (Day 15 for 7 Day Active and Day 22 for 14 Day Active and 14 Day Vehicle)

InterventionParticipants (Count of Participants)
7-Day Miconazole Oil (Miconazole 2%)1
14-Day Miconazole Oil (Miconazole 2%)3
14-Day Placebo - Oil Vehicle1

[back to top]

Secondary Efficacy Endpoints

"Percentage of subjects in MITT population with clinical cure at the Test of Cure Visit~Percentage of subjects in MITT population with a negative fungal culture at the Test of Cure Visit~Percentage of subjects in MITT population with a negative fungal culture at the Test of Cure visit as well as individual sign or symptom score of 0 or 1 on each of the scales for pruritus and debris and a score of 0 on each of the scales for fungal elements and pain (Secondary therapeutic cure).~Percentage of subjects in MITT population with individual signs or symptoms with a score of 0 or 1 on each of the scales for pruritus and debris and a score of 0 on each of the scales for fungal elements and pain (Secondary clinical cure)." (NCT03130738)
Timeframe: At Test of Cure visit (Day 15 for 7 Day Active and Day 22 for 14 Day Active and 14 Day Vehicle)

,,
InterventionParticipants (Count of Participants)
Clinical CureNegative Fungal CultureSecondary Therapeutic CureSecondary Clinical Cure
14-Day Miconazole Oil (Miconazole 2%)4556
14-Day Placebo - Oil Vehicle2314
7-Day Miconazole Oil (Miconazole 2%)2437

[back to top]

Development of Erythema on the Treated Non-irradiated Test Sites During Challenge Phase Reported as Number of Test Site With Different Erythema Score - All Treated Subjects

Evaluation of the test sites after irradiation used following scoring system: score 0=normal skin (no visible reaction); score 1= faint, barely perceptible to moderate redness with poorly defined margins (not clinically significant); score 2=moderate to intense redness with well defined margins; score 3=redness with well defined edema; score 4=redness with papules, vesicles, or ulceration. During Challenge Phase, each subject had the following four virgin test sites: Treated irradiated test site; Treated non-irradiated test site; Untreated irradiated test site; Untreated non-irradiated test site. All four test sites were evaluated according to the above scoring system at 24, 48, and 72 hours following patch application (3 different time points), and the number of test sites with available scores from all these time points were reported for all treated subjects. (NCT04532164)
Timeframe: At 24, 48, and 72 hours following patch application

InterventionTest site (Number)
Treated non-irradiated test site, score=0Treated non-irradiated test site, score=1
Butenafine HCl 1% (BAY1896425) - Challenge Phase3436

[back to top]

Development of Erythema on the Treated Non-irradiated Test Sites During Challenge Phase Reported as Number of Test Site With Different Erythema Score - All Evaluable Subjects

Evaluation of the test sites after irradiation used following scoring system: score 0=normal skin (no visible reaction); score 1= faint, barely perceptible to moderate redness with poorly defined margins (not clinically significant); score 2=moderate to intense redness with well defined margins; score 3=redness with well defined edema; score 4=redness with papules, vesicles, or ulceration. During Challenge Phase, each subject had the following four virgin test sites: Treated irradiated test site; Treated non-irradiated test site; Untreated irradiated test site; Untreated non-irradiated test site. All four test sites were evaluated according to the above scoring system at 24, 48, and 72 hours following patch application (3 different time points), and the number of test sites with available scores from all these time points were reported for all evaluable subjects. (NCT04532164)
Timeframe: At 24, 48, and 72 hours following patch application

InterventionTest site (Number)
Treated non-irradiated test site, score=0Treated non-irradiated test site, score=1
Butenafine HCl 1% (BAY1896425) - Challenge Phase3146

[back to top]

Development of Erythema on the Treated Non-irradiated Test Sites During Induction Phase - All Evaluable Subjects

Evaluation of the test sites after irradiation used following scoring system: score 0=normal skin (no visible reaction); score 1= faint, barely perceptible to moderate redness with poorly defined margins (not clinically significant); score 2=moderate to intense redness with well defined margins; score 3=redness with well defined edema; score 4=redness with papules, vesicles, or ulceration. During Induction Phase, each subject had the following two test sites: Treated irradiated test site and Treated non-irradiated test site. The mean score of test sites with available scores from all 6 induction patches were reported for all evaluable subjects. (NCT04532164)
Timeframe: Two or three days after each irradiation during Induction Phase

InterventionScore on a scale (Mean)
Butenafine HCl 1% (BAY1896425) - Induction Phase0

[back to top]

Development of Erythema on the Treated Non-irradiated Test Sites During Induction Phase - All Treated Subjects

Evaluation of the test sites after irradiation used following scoring system: score 0=normal skin (no visible reaction); score 1= faint, barely perceptible to moderate redness with poorly defined margins (not clinically significant); score 2=moderate to intense redness with well defined margins; score 3=redness with well defined edema; score 4=redness with papules, vesicles, or ulceration. During Induction Phase, each subject had the following two test sites: Treated irradiated test site and Treated non-irradiated test site. The mean score of test sites with available scores from all 6 induction patches were reported for all treated subjects. (NCT04532164)
Timeframe: Two or three days after each irradiation during Induction Phase

InterventionScore on a scale (Mean)
Butenafine HCl 1% (BAY1896425) - Induction Phase0

[back to top]

Photoallergic Reaction Evaluation Reported as Number of Test Site With Different Erythema Score During Challenge Phase - All Treated Subjects

Evaluation of the test sites after irradiation used following scoring system: score 0=normal skin (no visible reaction); score 1= faint, barely perceptible to moderate redness with poorly defined margins (not clinically significant); score 2=moderate to intense redness with well defined margins; score 3=redness with well defined edema; score 4=redness with papules, vesicles, or ulceration. During Challenge Phase, each subject had the following four virgin test sites: Treated irradiated test site; Treated non-irradiated test site; Untreated irradiated test site; Untreated non-irradiated test site. All four test sites were evaluated according to the above scoring system at 24, 48, and 72 hours following patch application (3 different time points), and the number of test sites with available scores from all these time points were reported for all treated subjects. (NCT04532164)
Timeframe: At 24, 48, and 72 hours following patch application

InterventionTest site (Number)
Treated irradiated test site, score=0Treated irradiated test site, score=1Treated non-irradiated test site, score=0Treated non-irradiated test site, score=1
Butenafine HCl 1% (BAY1896425) - Challenge Phase325243436

[back to top]

Photoallergic Reaction Evaluation Reported as Number of Test Site With Different Erythema Score During Challenge Phase - All Evaluable Subjects

Evaluation of the test sites after irradiation used following scoring system: score 0=normal skin (no visible reaction); score 1= faint, barely perceptible to moderate redness with poorly defined margins (not clinically significant); score 2=moderate to intense redness with well defined margins; score 3=redness with well defined edema; score 4=redness with papules, vesicles, or ulceration. During Challenge Phase, each subject had the following four virgin test sites: Treated irradiated test site; Treated non-irradiated test site; Untreated irradiated test site; Untreated non-irradiated test site. All four test sites were evaluated according to the above scoring system at 24, 48, and 72 hours following patch application (3 different time points), and the number of test sites with available scores from all these time points were reported for all evaluable subjects. (NCT04532164)
Timeframe: At 24, 48, and 72 hours following patch application

InterventionTest site (Number)
Treated irradiated test site, score=0Treated irradiated test site, score=1Treated non-irradiated test site, score=0Treated non-irradiated test site, score=1
Butenafine HCl 1% (BAY1896425) - Challenge Phase31193146

[back to top]

Development of Erythema on Treated Irradiated Test Sites During Induction Phase - All Treated Subjects

Evaluation of the test sites after irradiation used following scoring system: score 0=normal skin (no visible reaction); score 1= faint, barely perceptible to moderate redness with poorly defined margins (not clinically significant); score 2=moderate to intense redness with well defined margins; score 3=redness with well defined edema; score 4=redness with papules, vesicles, or ulceration. During Induction Phase, each subject had the following two test sites: Treated irradiated test site and Treated non-irradiated test site. The number of test sites with available scores from all 6 induction patches were reported for all treated subjects. (NCT04532164)
Timeframe: Two or three days after each irradiation during Induction Phase

InterventionTest site (Number)
Treated irradiated test site, score=0Treated irradiated test site, score=1Treated irradiated test site, score=2
Butenafine HCl 1% (BAY1896425) - Induction Phase27328275

[back to top]

Development of Erythema on Treated Irradiated Test Sites During Induction Phase - All Evaluable Subjects

Evaluation of the test sites after irradiation used following scoring system: score 0=normal skin (no visible reaction); score 1= faint, barely perceptible to moderate redness with poorly defined margins (not clinically significant); score 2=moderate to intense redness with well defined margins; score 3=redness with well defined edema; score 4=redness with papules, vesicles, or ulceration. During Induction Phase, each subject had the following two test sites: Treated irradiated test site and Treated non-irradiated test site. The number of test sites with available scores from all 6 induction patches were reported for all evaluable subjects. (NCT04532164)
Timeframe: Two or three days after each irradiation during Induction Phase

InterventionTest site (Number)
Treated irradiated test site, score=0Treated irradiated test site, score=1Treated irradiated test site, score=2
Butenafine HCl 1% (BAY1896425) - Induction Phase24823161

[back to top]